Loading...
The URL can be used to link to this page
Your browser does not support the video tag.
Home
My WebLink
About
2023/04/11 REGULAR SESSION 10:00AM
BRAZOS COUNTY BRYAN, TEXAS NOTICE OF MEETING AND AGENDA BRAZOS COUNTY COMMISSIONERS COURT THE COMMISSIONERS COURT OF BRAZOS COUNTY WILL,MEET IN REGULAR SESSION ON APRIL 11, 2023 AT 10:00 AM IN THE COMMISSIONERS COURTROOM OF THE COUNTY ADMINISTRATION BUILDING, 200 SOUTH TEXAS AVE., SUITE 106, BRYAN, TX 77803, THE PUBLIC MAY WATCH THE MEETING LIVE AT FACE BOOK.COM/B RAZOSCOU NTYTX THIS MEETING WILL BE CONDUCTED BY VIDEO CONFERENCE WITH AT LEAST A QUORUM OF COMMISSIONERS COURT MEMBERS PARTICIPATING IN PERSON AT THE COUNTY ADMINISTRATION BUILDING ,IN ACCORDANCE WITH THE PROVISIONS SET FORTH IN SECTION 551.127 OF THE TEXAS GOVERNMENT CODE. 1. Invocation and Pledge of Allegiance • U.S. and Texas Flag - Commissioner Watson 2. Call for Citizen input and/or concerns Consider and take action on agenda items: 3 -13 3. Approval of Grant Application to Texas General Land Office underthe CDBG-MIT Regional Mitigation Program. Grant funding is requested for engineering/generator for Wickson Creek,Special Utility District. Grant application will be posted on Brazos County website for public comment for at least 14 days. 4. Request approval to apply for the Drug. Court Grant for FY 2024 from the State of Texas. 5. Award of RFP #23-099 Pharmaceuticals. Recommended Award: Polaris Pharmacy Services of Philadelphia, LLC. previously known as Contract Pharmacy. 6. Approval of architect proposal for Cl P #2.3-572 Jail Shower Area Renovations with Vol. 394 pg. 77 Burditt Consultants, LLC in the amount of $48,920.00. 7. Consider and take action on the Wildfire Energy Operating, LLC utility permit to install a bore for a 4" pipeline crossing under Della Love Road located 1,060' NE of Deep Well Road. Site is located in Precinct 2. 8. Commissioners Court minutes for the following dates: • a. March 07, 2023 - Regular Meeting • b. March 14, 2023 - Regular Meeting • c. March 21, 2023 - Regular Meeting • d. March 28, 2023 - Regular Meeting 9. Budget Amendments. • FY 22/23 Budget Amendments 27.01 - 27.02 10. Personnel Change of Status. • a. Employment & Separations • b. Personnel Action Forms 11. Payment of Claims. 12. Convene into Executive Session pursuant to the following: • a. Texas Government Code §551.074 to discuss the appointment, employment, evaluation, reassignment, duties, discipline, or dismissal of the County Treasurer. • b. Texas Government Code §551.071 to consult with attorney about pending or contemplated litigation and/or a settlement offer. 13. Consider and possible action on Executive Sessions. 14. Acknowledgements of FY 2022-2023 Budget to Actuals by Fund as of April 3, 2023. Acknowledgements of FY 2022-2023 Contingency Budget to Actuals as of April 3, 2023. 15. Acknowledgement of the Budget Planning Calendar for 2023-2024. 16. Juvenile director's report on detention population. 17. Sheriff's report on inmate population. 18. Announcement of interest items and possible future agenda topics. 19. Call for Citizen input and/or concerns 20. Adjourn. E Pg. '� PUBLIC COMMENTS Public Comment during the Commission Meeting may be for all matters, both on and off the agenda, and be limited to four minutes per person. Persons are invited to submit comments in writing on the agenda items and/or attend and make comment at the Commission meeting. Members of the public are reminded that the Brazos County Commissioners Court is a Constitutional Court, with both judicial and legislative powers, created under Article V, Section 1 and Section 18 of the Texas Constitution. As a Constitutional Court, the Brazos County Commissioners Court also possesses the power to issue a Contempt of Court Citation under Section 81.024 of the Texas Local Government Code. Accordingly, members of the public in attendance at any Regular, Special and/or Emergency meeting of the Court shall conduct themselves with proper respect and decorum in speaking to, and/or addressing the Court; in participating in public discussions before the Court; and in all actions in the presence of the Court. Those members of the public who are inappropriately attired and/or who do not conduct themselves in an orderly and appropriate manner will be ordered to leave the meeting. Refusal to abide by the Court's Order and/or continued disruption of the meeting may result in a Contempt of Court Citation. It is not the intention of the Brazos County Commissioners Court to provide a public forum for the demeaning of any individual or group. Neither is it the intention of the Court to allow a member (or members) of the public to insult the honesty and/or integrity of the Court, as a body, or any member or members of the Court, or County employees, individually or collectively. Accordingly, profane, insulting or threatening language directed toward the Court and/or any person in the Court's presence and/or racial, ethnic or gender slurs or epithets will not be tolerated. Violation of these rules may result in the following sanctions: 1. cancellation of a speaker's time; 2. removal from the Commissioners Court; 3. a Contempt Citation; and/or 4. such other and/or criminal sanctions as may be authorized under the Constitution, Statutes and Codes of the State of Texas. The County Commissioners Court can deliberate or take action only if a matter has been listed on an agenda properly posted prior to the meeting. During the public comment period, speakers may address matters not listed on the published agenda. The Open Meeting Law does not expressly prohibit responses to public comments by the Commissioners Court. However, responses from the County Judge or Commissioners to unlisted public comment topics could become deliberation on a matter without notice to the public. To ensure the public has notice of all matters the Commissioners Court will consider, the County Judge and/or Commissioners may choose not to respond to public comments, except to correct factual inaccuracies, recite existing policy in response to an inquiry or to ask that a matter be listed on a future agenda. See Texas Open Meetings Act Section 551.042. INVOCATION Any invocation that may be offered before the official start of the Court meeting shall be to and for the benefit of the Court. The views or beliefs expressed by the invocation speaker have not been previously reviewed or approved by the Court and do not necessarily represent the religious beliefs or views of the Court in part or as a whole. No member of the community is required to attend or participate in the invocation and such decision will have no impact on their right to actively participate in the business of the Court. The Commissioners Courtroom of the County Administration Building, 200 South Texas Ave., Suite 106, Bryan, TX77803, THE PUBLIC MAY WATCH THE MEETING LIVE AT FACEBOOKCOM/BRAZOSCOUNTYTX is wheelchair accessible. Handicap parking spaces are available. Any request for sign interpretive services must be made two working days before the meeting. To make arrangements, please call (979) 361-4102. MINUTES APRIL 11, 2023 BRAZOS COUNTY COMMISSIONERS COURT REGULAR MEETING A regular meeting of the Commissioners' Court of Brazos County, Texas was held in the Brazos County Commissioners Courtroom in the Administration Building, 200 South Texas Avenue, in Bryan, Brazos County, Texas, beginning at 10:00 a.m. on Tuesday, April 11, 2023 with the following members of the Court present: Duane Peters, County Judge, Presiding; Steve Aldrich, Commissioner of Precinct 1; Chuck Konderla, Commissioner of Precinct 2, Present via Zoom; Nancy Berry, Commissioner of Precinct 3; Wanda J. Watson, Commissioner of Precinct 4; Karen McQueen, County Clerk. The attached sheets contain the names of the citizens and officials that were in attendance. Invocation and Pledge of Allegiance • U.S. and Texas Flag - Commissioner Watson 2. Call for Citizen input and/or concerns There was no Citizen input. Consider and take action on agenda items: 3 -13 3. Approval of Grant Application to Texas General Land Office under the CDBG-MIT Regional Mitigation'Program. Grant funding is requested for engineering/generator for Wickson Creek Special Utility District. Grant application will be posted on Brazos County website for public comment for at least 14 days. M 5 If Commissioner Berry thanked Gentry Woodard for the work that he is doing to save the County money through grants. Commissioner Konderla and Commissioner Aldrich both echoed Commissioner Berry's thanks. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. Request approval to apply for the Drug Court Grant for FY 2024 from the State of Texas. A copy of the grant application and resolution is attached. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Wanda J. Watson. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. Award of RFP #23-099 Pharmaceuticals. Recommended Award: Polaris Pharmacy Services of Philadelphia, LLC. previously known as Contract Pharmacy. The Court voted unanimously to accept the recommendation of the Purchasing Agent and awarded Bid Contract 23-099 Pharmaceuticals to Polaris Pharmacy Services of Philadelphia, LLC. previously known as Contract Pharmacy. A copy of the bid tabulation is attached. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Wanda J. Watson. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. Approval of architect proposal for Cl P #23-572 Jail ShowerArea Renovations with Burditt Consultants, LLC in the amount of $48,920.00. A copy of the service contract is attached. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 7. Consider and take action on the Wildfire Energy Operating, LLC utility permit to install a bore for a 4" pipeline crossing under Della Love Road located 1,060' NE of Deep Well Road. Site is located in Precinct 2. Motion: Approve, Moved by Commissioner Chuck Konderla, Seconded by Commissioner Nancy Berry. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 8. Commissioners Court minutes for the following dates: • a. March 07, 2023 - Regular Meeting • b. March 14, 2023 - Regular Meeting • c. March 21, 2023 - Regular Meeting • d. March 28, 2023 - Regular Meeting V01.2 9 a" Pg. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 9. Budget Amendments. • FY 22/23 Budget Amendments 27.01 - 27.02 27.01 Reallocate funds for Records Management. 27.02 Transfer funds from Purchasing to various departments. Motion: Approve, Moved by Commissioner Steve Aldrich, Seconded by Commissioner Nancy Berry. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 10. Personnel Change of Status. • a. Employment & Separations • b. Personnel Action Forms A copy of the Personnel Change of Status is attached. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 11. Payment of Claims. Claims 8121544 — 8121647 9007218 — 9007276 Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 12. Convene into Executive Session pursuant to the following: • a. Texas Government Code §551.074 to discuss the appointment, employment, evaluation, reassignment, duties, discipline, or dismissal of the County Treasurer. • b. Texas Government Code §551.071 to consult with attorney about pending or contemplated litigation and/or a settlement offer. At this point, the County Judge announced the Court would consider items 14 through 19 and then return to convene into Executive Session. Having considered the previously noted agenda items, at 10:09 a.m. the County Judge stated that the Court would convene into Executive Session to deliberate pursuant to the following sections, taking Executive Session (b) first: pg. !Vol. i° _ � a (a)Texas Government Code §551.074 to discuss the appointment, employment, evaluation, reassignment, duties, discipline, or dismissal of the County Treasurer. The following individuals were asked to stay for the session: Cheryl Coffman, Executive Assistant Ed Bull, Chief of Staff/Civil Counsel Laura Davis, Treasurer Jennifer Salazar, Human Resources Director Katie Conner, Auditor (b) Texas Government Code §551.071 to consult with attorney about pending or contemplated litigation and/or a settlement offer. The following individuals were asked to stay for the session: Cheryl Coffman, Executive Assistant Ed Bull, Chief of Staff/Civil Counsel Katie Conner, Auditor Charles Wendt, Purchasing Agent Kaitlyn Battles, Purchasing Buyer I I 13. Consider and possible action on Executive Sessions. At 11:06 the County Judge announced the meeting open to the public. On motion by Commissioner Berry, seconded by Commissioner Aid rich, the Court voted unanimously to approve the engagement letter with Allensworth Law, dated February 27, 2023. Motion: Approve, Moved by Commissioner Nancy Berry, Seconded by Commissioner Steve Aldrich. Passed. 5-0. Ayes: Aldrich, Berry, Konderla, Peters, Watson. 14. Acknowledgements of FY 2022-2023 Budget to Actuals by Fund as of April 3, 2023. Acknowledgements of FY 2022-2023 Contingency Budget to Actuals as of April 3, 2023. The Court acknowledged receipt of the 2022-2023 Budget to Actuals by Fund and Contingency Fund Budget to Actuals as of April 3, 2023. 15. Acknowledgement of the Budget Planning Calendar for 2023-2024. The Court acknowledged receipt of the Budget Planning Calendar for 2023-2024. 16. Juvenile director's report on detention population. Judge Peters read the report that there are 35 juveniles in the detention center, 31 are male and 4 are female, and 25 have electronic monitors. 17. Sheriff's report on inmate population. Chief Deputy Kevin Stuart stated there were 672 inmates in jail, 586 inmates are male, 86 are female and 52 have electronic monitors. 18. Announcement of interest items and possible future agenda topics. Following the Executive Sessions, Chief of Staff Ed Bull announced that due to Vol. 394 Pg. 83 employment recruiting and retention difficulties that the County has been facing since the COVI D-19 pandemic, the Court needs a Workshop to discuss the possibility of a consultant to advise on the matter. Additionally, Mr. Bull recommended another Workshop to discuss information regarding contracting an architect and engineer for the new Road and Bridge facility. 19. Call for Citizen input and/or concerns Risk Manager Leslie Contreras reminded Law Enforcement of the upcoming Railroad Crossing Training. 20. Adjourn. Vol 3 9 4 Pg. The foregoing minutes of the Commissioners Court Meeting held April 11, 2023, have been examined and are approved in open Court this 2nd day of May in Bryan, Brazos County, Texas. Duane Peters County Judge Chuck Konderla Commissioner, Precinct 2 Attest: Karen McQueen County Clerk Steve Aldrich Commissioner, Precinct 1 Nancy Berry Commissioner, Precinct 3 PgOf BR.AZOS COUNTY COMMISSIONER'S COURT ' DAY OF 920 1o,-oo-. (A-Mopmq (Lca�nl r IMP,�h�rnj Name 61A I r-I 60 n q sI\Qa � �� LcLIY-(0,n _.LAC, �e ���e►�c�r MG.�S I �1 G frta� Organization rZ G 5 v voi. Pg. —sG Pg ;L of )-- BRAZOSCOUNTY COMMISSIONER'S .COURT - 1 l DLAY OF 1 920 'A A /PM/pl 9 (ajOl I ))CA v- Name (PLEASE PRINT) vk\,-- r-A Organization (PLEASE PRINT) 7d—?1t7b:5 m Vol. 9 4 Pg. BRAZOS COUNTY BRYAN, TEXAS DEPARTMENT: NUMBER: DATE OF COURT MEETING: 4/11/2023 ITEM: Approval of Grant Application to Texas General Land Office under the CDBG-MIT Regional Mitigation Program. Grant funding is requested for engineering/generator for Wickson Creek Special Utility District. Grant application will be posted on Brazos County website for public comment for at least 14 days. TO: Commissioners Court DATE: 04/04/2023 FISCAL IMPACT False BUDGETED: False DOLLAR AMOUNT: $0.00 ATTACHMENTS:_ File Name Description !pe No Attachments Available APPRO i,la3 Duane Peters Date County Judge EVoi- 394 pg. Regional Mitigation Program Texas General Land Office Community Development & Revitalization Brazos County 2022-100349-RMP Vo4• :� Pg. Table of Contents Regional Mitigation Program Application General Activities Duplication of Benefits Fair Housing Citizen Participation Procurement Documents Project Project Info National Objective Environmental Permits Budget Activity Lines Mitigation Project Sites { Regional Mitigation Program Application Vol. 394 -pg. 91 :. _..�� -���� o •. _� -.� emu.-._ ... s �.: Applicant Information Applicant: Brazos County County: Brazos Program: Regional Mitigation Program: BVCOG - State MID COG: Brazos Valley Council of Governments (BVCOG) Phone Number: (979) 361-4102 Address: 200 South Texas Avenue, Bryan, Texas 77803 Website: www.brazoscountytx.gov Employer Identification Number (EIN): 746000433 Taxpayer Identification Numbers (TIN): 746000433 UEI (Unique Entity Identifier): D1 H3VK7MLAG8 Data Universal Numbering System (DUNS): 052960341 SAM.gov Registration Expiration Date: 12115/2023 Is the applicant an eligible subrecipient applying in conjunction with or on behalf of another entity (non -city) within the county? No How much funding was the applicant allocated by the approved COG MOD? $500,000.00 Is the applicant participating in the National Flood Insurance Program? Yes Fiscal Year End Date (Month): September Fiscal Year End Date (Day): 30 Application Contacts ZrJan_izatioY F��irs a LastVame 'F t�e�s ;one Y� ��ty { Engineer NIA NIA NIA NIA (000) 000- NIA@Na.co 0000 m Authorized Brazos Katie Conner County (979) 361- kconner@br Representati County Auditor 4350 azoscountyt- ve x.gov FVol. 394 Pg.92 I J Wax WN -La Grant Brazos Katie Conner County (979)361- kconner@br Administrato County Auditor 4350 azoscountyt r x.gov Primary Brazos Gentry Woodard Grant (979)324- gentry@the Contact County Director 0558 grantlablic.c orn Chief Brazos Duane Peters County (979)361- dpeters@br Elected County Judge 4102 azoscountyl Official I Ix.gov SF-424 Questions Applicant Type: County Government Application Title: Brazos County Regional Mitigation Project Is the applicant delinquent on any federal debt? No Vol. 3 9 4- . pg. 93 Activities Activity bRGR I`;ctivignT� Water Facilities $500,000.00 Project . =� x Site Protect Site'iitle offing Address , Wickson Special Utility District Water Well 17775 Harris Lane, Bryan, Texas 77808 Budget Line Summary Total Engineering over Total Construction: 4.17% Total Admin + Environmental over Total Amount Requested: 0% Allowable Fee Percentage Cap for Admin + Environmental: 11 % arn��BudgetCod,���x�-��� ..s.� 's`-- -' IRA, -�,_��`�,�PI tt ed/Re„ued�� ,aunt�. $0.00 Planning Acquisition $0.00 Environmental $0.00 Special Environmental $0.00 Grant Administration $0.00 Engineering $20,000.00 Construction $480,000.00 1Rg.y94 Vol. Duplication of Benefits r ' FEMA Coverage Did you receive any FEMA funding? No Do you anticipate any FEMA funding? No Was the proposed project eligible for FEMA? No Is the budget in this application funding for the nonfederal share of a FEMA project? No If yes, have funds been awarded? If FEMA funds were received, explain why funds are needed above and beyond the FEMA funding: insurance Coverage Did the applicant have insurance coverage on the proposed project? No Name of Insurance Company: Amount claimed/received for the project: If a claim was not filed, please explain below: Explain why funds are required above and beyond the insurance funding: Other Funding Has the applicant submitted a request to fund a part of or the whole project described in the application? No Are local or other funds available to address the proposed project in whole or in part? Have any other state and/or federal agencies been contacted concerning funding for the proposed project? No Disclose source(s) and use(s) of non-CDBG-MIT funds (Each row is a funding source): va. 3 9 4 Pg. 9 5 Wr. 9m: Fair Housing S What methods and criteria were used to prioritize the projects in the application, including . affirmatively furthering fair housing? Tier 1 "Hard data" including census data and population data from the Community Development and Revitalization Program GIS hub was used to prioritize the project and affirmatively further fair housing through the development of a public project that benefits the community through revitalization of resources. Residents were also invited to review and provide comments on the grant application and project. What are the identified protected classes, racially and ethnically concentrated areas, and concentrated areas of poverty that may be impacted by this project? According to the CDBG Mitigation Viewer, there are individuals in the Low and Moderate Income, Limited English Proficiency, Minority, Disability, and 65 and over populations impacted by this project. Provide a meaningful analysis that describes how these identified populations may be impacted by this project. The identified populations will benefit from this project as it is a Critical Action activity that includes necessary infrastructure for safety. For each fair housing activity, provide a name and status. If the activity is Completed, enter the Date Initiated. If the activity is Planned, enter the To Be Completed By date: u,t - . $flte Status 6a a InfiUa e ' �e�TQy: o b"ea r n�x�N ryiy'�y:Ts�"rjc. Fair Housing Post a Notice In Completed 4/6/2023 4/6/2023 Activity 1 the newspaper regarding the rant Fair Housing Set up a Completed .4/612023 4/6/2023 Activity 2 comment link for the proposed rant. Fair Housing Post the grant Completed 4/10/2023 4/10/2023 Activity 3 application for public participation Fair Housing Hold a public Planned 4/11/2023 4/11/2023 Activity 4 hearing to solicit Input on the project. Vol. 394 �Pg. 9 'X":v.-xT Procurement Have services been procured for Engineering, Grant Administration, or Environmental Services? No Are there any persons/entities with a reportable financial interest to disclose? No °Y�Y� .,F n V�ndary a .. �.� g o � `#1''iah'rn2' UgpO r NaMWWk�t;an�actP)��� .t �" -� ,.tea. �ontacWEina�t ai"eme Engineering Environmental Grant Administration Vol. 3 94 Pg. s �' Documents rZ�'n�Fl- --I W-1 �Ia. LMISD dita and/or CDBG-MIT Survey CDBG Mitigation Viewer Export.pdf documentation DP05 (ACS 5-year estimate) CDBG Mitigation Viewer Export.pdf Supporting census tract/block group or other CDBG Mitigation Viewer Export.pdf beneficiary data maps Race/Ethnicity/Gender Calculator CDBG Mitigation Viewer Export.pdf Certificate of Convenience and Necessity CDBG Mitigation Viewer Export.pdf (CCN) Environmental Exempt Form for planning and Environmental Exempt Form.PDF administrative activities Signed Applicant Certifications Certificatoin.pdf Documentation to support Urgent Need National Objectives.docx Mitigation national objective CDBG-MIT - Budget Justification of Retail Budget Justification Costs.docx Costs form (completed, signed, and sealed by a professional engineer or architect licensed to work in the State of Texas) Scope of work information, maps, and other Documentation of Failure.docx applicable documentation for each Local effort identified Maps indicating latitude and longitude for Latitude Longitude Coordinates.pdf proposed locations CDBG Mitigation Viewer Export CDBG Mitigation Viewer Export.pdf Single Auditor Annual Financial Statement FY22 ACFR Final 3.22.23 optimized.pdf Single Auditor Annual Financial Statement FY 2023 Adopted Budget.pdf SF-424 (completed and signed) SF424 Regional Mitigation signed.pdf .Current Printout of SAM.gov Registration Brazos County SAMs.pdf ) 98 vol. F g. _�:�+� �xma+nw,�'- r:33a :y. ,n.«s�tn._Y ^r rx a s:ti�N:�kr,Ci:�4�t._ _� . Y. _ iP •s 'z:...x. �" ag, .�4=t'�' _= __#�. � -' `;,;�.�`3 .. *�lyr rt 7�.....:.: .. _r�.3e... . r:. ti„�'�rn? :a_ .s :%kx+s: Brazos County Regional Mitigation Project Project Info Project Information DRGR Activity: Water Facilities Project Type: Water Facilities Project Title: Brazos County Regional Mitigation Project Does this project include replacement or relocation of a facility (i.e., lift station, water treatment plant, etc.)? No Provide a detailed description of the scope of work proposed. For proposed work involving a length of road, ditch, channel, etc., report the scope of the project in linear feet (If): The Wickson Creek Special Utility District was victim to power outages caused by the winter storm in February 2021, and the lack of electricity to operate pumps caused water customers to lose water. The CDBG Mitigation grant would provide funds towards the purchase of a new generator allowing continuous operation and the ability to provide water to customers even with electrical failure. .4 i1.,Y "s �, �sS � � � �,� !�k$.._ i k..n r Add,ess ;SiteProjectSiteTit-le y : k`Eetr{e�et Wickson Special Utility District Water 7775 Harris Lane, Bryan, Texas 77808 Well Describe a plan for the long-term funding and management of the operations and maintenance of the project: The maintenance of the generator will be maintained by Wickson Special Utility District and an MOU with Brazos County. Total proposed number of linear feet: Total number of proposed public facilities: 1 4Poect<Phaseh�t f % Startjl3ate _ ' ,'z .End Date,, ";L;erigth"(in months= Start -Up Documentation 411 /2023 5/1 /2023 1 Contract Closeout 2/2/2024 3/2/2024 1 Submit As- Builts/COCC/FWCR 1/1/2024 2/1/2024 1 Construction 12/1/2023 1/1/2024 1 Construction NTP 11/1/2023 12/1/2023 1 Contract Award 11/1/2023 12/1/2023 1 Bid Advertisement 8/1/2023 10/1/2023 2 Acquisition 7/3/2023 10/3/2023 3 E,v,,,?.3 9 4 i?�--- rdje�P=hase5 ��1at E ba5'rxti(�nontfis) Environmental Review 12/1/2023 1/1/2024 1 Engineering Design 12/1/2023 1/1/2024 1 Fvd. 3 9 4 pg. ol. National Objective National Objective Provide Total Number of Beneficiaries: 1,819 Provide number of LMI Beneficiaries 1,819 Percentage of LMI Beneficiaries:100% Is that applicant a HUD Exception Grantee? No ��� N i��l �' �? Tract yi310 roue f:st�'ext3 .�enss �„„ 1 Group 4 Male: 945 Female: 874 Total: 1,819 h 1 ,' k„' 11va%C+F..3`':Yz ''..s.-. .-... 3 eM?`,. ._ 959 1,787 White 828 American 0 0 0 Indian/Alaskan Native Black African 0 32 32 American Asian 0 0 0 Black African 0 0 0 American/White Asian/White 0 0 0 American 0 0 0 Indian/Alaskan Native/White Some Other Race 0 0 0 Other Multi -Racial 0 0 0 Native Hawaiian / 0 0 0 Other Pacific Islander Q HIT, 1'Y. i� '"•rYsx A �7v 6 � "M6§ 3/� Y`x 1s i�'2 ( Iiit a imh'��,h Y,u,S_ C MP • "` i F P r. ._., _..�i't, , American 0 0 0 Indian/Alaskan Native/Black African American Which HUD national objective does the project meet? UNM Describe activities that benefit low- and moderate -income people: Method(s) used to determine the beneficiaries: LMI Area Benefit What method was used for.Beneficiary Identification? Census (HUD LMISD) Provide a brief description of the beneficiary identification method used to determine this national objective and upload supporting beneficiary maps, census data, and/or survey documents: Census data as well as the required CDBG-MIT Viewer Guide was used to determine population served by the project. U.S. Congressional District #: 10 Texas Representative District M 14. Texas Senate District #: 5 yr �a�,-�. � �.z -: , _ :. , u -. �.�- � •.:�.sx. ,:��.�-,�:.:. � ,� -,-- Environmental What is the current status of the project? Not yet begun Will the assistance requested have any negative impact(s) or effect(s) on the environment? No Is the proposed project likely to require an archaeological assessment? No Is the proposed site(s) listed on the National Register of Historic Places? No Is the project in a designated fioodway or coastal high hazard area? No Is the project in a designated special flood hazard area or a designated wetland? No For projects in the 500 or 100-year floodplain: Does your project involve a critical action as defined in 24CFR55.2(b)(3)? Is any project site located in a known critical habitat for endangered species? No Is any project site a known hazardous site? No Is any project site located on federal lands or at a federal installation? No Is any project site subject to or participating in Fixing America's Surface Transportation Act (FAST-41) (P.L. 114-94)? No What level of environmental review is likely_ needed for this project? Exempt Provide any additional detail or information relevant to Environmental Review: None Provide a brief narrative regarding how CDBG-MIT funding is to be used. Demonstrate that HUD CDBG environmental requirements have been met to date: Vol. .394 Pa i 0. iasa z�%:.ucn�!s�oemuixexrhaalnuurtsu+!ens Does the project require any federal, state, or other permits, approvals, or waivers to complete the proposed work? No If yes, describe the type and purpose of each permit and its association with the proposed project. Provide a copy of each permit already executed: Does the project require any type of ratified, legally binding agreement between the applicant and any other entity to provide continual operation upon completion? No If yes, describe the type and purpose of each agreement and its association with the proposed project. Provide a copy of each agreement already executed or drafted: For sewer and/or water facilities projects, does the applicant currently hold the Certificate of Convenience and Necessity (CCN) for the target area proposed in the application? (if not a sewer and/or water facilities project, please choose N/A): No Vo4. 394 Pg. 0 m > G) m Cf) m > -u g "OM 0 M- @ CD =a =3 CD CD c�MIR 5. 3 B o CD 0 CD (D m AV; ME 00 Mo N) C� C) p C) p 61). p 40 p fi:� 0p 40 -ro Cl 0C) C) C) D C) C:) c) (c) o N C p p p p D n C C C C- CD 4h- V> 00 CD C) C) O 40 Im Co C) a C) c:l CD C� O C) a C) C> a b C) to CD 0 0 loel 0 0 ol 0 CD Mitigation Identify the specific risk the proposed project will mitigate against: Storms Describe as to how the proposed project addresses/mitigates against the current and future risks identified: The Wickson Creek Special Utility District was victim to power outages caused by the winter 'storm in February 2021, and the lack of electricity to operate pumps caused water customers to lose water. The CDBG Mitigation grant would provide funds towards the purchase of a new generator allowing continuous operation and the ability to provide water to customers even with electrical failure. Provide information about how the proposed mitigation efforts integrate into the community's emergency and resiliency plans: The Wickson Creek Special Utility District works closely with all emergency agencies during emergencies and implements emergency plans coordinated with Brazos County. In the space provided, list documentation provided to support the identification of the threat or hazard and how it relates to potential impact: Documentation of past failure.. Provide a brief description of how the proposed project addresses an integrated approach to mitigation: This community mitigation project considered an integrated approach to housing, infrastructure, and economic revitalization for the overall community served. Considering the local evaluation of hazard risks, responsible floodplain management, future extreme weather/natural disaster events, and long-term risks, describe how the proposed project promotes sustainable community resilience: The evaluation of future extreme weather and natural disaster events played a role in determining the project which will promote sustainable community resilience. Mitigating this future risk is to the benefit of everyone in the community. . Describe how the proposed project is consistent with local and regional planning efforts to effect disaster mitigation: Wickson Creek Special Utility District works closely with the Brazos County and helps coordinate efforts with local emergency responders during a disaster. Was a cost -benefit analysis used in the selection of the proposed project? No Describe how the proposed project impacts vulnerable populations in the local community.: This project impacts the low to moderate income population with water services. Describe how the proposed project creates economic opportunities for the local community: A functioning, reliable, and safe water system is to the benefit of all individuals and businesses in the community. Does this project disproportionately impact vulnerable populations in the local community? No Does the proposed project align with investments from other state or local capital improvements and infrastructure development efforts? Yes Does the proposed project employ adaptable and reliable technology to guard against premature obsolescence? No Describe the applicant's overall mitigation plan and how the project addressed in this application furthers that plan: The Wickson Creek Special Utility District was victim to power voi. ice" Pa. 107 Y outages caused by the winter storm in February 2021, and the lack of electricity to operate pumps caused water customers to lose water. The CDBG Mitigation grant would provide funds towards the purchase of a new generator allowing continuous operation and the ability to provide water to customers even with electrical failure. Describe how the proposed project will contribute to the community's resiliency against future disasters as a result of these projects: The reliability of water and electricity during future disasters helps mitigate the future loss of power with the installation reliable generators. Brazos County Regional Mitigation Project - Wickson Special Utility District Water Well 10 Vol. pg .. Project Site i Project Site Project Site Title: Wickson Special Utility District Water Well Street Address: 7775 Harris Lane, Bryan, Texas 77808 Street Limits on Street: 7775 Harris Lane From Street: 7775 Harris Lane To Street: 7775 Harris Lane Zip Code: 77808 City: Bryan County: Brazos State: Brazos Latitude: 30.789582 Longitude: 96.336817 Performance Measures: Public Facilities Provide the proposed number of linear feet: Acquisition/Uniform Relocation Assistance Does the project require acquisition of property, purchase of easements, relocation, or any other activity requiring compliance with URA outside the listed waived activities? No Has acquisition of the project site(s) been completed, in progress, or will need to be acquired? Describe the type and purpose of all acquisitions (easements, real property, etc.) associated with the proposed project. For acquisitions "Previously Acquired" or "Acquisition in Progress," include the date of acquisition, detailed information and supporting documentation to ensure compliance with all URA, 42 U.S.C. 4601 et seq., and environmental review processes: What is the planned number of parcels to be acquired? What is the associated cost amount for this acquisition? RESOLUTION Resolution Authorizing the Submission of a Grant Application for Brazos County Specialty Court WHEREAS, The Brazos County Commissioners Court finds it in the best interest of the citizens of Brazos County that the Brazos County Specialty court be operated for the 2024 Fiscal Year, September 1, 2023 — August 31, 2024; and WHEREAS, The Brazos County Commissioners Court agrees that in the event of loss or misuse of the Office of the Governor funds, the Brazos County Commissioners Court assures that the funds will be returned to the Office of the Governor in full; and WHEREAS, The Brazos County Commissioners Court designates the Director of the Brazos County Community Supervision and Corrections Department as the authorized official for this grant. The authorized official is given the power to apply for, accept, reject, alter or terminate the grant on behalf of the applicant agency; NOW THEREFORE, BE IT RESOLVED that the Brazos County Commissioners Court approves submission of the grant application for the Brazos County Specialty Court to the-9ffif the Governor, Resolved this of �L- A23 in Bryan, Brazos County, -Peters, County Judge Commissioner Steve Aldrich Precinct i CommissionerblaIncy Berry Precinct 3 x ssioner uck Konderia Precin Commissioner VyandA J. Watson Precin 4 Grant Application Number. 4692001 Vol. 3 9 4 — Pg. BRAZOS COUNTY, TEXAS GRANT APPLICATION APPROVAL FORM `Date: 4/4/2023 Requesting Department: Brazos County Auditor's Office Grant Title: Specialty Court - Drug Court Granting Agency: Office of the Governor Amount Requested: $ 160,653.65 Grant Term (Beg/End) 09101/2023-08/31 /2024 Project Description: According to Statute 123.006, it is mandatory..for a county with a Will this grant fund salary & benefits? G71 Yes 11 No Is there County Match requirement? nYes Fv/] No Are there financial reporting requirements? r7] Yes No Who will do financial reporting? Brazos County Auditor's Office Are there programmatic reporting requirements? ® Yes No Who will do programmatic reporting? Brazos County CSCD *Please include all available backup documentation with the approval form. All grants are contracts between Brazos County and the granting agency and should be approved by Com 'ssio ers-C-ourt-prior to the application submission. 'Authorized 'Signature ved by Com issioners Cod this 1 Commissioners Court Approval day of n P 9-7-1-- 9 D a 19. Vol. ____3 91 — Pg- RFP-# 23-09.9 Pharmaceuticals. Available Points Polaris Pharmacy Services of Philaclelp ia, 1. C sty lenown as Co tract P a Clinical Solutions Pharmacy Implementation 10 8 6 Oees/Pricing Structure 40 6 -32 Proposed Functionality, Performance, and Services 30 30 30 References 10 6 1 8 Resource Availability 10 10 Total 100 90 86 Recommended Award: Polaris Pharmacy Services -of Philadelphia, LLC, previously known as Contract Pharmacy Appro Co issioner' rt on this Y day of ji@ding the positio P P-T- Z- , 2023 by n of (�,OL L &5rY TuDGoG7 Clinical Solutions Pharmacy Pricing Option 1 Pricing Option 2 Blister-30 Day Supply Strip-7 Day Supply Strip-14 Day Supply 1 & 4 Brand Name -27.5% ACQ+ 2.95 ACQ + 1.24 ACQ+ 2.50 A 2 & S Generic -98.0% ACQ + 2.95 ACQ + 1.24 ACQ + 2.50 0 3 & 6 Over the Counter -98.0% ACQ + 2.95 ACQ + 1.24 ACQ + 2S0 *If AWP causes price to fall below *If AWP causes price to fall below acquisition cost, then medications acquisition cost, then medications Other Fees (List other fees below) will be charged at acquisition cost+ either a 2.95 dispensing fee for will be charged at acquisition cost + either a 2.95 dispensing fee for c blister cards or 1.24 for strip packaging. blister cards or 1.50 for strip packaging. Before negotiated cutoff time: Next Day o 7 Delivery time for regular orders (# of days): After negotiated cutoff time: 2 days 8 Delivery time for rush orders (# of flours): 2 hours 9 Charge for rush orders: Pass through on next monthly bill cycle AMMMM 10 Annual software/licenses charges (if any): N/A Mew- 11 Does vendor issue'credits for un-used Yes, see Section M.39.h, pages 143-148 Yes se a 1 se g pharmaceuticals? Does vendor have a local facility that Yes es 12 pharmaceuticals may be picked up from? Our backup vendor, Statim RX, has partnerships with all national Got r ar Ityes, list location: pharmacy chains. (e.g: Walgreens, CVS, Walmart, etc;) Brazos County may choose to store typically used pharmaceuticals on location. Does vendor have a Yes, Clinical Solutions will provide perpetual inventory count cards as 3 m to track inventory for pharmaceuticals seen in Section M.33.b, page 85 stored at the County? E� PROPOSAL PREPARED FOR: BRAZOS COUNTY PURCHASING DEPARTMENT A Vol. 3 9 4 Pg. 125 Titus Avenue I Warrington, PA 18976 800.555.8062 { www.contractpharmacy.com 0 Contract Pharmacy SERVICES Pharmaceuticals TABLE OF CONTENTS COVERLETTER....................................................................................................................TABBED SECTION REQUIREDFORMS..............................................................................................................TABBED SECTION COMPANYPROFILE.............................................................................................................................. PAGE 4 PROJECTOBJECTIVES........................................................................................................................... PAGE 5 SCOPE OF WORK/REQUIREMENTS.................................................................................................... PAGE 6 Licensure....................................................................................................................................................................................... Page 6 Delivery......................................................................................................................................................................................... Page 7 ' Emergency Pharmacy Page 10 EmergencyDrug Kits............................................................................................................................................................... Page 10 Credit........................................................................................................................................................................................... Page 11 BlisterCard Packaging............................................................................................................................................................ Page 13 PharmaceuticalLabeling.....................................................................................................................................I...........„..... Page 15 Automed(Strip) Packaging............................................................................................................................................... ... Page 16 StarterStock.............................................................................................................................................................................. Page 17 ControlledMedications.......................................................................................................................................................... Page 19 GenericMedications................................................................................................................................................................ Page 21 UnavailablePharmaceuticals................................................................................................................................................ Page 22 PatientProfiles.......................................................................................................................................................................... Page 23 DrugInteractions................................................................................................................................................................— Page 24 ComputerizedPrescription Order Entry............................................................................................................................. Page 25 Contract Pharmacy ee ' • Vol. 394 Pg. RFP #23-099, Page 1 SERVICES °I CONFIDENTIAL AND AND PROPRIETARY— DO NOT DISTRIBUTE Pharmaceuticals - Electronic Medical Records Interface................................................................................................................................. Page 25 BarcodeScanner System ......................................... ............................... ......... .............. .............. »........ ... ................. ............. Page 25 HIPAACompliance................................................................................................................................................................... Page 26 FormularyDevelopment........................................................................................................................................................ Page 27 FormularyCompliance/Non-Formulary Request System.............................................................................................. Page 28 ConsultingServices/Quarterly inspections....................................................................................................................... Page 30 MedicationCarts...................................................................................................................».................................................. Page 32 Billing........................................................................................................................................................................................... Page 33 MedicationAdministration Records.................................................................................................................................... Page 36 Reports........................................................................................................................................................................................ Page 38 PharmacyHours........................................................................................................................................................................ Page 47 "On -Call" Pharmacist............................................................................................................................................................... Page 47 FaxMachines............................................................................................................................................................................. Page 47 Toll -free Numbers.................................................................................................................................................................... Page 47 In -Service Training....................................................... .............. .................................................. ............................................ Page 48 ImplementationPlan............................................................................................................................................................... Page 49 EXPERIENCE..........................................................................................................................................PAGE 52 KeyPersonnel............................................................................................................................................................................ Page 54 PastProceedings...................................................................................................................................................................... Page 58 MaterialJudgments .... ...................................... ............. ............................................................................ „........... ................. Page 58 REFERENCES.........................................................................................................................................PAGE 59 eCorrRxTm..............................................................................................................................................PAGE 60 394 pg.. RFP #23-099, Page 2 Contract Pharmacy �Eee SERVICES �ul'Cu CONFIDENTIAL AND PROPRIETARY — DO NOT DISTRIBUTE Pharmaceuticals 7 INSURANCE...........................................:..............................................................................................PAGE 62 PRICING/FEES FORM..........................................................................................................................PAGE 63 Vol. 394Pg. ._ i Contract Pharmacy 'g SERVICES ago CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE RFP #23-099, Page 3 COVER LETTER Contract Pharmacy SERVICES Pharmaceuticals ... ......... voi.3 9 4 PCJ11-9 ■ Contract Pharmacy Services, Inc. 125 Titus Avenue I Warrington, PA 18976 www.contractpharmacy.com 1800.555.80621800.453.3938 [fax] -Contract Pharmacy SERVICES February28, 2023 Brazos County Purchasing Department Brazos County Administration 200 South Texas Avenue, Suite 352 Bryan,Texas 77803 RE: RFP #23-099 — Pharmaceuticals Dear Brazos County Commissioners Court: Contract Pharmacy Services, Inc. (CPS) is pleased to respond to your Request for Proposal for Pharmaceuticals for the Brazos County Detention Center and Juvenile Justice Center. As you may know, CPS is an institutional pharmacy, specializing in providing pharmacy services to the correctional healthcare community across the countryfrom our location in the suburbs of Philadelphia, Pennsylvania. As the Incumbent vendor since 2003 at the Brazos County Detention Center and Juvenile Justice Center, we appreciate the continued opportunity to service the facilities and look forward to an affirmative. review of our enclosed response. In a specialized niche market of correctional pharmacy, CPS sets itself apart with service and technology. We focus on the personal attention afforded each of our clients. From interaction with data entry personnel to on -call pharmacists, exceeding your expectations is foremost. Contract Pharmacy Services prides itself on always having key decision makers of the company available for client consultation. Customer service has always been, and will continue to be, the primary focus of CPS. Technology has been an important area of growth for CPS. Our proprietary Computerized Physician Order Entry system, eCorrRxT", is the first and only of its kind in the marketplace. This system has been implemented with great success at the Brazos County Detention Center and Juvenile Justice Center almost 19 years ago. While competitors'systems have been designed "in concept", CPS is proud that our system has been a working tool at over 120 of our clients during the past 19 years. Although the system is completely optional, eCorrRx7m, Including the hardware and software licensing, is included in the contract pricing. It is recognized that, with the recent installation of the CorrecTek Electronic Medical Records system at the facilities, eCorrRxT"' may no longer be necessary. Contract Pharmacy Services is the only national pharmaceutical vendor to have completed a bi-directional interface with CorrecTek, enabling the most complete exchange of information between the electronic medical records system and the pharmacy. CPS is large enough to meet all of your needs, yet small enough to customize to the needs of the Brazos County Detention Center and Juvenile Justice Center. We have been servicing correctional facilities nationwide for 35 years, including county jails, Juvenile detention centers, regional detention facilities, and state prisons. Our programs and policies comply with National Commission on Correctional Health Care (NCCHC) and American Correctional Association (ACA) standards. Heather Hutchinson, CPS' Chief Operating Officer, has been the primary point of contact during Brazos County's previous contract with CPS. If there are any questions regarding the information contained herein, please do not hesitate to contact Heather or me directly. Heather may be reached at (800) 555-8062 or via email at HHutch insonacontractpharmacy.com. My telephone number is (847) 395-2787, or via email at SSteresoa ontractpharmacv.com. Thank you for the opportunity to respond to the current proposal for pharmaceuticals forthe Brazos County Detention Center and Juvenile Justice Center. We look forward to a favorable award and to continuing our longstanding relationship with Brazos County. - , Sincerely, CONTRACT PHARMACY SERVICES, INC. Scott D.Steres Director of Sales and Marketing REQUIRED FORMS M Contract Pharmacy SERVICES Pharmaceuticals .............. ........... ®f 394 pgl REQUEST FOR PROPOSALS RFP NO.23-099 Pharmaceuticals SEALED PROPOSALS TO BE SUBMITTED BEFORE: Tuesday, February 28, 2023, 2:00pm CST TO THE: BRAZOS COUNTY PURCHASING DEPARTMENT 200 S. Texas Ave. Suite 352 Bryan, TX 77803 Phone: (979) 361-4290 Fax: (979) 361-4293 Respondents, their employees and/or representatives are prohibited from contacting any.official or employee of Brazos County, except the Purchasing Agent, regarding this solicitation from the issuing date of the solicitation until scheduled oral presentations or the date the Brazos County Commissioners Court meets to consider award of the RFP. Any such contact will be grounds for rejection of the vendor's proposal. In compliance with this solicitation, the undersigned proposer having examined the solicitation and specifications and being familiar with the conditions to be met, hereby submits the following RFP for furnishing the material and/or services -listed on the attached bid form and agrees to deliver said items at the locations and for the prices set forth on the bid form. Company Name: Contract Pharmacy Services, Inc: By (mot): Heather Hutchinson Title: Chief Operating Officer Physical Address: 125 Titus Avenue, Warrington, Pennsylvania 18976 Mailing Address: 125 Titus Avenue, Warrington, Pennsylvania 18976 Telephone: (800) 655-8062 Fax: (800) 453-3938 E-Mail: rfp@contractpharmacy.com von. 394 Pg. � E1 both types of packaging listed below, however it is not required. The Firm must propose pricing for at least one (1) of the following two (2) packaging methods: i. Strip Packaging I Blister Packaging c. Firms shall submit a set of fixed prices for pharmaceuticals list in the attachment, Pharmaceutical Pricing. All other drugs shall be priced based on the pricing option (either 1 or 2) that the County chooses at award of Contract. d. Pricing must include any dispensing fess, packaging, delivery, and freight charges. Brazos County is exempt from State Sales Tax and Federal Excise Tax; therefore, do not include these taxes in the proposal. e. Vendor must provide a hard copy of the current published basis for their quotation, showing the Average Wholesale Price and all current up -dates. Successful Firms must be able to provide the aforementioned documentation at the time of bid to the Brazos County Purchasing Department at no additional cost to the County. (Successful firms must be capable of supplying above criteria for auditing purposes anytime during the contract term.) f. Describe any refunds and rebate/incentive programs you will provide to Brazos County in conjunction with the type of packaging that your company is proposing, such as an annual rebate based on purchase volume, refunds for returns unused medications, etc. Describe any prompt payment discounts or quantity discounts you offer, including the percent of discount and terms. 42. Exceptions a. Any and all exceptions shall be listed in a detailed fashion. Any exceptions could impact the evaluation of the proposal. N. REFERENCES Respondents shall provide a list of at least five (5) references, where work comparable in quality and scope to that specified has been performed within the past five (5) years. This list should include the names, phone number and email of the company/entity for which the prior work was performed to contact these references. References received on previous solicitations for similar size and scope in the previous six (6) months may be considered in lieu of obtaining a new reference check. A negative reference may be grounds for disqualification of bid. Respondents are not allowed to use Brazos County as a reference. Company/Entity: Anoka County Jail Contact: Carrie Wood/Lieutenant, Health Services Phone: (763) 323-6169 Email: Carrie.Wood@co.anoka.mn.us W. n'NQ MR 3 22 ( Page Val. 4 pg. 23 Company/Entity: CFG Health Systems, LLC (6 New Jersey correctional facilities) Contact: Denise Rahaman/Director of Corrections Phone- (856) 419-7177 Email: drahaman@cfgpe-com Company/Entity: Fairfax County Adult Detention Center Contact: Laura Yager/Health Services Adminstrator Phone: (703) 246-2680 Email: laura.yager@fairfaxcounty.gov '5 E IT lf- 7 �-M Company/Entity: Livingston Parish Detention Center Contact: Courtney Chaney/Health Services Administrator Phone: (240) 773-9830 Email: crhaney@lpgov,com Company/Entity: Somerset County Jail Contact: Frank Apisa/Director of Corrections Phone: (908) 231-7150 Email: Apisa@r-o.somerset.nj.us 23 1 Page ,Vd. 394 pg. 12 4 -- O. V.T.C.A. LOCAL GOVERNMENT CODE -4262.0276 This Section must be completed. Failure to complete this section will disqualify the bid. Brazos County shall refuse to enter into a contract or other transaction with a person who owes a debt to the County per V.T.C.A Local Government Code 4262.0276. a. This refusal to award a contract to or enter into a transaction with a person, pertains to an apparent low bidder or successful proposer that is indebted to the County; b. "Person" includes an individual, sole proprietorship, corporation, nonprofit corporation, partnership, joint venture, limited liability company, and any other entity that proposes or otherwise seeks to enter into a contract or other transaction with the County requiring approval by the Commissioner's Court; c. "Debt shall include delinquent taxes, fines, fees, or delinquencies arising from written agreements with the County. d. Prior to award of a contract by the Commissioners' Court, the Purchasing Department will request a statement of account from the Brazos County Tax Office. . e. Any "debt" as defined above, that is reflected on the statement of account, will be documented and placed in the bid file. The bid or proposal from the person with the debt shall be considered "non -responsive" and "not responsible", eliminating it from any further consideration of award. ' f. These provisions shall apply to any "person" owned, partially owned, managed, operated or represented by a "person" indebted to the County. Please list all the names of the individuals that have ownership, officers, managers, and board of directors that you have associated with your entity below. Name Title (Owner, Officer, Director, Manager, Etc.) Wayne J. Shafer Chief Executive Officer Jean A. Shafer Executive Vice President --- 24 1 Page i dol. �3 9Egg. 12 5 P. PROPOSAL EVALUATION WAIVER By submitting a proposal or response, each Proposer/offeror indicated below agrees to waive any claim it has or may have against Brazos County (the Owner), Architect, Engineers, Consultants and their respective Commissioners, directors, employees, or agents arising out of or in connection with (1) the administration, evaluation, or recommendation of any proposal or response (2) any requirement under the Request for Qualification or related documents; (3) the rejection of any proposal or response or any part of any proposal or response; and/or (4) the award of a Contract, if any. The Proposer further agrees the Owner reserves the right to waive any requirements under the proposal documents or the Contract Documents, with regards to acceptance or rejection of any proposals, and recommendation or award of the contract. Note: The Statement of Affirmation Must be Notarized. STATEMENT OF AFFIRMATION "The undersigned affirms that he/she is duly authorized to execute this waiver by the person(s) or business entity making the proposal. Finn's Name: Contract Pharmacy Services, Inc. Address: 125 Titus Avenue, Warrington, Pennsylvania 18976 Proposer's Name: Heather Hutchinson Position/Title: Chief Operating Officer Proposer's Signature: Date: February 28, 2023 Subscribed and sworn to me on this / - day of 9L�94n the year 0,23 Notary Fttblic `- My Commission expires '10" /(o aJ- 3Member. ealth of Pennsylvania - Notary Seal stine TarzianBucks , NotaryPublic unty commission expires June 16, 2026 misslon number 1420079 ennsylvania Association. of Notaries 25 Page - Vol. P9• :LJ Q. ADDENDA The -undersigned acknowledges receipt of the following addenda issued during the time of Bidding and includes the several changes therein in this Proposal. No. ` No. No. Date a Laa/JQ0CL3 Date "Date R. CERTIFICATION OF PROPOSAL The undersigned affirms that they are duly authorized to execute this contract, that this bid has not been prepared in collusion with any other Contractor, and that the contents of this bid have not been communicated to any other Contractor prior to the official opening. Signed By: Title: Chief Operating Officer 4 /,. V Typed Name: Heather Hutchinson Company Name: Contract Pharmacy Services, Inc. Mailing Address:125 Titus Avenue Warrington Pennsylvania 18976 P.O. Box or Street City State Zip Employer Identification Number: 23-2013561 CORPORATE SEAL IF SUBMITTED BY A CORPORATION END OF RFP NO.23-099 By signing below, Brazos County agrees that this RFP 23-099 will be awarded to the vendor whose name appears above and both parties agree to the terms and conditions contained herein. By: Brazos County Commissioner's Court Date: P Rs-L- i of o as Attest: Brazos County Clerk 26 Page Vol. 394 pg. 12 d. S. LEGISLATIVE CERTIFICATIONS Brazos County is federally mandated to adhere to the directions provided in the President's Executive Order (EO) 13224, Executive Order on Terrorist Financing — Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism, effective 9/24/2001 and any subsequent changes made to it via cross-referencing respondents/vendors with the Federal General Services Administration's Excluded Parties List System (EPLS, https://www.sam.gov), which is inclusive of the United States Treasury's Office of Foreign Assets Control (OFAC) Specially Designated National (SDN) list. Respondent certifies that the responding entity and its principals are eligible to participate in this transaction and have not been subjected to suspension, debarment, or similar ineligibility determined by any federal, state or local governmental entity and that Respondent is in compliance with the State of Texas statutes and rules relating to procurement and that Respondent is not Iisted on the federal government's terrorism watch list as described in Executive Order 13224. Entities ineligible for federal procurement are listed at https://www.sam.gov.The undersigned affirms the non -debarment statement above, that they are duly authorized execute this contract. The company representative below further affirms, that the company submitting this proposal, under the provisions of Subtitle F, Title 10, Government Code Chapter 2271: .1. Does not boycott Israel currently; and 2. Will not boycott Israel during the term of the contract. Pursuant to Section 2270.001, and 2274.002 Texas Government Code: 1. "Boycott Israel" means refusing to deal with, terminating business activities with, or otherwise taking any action that is intended to penalize, inflict economic harm on, or limit commercial relations specifically with Israel, or with a person or entity doing business in Israel or in an Israeli -controlled territory, but does not include an action made or ordinary business purposes; and 2. "Company" means a for -profit sole proprietorship, organization, association, corporation, partnership, joint venture, limited partnership, limited liability partnership, or any limited liability company, including a wholly owned subsidiary, majority -owned subsidiary, parent company or affiliate of those entities or business associations that exist to make a profit. 3. If Respondent is required to make a verification pursuant to Section 2274.002 of the Texas Government Code, Respondent verifies that Respondent does not boycott energy companies and will not boycott energy companies during the term of the Contract. If Respondent does not make that verification, Respondent must so indicate in its Response and state why the certification is not required. .4. If Respondent is required to make a verification pursuant to Section 2274.002 of the Texas Government Code, Respondent verifies that it (1) does not have a practice, policy, guidance, or directive that discriminates against a firearm entity or firearm trade association and (2) will not discriminate during the term of the contract against a firearm entity or firearm trade association. If Respondent does not make that verification, Respondent must so indicate in its Response and state why the verification is not required. Company Name: Contract Pharmacy Services, Inc. Authorized Company Representative: Heather Hutchinson Address: 125 Titus Avenue Date: February 28, 2023 Contract #: RFP #23-099 27 j Page Vol. 3 9 4 Pg. E128 The following items should be completed and included in your bid submission. Failure to include these items will disqualify your bid. ' 12 References (Section P) 52 V.T.C.A. Local Government Code §262.0276 for Tax Verification (Section Q) ® Statement of Affirmation (Section R) 52 All Addendums (if applicable) 2 Certification of Proposal (Section T) 52 Legislative Certifications (Section U) 2 Exhibit A — Fees Form 28 1 Page vol. 394 pg. 12 9 Brazos County Purchasing Department 200 S. TX. AVE., STE 352 -BRYAN, TX 77803 PHONE (979) 361-4292 FAX (979) 361-4293 Addendum #1 to 23-099 Pharmaceuticals Issued: February 22, 2023 Change: Adding Requested Information Reason: Requested by Vendor Please see the attached backup material, Invoices, Preferred Medication List (Formulary), and Amounts/Number of Inmate on Medications for 2022 for our Juvenile Detention Center and our Adult Detention Center. This addendum should be signed by an authorized representative of the respondent and returned with the bid documents as specified in the bid. Acknowledgement of Mdu Signature: Printed Name•. SAD. Steres Vol. 3 9 4 pg. 3 0 ■ COMPANY PROFILE, Contract Pharmacy SERVICES Pharmaceuticals 01. 394 pg ! 3 1 -. Pharmaceuticals COMPANY PROFILE Name: Contract Pharmacy Services, Inc. Main office address:125 Titus Avenue Warrington, Pennsylvania 18976 Phone number: (800) 555-8062 Fax number. (800) 453-3938 Date of incorporation: November,1976 (privately held) State of incorporation: Pennsylvania Federal tax ID number: 23-2013561 Contact name/number: Scott D. Steres Director of Sales and Marketing (847) 395-2787 `;mail address: SSteres@contractpharmacy.com Ownership: Wayne J. Shafer, RPh Chief Executive Officer Jean A. Shafer Executive Vice President List of licenses: ■ :�:o IlIlIC=l Emma Contract Pharmacy SERVICES DRUG ENFORCEMENT ADMINISTRATION Registration Number. BC8199778 Expiration Date: August 31, 2023 (renewable bi-annually) TEXAS BOARD OF PHARMACY LICENSE License Number: 21057 Expiration Date: July 31, 2023 (renewable bi-annually) TEXAS DEPARTMENT OF STATE HEALTH SERVICES WHOLESALER LICENSE License Number 1000400 Expiration Date: March 15, 2024 (renewable bi-annually) Vol. Contract Pharmacy�'� SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 4 ■J ■ PROJECT OBJECTIVES I Contract Pharmacy SERVICES Pharmaceuticals 0s. 3 9 4 Pg.-- Pharmaceuticals - PROJECT OBJECTIVES Given our vast knowledge and experience in the correctional pharmacy marketplace, Contract Pharmacy Services (CPS) is most capable to service the Brazos County Detention Center and Juvenile Justice Center in the next contract period. Highlights of CPS' proposal response include: ■ Providing pharmacy services, meeting patients' needs and in accordance with all Federal, State, and Local legal requirements. ■ Meet or exceed applicable standards of the State of Texas, American Correctional Association (ACA), and National Commission of Correctional Health Care (NCCHC) for jails and prisons. ■ Maintaining and further reduce overall pharmacy costs through strict adherence to restricted drug formulary. ■ Continuation of bi-directional interface to CorrecTek Electronic Medical Records system (CPS in only vendor to have completed such interface with CorrecTek). ■ Detailed and sophisticated reporting, including ability to review data using a variety of variables. This would include analysis of medication cost and utilization data, quantifying medications ordered, processed, delivered, and disposed. ---i*ough this response, CPS will demonstrate its ability to continue and further enhance the above goals, if fortunate to be selected as the continuing vendor for the Brazos County Detention Center and Juvenile Justice Center. 13 Vol. Pg. Contract Pharmacy SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 5 ■ SCOPE OF WORK/ REQUIREMENTS Contract Pharmacy SERVICES Pharmaceuticals Vol. 3 9 4 pg•-�-- Pharmaceuticals SCOPE OF WORIUREQUIREMENTS -- 6censure Contract Pharmacy Services specializes in correctional pharmacy services, providing prescription drugs and other medications to inmates. CPS is a Pennsylvania licensed pharmacy, maintaining all professional licenses necessary to provide pharmaceuticals in the state of Texas. All services provided by Contract Pharmacy Services are in accordance with standards prescribed by the National Commission of Correctional Health Care (NCCHC), the American Correctional Association (ACA), the State of Texas, and Federal licensing agencies. A copy of the pharmacy`s DEA license, our Texas Board of Pharmacy license, Texas Department of State Health Services Wholesaler license, Pennsylvania Business License, Certificate of Registration, as well as our Certificate of Licensure as a Wholesaler/Distributor, both through the Pennsylvania Department of Health, have all been included on the following pages. Additionally, Coupler Enterprises, Inc. an owned subsidiary of Contract Pharmacy Services, is a Pennsylvania licensed wholesaler, as well as an FDA approved repackager. A copy of appropriate licensure for Coupler Enterprises dba Contract Pharmacy Services -PA is also included on the following pages. The FDA does not provide a paper copy of this registration; however, a screen shot of their website below details our registration in good standing. New Surd Seared Restdts for Coupler Erdetpd$0 Fsrrl CcWuEc1wpdses1ar- 3003r34440 Contract Pharmacy SERVICES Drug Establishments Current Registration Site 4 Snare j r heY_! )n Linlam � � 6nau ? i� Print i 4454297Tr REPACK 12�faslonRoaESultet019,HaShaOLPettnsylraNaDPA)19N4-14KUnikdStates(USA) vol. 3 Pg. 13 Ge Fi ter. 1213irm RFP #23-09911 Page 6 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE CONTROLLED SUBSTANCE REGISTRATION CERTIFICATE UNITED STATES DEPARTMENT OFJUSTICE DRUG ENFORCEMENTADMINISTRA-PON . WASHINGTON D.C.21437 OEARECtSTRpTIdTI ImsMOIWRAT3tar; ,. ' NUMBER FEE PAZ B0$1997M ` ::08PM 2023 $731 SCHEn4LE9 BIRINESSnC1Nr7y IS51.'E JaATE Z2N, R AIL PHARMACY 07-18-2020 3,3N,45, .. _. g-' CONTRAM.• r, • CY 90h VICES 125 TITUS;AVE ' - serlioRs 394 and 1{3R3 (zt u5C 024 and 958) of the " WARRINGTON.'-pA 18971z-2424 ' - Contnvlied Substanxs Act of 1970, as amended, provide that tho Attomey General may make or .} suspend B regis4•abon to manufacture, dfsinbute. dispense, Impart orexport a eontrakd substance. - THIS CERTIFICATE IS NOT1TF.i NSFERABLE•ON CHANGE OF OWNERSHIP, CONTROL_, LOCATION, OR BUSINESS ACTIVITY, AND IT IS NOT VALID AF`rER'YHE EXPIRi4TI0N DATE. Vol. 3 9 4 P9 1- - This certifies that the pharmacy named below is hereby licensed to operate as a Class E pharmacy. License-No.21057 Expiration Date.,?13112a23 Balances: Q CONTRACT PHARMACY SERVICES 125 TITUS AVE. WARRINGTON PA 18978 Allison Vordenbaumen Benz, Ah, M.S. Executive tDirectorlSecretary MUST BE DISPLAYED IN PULL PUBLIC VIEW q .L Vol. 3 9 4 Pg. 38 Com" mo'n3kfq"Ath bf -'Pe. I w-2 Pe 2 2 0 2 1 OtM.: "nsy v AFIA AA I D 6 p b m AM Uri uol� iiiisl6wanaoa6u I .. 110 BOX'S 94WAtibum-PA- -264 Pharmacx 'Cu 'A Es 06MIMAr,�?,ft,&M MA S R ,ICES 411,81,19ceod" Date %00403 I3WXjk--i4 IRKIRTRICK 126 TUTUS AVENUE WARRINGTq,Nj ?A.,IPP,6 W V. %P at CA eUdOnse-Numborber PP41213 iv y era 1,s IF-W in.. yio;;, %0- 'P. IV. s nifore Adflig-iComMui 99oft 394 9 Vol. Pg. CONTROL I SUBSTANCE RlEGISMT30M CERTMICALTE UNITED STATES DEPARTMENT OF JUSME, DRUG ENFORCEMENT AWAINISTAATibN WASHINGTON D.C. 20537 DFA Rmww=4 FCC NUMBEA FOJD RC03917m Supm 'PACT -- i KN: 3,3N.4. MANUFACTURER '07+QK022 coupLaRkoishmma IND. Sections 304 and 10DO (21 USO 824 and 955) of IM C0NTRACf-,#AA9k%CY SMJWR�PA-' Controlled SubgWAM Act of 1970, as amended, 1250 EASTOIN Rcitim i ai ti Provide st Cho Altumay Oncral may Mwoku or HORSM4. PAISW-!4fq - cmen$ a fasistmuse Do Wumdum, dwOL40, dispense, impmt or expri a wntmllBd afttamm. THIS CERTIFICATE IS NOTTPAWFERASMON CNANGAOFOYMRSHP, CONTROL, LOCAMMORGUSUGSBACTN", AND IT IS NOT VALID AFTER THE EXPIRATION DATE. Vol. -3-941 pg. 1 0 .1d 6 '10A ► TEXAS -D.EPARTkNlVNT PF,Sl'.ATE SERVICES l'."C.QlPEkk ENTERMISES"INC,''.. ; , , ',!2' .t I 50-EAST6XRD-STE --P I• F., Pursuant to fiedth and Safety Co Oi;pfer Draj, - Device, and &s*dc:Ai'tj and 27de 25 of the Texas Mmlolsfralive qo' llcefQa -shall be subject to sill appUcakle rules de by Code, and in relianize pn regulations and orders of the rexast Dqparftchl-;of; Slati% Heal#;, 46-9'W0lv.,'QP hereafter in effect The above licensee is authorized to engage in the following actwfies. OUT OF STATE` WHOLESALE D'1'StR'EBU`TOR-0F PRESCRIPTION DRUGS License 0 L000400 Expim: Marsh 15, 2024 CommissloatT i Cerrtifieate of Registration Certificate No. 1000002663 (A certificate starting with a number 4, 5 or 6 does hot permit the posession or sale of controlled substances or prescription drugs.) Category: Manvfaatusas (Psoaoript:ion) I• COUPLER ENTERPRISES, INC. .OTHER DHAr CONTRACT PHARMACY SERVICES —PA 1250 EASTON RD SUITE 101 HORSHAM, PA 19044 Drug & Device Registration 555 WALNUT ST-FORUM PLACE SUITE 701 • HARRISBURG, PA 17101 (717)787-4779 The above business is registered in the required category to conduct and maintain a facility -in accordance with the provisions of the Controlled Substance, Drug, Device and Cosmetic Act #64, approved September 9, 1972. Issuance Date: October 03, 2000 Expiration Date: The Last Day of October, 2023 pennsylvania' 'ate' - . J DEPARiMENTOFHEALiH Susan Coble Keara Klinepeter Deputy Secretary for Quality Assurance Acting Secretary of Health "--' NOTE: THIS CERT,FICATE MUST BE POSTED,IN•A:CONSPICUOUS PLACE.ON T. W PREMISES. Vol. 3 9 4 pg. IN i IBM °Certificate of Licensure Certificate No. 8000000826 (A certificate starting with a number 4, 5 or 6 does not permit the posession or sale of controlled substances or prescription drugs.) Category: wholesaler/Distributor COUPLER ENTERPRISES, INC. -OTHER•DBR: CONTRACT PHARMACY SERVICES -PA. 1250 EASTON RD SUITE 101 HORSHAM, PA 19044 Drug & Device Registration 555 WALNUT Sf-FORUM PLACE SUITE 701 HARRISBURG, PA 17101 (717) 797-4779 �. The above business is -registered in the required category to conduct and maintain a facility in accordance with the provisions of the Glholesale Prescription Drug License Act, Act #145, approved December 14, 1992. Issuance Date: October 03, 2000 Expiration Date: ThO. Last Day of October, 2023 pennayivanaj12�'?- ,! i • � la>�+ARt'MF�TOP HF.EtI.'i'H I Susan Coble -•Keara Klinepeter !j .]Deputy Secretary for Quality Assurance Acting Secretary of Health NOTE: THIS CEInMCATE MUST BE POSTED IN.A CONSPICUOUS PLACE ON THE PREMISES. Pharmaceuticals _ rivery '-V ` elivery to the Brazos County Detention Center and Juvenile Justice Center is provided once per day Monday through Saturday and as needed from the local backup pharmacy. Orders transmitted to the pharmacy by 4:00 PM Eastern Standard Time (EST) Monday -Friday will be delivered within 24 hours on the next business day. Cut-off time on a Saturday order, for Monday arrival, is 11:00 AM EST. Routine deliveries of pharmaceuticals are made via United Parcel Service (UPS) as our primary carrier. Contract Pharmacy Services also maintains a contract with FedEx as a backup delivery service. CPS provides emergency routine delivery, phone consultation 24 hours a day, and a pharmacist is on call with a pager 24 hours a day. In an emergency delivery situation or in situations after hours, a contracted agreement with a local pharmacy to provide emergency service is maintained. It has been the experience of CPS that such after hours situations are quite rare if proper ordering of stock medications through CPS is maintained. Delivery of emergency medications to the Brazos County Detention Center and Juvenile Justice Center is available on weekends, holidays, or after hours through a subcontracted agreement with a local pharmacy to provide additional back-up services. CPS, in addition to regular deliveries, is able to deliver or make arrangements for reliable delivery of emergency medications 24-hours a day, 7-days a week. CPS maintains existing contracts with backup pharmacy chains, such as CVS, Rite Aid, and Walgreens, as well as several other national and regional chains. CPS will also contact a local pharmacy of the facility's choosing, if preferred, to provide this back-up service. Consideration of distance to the facility and after hours �'tvailability is considered when selecting the appropriate backup pharmacy. Whenever possible, CPS -_'ttempts to have at least two pharmacies available as a backup for each correctional facility. Delivery and discrepancy logs accompany every order shipped. In every box of medications that we ship, CPS includes a delivery log that details all medications that are included in the box. The list is printed in alphabetical order, by inmate name, to facilitate the checking in of the medications received by the nursing staff. Additional information on the log details prescription number and quantity of medication. The delivery log is used to verify the medications ordered against what has been sent. The sheet has a signature line at the bottom so that the nurse who checks in the order can verify the receipt of the medications. Discrepancy logs detail anything out of the ordinary (i.e. changed order, refill too soon, etc.) about a particular order. In addition, in the unlikely event that a medication is backordered and out of stock, this information would be noted here. Samples of the delivery and discrepancy logs appear on the following pages. Names have been changed or blackened out for patient privacy and security. 4' LO: 9 4 Pg. ------ Contract Pharmacy RFP #23-099, Page 7 SERVICES '°�` CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals DELIVERY LOG — _ __DELIVE_RY LOG �+ _^ --- CPS CONTRACT PHARMACY SAMPLE COUNTY 125 TITUS AVENUE Sample County #123 123 Main Street WARRINGTON, PA 18976 Anywhere USA RX # PERSON NAME DRUG NAME DOCTOR NAME QTY INIT SIGNED 3835174 DOE, JOHN CLONI DINE (PP60) 0.1MG TABS SMITH, JOHN 60.00EA TB NUMBER:249516 BOOKING:249516 LOCATION:02 ENALAPRIL (PP30) 1OMG TABS SMITH, JOHN 30.00EA CMP NUMBER: 265038 BOOKING:255038 LOCATION: L5 RANITIDINE (PP60) 150MG TABS SMITH, JOHN 60.00EA CMP NUMBER: 740821 ' BOOKING: 740821 LOCATION: M1 GEODON 40MG CAPS SMITH, JOHN 15.00EA TB NUMBER: 800526 BOOKING: 800526 LOCATION: B2 CIPROFLOXACIN 500MG TAB SMITH, JOHN 20.00EA CMP NUMBER, 803400 BOOKING:.803400 LOCATION:17 PROPDXY-N/APAP 100-650 TAB SMITH, JOHN 42.00EA CMP NUMBER:803400 BOOKING:803400 LOCATION:17 NAPROXEN 550MG TAB SMITH, JOHN 30.00EA CMP NUMBER: 272795 BOOKING: 272795 LOCATION: D5 GLEEVEC 100MG TAB SMITH, JOHN 30.00EA TB NUMBER: 785197 BOOKING: 785197 LOCATION: A5 AMITRIPTYLINE (PP30) 100MG TA SMITH, JOHN 30.00EA CMP NUMBER:86361 BOOKING:86361 LOCATION: RISPERDAL "M-TAB 2MG TAB SMITH, JOHN 28.00EA CMP NUMBER: 783743 BOOKING: 783743 LOCATION: 83 HCTZ (PP30) 25MG TABS SMITH, JOHN 30.00EA CMP NUMBER: 802692 BOOKING: 802692 LOCATION: L2 ENALAPRIL (PP30) 5MG TABS SMITH, JOHN 30.00EA CMP NUMBER: 781628 BOOKING: 781628 LOCATION: L4 PAROXETINE 40MG TAB JONES, JANE 15.00EA CMP NUMBER: 239199 BOOKING: 239199 LOCATION: L4 KLOR-CON 10MEQ TAB SMITH, JOHN 52.00EA TB NUMBER: 64774 BOOKING: 64774 LOCATION: B3 ENALAPRIL (PP30) 5MG TABS SMITH, JOHN 30.00EA CMP NUMBER: 803675 BOOKING: 803675 LOCATION: 82 NAPROXEN 550MG TAB SMITH, JOHN 30.00EA CMP NUMBER: 755676 BOOKING: 755676 LOCATION: C4 CLONIDINE (PP30) 0.2MG TABS SMITH, JOHN 30.00EA CMP NUMBER:802662 BOOKING:802662 LOCATION:03 TOPAMAX 25MG TAB SMITH, JOHN 60AOEA TB NUMBER:21870 BOOKING:21870 LOCATION:05 3 Pg. 145. Vol. Contract Pharmacy, L RFP #23-099, Page 8 SERVICES �alliii CONFIDENTIAL AND PROPRIETARY — DO NOT DISTRIBUTE Pharmaceuticals DISCREPANCY LOG DISCREPANCY LOG^� SAMPLE COUNTY LOCATION: Al EXPIRED PRESCRIPTIONS, NEW PRESCRIPTIONS STARTED 741219 DOE, JOHN RX 3875792 stopped on 711912005 GENTAMICIN (30GM) 0.1 % CRM RX 3903028 stopped on 7/1912005 NAPROXEN 550 MG PROFILED ONLY FERROUS SULFATE 325MG TABS POTASSIUM CHLOR 10 MEQ TAB DISCREPANCY LOG SAMPLE COUNTY LOCATION: B2 PROFILED ONLY ALBUTEROL (17GM) INH kl ALBUTEROL (17GM) INH DISCREPANCY LOG i SAMPLE COUNTY I LOCATION: B3 PROFILED ONLY PRENATAL VITAMINS TABS REFILL TOO SOON RX 3875917, Reorder After 07/24/2005 POTASSIUM CHLOR (PP310MEQ TAB RX 3893153, Reorder After 07/26/2005 RANITIDINE (PP60)150MG TABS EXPIRED PRESCRIPTIONS, NEED NEW ORDER RX 3792934 Expired AMITRIPTYLINE 25 MG TABS Contract Pharmacy n�lill SERVICES C: Sent new Rx 3915686 on 7/20/2005 Sent new Rx 3915729 on 7/20/2005 394,14 RFP #23-099, Page 9 CONFIDENTIAL AND PROPRIETARY —DO NOT DISTRIBUTE Pharmaceuticals Emergency Pharmacv y Delivery of emergency medications to the Brazos County Detention Center and Juvenile Justice Center is available on weekends, holidays, or after hours through a subcontracted agreement with a local pharmacy to provide additional back-up services. Service 24 hours a day, seven days a week, is accomplished through an established relationship with a local pharmacy that provides delivery of urgent and emergency orders within two (2) hours of receipt of an order. CPS maintains existing contracts with backup pharmacy chains, such as CVS, Rite Aid, and Walgreens, as well as several other national and regional chains. CPS will also contact a local pharmacy of the facility's choosing, if preferred, to provide this back-up service. Consideration of distance to the facility and after hours availability is considered when selecting the appropriate backup pharmacy. Whenever possible, CPS attempts to have at least two pharmacies available as a backup for each correctional facility. Emergency Drug Kits CPS will provide an emergency drug kit to the Brazos County Detention Center and Juvenile Justice Center, as established by the Healthcare Administrator, Director of Nursing, Medical Director, and the consulting pharmacist. CPS will consult with the Healthcare Administrator, Director of Nursing, and Medical Director at the Brazos County Detention Center and Juvenile Justice Center to determine the contents of the boxes. When an emergency box is opened and a medication is removed, the medical department will notify CPS and a replacement item will be sent with the next delivery. uring quarterly visits, a pharmacist from CPS will check the contents of the boxes to assure all meds are in hie box and have good expiration dates. ` Vol. 394 Pg. 147 Contract Pharmacy P31h . SERVICES CONFIDENTIAL AND PROPRIETARY- DO NOT DISTRIBUTE RFP #23-099, Page 10 Pharmaceuticals credit CPS provides a system for return credit of unused or discontinued medications which remain in their original sealed blister cards. Medications maybe returned for full credit of the purchase price except where prohibited by Texas state law. Controlled substances cannot be returned for credit, but will be destroyed on site according to Texas state regulations, using an approved Reverse Distributor. Credit for full or partial blister cards will be issued based upon what the faciliW-paid fore medication. For example, if 30 doses of a drug are dispensed for a charge of $60.00, and 10 doses (one-third of the original quantity) are returned, then CPS will issue credit for $20.00 (one-third of the charge). Restocking fees are not applicable in this contract. CPS will arrange for the return of unused, discontinued, out -dated, excess, and unusable medications at no cost to Brazos County Detention Center and Juvenile Justice Center. A sample of the credit invoice is provided on the next page. I q48 E. 394 Pg. Contract Pharmacy SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 11 Pharmaceuticals RTN DATE RX NUM FILL DATE 9/28/2005 4529571 9/13/2005 4518402 9/8/2005 4482852 8/26/2005 4518461 9/8/2005 4534396 9/15/2005 4541140 9/19/2006 4530893 9/14/2005 4518407 9/8/2005 4529572 9/13/2005 4429310 9/19/2005 4494543 8/30/2005 4534401 9/15/2005 10/1/2005 4552970 9/22/2005 4562935 9/27/2005 4470128 8/22/2005 4562934 9/27/2005 4546468 9/20/2005 4541604 9/19/2005 4541526 9/19/2005 4552104 9/22/2005 4552104 9/26/2005 4466816 8/31/2005 10/5/2005 4541673 9/19/2005. 4521141 9/26/2005 4565190 9/28/2005 4541614 9/19/2005 4541514 9/19/2005 4565189 9/28/2005 10/13/2005 4559663 9/26/2005 4575256 10/11/2005 4523574 9/10/2005 4555971 9/23/2005 4575259 10/3/2005 4552287 9/22/2005 4552287 9/2812005 4552287 10/3/2005 4568750 9/29/2005 10/17/2005 4574072 10/1/2005 4561707 9/27/2005 4574074 10/1/2005 4578196 10/3/2005 4565603 10/6/2005 4574073 10/1/2005 4585602 10/6/2005 4534437 9/15/2005 4574078 10/1/2005 10/18/2005 4568733 10/11/2005 PATIENT CREDIT INVOICE CREDIT REPORT XYZ COUNTY JAIL 10/0112006-10/31/2005 DRUG QTY RTN COST AMITRIPTYLINE (PP30) 50MG TAB 30 27 4.87 DEPAKOTE (PP30) 500MG TAB 30 21 44.50 FLUOXETINE (PP30) 20MG CAPS 30 30 8.96 HCTZ 25MG TABS 15 15 0.36 LITHIUM (PP60) 300MG CAPS 60 56 2.71 MECLIZINE 25MG TABS 15 11 0.33 NIFEDIPINE 20MG CAPS 30 28 11.46 NORVASC 10MG TAB 30 19 37.53 RANITIDINE (PP60)150MG TABS 60 52 7.17 SENNA TAB 6 3 0.52 SEROQUEL 100MG TAB 15 3 8.58 SEROQUEL 200MG TABS 30 29 156.57 CIPROFLOXACIN 500MG TAB 20 19 30.45 CITALOPRAM HBR 40MG TAB 15 15 11.80 DEPAKOTE 250MG TAB 10 9 10.35 LAMICTAL 100MG TABS 30 30 101.48 PAROXETINE 40MG TAB 15 12 10.35 ZETIA 10MG TABS 30 23 54.38 ZOLOFT 100MG TAB 14 1 2.50 ZOLOFT 100MG TAB 30 30 75.12 ZOLOFT 100MG TAB 30 30 75.12 ZYPREXA 15MG TAB 15 3 42.95 CEPHALEXIN 500MG CAP 30 6 2.21 CLONIDINE 0.1MG TABS 30 18 1.12 DILTIAZEM SR 120MG CAP 7 6 2.02 NORVASC 5MG TAB 30 23 33.10 PAROXETINE 40MG TAB 15 12.5 10.78 TRUVADA 200MG/300MG TAB 7 6 144.09 BUPROPION HCL 100MG TABS 42 19 5.48 BUPROPRION (PP30) 75MG TABS 60 30 6.48 DEPAKOTE (PP30) 500MG TAB 30 25 52.98 PAROXETINE 40MG TAB 15 10.5 9.05 PAROXETINE 40MG TAB 15 15 12.93 SEROQUEL 200MG TABS 15 15 80.98 SEROQUEL 200MG TABS 15 7 37.79 SEROQUEL 200MG TABS 15 15 80.98 SEROQUEL 200MG TABS 15 14 75.59 COREG 6.25MG TABS 30 9 14.26 LEVAQUIN 500MG TAB 14 5 48.69 LIPITOR 80MG TAB 15 10 32.67 MIRTAZAPINE 30MG TAB 30 22 18.45 MIRTAZAPINE 45MG TAB 30 28 23.94 QUINAPRIL 40MG TAB 30 9 3.30 SEROQUEL 300MG TABS 30 28 198.21 STRATTERA 40MG CAP 30 29 88.75 ZETIA 10MG TABS 30 19 44.92 EFFEXOR XR 150MG CAP 15 15 48.14 1155 862 1,774.87 TOTAL= 1,774.87 " Contract PharmacyVol. 9 pg. 14 9 RFP #23-099, Page 12 SERVICES I'M, _ CONFIDENTIAL AND ARY - DO NOT DISTRIBUTE Pharmaceuticals Blister Card Packaging - PS will provide medications to the Brazos County Detention Center and Juvenile Justice Center in blister card packaging, compliant with all state and federal laws pertaining to such packaging. Each individual bubble of the blister card is labeled with a medication's name, strength, manufacturer, NDC number, lot, and expiration date. Exceptions will be made if the medication is not suitable for blister pack. Other dosage forms (liquids, creams, ointments, etc) will be dispensed in the manufacturer's original containers. If requested, CPS can provide liquid medications in unit -dose packaging. Parenteral (intravenous) drugs will be supplied in the manufacturers' packaging, to preserve sterility. An example of the thirty day blister pack is depicted below. A sample of an actual blister card has been included in the enclosure on the next page. THIRTY DAY BLISTER PACK (size not to scale) FILLED BY CK'D BY MED. RECEIVED SY STRENGTH START DATE LOT NO. REORDERED SY EXP.'DATE ORDER DATE MFG. R Contract Pharmacy SERVICES E 3S NFIR : IIgIPAR �INIFAR 51PAR Q o I Fjp: AJnB/1BAB I ' E>tpu: O3 E119� EspPy 01110119AB ' F.P Ordwig a S Pr173{59 , Lot:$234 Lof:Y e f lv 17:.tSti N o- �� AMCEN AMGEN _ w�aEn W _ nMeEr1 _, f S ' •j%IJIPAR TABN�SIPAR Tae `M151PAR TAB 3onnfGSIPAR raB h p t lo� C�31400 i rp:OpB0f,��yy19 UP:OBppana FtP.ORt�jg w 1 LPI: 173K0 LPL' 177A50 lel. 177ALG O e ��- _AMGEN AAIGEN AMGEN IfMr.F.N I SENSIPAR SENSIPAR SENSIPAR. SEN3IPAR 30MG TAB 30MG TAB 3'JMG TAB 30MG 1AB 26 E p�p'Oen0119 EaC; oeA0N9 ELD OTAe119 pp nimni1 LOI:1231cause Lot: 17u Let 1731GG !!tom T_ MGEN _ AK.GEN _ Zmari AMGFlI SENSIPAR SENSIPAR I SENSIPAR SENSIPAR I Up TAB MG rAe 'pMG TAB TA u Q ? L01: 125�8"D t02Bu11 10 Epp: OOn 19 C>tP G OGn0118 LbE: AM6EN i Lof: N 1" 17 fl ,k Qi9 I gFIPAR r 98$ PAR I SE�ISIFAR SS9MSIPAR �.2 1 � jAB EaaM: en6/1JAB .GO6nel10[AB r,�jp CN9TaB ,L�. La' 127 •, ELaPt: 12jW�EN LoP'12N .lm• 17N �O .......Y._..— 4.`� JFFSIPAR i JI�PAR I S N6IPAR SENSIPAR I TAB TAB 3 G TAB ZVG TAB - EEspp: O2W19 1pOar IVIO W1: 1219 F.P.' LW: /21 N 1 L°'A. EN g SEN5IPART 1 SIISPAR 6ENSIPAR SENSIPAR m 1 79NA Tao 3 G Tab 30M0 TAB 90MG rae 1 I Eap: OOn0/1a I BSpo: OBnOrIB Erp: W26119 Em' OAndI18 L°C Huse t LW= 12uss Lal: 127430 Lol uuu a A!.- 1, AMGEN aM 161 AtIiGEN ._. �.._. .� ..._� C tIPAR I S_I�QPARENSIPAR SENSIFAR TAB """`''CCO8�I7g8ff TAO 9pMpGp��ngg11 TaB 3IM13 y/ TAB Te�ie018 'a 17 8t9 LG.� 173e59i9 lal /i1ZGIP I �S9 AMGEN ` AM EN -TAMGEN aMGEN —*ITEMffi343-19 Contract Pharmacy Vol. 4 Pg�- --- SERVICES CONFIDENTIAL IND PRePRtETAVr_—_C0NOT DISTRIBUTE RFP 023-099, Page 13 Pharmaceuticals Solid Medications f All oral solid medications (tablets & capsules) will be dispensed in unit -dose blister cards. Controlled substances will be dispensed in blister cards, with a count sheet attached to facilitate documentation as medications are administered. All medications will be labeled according to state and federal guidelines, and will include at a minimum the following information: a) Patient's name b) Physician's name c) Name and strength of drug. (including generic name, where applicable) d) Drug form (tablet, capsule, etc.) e) Dosage and directions for administration f) Route of administration (oral, rectal, topical, etc.) g) Patient education material (take with food, may cause drowsiness, etc.) Liquid Medications If requested, liquid medications will be supplied in unit -dose containers. If the drug is not available from the manufacturer in unit -dose format, CPS will repackage the medication into unit dosage containers, using FDA approved packaging supplies and procedures. CPS has an agreement with a FDA registered repackaging company, Innovative Pharmacy Solutions, to obtain liquid medications repackaged by that firm. All unit -dose liquid medications will be properly labeled, with the following information provided on the label: a) Name of drug (trade name as well as generic name, where applicable) b) Strength of the drug dispensed c) Name of manufacturer or distributor d) Lot number e) Expiration date f) Amount of drug (volume) supplied in the container Vol. HER, � Contract Pharmacy SERVICES ° RFP #23-099, Page 14 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals _,Pharmaceutical Labeling PS provides a peel -off prescription label, used when reordering medications for the Brazos County ; Detention Center and Juvenile Justice Center. All prescriptions will be labeled according to state and federal guidelines, and will include at a minimum the following information: ■ Patient's name ■ Physician's name ■ Name and strength of drug (including generic name, where applicable) ■ Drug form (tablet, capsule, etc.) ■ Dosage and directions for administration ■ Route of administration (oral, rectal, topical, etc.) ■ Patient education material (take with food, may cause drowsiness, etc.) Below is a detailed example of the medication label used on all blister cards. Common components of the blister card label have been identified. CONTRACT PHARMACY SERVICES 125 TIT US AVE WARRINGTON. PA 1897B BENAZEPRIL HCL I OMG TAB RX 23798451-0 456743 BUNKER, ARCHIE 250 QTY 30 $ENP2EPMLHCL MC- TAB II IIII1IIIIIIIIIII1IIIIIIIIIIIIIIi1110 WELBY. MARCUS MWIMW O 43547033610 Number of blister cards Dolor name and data Removable bar code label for refills entry technician initials Contract Pharmacy pffill SERVICES 8007824696 SC-8199778 03/09/2019 Fill Date: 03108/2019 Stop Date: 09105120i 9 Patient name, facility number, location, and patient ID number Drug name, quantity, and brand drug name Dosage and directions National Drug [ode number, manufacturer, color, shape, and markings Start date, fill date, and stop date Prescription number 39 PP9. RFP #23-099, Page 15 CONFIDENTIAL AND PROPRIETARY —DO NOT DISTRIBUTE Pharmaceuticals Automed (Strip) Packaging -::PS current provides medications to the Brazos County Detention Center and Juvenile Justice Center in multi -dose "unit of use" Automed (strip) packaging, compliant with all state and federal laws pertaining to such packaging. Each "packet" contains all of the medications that the patient needs for a certain date and time. Packets are attached to each other in sequential order and form a strip. Examples of CPS' unit dose packaging have been provided in the enclosure on the next page. Exceptions will be made if the medication is not suitable for unit dose. Other dosage forms (liquids, creams, ointments, etc) will be dispensed in the manufacturer's original containers. if requested, CPS can provide liquid medications in unit -dose packaging. Parenteral (intravenous) drugs will be supplied in the manufacturers' packaging, to preserve sterility. In using Automed (strip) packaging, the credit policy as stated on page 10 would differ, as this applies to blister cards. Single -dose medications may be returned for full credit of the purchase price using the same credit methodology as blister cards, except where prohibited by Texas state law. However, credit of unused medication is not available for multi -dose Automed (strip) packaging. Controlled substances cannot be returned for credit, but will be destroyed on site according to Texas state regulations, using an approved Reverse Distributor. Vol. 3 9 4 Pg. Contract Pharmacy E68e SERVICES RFP #23-099, Page 16 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals Starter Stock ;PS will supply a variety of starter medication packages to be used in situations that require the immediate start of medication. In conjunction with the Medical Director, CPS will establish the items needed for stock medication. All starter/stock drugs will be packaged in 30-dose blister cards, with a sign out sheet attached to the back of the card. The sign out sheet, depicted on the next page, allows the nurse who is administering a dose of medication from the starter card to document easily the date, inmate name, quantity administered, and balance remaining in the card. This system allows for easy tracking of the doses administered from each card. Labeling is two-part and provides appropriate documentation for distribution by staff and replacement by the pharmacy. Inventory will be restocked as needed. Reordering of stock medications is completed using the order form depicted on the following page. STOCK DRUG RECORD -' �Iillli• ®�� -Iiliiililiiili -IIIIIIIIII1 -� ®iillil•� Y I. I Contract Pharmacy RFP #23-099, Page 17 SERVICES LIM, E, CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals STOCK MEDICATION ORDER FORM CONFIDENTIAL ����� ■ Page # of Contract Pharmacy I WE SERVICES 111.11 Phone 800.782.4696 Fax 800.664.5063 STOCK MEDICATION ORDER FORM Facility: Prepared By: Date Ordered: Medical Director/Prescriber Name: *must provide the name of ordering practitioner in order to process* DO NOT ORDER CONTROLLED SUBSTANCES ON THIS FORM t�r DRUG CITY of Cards (30 per card) y .%.::••.r Name/Strength/Form/Quantity or Items STOCK STOCK STOCK STOCK STOCK STOCK STOCK STOCK STOCK STOCK STOCK UU4 Pam. Contract Pharmacy Vol. g' RFP M-099, Page 18 SERVICES ■ CONFID AL AND PROPRIETARY —:DO NOT DISTRIBUTE Pharmaceuticals __.Controlled Medications Controlled medications will be dispensed in tamper -evident blister cards, with a count sheet attached to facilitate documentation as medications are administered. All prescription orders for controlled substances will be shipped to the facility with a count sheet attached, to facilitate the documentation of the administration of these drugs. An example of the controlled medication blister pack is depicted below. CONTROLLED MEDICATION BLISTER PACK (size not to scale) FILLED BY CHECKED BY MED. STRENGTH EXP. DATE MFG. LOT NO, O '�r Contract Pharmacy g 1s SERVICcS 7 18 23 s0 6 14 22 29 5 Is 21 28 4 12 20 27 3 19 99 ZB 2 10 18 25 1 9 17 24 M OD= 1 �o�. V v -a �� JL Contract Pharmacy Q„a I SERVICES 111W RFP #23-099, Page 19 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals In addition, all blister cards of controlled substances will be placed in a separate Tyvex bag within the ;`iipping box. Inside the bag of controlled substances is a separate count sheet which documents the number of cards, the name'of each patient, and the number and quantity of each card of controlled medication. This sheet will be used by nursing staff to check in and verify the number of prescriptions for controlled substances sent and received, to assure accuracy and accountability of these controlled substances. An example of the front and back of the Individual Narcotic Record is provided below: PROOF OF USE SHEET (POU)/IN DIVI DUAL NARCOTIC RECORD 21 a= r+ a Eo d n t+ isIl 7 � n i Et eI e a 1¢. iker 1Z7DIPIDIIAL NASZCOI[G Eed'COim Yvmny — R... — 6wiNA+�+tt _ tknTiufia +naq zw Gb Tna I t:01.;6ua4w MagtNtt.aa�. 1; I+u �G c e� � I t t I I I I t t 1 i 1 I F' 1 I t _ cmdttcmta+,: Oltpel"a D@aSIItON Or VN{LSSa DAIit: +"'>rf+AiTWlfa ME ME iC ttttt��ttt�tttt��� ems' �® It�Wf�� �,II�IIIC=�7 Vol.3 4 pg. �J Contract Pharmacy IN&SERVICES CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE RFP #23-099, Page 20 Pharmaceuticals Generic Medications `--PS will dispense generic drugs whenever they are available, unless the Medical Director specifically informs us to dispense a brand name drug. Only generic products manufactured by approved FDA manufacturers with a rating of "AB" or better will be dispensed at the Brazos County Detention Center and Juvenile Justice Center. 3994 Vol. Pg. Contract Pharmacy ps SERVICES RFP #23-099, Page 21 CONFIDENTIAL AND PROPRIETARY- DO NOT DISTRIBUTE Pharmaceuticals Unavailable Pharmaceuticals for any reason, a product is not available through normal ordering procedures, CPS will notify the nursing supervisor or designee in writing. Such occurrences of back ordered medications are extremely rare and may be due to shortages from the drug supplier to the pharmacy. All shortages will be corrected within 24 hours. Every attempt will be made to fill the medication order the day after the medication is not available. If necessary, CPS will make contact with the local emergency pharmacy provider to see if the item is available there. An example of the Back Order Form provided in such occurrences is provided below. BACK ORDER FORM a A3 BACK ORDER FORM Contract Pharmacy SERVICES RX# Patient name Quantity Sent The Site Date Quantity Due you requested is on order from our supplier and will be sent as soon as it is available, Thank you. Rph/Tech Quantity of Balance sent Date Rph/Tech This is the balance of the order sent above. Thank you for your cooperation, ' Vol. Pg $59 Contract Pharmacy . . SERVICES RFP #23-099, Page 22 CONFIDENTIAL AND PROPRIETARY — DO NOT DISTRIBUTE Pharmaceuticals Patient Profiles i contract Pharmacy Services will maintain computerized patient profiles. These profiles assist the pharmacy in monitoring all patient specific prescription orders and review prior to dispensing for appropriateness and accuracy. The profile includes the patient's medical history, as well as other information regarding the patient's drug utilization. In using the eCorrRxTM system, the medical staff of the facility will have the ability to view and print, onsite, a patient's medication history. A computerized patient profile is provided below: PATIENT MEDICATION PROFILES (screen shot - can be printed to report) - P krit•SEINiELD, JERRY pe a1123456! _ —ter scairg0 I129956 ,-- r D0E �Ostas 1.952 ' Lw,gJ.250-- TELEVISION JAIL-- •_ ., ..__s....:..,__.,....; 5 - I - I ' Patient HNtoty r1 ShowA11 22 (All Shown) qp 5t9 " Rc i States Last Fa ' Qty ' 0rag , r •r o r'_;C. Not•Ac6ve et Rels1able I1 i/26/07'. •10 RISPERDAL, 4NG, TAB - )= CNotAetivoatflefillable 103=07.I TINULALHALEATE(511L).0.5Z.DROP(TIMUPTIC5 15t&nDatoj§1cyDaXo ' DocWr i r 11/271W Ill/25/OB I WELBY, EtAACUS D3/17/07 -09/12/U7iWELBY,MAACUS . FaaHp ' Lacation ' Sig r a o ORI 250 jCBS 1/2 TAB (ZMG] 0 250 . !CBS �!INSTILL1/2TAB _ _ ^ •r C Not AeGre at Re131aWe-103/16/07 (� FUflOSEMIDE, 40MG, TAB (LASIXI! 103/17/07 IOU12107 iWELBY, MfflcuS J 250 _jCOS iTARE ONE (1) TAB .r 1CNot Active ofReWoUe. 103107M -I0.' IFUROSEMIDE,40MG,TAB PASIXI' '03/08/09 'IMM7110 'WELBY,MARCIIS 250 1- ;TA&EONE.(])TAB r-HotAetivo'orn,e0able j0310TM r -CNi at Activeatfle00ahle .11/4E/07 W •'-ITtMOLOLMALFATE(SNL],.D.5Z,DROP[[TTIMOPSICSEC] ' •C_ 1TIMOLOLMALEATE(6MLj,0.5x,DROP [TIMOPTICSCC) MOM` la3107/10 _.'WELBY,MARCUS 11/27/07 j111251118, jWELBY_MARCUS 2SU- j - INSTILL 112TAB iINSIFILL112TABC. 0 . FUROSEMtDE.4DMG; TAB 1AASIXI 130 - (FUROSEMIDE, 40MG, TAB I ABIX) _ - y4 1127107' 11/25/09 j_WELBY,MARCUS 11130)M 10MM281flS QUINLYAICHAAD•MD 250 ices TAKE ONE (1) TAB 250, — S AKE ONE 0) TAB ❑_Ic Not Active or RrZaWc 111129107 r - C NotActive ar Reltllable 111MIGS. r 1NelAtpe at ga112/S10' - 4 AD•M259 13002/OOUOIYRDC _ ZONE p) TABLET 0 it -jr- NotAc iva or ReWabla 11129/05 . IGO -1AANITID[NE,150MG„TAB IZANTAC 150MG.TABS) tt130l05.'- liFJ28/06 �Qu1NLY,AfCHAAD-MD 1250 -- 1-- TONE (IYTABLET 0 15 jTIMOL13LMALFATE15ML1 0.5X pAOP(TINOPTICSCC)_ 1111 iINLY,ASCHARD-MD 1250_ INS71LLS12TAS C IC. Not Active atIldillaWo 11MM j_ MRot Active orRe131ab1e 08/09IGS J30 FMROSEMIDE QO TABILASD I1BIt0/06 !0?JD5107 QUINLY,R[C11AfiD•}ID i250 1 I7AKEONE(I)TAR r 1GNatAetivaarAelNable 109189/06 •j5 ,TIMOLOLMALEATE[SNL),O.SZ,OAQPjTINOPTIC ECC] 100111010G._T102105107 IQUINCY,AtCffARD•MD 1950,1 INSTILL I/2TAB C. ]..•LNotActivcor90illoblo 1-IMS19S r 1CNotAeWaorAetdlable - a8/09160 15-1RISPEROAL,4MG,TA11- 15- (RISPEHOAL,4HG,TA9 L1/3U105_lO.rSM106 1QUINLY;RICHAAD-MD OBII'0/O6 {07%05Po7 IQUINCY,AtCHARD-MD 250 112TAB (2M6)O_ y250~ IT2TA13(2M6)DEL 0'--[AISPEADAL,4MG,TAB jt11J10/65 112/66/05 iJOHN,TIWPER-MD 1250 - JUNEQLTABLET0 •jJ,1CNolAetivoorRoPolable' O6I09/a5; 'r jr Not Active or nc1M Wo 106/09/05 ' _ 15 - {RISPERDAL, 4M6, TAB j0"'6"/''1'8'/'0"�5 W�}L0-6/f..0.�1g5 `1'1�2 QEDS J_0_HN. TRAPPER-1250,D_ 112 TAB (2MG) 0 G C,NctActiveorRef'dlabk ?O6/119/a5•-2_0 f (IOPROFLOXACtN,500MG,_TAB (CIPR_Oj�v4 j06I181D5- jJOHH,TRAPPER-MD _ 250- JUNEEl)TABLETO [_ C Not Active at MmaMe `U7/13/05 - 60 ;RANITIDINE.150MO. TAB FCAHTAC 1SUMB-TABS] 10S/10I05 12IW05 1JOHN. TFWPEH MD 112JMDS 1JOHN,TRAPPER•MD 250 � :ONE ill TABLET O 1250 1 dHSTILI:12TAB r 1CNotAc&oofRM31S1. 18C/M/l5 SDROP (TIMJ)PTICGC j r jr- Not Active or Rct0lablc i06A19/115 . _MMOLBLMALEATE(MLL0.5%. j30 ;FU IUSEKIDE, 4UM6. TAU (IASDO JOK2185 10311D185 712/0 115 'JOHN, TRAPPER•MD t - Vol. I'9• - J Contract PharmacEMIR SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 23 Pharmaceuticals ,._Drug Interactions - he pharmacy will process and update all orders, changes, and discontinues on a daily basis. Use of eCorrWm enables medical personnel to access a current patient pharmacy history, detailing all orders, changes, and discontinues, in real time. Prescriptions will be screened for: 1) Duplicates 2) Medication interactions 3) Excessive dosages 4) Appropriateness of medication 5) Medications refilled too soon b) Patient allergies 7) Medications ordered past stop date Contract Pharmacy Services will notify the Brazos County Detention Center and Juvenile Justice Center of any and all incidents of poly -pharmacy. CPS' sophisticated dispensing software system assists our staff in monitoring all orders for duplication, drug interactions, dosages, allergies, and timeliness of order (i.e. too soon or too late). If the event one of the above adverse actions occurs, a fax will be sent to the facility detailing the issue. In the event of a drug interaction, allergic contraindication, or incorrect dosing, a phone _call will be made to the facility. Additionally, discrepancy logs, sent with the next shipment, detail anything gut of the ordinary (i.e. changed order, refill too soon, etc.) about a particular order. An example of a screen shot, indicating a drug interaction warning is provided below. PATIENT DRUG -INTERACTIONS (screen shot — drug interactions report included with daily delivery) Medispan Screening Results DRUG INTERACTION 2 DRUG DISEASE 1 DRUG DISEASE 2 "WMIn9 l- gepa�t Odds _�- _ PaUcrzt -RxNolas IDRUG INTERACTION 1 ! RISPBRIDONE 1110 TAB Rx:NEW SCRIPT with FLUOXETINE, 20XG, CAP (PROZAC ) �Rx:9127785 (On 06/0912010) _ Onset: Rapid Severity: Major Documentation: Probable i j' MFOXETINE, ZORG, CAP (PROZAC I may increase plasma concentrations and pharmacologic effects of RISPERIDONE 1HG TAB. Additionally, concomitant jjjuae has resulted in reported cases of serotonin syndrome. Worsening of Jobsessive-compulsive disorder hem also been reported with combined use. ! VOI. R 4 Pg. 161 Contract Pharmacy �• RFP #23-099, Page 24; SERVICES CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE Pharmaceuticals Electronic Medical Records Interface CPS maintains a relationship with CorrecTek Electronic Medical Records and currently provides a two-way interface to the electronic medical records system currently in place at the Brazos County Detention Center and Juvenile Justice Center. Contract Pharmacy Services is the only national pharmaceutical vendor to have completed a bi-directional interface with CorrecTek, enabling the most complete exchange of information between the electronic medical records system and the pharmacy. The ability to interface CorrecTek, including orders, records, and medications, is at no additional cost to the Brazos County Detention Center and Juvenile Justice Center. Computerized Prescription Order Entry CPS will provide the Brazos County Detention Center and Juvenile Justice Center with our proprietary Computerized Physician Order Entry (CPOE) system, eCorrR)Jm. eCorrRx7 has been designed to eliminate the time spent by nursing staff to transcribe orders to pharmacy order sheets, Medication Administration Records (MARS), and other paperwork, thereby allowing more time for patient care. This system provides the medical team immediate access to patient pharmacy data and creates a more efficient process for the ordering of medications. eCorrRxTm eliminates the previous method of handwritten transcription of orders, which would then be faxed to the pharmacy. Eliminating transcription greatly increases accuracy and reduces the possibility of medication errors, either from incorrect transcription or Y illegible handwriting. eCorrRxTm allows for immediate access to patient data when a chart may not be available. It aids in containing drug costs, as Brazos County Detention Center and Juvenile Justice Center's customized formulary is loaded into the system. The system flags a prescriber when a non -preferred medication is ordered and provides for preferred alternatives, if available. Labels are printed onsite for application to the patient's MAR. Orders are automatically transmitted, via secure file transfer, to the pharmacy in "real-time". After all orders have been processed by CPS for the day, the system at the facility details the orders current disposition. This ensures that any changes in orders have been communicated back to the system, giving eCorrRxTm the most current patient drug information available. Reporting capabilities available within the system will aid in monitoring utilization, cost controls, and would enhance the jail's ability to monitor statistical reports for budget. All hardware and software necessary for the use of eCorrRxTm is provided as part of this contract. Additionally, CPS will provide a fax machine for the receipt of pharmaceutical orders, in the event online access is not available due to unforeseen reasons. Additional information regarding eCorrRxTm has been provided in the tabbed section of this proposal response titled "eCorrR)Jm". Barcode Scannef System As a module of the eCorrRxTm system, CPS will provide barcode scanners, used for the ordering (reordering) I prescriptions, maintaining inventory through accurate delivery check -in, and for processing turns/credits. All equipment necessary for the operation of the scanning module will be provided by CPS. Contract Pharmacy ,'�",�,� RFP #23-099, Page 25 S E R V I C ES' b ----- �'-- CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBLUE ®I 394 pg. 162 Pharmaceuticals __ IPAA Com ii� ante r ' --ems part of our standard business practices, Contract Pharmacy Services complies with all provisions of the Health Insurance Portability and Accountability Act of 1996 ("HIPAKI, Code of Federal regulations ("C.F.R.") at Title 45, Part 160 and Part 164, and, in particular, complying with the Standards for Privacy of Individually Identifiable Health Information, C.F.R. at Title 45, Parts 160 and 164 (the "Privacy Rule"), and the Standards for Security of Electronic Protected health Information, C.F.R. at Title 45, Parts 160 and 164 (the "Security Rule"). vol. Pg. 163 Contract Pharmacy SERVICES .P' RFP #23-099, Page 26 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals �Formulary Development Contract Pharmacy Services' pharmacist will meet with Brazos County Detention Center and Juvenile Justice Center medical staff to develop or refine a customized formulary. Our 35 years of experience in providing medications to correctional facilities provides us with a vast background in this field. We will provide sample formularies that have worked in jails and correctional facilities of similar size, and ask the medical team to evaluate it and make changes based upon local prescribing trends, and other criteria. After the medical team has reviewed the formulary and made alterations to customize it to meet the Brazos County Detention Center and Juvenile Justice Center's needs, we will print the final document and make it available to appropriate Brazos County Detention Center and Juvenile Justice Center personnel. CPS will monitor medication usage and make suggestions to the Brazos County Detention Center and Juvenile Justice Center regarding formulary changes that could reduce overall price. We include this information as part of our routine quarterly Pharmacy and Therapeutics Meeting with appropriate members of the medical team. During each quarterly Pharmacy and Therapeutics Meeting, our clinical pharmacists will review drug utilization, inform clients of new generic products and the potential cost savings associated, and provide details about new brand name drugs that may be applicable in the correctional healthcare setting. Many times, we revise the formulary after these meetings because lower cost generic drugs have made treatment more economical on drugs that were previously only available as expensive brand name products. Formulary development and the Pharmacy and Therapeutics Meeting mentioned in this section are at no �_ditional cost to the contract pricing proposed. Voi. 3 9 4 Pg. Contract Pharmacy„' SERVICES a' RFP #23-099, Page 27 a CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals Formulary Compliance/Non-Formulary Request —Sy —stem Contract Pharmacy Services will work with the Medical Director and Health Services Administrator of the facility to develop a non -formulary approval system that meets the requirements of the Brazos County Detention Center and Juvenile Justice Center. Our experience in the field of formulary enforcement will also be valuable in the implementation and compliance area. Over the years we have developed various protocols that can be implemented, based on how strict the Brazos County Detention Center and Juvenile Justice Center wants CPS to be in enforcing the formulary. Typically, ordering a non -formulary drug would require the approval of the Medical Director and the documents currently in place facilitate this process. At our recommendation, some clients have implemented a "three day policy" that authorizes CPS to send no more than a three day supply of any non -formulary drug. The prescribing physician must fill out a "Non - Formulary Authorization" form (example on next page) to be sent to the pharmacy with the order. We forward the form to the Medical Director for approval and send three days supply of the drug to the patient. After reviewing the form the Medical Director will authorize or deny approval and fax it back to CPS. If the order .is authorized, CPS will fill the balance of the order (minus the three day supply already sent) and send it to the facility. If the request is denied by the Medical Director, the refusal will be faxed back to the facility. Several clients have modified their process to allow certain non -formulary medications that have no other therapeutic alternative, to be filled by CPS without receiving prior authorization. These drugs would typically be for chronic conditions such as renal dialysis, HIV, and muscular dystrophy. PS will continue to convey to the Brazos County Detention Center and Juvenile Justice Center our experience in developing these non -formulary authorization processes, and assist in developing a system that will help to control the use of these medications. We will also work to develop a system that is not too burdensome on the medical team, keeping in mind that the system must be easy to use if it is going to be successful. CPS will be'as strict or lenient in enforcing the formulary as desired and we will assist you in analyzing the system periodically to see what alterations need to be made to make it easier to use. Vol. 3 9 4 Y pg. 6� Contract Pharmacy �e SERVICES :17sf CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 28 Pharmaceuticals NON -FORMULARY AUTHORIZATION FORM Contract Pharmacy SEli %IIrEs Contract Pharmacy Senvices 4P5TAw Ave Warmq m PA 1887® Fax 8CI1(IN.5=1 eW47aM78 CONMENTIAL REQUEST FOR UTIL WAMON OF NON -FORMULARY DRUGS Idanwr utwy dnap wE E 8E MM*Mmd a 4mnp6eted ark SIGNIM v= fa m ffaquestffirm Facility [dame and#. n9le: Inmate Name ]Do Last Fffid !musing iacatimp AlerWw grade name of Han -Fawn DM tetga tdW Str+�gt� Directions fornse Reasonformquest Lensm of anwStop date- Have Farmulwy at onaftm been bied? (Ustmedicat'ron and+dme) ft swing Dcdnr Print Name suamn MIMICAL DREDWR; Pzbd Neme 03E7 mgdred farcontraged mots APFa,ROVED YES NO Dab Explanation: cm Ordeft PhyAdum Medcal gmctar FlumpUft Heats Sennos Admintstraltor v®1. 3 9� Pg. f 6 Contract Pharmacy MEN 0 SERVICES RFP #23-099, Page 29 CONFIDENTIAL AND PROPRIETARY —DO NOT DISTRIBUTE Pharmaceuticals a facility usually keeps as starter stock is provided. If the Brazos County Detention Center and Juvenile Justice Center already has a list developed, CPS will fill from this list. CPS will need to know the quantities of starter stock to send. Stock is packaged in cards of 30 doses per card. Days 30-25 Facility is asked to provide a copy of all current Medication Administration Records (MARS). ■ Staff is reminded to have any specific inmate locations that they want printed on the MAR to be clearly printed on the MAR. In addition, inmate name must be clearly printed. ■ The stop date of the order should also be clearly printed near each order. CPS will only be filling orders for active maintenance orders. If something is taken from stock (i.e. over the counter medications) then CPS will only profile the order. If a medication is a "profile only", then please indicate that on the MAR. We won't fill and send medication for "profile only orders". ■ Previous orders that have been discontinued on the MAR should be marked as a "D/C" prior to copying. Oftentimes, facilities use yellow highlighter to denote a discontinued order and the highlighter does not photocopy. ■ If an order was DC'd and "yellowed out" on the MAR, remember to mark it as a "DC" prior to coning. Upon photocopying the yellow won't come up and we won't realize that the order was discontinued. ■ Once the MARs have been copied, the medical staff must duplicate fax. CPS needs all orders faxed/sent to the current pharmacy vendor also faxed to CPS Pharmacy. CPS wants to review the patient profiles so that we can keep the patient profiles updated and accurate until our start date. CPS requests that a cover sheet accompany all faxes to CPS, with the total number of pages contained in the fax clearly stated on the cover. Fax cover sheets will be part of the start-up materials that are shipped prior to the start date. After review of the detention's current pharmacy system, a CPS representative will determine if it will be necessary to send in patient specific medications for the first day of start up. This will depend on how your current pharmacy vendor dispenses medication (i.e. unit dose or Automed packaging or vials). 'if necessary, CPS will fill all active orders for oral tab/caps. On maintenance medications, CPS will send 30- 60 doses, depending on the frequency of dosing. We will dispense 30 doses on PRN orders. CPS will NOT fill and send any non -measurable medications. For instance, CPS will not fill and send any topical medication (creams/ointments), inhalers, eye/ear drops, etc. The staff should use up the medication that is remaining on the non -measurable items and request a refill when needed. Typically, OTC (over the counter) items are administered from stock bottles. Unless directed otherwise, CPS will NOT send any OTC items. If a maintenance order is for an OTC item. CPS will profile the order. Contract Pharmac n:3 Vol Pg.RFP #23-099, Page 50 SERVICES y C- CONFIDENTIAL AND PROPRIETARY --DO NOT DISTRIBUTE Pharmaceuticals MI-5 Materials (forms, in-service manuals, etc.) will arrive at the facilities one week prior to start date. Our CPS team leader will work with the designated jail staff person to coordinate the trainingrn-service schedule. In order to accommodate all medical shifts, CPS understands that it may require more than one training session. CPS recommends including all necessary medical personnel (nursing, clerical, practitioners and even correctional officers in some situations). CPS will be happy to perform additional training sessions to accommodate different shifts of the facility's personnel. Days 10-5 Medication cart(s) arrive at facilities approximately 1 week prior to start date. IMPLEMENTATION DAY When warranted, a CPS representative will be on site the day of transition to assist the medical staff on placing orders. The above implementation plan is a guideline. If there are areas that do not fit into the facilities' schedule, adjustments can certainly be made. Contract Pharmacy Services' goal is to do our best in making the transition as smooth as possible. 394 Vol. Pg. Contract Pharmacy SERVICES RFP #23-099, Page 51 CONFIDENTIAL AND PROPRIETARY- 00 NOT DISTRIBUTE l� ■ i EXPERIENCE 0 Contract Pharmacy SERVICES Pharmaceuticals Pharmaceuticals EXPERIENCE Contract Pharmacy Services, Inc. (CPS) has continuously provided pharmacy services to correctional facilities since 1988. CPS currently services over 125 facilities in 28 different states across the country, many comparable in size to the detention facilities of Brazos County. As the current provider of pharmaceutical services to the Brazos County Detention Center and Juvenile Justice Center over the last 19 years, CPS is especially familiar with the day-to-day operations at these facilities. CPS provides service to correctional facilities with a population as small as 50 and as large as 4500. Clients include county jails, juvenile detention centers, regional detention facilities and state prisons. Our programs and policies comply with National Commission on Correctional Health Care (NCCHC) and American Correctional Association (ACA) standards. CPS is a privately held corporation whose owners, Wayne & Jean Shafer, have been working in the pharmacy supply, service, and support business since 1972. Wayne Shafer began his career in pharmacy in 1972 as a community pharmacist starting with one location and expanded to three retail operations in the Philadelphia area. When the local county detention center was soliciting bids for pharmacy services in 1988, Wayne submitted a bid and began his foray into the corrections market. After being awarded that bid, he investigated providing service to the other surrounding community jails. When he was awarded additional contracts, he opened Contract Pharmacy Services as a closed -door shop to specialize in serving the correctional healthcare market. Over the last 35 years, CPS has gained experience not just in filling prescriptions, but in developing '�rategies that cut -costs and improve outcomes. We customize programs to fit each facility, realizing a 1,178 i ,;gad county detention center has different needs than a smaller juvenile facility of 80 beds. We have experience instituting plans that reduce paperwork and improve tracking. Our clinical pharmacists work closely with the facilities we serve to provide optimal care while reducing costs. Controlling costs requires accurate utilization reports that focus on various indicators such as percentage of residents on medications, number of medications per resident, etc. A comprehensive disease state expenditure analysis is prepared to inform the healthcare team which clinical areas are the most costly. This knowledge allows the facility to target the appropriate high -cost areas to effectively reduce expenditures. After discussion with the facility health care team, CPS can develop strategies designed to cut costs, such as: ■ formulary development and enforcement ■ automatic substitution ■ standing protocols • automatic stop orders CPS employs over 170 pharmacists, technicians and support staff, striving to provide cost-effective service to our clients. Even though some of our competitors may be larger in size and in number of employees, we believe CPS' strength lies in our staff and the personal attention afforded each of our clients. Each of our clients is.assigned a CPS technician and pharmacist, who act as the point -of -contact for all questions that may arise. CPS believes this commitment to good communication gives our clients a high level of personalized customer support. 39� Vol. PC t Contract Pharmacymo — RFP #23-099, Page 52 SERVICES Ci CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE Pharmaceuticals ,--,Whenever a client calls CPS, the call is sent directly to the point person. Your nursing and medical staff will ..et to know your point person very quickly, and will appreciate their responsiveness to your `questions. The system was designed to make communication between the correctional facilities and CPS staff very easy, and eliminate the need for nurses to explain who they are each time they call. Our clients appreciate this aspect of our service and constantly tell us how nice our staff is whenever they call. CPS also provides a point -of -contact pharmacistfor each of our facilities, to respond to medication related questions that arise. The two people on the contact team (pharmacist and technician) for each facility handle most of the customer service issues for the company. However, our clients can contact our senior management team and the owners of the company at any time. In -fact, as part of our training for a new startup, we provide the name and direct phone number for every member of the senior management team as well as the owners of the company in our in-service manuals. CPS employs 18 registered pharmacists on staff to service your needs. A registered pharmacist is always available to the Facility's medical services staff for consultation regarding all aspects of medication use. An on -call pharmacist is available 24 hours a day, 7 days a week, 365 days a year, in the event any after hours needs or questions arise. _T !Vol. 39 4 pg.171 Contract Pharmacy SERVICES MM RFP #23-099, Page 53 CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE Pharmaceuticals _ .,Key Personnel -vtlayne Shafer, RPh, Chief Executive Officer, would continue as primary point of contact once a contract with the Brazos County Detention Center and Juvenile Justice Center is renewed. Day today operations will be coordinated by Heather Hutchinson and the Lead Pharmacist assigned to the Brazos County Detention Center and Juvenile Justice Center would be Jo Marie Fields, RPh. Resumes and summary information of key personnel may be found on the following pages. Additionally, an organization chart of CPS' key personnel assigned to the contract at the Brazos County Detention Center and Juvenile Justice Center has been provided below. C� Contract Pharmacy Services Contract Pharmacy Organizational Chart Contract Pharmacy SERVICES SERVICES i Wayne Shafer,•RPh I Chief Execi,tive.Officer I Heather Hutchinson i Jean Shafer i Kimbede Masson Chief Operating Officer y i Executive Vice President' i Director of Finance Soo e • •fe0 G 0 � a Ma lAn LaumSniscak, RebeccaDiszyk AlexWerrblcW, ConsuftantPlwmacists FharmacyManager Data Entry Manager FulfittmentManager Slatt Phartnacisls StettData SGEntry shlpping Deparsnent Technana Vol. 39Pg Contract Pharmacy SERVICES Ell Accounts Receivab Christine Taman Accounts Payable Diane Lamuche RFP #23-099, Page 54 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Pharmaceuticals Office 125 Titus Avenue Warrington, PA 18976 (800) 555-8062, ext. 9001 EDUCATION: Wayne James Shafer mtlshafer s contractpharmacy com Bachelor of Science in Pharmacy,1972 University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Science) PROFESSIONAL EXPERIENCE 1995 — PRESENT Contract Pharmacy Services, Inc., Warrington, PA Chief ExecutIve officer and Founder Merged two corporations and spun -off the retail operations Sold all existing retail pharmacy operations Expanded the current base of corrections clients Expanded the current base of nursing facility clients Home 139 Peggy Lane Chalfont, PA 18914 (215) 947-6267 1986 —1995 ,4 Contract Pharmacy Services, Inc., Hatboro, PA OwnerandFounder Institutional Pharmacy specializing in Corrections & Long Term Care Facilities Moved the correctional and long term care pharmacy operations from the retail operations to CPS Opened a Long Term Care pharmacy operation within a nearby Continuing Care Residential Community (CCRC) providing in-house pharmacy services Developed the "Correctional Spreadsheet" report now an Industry standard 1976 —1988 Wayne Pharmacy, Inc., Hatboro, PA Ownerand ChlefPharmac/st Pharmacist/Manager Retail Community Pharmacy Owned and operated several retail pharmacies in Philadelphia, PA and the suburbs Supplied pharmacy services to two local nursing facilities 1972 —1976 Gene Pharmacy, Abington, PA Co -Owner Pharmacist/Manager Retail Community Pharmacy Owned and operated a new pharmacy location building volume up to 150 prescriptions per day Yr . 394 Vol. Pg j 7 3 Contract Pharmacy ■ SERVICES RFP #23-099, Page 55 CONFIDENTIAL AND PROPRIETARY — DO NOT DISTRIBUTE Pharmaceuticals Wayne James Shafer Page Two PROFESSIONAL LICENSES Licensed in the following states: Pennsylvania Arizona Louisiana Maryland Michigan North Carolina Ohio Oregon PROFESSIONAL AFFILIATIONS Pennsylvania Pharmacist Association Montgomery County Pharmacists Association American Society of Consultant Pharmacists REFERENCES Provided upon request PERSONAL BACKGROUND Married with two grown children Member of Pennsylvania United Medical Association -Travels to Nepal to assistwith set up and maintenance of orphanages in Kathmandu and six small medical clinics In remote areas. Vol. Contract Pharmacy SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 56 Pharmaceuticals Additional staff will maintain key roles in the contract with the Brazos County Detention Center and Juvenile t .istice Center. A summary of other key personnel is listed below: Jo Marle Fields, RPh, Pharmacy Manager Jo Marie is responsible for the day-to-day provision of services to the Brazos County Detention Center and Juvenile Justice Center. She has worked for CPS in the correctional pharmacy division since 2015. Jo Marie will monitor the technicians performing the services to the Brazos County Detention Center and Juvenile Justice Center to ensure accuracy. Her extensive knowledge of the special needs of correctional facilities is extremely valuable. Jo Marie heads up our CQI program and is responsible for evaluating all aspects of our operation, with respect to quality indicators. The Contract Pharmacy Services CQI program focuses on system resolutions to ensure problems are resolved permanently. Laura Sniscak, RA, Pharmacy Manager Laura has been a pharmacist for Contract Pharmacy Services since 2018. Her experience with the special requirements of providing medications to jails and prisons makes her an excellent resource with customer service issues. Laura directs and assists the data entry technicians and works closely with the pharmacy manager to ensure a quality product. Scott Steres, Director ofSales and Marketing/eCorrftrm Project Manager Since joining CPS in 2003, Scott has been responsible for the prospecting and development of new correctional clients, as well as retention of existing clients. In this sales role, Scott is the lead for correctional Requests for Proposal (RFP) and bids. In addition to corrections, he oversees the marketing department across all business lines of Contract Pharmacy Services. Additionally, he has been instrumental in the final development and implementation of our eCorrR)P Electronic Physician Order Entry system over the last 19 years. Over 120 clients are currently using the system. He will serve as the primary point of contact for the installation, support, and growth of eCorrR)Jm at the Brazos County Detention Center and Juvenile Justice Center, if the system Is desired. Vol.39 . Pg. 175 Contract Pharmacy SERVICES RFP #23-099, Page 57 CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE Pharmaceuticals ,,---Past Proceedings There are no past or current proceedings, actions, orders, or other stipulations against Contract Pharmacy Services, Inc. by Federal or State regulatory agencies. Material Judgments There are no material judgments, decrees, stipulations, arbitrations, investigations, labor disputes, other administrative proceedings, or claims threatened against or affecting its business, its financial conditions, or its assets and property, which may alter the terms and conditions of Contract Pharmacy Services' proposal to Brazos County. Vol. �'9 - Contract Pharmacy Wqq��� SERVICES R�fP RFP #23-099, Page 58 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE REFERENCES 0 Contract Pharmacy SERVICES Pharmaceuticals 01. e10`1 Pg j7 Pharmaceuticals REFERENCES 7 1 '.-oelow are eight (8) references of most similar size and/or scope to the pharmaceutical services detailed in the proposal specifications. Additional references will be happily provided upon request. Account Name: Anoka County Jail Account Name: CFG Health Systems, LLC (6 New Contact PersonMtle: Carrie Wood/Lieutenant, Jersey County Jails) Health Services Contact Person/ritle: Denise Rahaman/Executive Address: 325 East Jackson Director, Correctional Services Anoka, Minnesota 55303 Address: 765 East Route 70 Phone Number: (763) 323-6169 Marlton, New Jersey 08053 E-Mail: lindsaysent@co.anoka.mn.us Phone Number: (856) 797-4709 Contract Dates: July, 2006 -- PRESENT E-Mail: drahaman@cfgpc.com Contract Dates: September, 2003 - PRESENT Account Name: Cobb County Detention Center Account Name: Fairfax County Adult Detention Contact Person/Title: David Howell/Health Services Center Administrator Contact Person/Title: Laura Yager/Health Services Address:1825 County Service Pkwy. Administrator Marietta, Georgia 30008 Address:10520 Judicial Dr. Phone Number: (678) 355-7068 Fairfax, Virginia 22030 Fax Number: (678) 355-7077 Phone Number: (703) 246-2680 E-Mail• David.Howellacobbcounty.org E-Mail: Lau ra.Yagercafairfaxcounty.gov �ontract Dates: August,1998 - PRESENT Contract Dates: December, 2007 - PRESENT Account Name: Livingston Parish Detention Center Account Name: Morris County Correctional Facility, Contact Person/Title: Courtney Chaney/Health Contact Person/Title: Donna Grubel/Health Services Services Administrator Administrator Address: 28445 Charlie Watts Rd. Address: 43 John St. Livingston, Louisiana 70754 Morristown, New Jersey 07960 Phone Number: (225) 686-2241, ext. 516 Phone Number: (973) 631-5234 E-Mail: cchaney-@Igaov.com E-Mail: DGrubel@co.morrls.nus Contract Dates: April, 2010 - PRESENT Contract Dates: January, 2004 - PRESENT Account Name: St. Charles County Adult Detention Account Name: Spartanburg County Detention Facility Facility Contact Person/Title: Debbie Echele/Health Services Contact Person/Title: Katherine White/Health Administrator Services Administrator Address: 301 N. Second St. Address: 950 California Ave. St. Charles, Missouri 63301 Spartanburg, South Carolina 29303 Phone Number: (636) 949-3003, ext.4520 Phone Number: (864) 596-2626 E-Mail: dechele(epsccmo.ora E-Mail: kawhiteaspartanburgcoun%oW Contract Dates: June, 2014 - PRESENT Contract Dates: June, 2015 -- PRESENT r �-' v Vol. Contract Pharmacy Who i'9- SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 59 (7) ecorrRx TM 1-1 Contract Pharmacy SERVICES Pharmaceuticals • `�,��' /moo • r 394 pg-179 Pharmaceuticals eCorrRxTM -'CPS has developed a proprietary computerized physician ordering entry (CPOE) system, eCorrRxTm, designed to eliminate the time spent by nursing staff to transcribe orders to pharmacy order sheets, and Medication Administration Records (MARs). eCorrRxTM was designed to allow nursing and medical staff to be more productive by eliminating the amount of time spent on paperwork and other tasks, thereby allowing more time for patient care. The -system also eliminates med errors caused by interpretation and manual transcription of physician's orders. eCorrRxTM brings correctional healthcare to an exciting, innovative, new level. Our paperless solutions give physicians the ability to write prescriptions electronically and transmit them directly to the pharmacy for processing. eCorrRxTM gives physicians and nurses immediate access to patient information, without the use of traditional paper tales. All.user input is entered on a Tablet PC, or comparable hardware, using the latest encryption methods which limits access to data only to authorized users. While others in the correctional pharmacy marketplace have promised electronic ordering, eCorrRxTM remains the only system of its kind in use today. CPS is -proud that we have been the first and only pharmacy provider to bring such a system to market. In the 19 years since its release, it has been installed at over 120 of our current clients, including the detention facilities of Brazos County. All are enjoying the increased accuracy and efficiency, as well as the time savings that the system affords. eCorrRxTM is a working tool, enabling facilities to control costs, increase accuracy, and save time. The ability to print reports on demand at a County or facility level will aid in staying informed on pharmacy utilization and DStS. CPS will continue to provide the Brazos County Detention Center and Juvenile Justice Center with our proprietary Computerized Physician Order Entry (CPOE) system, eCorrRxTM. In doing so, all hardware and software required for this system is provided at no additional cost to the Brazos County Detention Center and Juvenile Justice Center, eCorrRxTM has been designed to lessen the workload and eliminate the time spent by the contract physician. and medical staff to transcribe orders to pharmacy order sheets, Medication Administration Records (MARS), and other paperwork, thereby allowing more time for patient care. This system provides the medical team immediate access to patient pharmacy data and creates a more efficient process for the ordering of medications. eCorrRxTM eliminates the previous method of handwritten transcription of orders, which would then be faxed to the pharmacy. Eliminating transcription greatly increases accuracy and reduces the possibility of medication errors, either from incorrect transcription or illegible handwriting. eCorrRxTM allows for immediate access to patient data when a chart may not be available. It aids in containing drug costs, as Brazos County's customized formulary will be loaded into the system. The system flags a prescriber when a non -preferred medication is ordered and provides for preferred alternatives, if available. Orders are automatically transmitted, via secure file transfer, to the pharmacy in "real-time". After all orders have been processed by CPS for the day, the system at the Brazos County Detention Center and Juvenile Justice Center details the orders current disposition. This ensures that any Contract Pharmacy 1100.1, Vol. 394 PJ 8 :® RFP #23-099, Page 60 SERVICES CONFIDENTIAL AND OMETARY---DO NOT DIST TE Pharmaceuticals changes in orders have been communicated back to the system, giving eCorrRxTm the most current patient r' !rug information available. eCorrRxTm is truly the only system of its kind in the correctional pharmacy services marketplace. CPS would be more than happy to demonstrate the features and benefits of eCorrRxTm. This system is completely optional, and if the Brazos County Detention Center and Juvenile Justice Center chooses not to use eCorrRxTm for ordering medications, CPS can continue to provide services using the traditional fax ordering system, using toll free numbers. Contract Pharmacy o a SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE RFP #23-099, Page 61 0 of 0 0101 ME I eCorrRx� "PRESCRIBING withoutTRANSCRIBING55 eCorrRxTm brings e-Healthcare to an exciting, innovative, new level. Our paperless solutions give physicians the ability to write prescriptions electronically and to transmit them directly to the pharmacy for processing. eCorr;WM gives physicians and nurse immediate access to patient information, without the use of traditional paper files. All user Input Is completed using a Standard or Tablet PC, limiting access to data only to authorized users. ADVANTAGES OF eCorr'RXTM: Reduce or eliminate the amount of time nursing staff need to... ✓ Transcribe physicians' orders from charts to pharmacy order form ✓ Transcribe physicians' orders from charts to medication administration record (MAR) Improves efficiency of nursing staff by... ✓ Eliminating time spent transcribing prescription orders ✓ Eliminating time spent faxing new orders and obtaining verification ✓ Eliminating time spent answering requests from pharmacy for clarification of inmate name, ID number, drug name or strength ✓ Creating time for other duties that improve patient care Nursing staff can easily... ✓ Update database on inmates that have been released or transferred to maintain accurate MARs ✓ Enter discontinued orders to maintain accurate MARs ✓ Print essential reports and MARs onsite, reducing time at end of month to review MARs ✓ Have access to patient pharmacy history without referring to the medical chart 1 ✓ Enter verbal orders from physicians ✓ Have access to diagnosis and allergy information without pulling the chart Vol. 394 P9183 eCorrRx- ® Physicians can easily... ✓ Review patient pharmacy history, diagnosis, and allergy information even when medical chart is not available ✓ Have access to current pharmacy orders, updated as of midnight each day, for all inmates within the detention system, regardless of location ✓ Obtain profiles for released inmates upon re -admission by accessing booking number ✓ Access system from remote location to enable assessment of patients when not onsite ✓ Receive reminders when non -formulary drugs are prescribed with suggestions for formulary alternatives Pharmacy will... ✓ Receive new orders upon upload after physician is done prescribing ✓ Capture diagnosis and allergy information that is important in determining proper drug therapy ✓ Receive accurate Inmate name and ID information, eliminating duplicate names and ID's which can cause confusion Vol. 3 4 Pg. 184 1 INSURANCE Contract Pharmacy SERVOCES Pharmaceuticals ........... C.) Vol. 39 Pg�B Pharmaceuticals INSURANCE contract Pharmacy Services warrants that the company has sufficient liability insurance, as well as workers' compensation insurance, coverage meeting the requirements for contracts of this nature. This coverage will remain in force for the duration of the contract. A Certificate of Insurance evidencing the liability insurance coverage, as well as workers' compensation insurance, is provided in this section. Upon notification of proposal award, CPS will instruct its insurance agent to continue coverage with Brazos County named as an additional insured. a Pg. 6 . _ Vol. _ `---- Contract Pharmacy SERVICES CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE RFP #23-099, Page 62 CERTIFICATE OF LIABILITY INSURANCE DATE(MrA/DDIYYYY) 9/1612022 THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS ^ERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES ,.,FLOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A CONTRACT BETWEEN THE ISSUING INSURER(S), AUTHORIZED •EPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER. IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the policy(ies) must have ADDITIONAL INSURED provisions or be endorsed. If SUBROGATION IS WAIVED, subject to the terms and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the certificate holder in lieu of such Endorsement(s). PRODUCER Arthur J. Gallagher Risk Management Services, Inc. 4000 Midlantic Drive Suite 200 Mount Laurel NJ 08054 CONTACT NAME: KathyHeer PHONE 267-537-2981 NC No EMAIL ADDRESS, kathy—heeE@ajg.com INSURERS AFFORDING COVERAGE NAIC# INSURER A: West American Insurance Company 44393 INSURED CONTR-2 CONTRACT PHARMACY SERVICES INC 125 TITUS AVENUE INSURERB: Ohio Security Insurance Company 24082 INSURER c :Ohio Casualty Insurance Company 24074 INSURER D : WARRINGTON PA 18976 INSURER E: INSURER F : COVERAGES CERTIFICATE NUMBER:671106604 REVISION NUMBER: THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS, ILTRR TYPE OF INSURANCE D SUBR POLICY NUMBER MMIDDY EFF MMIDD� LIMITS A X COMMERCIAL GEN ERAL LIABILITY BZW59084760 9/15/2022 9/16/2023 EACH OCCURRENCE $1,000,000 CLAIM5MADEMOCCUR PREMISES(Ea occurrence) $50,000 X MED EXP (Any one person) $ 6,000 BLANKET ADDL INSURED ENDT PERSONAL & ADV INJURY S INCLUDED GEN'L AGGREGATE LIMIT APPLIES PER, GENERAL AGGREGATE $2,000,000 POLICY PRO, 7 7 LOC PRODUCTS -COMPIOPAGG S2,000,000 S ` OTHER: AUTOMOBILELIABILfTY BAS59084780 9/15/2022 9/15/2023 COMBINED SINGLE LIMIT Ea accident $1,000.000 X BODILY INJURY (Per person) S ANY AUTO OWNED SCHEDULED AUTOS ONLY AUTOS BODILY INJURY (Per accident) $ X PROPERTY DAMAGE Per accident $ HIRED Ix NON -OWNED AUTOS ONLY AUTOS ONLY S C X UMBRELLA LIAB X OCCUR U8059084760 9115/2022 9/16/2023 EACH OCCURRENCE 56,000,000 AGGREGATE S 6,000,000 EXCESS LIAR I CLAIMS -MADE DED I X I RETENTION $ in nnn S WORKERS COMPENSATION AND EMPLOYERS'LIABILITY YIN ANYPROPRIETORIPARTNER/EXECUTLVE ❑ OFFICERIMEMBER EXCLUOEDI NIA PER OTH- STATUTE I I ER E.L. EACH ACCIDENT $ E.L. DISEASE -EA EMPLOYEE S (Mandatory In NH) If yes describe under DESGLRIPTION OF OPERATIONS below E.L. DISEASE - POLICY LIMIT S A PHARMACIST LIABILITY BZW59084760 9/15/2022 9/15/2023 LIABILITY LIMITS $1.000,000 DESCRIPTION OF OPERATIONS I LOCATIONS I VEHICLES (ACORD 10 1, Additional Remarks Schedule, maybe attached if more space is required) PHARMACISTS PROFESSIONAL LIABILITY & PRODUCTS COVERAGE INCLUDED. COVERED LOCATIONS ON PROPERTY POLICY #BZW (22) 59084760 EFFECTIVE 9/15/21- 9/15/22: 125 TITUS AVENUE, WARRINGTON, PA 18976 1660 EASTON ROAD, WARRINGTON, PA 18976 816 MAPLEWOOD DRIVE, HARLEYSVILLE, PA 19438 6600 TABOR AVENUE, PHILADELPHIA, PA 19111 1660 EAST STREET ROAD, KENNETT SQUARE, PA 19438 1400 WAVERLY ROAD, GLADWYNE, PA 19036 SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DELIVERED IN CONTRACT PHARMACY SERVICES INC ACCORDANCE WITH THE POLICY PROVISIONS. 125 TITUS AVENUE WARRINGTON PA 18976 AUTHORIZED REPRESENTATIVE USA V ©1988 2015 ACORD CORPORATION. All rights reserved. ACORD 25 (2016103) The ACORD name and logo are registered marks of ACOR 3 Vol. P18 7 CERTIFICATE OF LIABILITY INSURANCE 02/017202 t THIS CERTIFICATE IS ISSUED AS A MATTER OF INFORMATION ONLY AND CONFERS NO RIGHTS UPON THE CERTIFICATE HOLDER. THIS CERTIFICATE DOES NOT AFFIRMATIVELY OR NEGATIVELY AMEND, EXTEND OR ALTER THE COVERAGE AFFORDED BY THE POLICIES BELOW. THIS CERTIFICATE OF INSURANCE DOES NOT CONSTITUTE A, CONTRACT BETWEEN THE ISSUING INSURERIS), AUTHORIZED REPRESENTATIVE OR PRODUCER, AND THE CERTIFICATE HOLDER. IMPORTANT: If the certificate holder is an ADDITIONAL INSURED, the polrcyiresl must be endorsed. If SUBROGATION IS WAIVED, subject to the terns and conditions of the policy, certain policies may require an endorsement. A statement on this certificate does not confer rights to the PRODUCER SALLY KENNEDY C/0 AMERITRUST SERVICE CENTER 11880 COLLEGE BLVD STE 500 OVERLAND PARK KS 66210-1224 CONTRACT PHARMACY SERVICES INC 125 TITUS AVE WARRINGTON PA 19976-2424 INSORERISI AFFORDING COVERAGE INSURER A: STAR INSURM INSURER e: INSURER C: INSURER D: INSURER E: INSURER F COVERAGES CERTIFICATE NUMBER: REVISION NUMBER: NAIC N THIS IS TO CERTIFY THAT THE POLICIES OF INSURANCE LISTED BELOW HAVE BEEN ISSUED TO THE INSURED NAMED ABOVE FOR THE POLICY PERIOD INDICATED. NOTWITHSTANDING ANY REQUIREMENT, TERM OR CONDITION OF ANY CONTRACT OR OTHER DOCUMENT WITH RESPECT TO WHICH THIS CERTIFICATE MAY BE ISSUED OR MAY PERTAIN, THE INSURANCE AFFORDED BY THE POLICIES DESCRIBED HEREIN IS SUBJECT TO ALL THE TERMS, EXCLUSIONS AND CONDITIONS OF SUCH POLICIES. LIMITS SHOWN MAY HAVE BEEN REDUCED BY PAID CLAIMS. _ INSR ASUBR POY TYPEOFINSURANCE IWPOLICY EXP I LIMITSLTR NSR hOY GENERAL LIABILITY COMMERCIAL GENERAL LIABILITY CLAIMS -MADE 7 OCCUR EACH OCCURRENCE s DAMAGE TO RENTED c 9 MED EXP lAny one person) g PERSONAL & ADV INJURY GENERAL AGGREGATE " g g S GEN'L AGGREGATE LIMIT APPLIES PER: POLICY PRO- LOC OrT El PRODUCTS — COMP/OP AGO_ JAU TOMOBILE LIABILITY ANY AUTO ALL OWNED AUTOS SCHEDULED AUTOS HIRED AUTOS NON -OWNED AUTOS _._.� COMBINED SINGLE LIMITIEa occident) BODILY INJURY IPer parson) BODILY INJURY (Per accident) 0 PROPERTY DAMAGE (Per accident) 0 g T UMBRELLA LIAB EXCESS LIAB OCCUR CLAIMS -MADE EACH OCCURRENCE 4 $ _._ .._...._.�.. AGGREGATE DEDUCTIBLE RETENTION 0 $ g A WORKERS COMPENSATION V AND EMPLOYERS' LIABRITY ANY PROPRIETOfb?ART MAXECUTIVE g OFFICERIMEMBER EXCLUDED? (Mandatory in NH) Ir yyes, dag under DESCflle ION OF OPERATIONS below NIA WC 0193308 02-01-23 02-01-24 X TOAY U ITS OE)µ _ g 1,000,000T g 1,000,000 E.L. EACH ACCIDENT — E.L. DISEASE -EA EMPLOYEE E.L. DISEASE •POLICY LIMIT g 1. 000. 000 DESCRIPTION OF OPERATIONS I LOCATIONS I VEHICLES (Attach ACORD 101, Add(donal Remarks Schedule. If more apace is requiredl CANCELLATION SHOULD ANY OF THE ABOVE DESCRIBED POLICIES BE CANCELLED BEFORE THE EXPIRATION DATE THEREOF, NOTICE WILL BE DEUVEREO IN ACCORDANCE WITH THE POLICY PROVISIONS. AUTHORIZED REPRESENTATIVE 0 1988-2009 ACORD COPRORATION. All rights reserved. ACORD 25 (2009109) The ACORD name and logo are registered narks of ACO -- , Vol. 394 pg.g� ■ I C) i PRICING/ FEES FORM Contract Pharmacy SERVICES Pharmaceuticals .............. It: • r Vol. 394 Pharmaceuticals PRICING Contract Pharmacy Services, Inc. (CPS) is pleased to submit pricing contained herein to the Brazos County Purchasing Department in response to the Request for Proposal for Pharmaceuticals. Pricing has been provided on 'Exhibit A: Fees Form" using formulas based on Average Wholesale Price, as well as Actual Acquisition Cost of the medication plus a cost per script, as requested in the proposal specifications. If CPS is awarded the contract, both methodologies will be priced during the first three months of the contract. During that time, Brazos County wil I have the option of paying the lowest price of these two billings. After the initial three month period, Brazos County will select the billing option that provides the lowest price for the facility and this formula will be used for the duration of the contract. Option 1 — Average Wholesale Price: Medications provided to the Brazos County Detention Center and Juvenile Justice Center will be billed at Average Wholesale Price (AWP) minus twenty-six percent (26%) for brand name/single source drugs and Average Wholesale Price minus ninety-six and one-half percent (96.5%) for generic/multiple source drugs. There is no per prescription dispensing fee using the Average Wholesale Price methodology. Pricing for both Blister Card Packaging, as well as Automed (Strip) Packaging, remains the same using the Average Wholesale Price methodology. Medications will not be sold below Contract Pharmacy Services' Actual Acquisition Cost (AAC). If, in using the stated pricing formulas, a medication calculates below cost, the medication will be charged at CPS' Actual Acquisition Cost. Option 2 — Actual Acquisition Cost: Medications would be billed at Actual Acquisition Cost plus a per prescription dispensing fee (dependent on packaging type) for brand/single source and generic/multiple source drugs. The dispensing fee for Blister Card Packaging and Other Dosage Forms, such as creams, ointments, etc. for up to a 30 day supply is $2.25 per prescription. Automed (Strip) Packaging is priced at $1.25 per prescription for up to a 14 day supply. This pricing methodology includes the cost of the medication, packaging, dispensing, and shipping, and all other charges incidental to the delivery of the pharmaceuticals. Contract Pharmacy Services will provide monthly suppliers' invoices at Brazos County's request. These invoices will detail CPS' acquisition cost of the pharmaceuticals purchased by the County. Both of the above pricing options include the cost of the medication, packaging, dispensing, and shipping. There are no additional dispensing fees. Potential rebates available from some manufacturers are taken into account when computing the pricing formula. CPS has calculated the anticipated rebates and price `jdjustments when computing the above pricing formulas. Contract Pharmacy �a RFP #23-099, Page 63 SERVICES CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE Vol. 394, Pg. Pharmaceuticals CPS will dispense generic drugs whenever they are available, unless the physician specifically informs us to ispense a brand name drug. Only generic products manufactured by approved FDA manufacturers will be dispensed at the Brazos County Detention Center and'Juvenile Justice Center. "Exhibit A: Fees Form", detailing unit costs of medications, inclusive of all fees, for both Blister Card Packaging and Strip Packaging, has been provided in this section. Because of the extremely low unit cost on many of the drugs, pricing has been provided to four decimal places (hundredths of a cent). Costs of the drugs on this price list are current as of February 28, 2023. As requested, hard copy documentation, inclusive of a complete Average Wholesale Pricing list for every medication, has been included in this section. This pricing list supports Option 1 — Average Wholesale Price. Dated: February 28, 2023 Submitted: &A� Scott D. Steres Director of Sales and Marketing r 394 pg. �-�-9 ' Woi. Contract Pharmacy UFO M RFP #23-099, Page 64 SERVICES CONFIDENTIAL AND PROPRIETARY -DO NOT DISTRIBUTE RFP 23-099 - Pharmaceuticals Exhibit A: Fees Form Brazos County is requesting Firms to provide two (2) pricing options. The County will choose one (1) option at the time of award based on what is considered to be the best value to the County. Pricing Option 1 Brazos County is requesting bids for percent discounts off the current AVERAGE WHOLESALE PRICE for all pharmaceuticals to include name brand, generic, or over the counter. Percentage shall remain constant for entire Contract. The Firm may offer different percentages for various categories if needed. Cost shall include all shipping and handling charges. All dispensing fees shall be figured in vendor discount, as dispensing fees will not be considered in the tabulation of this bid and could disqualify the bid. Bidder acknowledges and agrees all (mail/retail/specialty) discounts are based on Average Wholesale Price methodology utilized by Red Book (current edition). Firms shall list discount percentage on the following: 1. NAME BRAND PHARMACEUTICALS: AWP minus twenty-six percent (AWP - 26%) 2. GENERIC PHARMACEUTICALS: AWP minus ninety-six and one-half percent (AWP - 96.5%) 3. OVER THE COUNTER PHARMACEUTICALS: AWP minus twenty-five percent (AWP - 25%) Pricing Option 2 Brazos County is requesting bids for vendor actual cost plus/dispensing fee mark up for all pharmaceuticals to include name brand, generic, or over the counter. Mark up shall remain constant for entire Contract. Vendor may offer different mark up for various categories if needed. Cost shall include all shipping and handling charges. Vendor shall list mark up on the following: 4. NAME BRAND PHARMACEUTICALS: Actual Acquisition Cost (no markup) 5. GENERIC PHARMACEUTICALS: Actual Acquisition Cost (no markup) 6. OVER THE COUNTER PHARMACEUTICALS: Actual Acquisition Cost (no markup) Other Fees (List other fees below) Pricing Option 2• Blister Card Packaging/Other Dosage Forms (i.e. creams, ointments, etc.) - $2.25 per prescription (up to 30 day supply) Strip Packaging - $1.25 dispensing fee per prescription (up to 14 day supply) -9 2 1 Vol. 3 9 4 Pg. Items listed below are to be used in the evaluation of the bid. The items listed are a sample of r items that could be purchased during the term of this contract. Firms should list the price that would be charged to the County with the discount and markup offered. Blister P ckaging Strip Packaging Drug Name/Dosage/Form Option 1 Option 2 Option 1 Option 2 ABILFY 5MG $1.0665 $0.2672 $1.0665 $0.2339 ABILFY 10MG $1.0665 $0.3078 $1.0665 $0.2744 ABILFY 15MG $1.0665 $0.3657 $1.0665 $0.3324 ABILFY 20MG $1.5082 $0.3378 $1.5082 $0.3045 AMOXICILLIN 500 MG CAP $0.0127 $0.1377 $0.0127 $0.1044 APLISOL 5ML VIAL $58.1086 $61.3450 $58.1086 $61.3450 ATENOLOL 50 MG TAB $0.2777 $0.1013 $0.2777 $0.0680 AZITHROMYCIN 250MG $0.2588 $0.5950 $0.2588 $0.5616 AZITHROMYCIN 500MG $0.6176 $0.8800 $0.5176 $0.8466 BENZTROPINE 2MG TAB $0,0164 $0.1687 $0.0164 $0.1354 CLONIDINE 0.1MG TAB $0.0084 $0.0950 $0.0084 $0.0616 CLONIDINE HCL 0.2MG TAB $0.0122 $0.1187 $0.0122 $0.0854 CLONIDINE 0.3MG TAB $0,0174 $o.1431 $0.0174 $0.1098 CYCLOBENZAPRINE 1 OMG TAB $0.0363 $0.0997 $0.0363 $0.0664 DIVALPROEX SODIUM ER 500MG TAB $0.1355 $0.1991 $0.1355 $0.1658 LISINOPRIL 10 MG TAB $0.0327 $0.0896 $0.0327 $0.0562 LISINOPRIL 20 MG TAB $0.0350 $0,1026 $0.0350 $0.0692 METFORMIN HCL 500 MG TAB $0.0234 $0.0915 $0.0234 $0.0581 METHYLPHENIDATE ER 1 OMG $0.2494 $1.3733 $0.2494 $1.3400 METHYLPHENIDATE ER 15MG N/A NIA NIA N/A METHYLPHENIDATE ER 20MG $0,2577 $1.1909 $0.2577 $1.1576 NAPROXEN 500MG TAB $0.0397 $0.1336 $0.0397 $0.1003 OMEPRAZOLE 20MG CAP $0.1479 $0.0988 $0.1479 $0.0654 PERMETHRIN 60GM 5% CRM $0.0654 $0.4349 $0.0654 $0.4183 VAR INH 40MCG $16.6737 $18.9846 $16.6737 $18.9846 VAR INH 80MCG $22,3242 $25.3478 $22.3242 $25.3478 STRATTERA 40MG TAB $10.8724 $1.1837 $10.8724 $1.1837 THIORIDAZINE 10OMG TAB $0.0397 $0.9924 $0.0397 $0.9591 TRAMADOL HCL 50MG TAB $0.0265 $0.1124 $0.0265 $0.0790 TRAZODONE 100 MG TAB $0.0364 $0.1697 $0.0364 $0.1364 VYVANSE 20MG $10.3852 $11.7701 $10.3862 $11.7368 VENTOLIN AFA (INH) 90MCG 18GM $2.6722 $3.1344 $2.6722 $3.1344 1931 2 VOL 3 9 4 Pg. i AdditionaI Information 7. Delivery time for regular orders (# of days): 1 day - overnight delivery by 10:30 AM next business day 8. Delivery time for rush orders (# of hours); 2 hours 9. Charge for rush orders: No additional char es other than cost of medication (it using local back-up pharmacy) 10. Annual software/licenses charges (if any): No software licensing charge 11. Does vendor issue credits for un-used pharmaceuticals? Yes, see proposal response page 11 If yes, vendor shall attach information explain credit program policy. 12. Does vendor have a local facility that pharmaceuticals maybe picked up from? Yes If yes, list location: Contracted local, back-up retail pharmacies are used 13. Brazos County may choose to store typically used pharmaceuticals on location. Does vendor have a system to track inventory for pharmaceuticals stored at the County? No If yes, vendor shall submit information explain or a website for viewing inventory system. i � pg. -f94 " Vol. - KUM Contract Pharmacy SERVICES Contract Pharmacy Services, Inc. AWP Pricing List Pharmaceuticals - RFP #23-099 February, 2023 CONFIDENTIAL AND PROPRIETARY - DO NOT DISTRIBUTE ACETAMINOPHEN 473M� - - 160MG/5I�e'IL' SOLN: ' � 5865f4525-116 ACETAMINOPHEN (APAP/MEDIQUE} ;, 32SMG_ r _TAB_ d 47682 0145 64 _ _ 24 _�,.. _ `,_ _._ _ a. _ $137 _ ACETAMINOPHEN ER 6SOMG CPLT 49483 0699 0� 100" 510y_ 2Uv `ACETAMINOPHEN ES _ - _ i_ 500MG _ ;', CAPE :w' 161030350-11..,'._ _... , !D,CETAMINOPHEN ES = S00MG TAB -]0090� � 4-6730-80 $24.41. �+W ACETAMINOPHEN ES (237ML) ACETAMINOPHENRAPREL SOOMG r GCAP 009d4-5816-6Q lOdy-� 5569r_�„".,,__q ACETAMINOPHEN/COR �120/12MG/5ML �� ELXR 50383 0079 473 _ $18.40 _.. A ETANtINOPHEN 6(?D #215MG/3ddMG _ _ . TAE dQ603 2337-211 " V` 2�'$QI; _ _ 52.65 COD#3 300MG30MG, ITAB 'ACTAMINOPHEN / - 0 _$$967µ,.524. ACETAMINOPHEN/CO 3Q0NiG 719300056-12 -_Q 4,80 � ACTAMINOPHENUD .7193_ 25B 009Q4-1982 6i 10,_0 n . : ATAZOLAMIDE I20MGTAB 2858-01 1100 288.31_ ACETAZOIAMfDE EXT-REt ' S40MG - _ . ; CAP 42571-0243 01. _ 100 ;� • __- $429.35.._ Y ACETICACID HC OTIC (10ML�__�_ _ ._,_1 2� SOL1V Si672 3007 01 iQ 4y$225 77 - ACET(CACID IRRIG.(1000ML-EA) U90 SOLN ' 00338 0a56-04 " AC R ACIDOTIC 15MLL_m� 2 • � 5OLN V 60432 0741'-16 1tQild 15 $10i 70- 540�00 ACETtCACID/ALUM-ACETATE(60ML} _ -, _. ,w 0,02. . ;.. . SOLN_ '. 24208.0615.-77. ._ _ b.0..,_ . ,> _ _ _$72.00 ACETONE (120ML)_^ SOLN -� 00395-0029 9`t� 12012.04 ACETYL DIPEPTIDE-1 CETYL ESTER _ _ _ CETYL ES _ . _501 _ 51927 3771-QO ;. 1 _ $3.93 'ACETYLCYSTEINE_(10ML E4)_,_ _ � -' -: 10� � %���. -- l=VIAL, 63323 0693-10 _ 30 � A M 47.88 _ VIAL 63323 0690-30 ACETYLCYSTEINE (30ML-EA) 20% � 0 !ACETYLCYS7EINE 4ML EA} " �� .' V'� 0.1�VIAL �' Q0h 57 7504 2 � �100 ACETYLCYSTEINE (4ML-EA} 2000 VIAL 63323-0694-04 ACID GONE{355ML1y _. _---�--_ - SUSP 009647727�1`L.l�__ ,ACID MANTLE (48OGM) 10 - 337 0904-42 �]i _ TAB S 904 5365-60 �.._ __ ACiDOPH1LU5 CAP �. 43292-0500.22 ACIDOPHlLUS P_EC7lN-w�TCAP =OQ904 4213-60 �100 ACIDOPHILU5 PROBIOTIC TAB 80681-002b-00 ; 90 _$82.15 __ - 276.60- 100 , $420:3fl 355, r $5.27 ___...._i 480 $86 24 100 �� _ S5 23 100 $3.35. T 3.42 100 $3.36 ` _ CIDOPHlCUS W L-SP ROGEtVES ACIPHEX _.- - ACTRETIN--- _ � EX B�TfiG TAB 00536 7181-0 r ---id0 _ 20MG . TAB _ ..62856-0243-30 (' -�- CA` 00378 7Q2U-93 ji � ( 30 30 _ _ - 4.43 - $714,90 $936.Q5 `AC ITRETIN 2WG '. ,'_. CAP, . ' 00378-7023-93_ 3O' _ .. ._$1,153.-78 NdFA 36GM) r^ -� ----lF- ADULT __.]=CRM=E384850911-61 j_ �Y ACT ANTtCAVlTY (532MC} _ gl DR MOUTH GUM � MINT -', 41167 0942-08 $6.45 _ -- - � �� A.� � �E41167-0099�27 ti. 20.... �w��? .• _ ACT -MOUTHWASH (532ML} F TOTAL CARE ., 41167-0963 00 =~ - _532. 6ACTTOT,ALCARERNT{1000ML) �' LIQ-- 411fi7-0962-04,!�_ 1000 L $-8 9_____�.11 j ACTEMRA PF SYRINGE IAGTHIB {1ML-EA ACTlCOAT BARRIER.((12)- I]A IGALL ._-__--___•_. _ .._.-262MG-1 .9ML . ;, k-. " 50242-0138-01._' 0.9 -_ ;' E(� W%DiIUENT ._VIAL j492$10545 03 5i$122.89�i 4X4 _ . DRSG _ _ � 40565-1216 43 _ 12 300MG .-.�•.�;L.. CAP � 5254C� 4-0930-41.iCiQ0 '�_._ _ $11368.71 . _ $1,142.66 ACTIVE LIFE-i-PC DRNQI-t U2759_ -_ ..�------�._ . . _. 1.1/40LN_ : __POUCHY �. _68455 0101-49 5 10_ - ACTIVE LIFE i-PC DRiVBLE #22771 _ L2IN POUCH 68455 Qd10-1, 6�_ _10 ��„• ��---� ' h `; $36 97 .� -$443.20 _ ... .. __30MG TAB E 60430-0470 15 �i30 -{^____,._�°�,2 925;42 ACTONEL _ , .� . __..._ 35MG� �_- €; TAB. _ 00430-0472 03 : . 4 _ Sg09,18_.- ....._....,...,,._..._. L.._....�.-..�_.,._._ 1�� 5MG'.�-��_ TAB�00430.0471-IS._V 30 �•���4�� _ A&WIL S-MET _. - - b4764 J _ -:�438.67 .. . _. _ CT{?PLUS MEi -. .: --15 850MG TAB 64764-0158-60 r 60 ACTC15 15MGTAB _ ' 64764-015144y 3Q 2y137.67 �.�, 64 6d i]b51 25. t 40 _ _. 8 _ CA ULAR,LS SML! 0.004'=SOLN OOd23-9277-d5-5, 33_9.78 - 0 005 - .'--- 50LN ACUVAiL OPTH :..�- _ N4�,-�•v O'4590 _ , _ .µ A_ MG 200CAP 72578 0002 01_ 100 _ $30 00 �CYCLOVIR CYCLOVIR - 400MG I�_TAB 31722 0777 OS' [--.. y 500 500 A, gCLOVIR 1QML EA -SOQMG7 OML`�t VIAL _ 63323 Q32S14 100 '', � S5i.60 :1 ACYCLOVIR (iSGM) -. _rt _ _ .`:._:. _ , .OAS, ._ ;_ _ _OINT 65162-0835 94„ ' i_ 1S : ..___$398.80 - ACYCLOVI�JUQML-EAR JL SOMG ML VIAL• E53323 0: 25 2 ACYCLC)VIR (30GM) 1.0 (33: , . 01 11 tl 6846E-0746 3S , jd ACYCLOVIR (473 - 2OOMG 5 L 5US '`23155.0485 S2«+ L 473 $ryi.5y " _ R4S:2O ACYCLOVIR (5GM} - _ _ 0 05 CRM , 65162-0836 14 + 5 _. $962.49 ' AC NE 30GM)�w Q 4S GEC ,�`--70 30. ACZONE (60GM). _ . _ _ ._ 0 05 _ .. ,. _ GEL ....1 00023 3670-60 ,' _ _ _ _ 6Q _ _. ` $824 90 WDALATCC _ _ W_;� °60MG50419=0702 Q51 4 100 µ358333 - r ADALAT CC 90MG TAB _ 50419 07Q3-05 -� S00 $419.89 _ ADAPALENE {iSGM Oi _ 1 GEL .: ,, 0Q43 "01.: t� 20:60 ADAPALENE (44GM} ' _ 0001 _ CRM ;: . 45802-0453_1} E-_.. __V _45_ __.._ _ •' $27117 zo Fin 30 E IE' AUYAIHUISKUS(bUta.Ni] � n. k LSU,(i,'SU i�� IIVtiL�,�„f� UU7l3-UbyE�-,LUV�} 4U ." + t _ x$47Z72,�� .: D11AlR DlSKUS 60GM 5o0 o lNHt, 00173 0697 tjp; bQ' 7,, 62172� h f �ADVAtR HFA (12C�M) C. 11 1 iC lNN4 00173 0716 4$6 90 s� VAtR H A 12GM uy 230 21t GG !N .04173-071%2t} �..,x _ �.a.r....y 2 640 ft AlGOHOLSWABS/PADS, ,_ __ , ___ PAD - _08290 3268 95 , _ 100 ,. _ _ i, $2 OS - 1C0'v NC}t=150PROP L73ML-EA} u �Y _ � 0.7 SOLN 00574 0067=16 y 473 ' ;:-;=52 75 i _ SOLN)z 00395 1245;16 _ .. ._ '$�.� t _ _ $0.95_ - { ALCORTIN 2GNi-EA _ 0,02 r=-" ,f GEt :' 68040 0705=33 48, ` �4186.80 ALDACTAZIDE _. _ , ._ _50/50N1G _ _!� __.TAB 1 00025 102131 E' _ 1 r _ ._ .;_.. _ _ _:.. $603.16 ALDACTONE y 10N1G : JIB "? TQ0025=1031=31 10947:46 00025.1001 31 i _._. .. _ _ 1Q0- _ __- l .._ _ _ ..321.83_ Ai D D_TAB ; :., . 00025-1041-3 L -IW _ i _. v: _ 5565.15 � ALENDRONATE_ _q - IF 10MG ' _ TAB. � 64980.0340-61 (�_ ALENDRONATE 35IViG _ . `, 7A8 _ , _69097 0223.76 r ._. _ .m_ _ _ _ ._ $245.85 , AL D dN__A_T _ TAB 00093 5140-5 30 TAB. 69097022476 _,__..._.._12 0M4,.G,,�.� ? TAB 25$66�0591 9�L,_�.." -ALEVE LIGUIDGELS I 220MG _ _ • _ CAP, a 25866 0528 13 1 20 $4 96 SALFU20SIN�ER _! 101VlG.: ��'- TA& yq 47335 095618� _ 1000:(� ,$4,213,61 ALINIA 500MG IAS �67546 011114'! - 12 fo n o �cv86:o0 ALKA SELTZER BLUE.C}RIGIPlAL"_ TABS �., "I 06280 4000 0'� 36 $8.33( 180NIG ;, TAB. r .41167 4120-06 t .. _ _ _ . 7Q- _ALAL GRAALLERGY _ ;�� 1801V1G _TAB 41167 4120-03 � 30 530.33 �= 'ALLEGRA ALLERGY �- 66MG _ _ TAB 41167-413104 24 $21.16 _ AtLEGRA D 24 HCUR180J240 _ � TAB '![ 4110fJ7 67 432 15_ _ i 30-33 � ALLEGRA-D 12 HOUR , 60MGj120MGy - TAB, 41167 4310-04 - 20 $27.62 _ KL EEVYN IO • _ _ Iry ' 3 X 3' � � DRSG 08026-0000-43 j� _ �10 µ _ �; _$99. 99 ALLEVYN (10), . 5 X 5 I DRSG _..,._08026 0000.44 . _ 10 $153.29 _ ALLEVYN, t�ON ADHESIVE ��,' 4i R'� 4 X 4_ PAD, 00223-0438 42 ALLOPURINOL 100MG TAB 23155 6693-1Q 1000 , TAB' 16729-Oi35-16 gg�__.500 -_ , _ _$436.37 $461.75 _ ALMAYAJP DEODORANT(67MLJ FRAG FREE 30997-3664-06 67 $3.98 A MAY ROLL ON (45GM) _ _ _,_ �1kU4SCENT�g997f __a 51220 i12M__� AS._s�. ALMOTRIPTAN 5MG TAB 00378 5246 85_ ' ,12 $503.03 . ,. ALO RIL OPTH {SMLj`. _ _12 _.j.__ 2 00% _�SOCN OOJ b23-$$A2-Q5_ _ _ :' V' __..p...,.- 5 - 5269,41 l ALOE VERA (120GM)� _ CRM 71661 0001-04 �' 120 $3,58 ALOEVERA{170M1� Y. E V 7 r _ . _ Cj _FGELJ'71&,6100D 3_ _ 170' _ _ii. __gg . WOE VERA(340GM)" GEL - y71661 0001 20. `,-- n $8,38 - ALOE VERA71661-dQ01-16. _ _ _ _ - r340` 48{1 AtOEVE§TA(56GM) _ _ _ 0.02 - flINT ;,435530003-02 s0_ ALA OE VESTA CtEAN51NG (240GM)__ - _ _ _ -1 �,___FQAtv1 68455 0148 41 _ _ -- 2A0 _. A_C E VESTA DAILY MOISTURIZER . 0.03. , LOW " 43553 000168 _ 236. -_ .- - $6.00- �ALOE VESTA PROTECTIVE 60GM)-_ ; �a 0 43 O1NT [ 435_ 53-324,9 13 6fl . �(�; $4.71 ALOGLIP TIN 7A6, t 45802 ©103-65 $234.00, _ _ _ _ AA OGLip7IN -._-12.5MG..30 a _ _ 25NIGI' TAB -01 458(j250-65� ALOGLIPTlN 6 25M,G _ ; TAB_ -_ a;. 45802 0087 65 .,:. _ -30- $234.00 •A OGLIPTINjMETFORMIN _ , r 12,5/500MG TAB: 45802 0169-72 Ii%~ _ 60 L �w �$234.t}0 ALOMIOE"OPTH --- �.. 0.10% SOLN 00065 0345 10 _ . _ _ IO ._ _ .' _ _ _ -. $236.88, NkLOSETRON _ _ _ y;L 0.5IY(G TAB 65162 0248 03 _ d a 3Q _ _. 1033.56 _ ALPHA LIPOIC ACID _ _ 100MG CAPtS4629-0110-76 .,} - 60_ $4.43- 'ALPHA LlPOlC ACID - Cg--��'--=-"" �j;300MG � CAP ��47469 0003 12 50 ALPHAGAN-P {lOMI) _ _ _ .__ . _ . 0.10% SOLN 00023 9321-10 10 - ALPHA GAN, PSOLN;0002 3-91771; 10 V )_$497.38 ALPHAGAN-P SOLN 00023 9321 15_ � _ . 15 ,. .. _ _ -.. $699.77_ ALPHAGAN-P 15Mt � � 'F�� 0.0015 C_ SOLN 00023 9177 15 � 15 746.14 ALPHAGAN-P (SMLJ SOLN_ _) 00023 932105 �i_ _ 5„- _ _ , $233.33_ A HAGAN-L(SML) _ _ I`_.._.__.O O jlL SOLN: 00023 9277-{ 5 S i 248 75 4 a ^LPRAirnnFq Q.2 MG s' TA&... i 658621J�7 951 _.500 ... _ _.. S347;SOm ALPRAZOLAM 4 65862-0677 99 {' 10007 822 80 - _ 6862 0678 70kPRAZOLAM AtPRAZOLAM JAW,62067941 10 _$577 �519645 'ALPRAZOLAM 30ML _ SOLN j' 00054 3068 44 30„_- ALPRAZOLAM ODT : 1MG` TABS ' 49884 0213=74100„ _ _{u> 252:22 ei LALA PRAZOlAM XRM,. TAB 6586Q, 50 160.44. _ 'A~LPRAZOLAMXR_. TAB' ._-,_,56 . _J 2_ 12,93 _ _ _ IALPL4ZCLAM XR _2MG u60 -�3MG jC�96264801 ?MG _- . �_ _ 510790/isy 2 IAB-0 l0u $7� yT APAQAM_ U(D TA7�1 063' AIREX OPNTH (5ML)_ _ i _ _ _ 0 002 _ SUSP ( 24208 0353 05.' A TALECAP: - 61570-01103o1DL 100 _ �] ~ 640:04: tM AL►ACE- -` _ _ _... _ _ 10MG ;i CAP . ^ 61570.0120-01_ ,'.�_ _ _ . 1b0 RALTACE '� MG CAp 61570 0111 bi �4100 "' 755 45' AITACE _ SMG _;.w CAP 61570 0112 Ol I 100 i, $ 792 64_T LTAYERA-28 r ) „b 15 0 03MG i�Tgg 7b70b Oi16 85' '`:_ 92.76 _ O :ALTOPREV EXTEXT REL� �, -4-0NIG_ ,__ E( TAB „ 70515 0629-30 Y - 3�? __ __ _ _ _ ..__$1�299.77 _ HIY�Y{1.16tJIV 11-i .. _ I, r - -- 6g PILL GIIN_ l EAj"., � VIAG Mr 55250 0112 20 ��-10 =L v tl504MG AMPIClLLIN+SULBACTAM_(1_EA};• 1,SGIN VIAL 44567 0210-10 s 30 A Al ILUNISULBAg M' 1-EA - 3GRVIAL 1 71258 0006 30 _10=_ IOMG ; TAY t 16144 0427 60 Ii 60 _ [' $4 643 90 AMRlX i 15MG CAP [:673-4—S90700 6 60 S_ �8 9 84 �ANACEN� 460 32MG_ TAB _ F' 63736 0200 453 .. 100$11.90� A ADROL �( SONG TA@` f 68220 0055 1U ( 100 ; $5 96.24 `RrvArrcAiviL � ca iu !;'CAP,-- ! vOwuw�y 6,ff3 130�� A A RAN1L SONG4f GAF t' 0040r,99d7 03]]1,294 79 __.._. Cd3 .7575MG ANC 'A6REltQE M 0017 i5241.-0 t100 Is116.35 t e $2,406,$5_ ANALPRAM HC 30GMj 3 � CRM 54766-0799 04 30 ` �, - $135.70 R ANAPROX DS _ 550MG" TAB ' I> 00004-6203-01 < v 100$558.58 REG STRENGTH...'_ .. LiQ ,. , 60573 0213;41 ii. _ _. _ .._ IZ�._ "t�11\hGG.o(v'1\.G GiJ4dll�K ... t. ', ♦ s: -.. - L.,_. �+ yv.� _ AN �FRtMAC EOPRENµ 2XL` 5742 420 M S00000 .ANKLE SUPPORT NEOPRENE `� UN> UN t _rl2a ' 51131-OIA 6 la,_: ;ANTABUSE y�_ ter„ s 250MG �__ TAB 512$5 0523 02 = _ 20Q 1_$2 T pANpRUFF 207ML _ 4 41` SH6MM 0055 I9W9 cS 207 $4-57 NTt DIARR'HEAL M _ 2MG" i CAPL Q0904 7725 24$_.. _ 12 $3 52 J DTI t31ARRHEAL 7 2M,W .772512 ? M-7 , 2 21 = Atli ITCH {222Iv1, 0 S 05% LQTN` 00536 1268 12 F 222r I $620 St)LHC� 34GM �';. �-a4.Q25 CRM ,`•� 65fi49 O4Q1-30 � �. �'� APAP%ASAFFEIC�tE # _ ' ?SO 250 6SMG b �243$5 01 APAP CTM E �325 2 SMf CARL �� 47 62 24 $3 99 �P�4P DM G� FENESI P 325 1Q-2Q0 5,� CPL, T, 46122 007 62 �2�, ,�x„�, '�� �#$6 29 `AFEXICON E (6QC,M} 0 0005 °r CRM ; 10337 0395 6Q t 64 ; $1472 45 4 APIt}RA IOML s,, s AL C34�882500 3 �� ' 34074 LE+ 21N 5" 22iV1G '; TABS j 4402 0 APLISQL 1ML EA` VIAL :t # 42023 0104 01 „1 106 60 A LI9L ML �} ° >', ViAL.' 42023 01405 r f.� CL .WAR_.,...�_�_...3_ .ARIPIPRAZOLE�_ _5,1 �� TAB 090i 03 s` C_ 2MG .� TA8 �; 65162 ARIPIPRAZOLE - _ 30MG TAB y 1 65162 0902 09_;_ _ 90._. _ $4,082.23 _ iRIP1RRAZOCE 5MfTAB 65162-0897-09. 6 90$2 88 676 - 'ARIPIPRAZOLE iMG/ML (' _,_SO_LN yl; 66689 0735 05 C _,_ _ j _ Y$312.54_ AWRIPIPRAZOLE ODT ' W ' I f OMG FTAB 62332 0103-30 30 ` --. ARIPIPRA20LE_ODT`' 15MG ,_ _ _ TAg _1: 62332 0104_30.. , - 30-. 51255.80 - 441MG 1.6ML, K!T 65757-0401-03 1.6 51�799 60 ?2,701:45 RIFE STADAy3.2ML882MG/3:2ML KlT 1 6575 7-0403W03 - 3.2� �__„_..__$3,599:2Q �... ,ARISTADA (3.9ML};_ 1064MG%3.4ML KIT.- .: 65757.0404-03,-?. 39 _ -_- A IS:TADA INITIO (2w4NLiT 61 N G/2.4ML SYRG 657S7 MC6-0 L 2 4 ARISTOSPAN INTRA-ART (5ML} y 2043jMl ?: _ VIAL' 00781 368S7S _ _ _ _ Sg 542.79, iARU TRA (0 4M_ EA), P 5MGj0 4ML ]=SYRG Q0007 3232- 1 4 __d _ j ,51,570.49 ARIXTRA {0.5MC EA) _ - 2-5MG/U.SML_ ,. - SYRG -. ' _60661-3230,11, . _ - 5 _ $667 37 ; ARIX 0 6ML 7.5MC�i 4�$MI SYRG - �QEOOE-3234 21� 6 s14570.49 . ARIXTRA (0.8ML-EA), 3uPVt�/O:Bivrl " ,. �rrc�= ` 00007 32sn-11- " - a _ _ a15 v'A _ = _ `ARM SLING {UNIVERSAL 19629y 0121 52 i �� - ���-,�- 5 r _.� - - 14� �i�� ;,8.99 � I _ ARMOUR THYROID _ 15MG TAB -_- �' 00456.0457-01_ _ _ -_ 100_ _-- i, -$93.70 - ARMOUR4THYRd[D�4 OME(3G TAB 00456�0462-01 [ T 200 -=E- _ 67.72 N j ARMOURTHYROID __ -61 _ . _ _- -_ 30MGTAB 1,00456 0458, a00 .. , . ,_...$110A2 „ _--i V ARMOURTHYROID_ M: TAAd 40455 0G5901 _1000 _2.22 � _ C ARMOURTHYROID 90MG TAB 00456-0450-01 200 $191.47 kRMOURTHYROIE ZGR ._ C�� 320MG � TAB ;��00456-OA61-OlW;: 1i 00 ��� ��$224.08 71 A ARNUITY ELCIPTA (14)100MCG LL 1NHL_ OD173-0874-14 14 . $126.75_ iARNl1ITY.ELLIPTA (14_ _ ARNUITY ELLIPTA (30) 100MCG f INHL "; O6i73 0874-1Q 30 $250.14 _ _ ARON1A51N - 25MG :` TAB, 00009-7663-04 30 $1,381.42 ''ARTHRITIS FORM7gj; Y(S6<6GM) _ 0.0003 1 _CRM'' s` 54356 2E92-OG li _. _ 56.6 ARTHRITIS PAIN RUB=(85GM) - - CRM - 41167-0500 02 ' 85 - - $5.19 ?ARTHROTEC S(i - �. � 50MG/O.2MG TAS �'�00025 1411-50. _ _ 60 (� _ $6 -3.75 ARTHROTEC75_ . . . - 75MG10:2MG. TAB__ 00025 1422 6O 60 . -, _ _ - _ °VRIFICI TL TEARS L5M SOI N _00536 1325 94 15 _ _.56 28_ ARTIFICIAL TEARS (3.SGM)_ OINT ;= 17478-0062-35 ' 3.5 _ • . $8.74 `ARTIICIALTEi3RS (3QML}�� _; - ^SOLId; j 78112-011� 41 _ _ . _ - _ - _ 'ASACOLHD _ 86OM6 TAB_ . ;? 06023-59Q1-18 180 - $2,031.00 A ENAP(NESUBL{BLKCHERRD _ w.. -7E= OEA ai 7AB 59762288806 60 Y" �-� ^^$1,296.87 ASENAPINE SUBL (BLK CHERRY) . _ 2.5MG _ - TAB, - . _59762-109i-06 _ . 60 _ _ $2,296.97 WS_ NINE 5U8L (BLK CHERRY) SMG � TA6 5 762 2012-06 ASMANEX_HFA {13GM} .. _.. - _- _ _. 100MCG.. : _ INHL..: ; 00085 4333-t)1 13 $229.63 ASIdIANEXHFA 13GM _ i 2QOMCG ji INHL; F 000854334-0 lw_ i3 52691 ASMANEX TWISTHALER {120 INH) _ _ _ _ 220MCG ` INHL - 78266-0114-01 1 $405.45 _ 'AYMAMEX YWISTfj) LE R j301NH �1EOMCG � INHL 78206 0115 Q1 I; 1 j . 223;34 _ ASMANEX TWISTkIAIR (3QINH) :, _ 220MCG _ ;. INHL . ;_ 78206.0114-04 _.. _-_ 1 __.$241.12 AAM NEX TWtSTHALER j60 !NH OMGG ' INHC Q00 341-02i� TM{i� _ _ S269.74 _ M ASPERCREME (141.7GM} -, _ w _ _ - _ CRM 1 41167 0057-05 , 142.7_ v$6.85 - IqSPERCREME i77MLL. - -_ �_�_.;,, _ _ _ j 01 '�'� LOTN 41167 0057-OS '•' �{ vµ,S4.91 ASPERCREME(85GM}. _m '_ _. . _ - - _ CRM _ _ 1,_41167 GO5703 s'_ _ -177. .- • 85 _. _. _-_ $10.60 JS £RCREME W CIDp M 4 0395 v� PTCH V' 41167 0058-40 ?ASRI RCREME W/CIQQ {76 5GM) _ _ .. 0.0_ -�.. 41167-0658-77 ,'_;. - _ 4 CRM- ' - , 76.5 _ _ - �� $9.87 'ASPIRIN IN�-_� L 3� 25NtGT� 8 - 00S36 1054-29 fr 100 -' $180 - 'ASPIRIN _7 - 325MG_ - ; : , TAB _ 70006�0253-04 _ ; _ _ _ . 500 �.E � �ASFCRIN CHEWABLTAB .`' I6� 2t73 0365-05 36 lnceIalN EC'- 325Mr . TAB _ �S 70000 0024.01 I` 300 . _ ,. - - ,S7.99 u 325MG C_ TAB OQS36 1232 01 I SG* 2.75 r _ _ 81MG _ . -.-TAB _ 00536 1149 41m i,__ ASPIRIN LO DOSE $1MIG� TAB 16103 0366-11 I 1000 ��• $10 41 °`� .- - `ASPiRIN LO-DOSE EC _ _ � 81MG �' � TAB _ + 15103 Q356-11 V SPIRIN UPS 14Q0 - $13 47 - SUPF 10GR v 600MG(r _ _St 005Z4 7036 12` itµ-77 S1$ 10 a =A SPIRIWDIPYRIDAMOLE- _ 25MGJ2,00MG -ii CAP ......... ! 7043_6-00__92-05_i_____ 60, `.�_ _' -_ '.$505.00 ASSURE PLATINUM'{50} � :: STRP. 08317 SOOE•S { _ :TEE _. TEPtiO 0.1596 (30ML) E 205 SMCG I' SPRY v 00037 0243 30. 30 M _ $193.90 T tGfNTSOCUTiONPWDR �j P_, CKT j, 51224Qi62-12 12 $,3.6_ Qom_-.� .� _. wAfiAtAtVD _ __ ;_ 16MG __, Tt��s � OutBtiu0t66't', 9v $383.3v_ 1 iTI ACAND V 32MG__�I� TA'� S • W 00186 0032 54.`Y ATACAND 4MG_ 4 _ TAB i 00186 0004 31 3� _ 30 $127 86 _ TAC ND ". _. -. SPVtG TAB {00186 000 31-- 30 _ w$127.86 ATACANU/HCT TA D HCT w 32MG 125MG'][ -TAB 00286 0322 S(77 4,, 90 ATAZANAVIR SULFATE_ - _ _ 150MG CAP yj, 59762 _ ATAZANAVIR SULFATE{ 2WMG CAF 65862 0712 6Uv r760 '. _ 1568:1i .- ATAZANAVIR SULFATE 3t}QMG. ! CAP . }? 65862 0713 30 30 $1552.33__ _ MUWMI� _, 7 AVEENO SKIN RELIEF ,(354ML)- _r ., ... _. _ ..._ LOTH . ,? 81370 001579.: " 1 , 354 - _ $7_18 __ AVEAVE O _ �f 400MG TAB 00085 1733 U1 30 $1,046.08 ;j ; 400MG[250ML SOLN F t�_ AVENOxVA_D( LASH (4OML _ .. 0_ _000j�SPRY .57:024 _,` f 1005 Q004 U _ 40 5356 4Q AVIANE {28-EA} + 0.1J002M�G; _ _ TAB -_ ,( 00555 9045 58.1, $210 96 VINZA 120MG CAP - 60793 0608`01 � 100 _._. _. -- -- Y _ . 30NIG. $636,62 AVINNZA -um ; 60µMf -'4 }LM CAP =6 3 0506-01 f 100 fAVINZA" 90MG___ t _ CAP, I 60793 0607-41_ t .100 Ji 858.80_ AVITA 20GM 0.00(03.... GEL'4 0037L__ 4�__:. 20 __- _ .. $10718 :-T ..I 5 6.SM6_ _ CAP : 00173 0712-15-_',..., . _. 30 _ _ a'- . _ __. .. $312,90 _ . ,. _ _ } IgVONEXADMIN PACK 4 EA,L ---r 30MCG tN7 59627 0111 03 � yN- 4 58 310 90 �AVONEX PREFILL {1 KiT 4 SYRG} 30MCG/0 SML ` KIT 59627 0222 OS 1 -_ $9 396,58 -f AV CAZ 1-EA} " " w _ �2GM Q.A6Gm VIAL ' 00456 2700 10Y 54 520.99 �� AXERT 12.SMG" TAB. m_i;. 00062 2085 12_ . _ 12 u AXES �RT UD ~ice fi 25MGn 1 7AB flC}062 2080 06 6_19151_ -^- AfGEST! N aMG at2o5 ^v42"+ i0 _ _ __- SO " $363.95 ` AYRSALINE NASAL 141GM)_ _ �. GEL 00225 0525-4? � 341 $3.18 _ - AZASITE - - 6.d1__._. _ SOL :_ 17478-0307-03 ; _ . _ 2.5 _. _ _ . - . - $267.25 ` FAZATEIIOP RINEy;� }-- 4�=::�50MG�,? TAB'S_ 100' AZELA57/FLU - C (23GM) _ ✓5$382_0003-01: 137/50MCG - _ _ SPRY- 60505-0953- ,3 23 , KELA5Tlt HCL{6Mi _ � 0(}005 _$OLN }E733S0938_90 _$227.79 AZELASTINE NASAL,(30ML) 137MCG SPRY 59651 0214-30„ _ 30 $105.24- _ r® m. kZELASTINE NASAL(2P-W _....__ - 205.SNiCG _;j_ SPRY ` 45802 0026-83 30 �•-_ _ z $36.00 AZELEX (30GM) 26% CRM 00023 8694-30 - 30 _ $557.24 AZILECT ! OSMG' TA6 68S46-Ct]42-56 ' �_ - 30 $125d.36� AZILECT - 1MG TAB ? 6E8-0229-56 , 30 $1,254.36 , ZITtiROMYCiN M �y_�� _ _ �___w 1GM"PAGKE LPWDR .. [_:.2762-33051- 2 �AZITHROMYCIN.- - _ 200MG/StML _ SUSP_ n,= 00093,2026-31 ,; 30_ $34.88 AZTTHRtSM_3CIN_� _ �v_T ;� 200MG/5ML, SU5P 59762 3120 01j'. i5 �; _ S3d88� AZIT.HROMYCIN _ _ 250MG 007818099-31 ,. 30 _TAB" AZtEHR(iMYCIN � rL= 500MG � � CAP 1L 2332-0252-30 'AZfTHROMYCIN w m 6001U1G TAB62332 0253-30 -30 $560.45 !AZITHROMYC{N{1 EAj _ _ _ -_ . " _. S00MG i J V1A TM , 7086 0.0100-10 !� T-v_e N-00 AZIT"OMYCIN (U/D) _ .; - 250M6- , TAB - 51224 0022-06 ;;- 6 : ..._ _ . 546,70_ A QDiNEMAXIMUMSTRENGTH TA3 -�S _ t 33_10 AZOSTANDARD ' $,5113.9.370 �40_9&6025 1; 10/40NIG 65597 0113-30 30... 5456.T2 _ .. . _TAB . AZQR� Iz 5/20tfIG L TAB.' 65597 0110-30w ( _ 30T _� _;i $361.44 s �'AZOR" __ __ _._ _._... -.- _ -_ --5/40MG _ �• _ TAB._. „ 65597.0112-30..:.____ - _ -30 $456.12 _ RZiREtiNAM 1-EA _� _ 1GNf' i( _ V_ __JL 3323>Q401-20 'AZULFIDINE . SOOMG TAB- ; 00613.010101 100 -, _-_°-„$181.13 fALFiDINE ENTAB� ZU _ j1500MG - }# 7A8 0102-01 100� BABY ✓OIL (420ML)_ OIL ._. ' "-� -PWD I+_ 81370 0033 14.:_ , 420 B BY POWO CORNSTARCH {425GM}°` - M�}[ 96295.0129-844 435 BABY PO4VDER j270GM 11)_ PWDEi ;, 81370 0030-21 [BABY PdWDER(450GM J1} v]_ _ _ PWDR 81370 003O-S8 d50` Ji-$5.35 j BABY SHAMPOO (2QOlVtL-J1} - . _.. _ . _ .. _' _ _ _.. ,._' -- _ . - .f.SHAML_ _ .. 54522-1440-00 j; - -_ _ _ 200 $S.QO kBY SHI. AM POO (207ML)IL� _n.�� Llq 38137C?037--� 8 �207 s_�_ _- _ ' ,$3.17 SHAM 38137 117S-71 I,__ 40-0'- jBABYSHAMPOQ 4MML} {{ �I�,- � SHAM AM ��}-..38137 0637 24 jE 444 ' �L� S4.76 _ BABY SHAMPOO (591ML} SHAM ,38137 0037 40 ;, _ r 591_ 6, A8YSHAMPOO{64f)tviL} - SHAM^ 5453, 5-190U_O„0 600 06182-0747 67 S0 ,, $4.95-- _ BABY WIPES;; w 3600 0289=75�� 64: CAPL__ ----- BAC� ITRAG N 144 X 0y9GM OINT 61f78 4116 ? 14Ay V �L_.-„ BA Ct,TRACIN(284GM1Ii} _._ 5000/GM ,_ OINT_._ 00713-028D.31,, 284_ _ _ .,i_-.__�_ $3.47_ BA 'INOPT 3 5Gt;4} -_ ' . . 5OOU(GM' ° s "j� 01NT-, 00574=d022_ 35] 3 5:�]:" _ 1`99 23: Ltj BACITRACIN ZINC/POLYMIXIN-B_ OPTH OiNT 24208 0555 55 - 3.5y _ _ _$28 65 BACITRAc-IN /Z{NG 14GM 500 GM~ DINT 61269 0105 34 BAGK BRACE/SUPPORT PAD UNIVERSAL 74676 0672-11 , 1 $17 48 ._ 'BACK SUPPORT " ' i ->_ 91709 0000 5S }_�- 1 60:00 dA4I(sUPNORt Bela ._. - ... , ._ . w/?�.4u :' - _._ _.. ,,..96295- 0124 62 .__ _ _ i ..` _ . _ .. -- $30.00_ BACK SUPPORT UNIVERSAL --- r. L---�� . J... .__.. 96E._, IOMG _._ ,; TAB001734096.80 _� 3000_ w $226233 _ p �BACLOFEN__ 20C IG _w TAB 17Z-4097 86 l 1000 $4,69705 ; �� i BACT SODIUM CHLOR (30Ml-EA} 0 009 MDV ` r 00409 1966 14 750$50.10 _ (BACTERIOSiATIC WATER (30M11t1 Ej y� MDV 0040.9 397?-03 *750 - * :; 551.66. _ _ _ 6ACTtNE PAIN RELIEF (150MLj_ _ SPRY - E 00280 0730 OS , 150 _ ARIM 40O 80MG „� TAB 49708 Olds Qi 1Q0 $17Z 86 BACTRIM DS _ `V �100 _ _ $311.95 _ __ _,_ _ �� 0 d 1BELLAD4(dIVA/PHENOBARBITA_ L $28956.9.050 LA B`60258044LAHISTD 9 02 __TABLL BELSOMRA _ 10MG }, TABM6 0033 30 j 30 25MGCAP- 5MG/5ML L 35058 0534 08236� ,`BENADRYL-(60ML) EXSTRNGTH -,; SPRY,045013203,02 . 60,- _ _.' _ _ ___ 55-03__-. .r BENAD'tYI ALLERGY- - 0 EEa [=aLP ;` ][' 5_41-2001 2A 24 � 4 $4 55 r +SENAORYLALLERGYFA5T--MELT f2,5WIG TABv�[:Q 45 0180 18 24� 7 �5520 B(120M� ENADRYL DYE-FREE 125MG/SML $6.72 7 ., SENAD XTRA STR 30GM _ , y� - y 2 0.1••9° RM y 12547 0171-67_ jr�.___ - 120 }54 _ BENADRYL ITCH STOP (28 3GM) - _ _- i 0,1% _ _ ;!_ _CRM12547;0171-62 B ADRYL M%S ITGHSTOP _ j � GEL 12547 0172-57 3` i . _ $., _ BENADRYLULTRATA_B _ 25MG - _;. _ TA&--_ 00501 2Q09-24 _ 103 _ $4.49 _ _ _ BED NADYLALLERGYCH£ifi/ABLE _� 12.5MG�- TAB 5Q5800232`Oi__ 24 BENAZEPRIL HCl ' _ 10Mb . :- TAB o585� 02's6 v1 `` _ 20 _. _ _ ;8EN EPZA R!L HCLHCL _.,.._. _ _ �„ 2QMG _% TAS �L 65862 O1S7-01M}(� 100.j $14S.i1 BENAZEPRIL HCL_-.- ; 40MG TAB 65862 0118 01 --_. 100_._ $105.11 _ - _ __ _ BENAZEPRIL HCL ' 5M0t TABYµ 43547-0335 10 10- t}y _�� LIE d 5105 00 ,BENAZEPRILHCL/HCTZ 10/1215MG TAB _ , ,00185.0325 01 . 100�.._ . $206.74 jBEWAZEPRIL NCL/HCTZ A.� 20%12:SMG TAB�_"l00574 0229-0i�-m� 1flQ`� v. . $107.36� BENAZEPRIL HCL/HCTZ 20/25MG. TAB 60574 6228-01 : ' - - 106 $167.36 (BENAZEPRILHCL�CTZ _ _ _ f6.25MGj -TAB-, -1 00185 0236-0%� .� 100 �,; _ $206_.71 BENEFIBER (152GM)_ PWDR 86790-0213-80. ,'- 100 $7 88 - , $EN£FIBER (248GM)._ _ _ .. �f: -_ = I' PWDR" �86790 0216-24 t 152 SENEFIBER{500GMj� _ PWDR 86790-0218.30 ;_ - 248.- - $19.48 _ _ N PWDR�867900162_80_ _ 500 BENEFIBER S/F (245GM) PWDR 00067-0044-62 . 28 _ - _ $10.66 ENGAY ARTHRITIS 57GM. _ i__ r CRM== 4 OQ 0005 _ BENGAYGREASELESS(57GM) CRM 74300.0081-86 '_ 57 53.95- ,BENGAY ULTRASTRENGTH PTCH 743Q81 ,BENGAY ULTRA STRENGTH (113GM) 74300 0681-94 4 $7.58 f3ENGAYULTRASTRE_NGTH(57GML__ _CRfvi , _ - -- - BENGAY VANISHING SCENT {57GM} GEL ;, 74300 0081-97 , 57_ -- $4.32� �BENICAR _ 20MG TAB 65597 Q103-90i � l_ _ v- BENICAR __ 40MG TAB 65597 O1Q4-90 90 $1,647.60 BNICAR 5MG ([� TAg 65 597-0101-'30 Y _ _ -PENICAR HCT _ 20/12.5fviG TAB 65597-0105-30 s' , .9 30 _ __ NtCAR HCT� _ ';= O:/12 5MG = _ TAB,' 65597 0106-90 fit, _ _$289,80 _ 'BENtCAR HCT 40/2SMG TAB_ 65597-0107-30 90 _ $402,84 BEND YSTA {1ML-EA� LY- _ _ j _ 200MGj(YtL�L SYRG 494010488 47 j� - 30wt�'$5,534.28 . �..� _. ;BENTYL 16MG _ _CAP - - 58914 0012,10 4 $66.20 �. +BENTYL ._.J20MG 3:_ TA8 �_� 5i._.8914 0013'10, BENTYL (ZNIL EA} ;,_ . ZOMG/ML _ _AMP: 58914 0080-52, B Z_ACA 60GM}� _ 546 „-_ice CRM ,I E 07 299-3625�60 1 � w 113.04 BENZAC W A. GEL 00299 3590- jRENZAG£L 515OZ590 _ GEL :0056 Q430-I5 _"dC 60 _ 527_Sl_( BENZAMYCIN_{233GM}. _ 3.50% _ `, GEL : 00066-0510-23j: -__ ._42.5 _ CBE NZAMYCIN (?16 6GtYl} _.__..-{i 3 50°Io- EL 000fi 6 OSI()444 3" $405.31 BENZIQ,(17q§M)_ ._ _ _ _ _ _ -- ._ _ r...-. , .. _i. 5,25% ;- . WASH,._ - 29336 0210 18 _Y. _. - . -. _ 46.6 - .. a_. . ` --_._ "_$80.09 .8RNZO�I..____�,20.00% �� R _]71587-0105.32 2.62 BENZODENT DENTAL PAIN_(2$GM) _ ; __ _ 0.2 CRM ` 71687 0105m34T5. _ r7-_ ._ _ $5.90 46ENZODOX 60 ��F' _ j( K!T 1 42783 Q663.60 28 j -.L1097.95 gGN�nlr� riNr 60!1!L r = w I !Q ,. nags-0Z47 9Z Y (. } 1 _ S12.62 ±BENZONATATE I CAP 42806 0714 YO 1134 75 iBENZONATATE _ _L-MG 200MG �. -CAR,_ �? 42806 0715 05 };m - 500 __-__ __ �� .-. _ __$2,145.45 BENZOYLPER OXIDEt 148GMj� "" 0 % WASH` f 35573-0454=91: 500 '=_ 9.3d~ 35573-0453-9'. _ . _ 548 _ _ - -LL---, $8-98_ _. BENZOYL PEROXIDE" 703GM 0 0& WASH 6T4d5 0835 06 L_ _. 148, �,� __„ 1644 BENZOYL PEROXIDE (227GM} _ ;+ 3% WASH 4 24470-0911_d8 170 3 $247.18 _ _ g $ENZ' ^ zOYL PEROXOE:(237GMj y 1030 WASH 35S73 0454 08 (�:�_��� 227 _-" 14.16 . 1d05 WASH _ 35573 0453 08 , _ 237- -- _ a $13.49_ �y BENZOYLL PEROXIDE (29.5ML) _y- LLOTN"v536 1 -,. _105745` 1 E�237 ' =_JI _ __ $3702 BENZOYL PEROXIDE ,(29 5ML) 1U 00% LV I N:",- 29 D BENZOYL'PEROXtDE 42 SGM 5 00h I GEL - �00536 2055 56 29 5 - 5 68 BEN20YL PEROXIDE (42 SGM)_ - BENZOYL PERQXiDE 60GM 10% ; GEL 00536 1055 55 42 5 5( 45800 2 14195 42 5r ; 0,_GEL _ BENZTROPlNE 0 5M�__,_^� TAB,' , 69 p136 01 60PE_ $2BEN2OYL Q 259 _ - B( NZTROPINE _ _ _ _ !�._ 1MG . _ �- 3 TAB w i� 69315 013� ,10 r _ .. 100_ _ .+; a' $388.63 BENZTR4PINE [ 2MG- - e v-� T-AB 19315 0138 10 L 000 n BENZTROPINE_(2ML-FA}, -_- _ 1MGjMl_- _I_ _SDV _�x 68382086040.1 14�- .._. _'529375_ _- _, _'r BILTRICIDE �� ��_ 600MG TAB _ ({ 50419 Q747 Ol ; 30 _ $597 88 _ _ B N1ATdPROST OPTH 2 5ML ; Q 03"% - i, 50LN 60505 0583 O 6 _� 234 63 tBIOFREEZE_(84ML} • �59316 Q103 12 25 _ - $1198_ _• _ _ -,_GEI _ .. B; IO- GLO OPTH__. ---h- -a .�` 12-38 0-9ii- _$j $2124 TEARS PF (28) i 2%1.1N _ 0SQ4 BIDNECT(25GM" o42ti CRRM !Bl9PATCH PROT DISK WITH CHG _560910021-50 t•_:-- _ 25 _ _ f, $225 00 °LBtOTENE DRY MOUTH 1000ML__... __#4150" H MINT j 48582 0004 44 �iQ- DRY MOUTH(1214GM) .FRESyQ _- 1000 01;BIOTENE j8I0TENE DRY Md UTH M a fi00135.05707 04 1219MOR-- -- 'BIOTENE DRY MOUTH GENT (473ML) MILD MINT UQ _ 48582 0045 66 , _ _ 44 3 ' _ $5.65._ _ -,, Y810T EN ME EN ME OUTHWASH Z37ML) _ _[( 485820802-20473°` i -.: 354 i410 ENEAS (473ML} _ _ _ ;' L!R M 48582 .0 -36K __- 237 _ $5 65 _ -MOUTHWH t$iOTENET00THPASTE MINT GEL Q02'Y 35 055�7-41j��473_� $5 65 BIOTIN 1400MCd " SFTGEL 31604 0042 73 ', 1219.. (BIOTIN _ w 1000IVMCG TAB =629 3985.0i g{ 2500MCG CAP i 31604 0425 46 ;, 120' ._- - - - i 5000MCG j CAP30768 0134 34 v 94 i - BIOTIN CAP _ 74312 FitOTIN FORTE � 3MG '� _TAB CS4022� 1 Q 7a j _ $$,AZ — = _ BIOTRUE MULTIPURPOSE SOLN SOLN 10119 0358-63_ ii 60 - $9.52 ; BISACODYL ZOMGJ! SUP i 00574 7050-12 300 �v BISACODYL EC :.. 5MG 06904 6748-60 � _ 12. TAB $1.86 .._. .. %1SACODYL EC _ _ - ! �^ 5ML J TAB_' ]; 00904-6748-80 BISOPROLOL 10MG TAB 70954-0456-20 ' 1000 _ 0215.30 SOPRQtQL 4 _ _ - 5MG_ ] TAB. 70954 0455-Z0 200 _ _ f` _ ~ 5225.30 BISOPROLOL/HCTZ - 10MG/6625MG TAB _ 42799 0922-30 i 100- $221.16 iBISOPROLO HCTZ.� _ _ vr? 2 51NGj6:25MG }TAea�29300 Q187-030L.Y�-_, 1,170.35 BISOPROLOL/HCTZ 5MG/6.25MG . - TAB 29300-0188 05 ' S00 $1,170.36 :6iACK CQHOSH v _w _ i' ..� 40MG �w it _ CAPS { 11845.013Q 4 _ ;BLANKET 999999000-76: 60 $000 _ BLEPH 10 OPHTH0.3� ji OtNT 04023 0311- 1 ]� _ $416 ;BLEPH-lO.OPHTH 01 DROP(S_) 11984 0011-15 3 S $17 14, . __ -_ ;BLEPH 0 HTH i4MQ__ !' 10So�_2% '( SWP{ BLEPHAMIDE OPHTH (5ML} 10%J0 21 SUSP, 11980 0022-05 ,; 10 $192.48 <BLE AMIDE OPTH _ ! _1Q9o(0 2% Y (7zm 104023 0313 04 BLINK TEARS (15ML) _,. 0.0025 SOLN 29943 0002-15 3.5 _ $9.37_ BLISTER 24X0 214Z) " _ _ _ II. , OI T ��10157-9 551-02 SIiSTEX LIP_MEOEX(12X0.25} OiNT " '. 04138 8000-09 ! _ 24 i' - $10,35_ GISTEX MEDICATED �✓~�{0.35C1Z Jr dIN C ] 10157 9920-03 12' _ 1.89 ;BLISTER MEDICATED (7GNi} OINT 41388 0214 21 t 14.5 - - BL(}OD GLUCOSE LEVEL BCOODGLUCOSETEST- STRIPS STRP 52735-0694-12 i _ 1 _. $22.49 _ _",- rBL000 PRESSURE 99999 9999.53� Y- �W- - 'BLOOD PRESSURE CUFF _ _ .,, _. LARGE, ;, 93764 0010 69 1 $31.66 IBt00DRESSURE G POFF - __S .IF REUSABLE ' j( ,BLOOD_PRESSURE CUFF" - X LARGE 99999 _ Bt00D PRESSURE CUFF MEDtCIUE �,;-_ 4 682 Q719-Di Y ;BLOOD PRESSURE CUFF_(MEDL!NE)_ _ -� I , ADULT_ _ _ 43317 0400-03_ �;- 1 _ $60.00_ _ BtOODPRESSURECUFF :BLOOD PRESSURE KIT -MANUAL WITH STETH - '_ _ 5279$ 2300 00 i 1 - _ _ $17.99 _ (BLOOD PRESSURE MONITOR-w-M��LARGE. ._]' 93764 0601 588s$52 99 ! BCU£GEL (227GM} 4 4 02L GEL rl 00536 23t}2-59 ;BLUE STAR MED ANTI -ITCH DINT 68429 0201-02 _227 LBOPL EA (28GM} : t7 2 OINT-; 63736 004130 4� _ q -.-SE _.. -80NIVA �� _ 150MG TAB 00004 0186 82 28 _ $687 41 :BONiESTA`ER 20 20MG �1 TABji 55 94-0120 6035835 54 BOOST (Z37ML EA)" CHOCOLATE , ;•_ " CRTN_ 43900 0675 39 l 60 r _ — - $36 35- m__. BOOST(237ML EA - CHOCt}LATE�t����LiQYry 43904 0169 7Z 56$$ 32 31 ,BOOST Z37ML-EA ( } - _ N - VANILLA_ ', � _ CRTN, 434Q0-4674 39 5688 6__OU (237ML EAI :: �(� _ _ _. UANILCA UQ, 436 5688w .__ STRAWBERRY BOTTLE 439Q0 0576T$$ t . 5688 _- $33.10 _ Bd05TGltlCOSEZCONTL 237M1-EA} CHOCOLA?E UCl' - 41679 0216 42� 568$' $65 04 r._ _. _ BUU�{ NivH PROTEirl (c3/mi tx - _ - c ndc tiLa�� LICt 41079 Q94Q v`v 5558 $an o5 BOOST HIGH PROTEIN Z37ML EA}_T - F Ql 4167„ �9 094� 66 1P444 ,_$40 9a _VANILLA- - ;BOOST PLUS (237MGEA} _ ', CHOCDLATE . _ i; LICI 43900 065142 ii _ 5688� _ . -- $34 Q7 $OQSTPLUS Z37ML=EA [7 VANILLA 11C�'; s" 4390Q 093139� S68$- 'BOOST PLUS f240ML EA} STRWBRRY BOTTLE 41679 0933 66 F BOSTON ADV CONt 105MLq "- SOLN 10119 0056 0 1440 , � 9.53 BOSTON ADVANCE CLEANER(30ML) _ _ SOLN I' 10119 Q054 V21 �BDSTON ADVANCE REWTTNG (10ML) " < 47544-0055 09 BOSTON CLEANER (30ML} _ T N ySOLN SOLN_.__ , _31011 9054-20_ 10 - _ _ �' • - BUPREN/NALOXSOBL 8MG/2MG TAB i d0054 0189 13 34 _ $312.64 1 IBUPREN NALOXSUBL U�Dj 2MG 0�` G �1�?A.B 009d4 7009-06 30 w{ _,�•,._.a,g7.44== ---_ ... BUPREN/NALOXSUBL(U/D)__ 8NIG 2MG ,, TAB , } 00904701006 50_, $23910 BUP� iiENEX_ iML-EAj' - 0.3MG ML , AMP 12496 0757 05 50= $9102 BUPRENORPHINE _ _ IOMCG/HR __'� PTCH �s 00093365140 _ 5 !_$45906 _, B PREIVORPHINE 4 20MCG'HP PTCH 69238 12d5 02 _4 y . 884 22 BUPRENORPHINE 2MG ii TAB 00054 0176 13 4 $124 2 BIIPRENORPHINE SMCGHR PTCH 69238 12d2 02 r 30�1._.___�__?$32 97 BUPRENORRHINE ._ _ 8MG TAB L00054Oi7? 4 BUP EN ORPHINE U/ TAD6 Qj _ -• - . e „ 068? 04812-1 30 R _ 7350 BUPREPlORPHINE,(UID)_... 8MG TAB 60687 0492 21 30 S226.00 BUPROFtON HCL 100MG r. TAM 605Q_:& 57 Old" 3Q ? :;,5106 0�,1 - -- �BUPROPbN HCL _-_ �;__ _ 75MG �s TAB. _ `� 60505 0158.01 _ 100 _ $79 34 L a r��� _V - $844.50 t BtIPROPiONSR ti --r _ _...1001VIGj TAB 70435Q058.d2 i0� ©_ _.,•_ey 150MG ; - TAB _ , _ 70436 6659 42 500 _ $968.55 BUPROP(ON SR - �BUPROPION 200MG m`� TABw' 74436 04GQ,.,QOL __$337:80 BLIP PION XL _ _ _ _ -- _ _ _ . _ __ _" -----150MG _ _TAB._ _ 70436 0010-02 s. 100, JU�U ROPION xE=_ X _ C:t 300_ QMG 3 TAB , 68180 6320 02 L _ _ 50__�y6 `q�� 384.05 ,BURN�JEL_ V� GEL _ 86169 0020-23 _. S00 $15 00 _ "_$20518 _ _TAB; 00 0819 41_ 90 ��� _ < - BUSPAR _ _ _- ,_ _ 15M6 - - , - TAB 00087-0822-32 100 - 9183.96 BUSPAR A y.1 00087 081&41 ; _ 60__5127.bS v _ _ AI BUSPIRONEHCL� _ 10MG TAB 23155-0024-05 100 $652.33 UBPONEH_CL _._�+5995.176 " _ 68382-0183-14 500 _ - $218:00 _ .BUSPIRONE HCL 30MG TAB _ _ BUSPiRONE HCL J!B 23155 0023 60=mt $37400 _ �BUSPIRONE HCL � 7.5MG _ TAB . 16729-0201-01 Soo' �_ $158.03 � BUTALjAPAP �50MGj32SMG 11._ 7AB` H 00603 2540-21 � ___ 100' 156.26 _._._ _- __- BUTAL%APAP)CAFF 50/300/40MG CAP 70010 0044-01 100 _ $481,41 _ _�_... as m BUTALjAPAPjCAFF ___�_ _I 50 325 40_MG_ ; _TAB �, d0527 2695-05 104 BUTAL/APAP/CAFFPLUS 50/S00/46MG _ TAB 00143 1115-01 500 BUTAL%APAP/UFF(COD t 50/325/40 Q P 1005913220-01 i00 t� 'BUTAL/ASA/CAFF 50/325/40MG CAP 00591 3219-01 100 $169 98 8TAA5f�0_ P 52S4045 _;3 04 --. BUTENAFINE HCL {30GMj_ 0.01 CRM 51672 2100 D2 100 $12 04 ;. __ . _ _ _ 4® M t. 30..LL 9632 = s •BUTORPHANOL TARTRATE 10MG PER LPER L � SPRY`��00054 3090-36 ,_� BUTC?RPHANOL (iML EAj 2MG)ML _ ' _ 5DV 00409-1626-01 2 S _ _ . _. _ _ ._ _ _ _ , _ _ __ BUTRAN5_.� 10MCG/HR PTCH Y ,590110751-04 BUTRANS 20MCG/HR PTCH ,, 59011-0752-04 4 ; $1139.58 _.w jBUfRANSSMCGLHR� PTCH 590110750.04 ?n A (( $428.75 ,BUTT PASTE (454GM) _ PSTE 62103 0333-06 4_ $21.44 !BUTT PASTE {57GMj� 40.00°fa�ONT�� 62103 0323 Q2�� _ 454 _ I -. - - BYOUREON (1 EA} - __ , , 2MG PEN _ 00310 6530 04 57 -_ $908,68 B? YOUREON {2 E •N� �2.,_,•__MG VIAL 00310 6520-04 ;BYDUREON BCISE_(0:85Mt EA} 2/0.&SML SYRG , - _00310 b540 Q4 4 r - - _ . _ __ _5964.02 _ , ____. - BYElTA (10h1CGj. .•w [ 250MCG(M! i PE 6 780 0212 01T 3.4 BYETTA(SMCG) . W 250MCG/ML.. PEN �. _00310 6512 61 _ 2.4f t62AANTISEPTIC TOWEiETTES � ' ' -67777 0245-q1 --__... _ &&NOVA (6MC}_ 600 900MGj3ML . 5DV 49702 624U 15 _ _ 1060 y _ $7,60L28 CABERGOLlNE - �� 0 SMG __, TAB 50742 0118-08 ,� GADD MS3.;+-00021 7450 24 _ _ $___ $125.Q0 ,GADUET _•, ,� _, _�µ���� ?0/10MG �-`TAB 00069 2i60g3D �10 ?$628.2D wCADUET _ - a, SO/ZQMG TAB OQ059 2180-30 30 :w CAC)UET FJ +]�10/4©�- MGM __1 TAB 00069 2250 30 - 30 � f LL 5859 37 TAB ; 1` if 2960 30. $388 02 'CADUET yi^ 5 10MG Wk VTAB 00069-2150 30 30,� $628.20 5j20MG _ il_ TAB ;' 00069.217030 ' 30 C" �ADUET 80�G _ �,7A6 . 00069 2260 30 ,a0-"���'� _ $859 3? - - -' - tAFFEINE _ ._ r_ .__ _rt :.- ^_200MG_ TAB:._; 700000409-_Ql.11__.____. 3Q._. _ i_ _ _,_ 5279•_ MAG INC�� 12 0442=90 15 $3 73 CALADRYL(177MQ _ _ _ -`_ _d _ _ - _ ' ._ ._. LOTH _ t _00187 5465.06 $4.¢6 _ CAiAMINE 180ML _ v:- ` . �iI LON' L.00904 2533-21 l 177 CALAMINE•PLUS (177ML)_ _ _ LOTN 70000 0404 01_•, __ 180_ $3 99 N- 120MG ( TAB 00025 1861-31 177 $546 R. CAIRN _ �i _ SOMG TAB - 00025 185131 100$369.42 'CAt AN SR mow- j 24dMG TAB ;00025 189131 ��' 10(} - ' i� �$1 Q6717 ,CALCET CREAMY BITES__ , _ 500 400 CHEV+/ 01780 0277 30 1 100 _ $8 99 �CAECtBIND� PWDR t 0017$ 02S5 30! 3d( 163 13I CALCICNEVV _ ; _ 1250MG TAB._ ;, 00536 3?92 Ql 300 _ $1166 _g ' CALCIFEROL(60ML 4 - [ =-DROP(5j 9 41506�00___..%$z06,2z CALCIP/BETAMETH:(60GM1 _ Q005/0.064% OINT• 66g93 0939-61 0 _ � 5788.94 CALClP%BETAMETH SCALP 60GM s 0 005 0 064% SUSP £ ?` 66993 0937 61 12�5.78 > - - CA OTRIENE {C120GM),_ .__ 0.0001 CRM 56993 0877-78 ; LL- 60 _-_. _:_ . _ $810 21 ,CARDUR.4 CARDURA _.. 4iVlG - O4649 277{} 66� � 100 $690 56 v u,_�LTAB , TAB A -� GARDt1RAXL 4MG �" L TAB ;` 000491030 10 27-: � _� -.�.. �t�w $23802 -- _ CA-REZZ.ANTIBACTERIAf — k.. _ SOAP 60762 0108`12 ;, - 30 C SOPRODOLQ 250MG TAB.: �= 42543.0434-01 --_- --- _.._ 354MG TABS p' 50228-0109-10 lOV 7�yb•�� CARiS,_ ___ OPRaDOL/ASPIRIN 200j32SMG] - TAB 00185-0724072h-Ql$239:20 rye oeew ror•ei_ ,,. _ ... ...____ _ __ T- `iiiki+ . >zzmu nl aZl F1 f CARN__._ AiIUNB 23?MLEA_ F CHOC FU 50000-041516 8 �3 ; $7S.W .—._- `s - CARNATION B/�_taX6�zgzN_It.'l ;- : F R VAN �'LiQ_" , �tifu�3 04ia 38 563$ . $� 14 _ _ .:._ _ _ _.._ KG RNATION INSTANT237ML-EA} Cl�BRKFAST [::B TILE S-W-0 0915 10 5588 1 v]�_,^_ ;CARNITOR _ 330MG r TAB s-; _54482 0144-07 __ " 2844 ! _ $12814 �CARRA KLENZ 480ML _ C: SPRY,' $019 6049.�1 $1303_ 480 $17 44 _ _ CAP _c__,_62037 05989Q_:___ _ _. 90y 'CEFPROZIL _ . 4 �� e 250MG TAB . 69180-0403-01 � 54DNiG� TABS) 6818Q 0404 01 lt}0 � . _- _' .. 452. 99� _ . GEFPRO_ �Z1L iCEFTAZIDIME"{i-EA) _ _ 2GNi VIAL 1, 44567 023610 Sd _ $12040 'CEF'TAZIDIME 1GM-EA} 1GMllt� 1A.__ l.j 254210227 6 10 597 ;CEFTIN 250MG TAB 00373 0387 42 j 25 _ „ $355 O8 _• ___ CEFTif� � v SOOMG t TAB 65939 6394 42 60 a $80418 _.. CEFTIN (100ML) _ " _ _ ," 250MG/SML , ;, 00173 0741 00 _ 60 3GMA_D_V_ Q0409 7333 04 I 100� _�49 7Q yCEFTRIAXONE (1 EA Ye ? ;CEFI RIA}{ONE (1-FA) --=-, 1GM �: VIAL __I;_ 00409 7332 01 ,. _ _ _ 10.. _ . _ _ $18.28 _ _ _ _- . _ ,. _ _ _ _. GEFT�w XONE.1-EAR_ 250M r VIAL S 047813206�95 _. . RIA �,CEFTRIAXONE (1-EA} E AOV _ iI 00409 7336 04 , _ 33 zGM--VIAI409 75-03 10. , . $95 68 1034 72 EFTRIAXONE {1 ;CEFTRtAXONE a �-__ .' - , k 00781 3207 95 1_0 ' " -- S268 84 CEFUR{}XIME AXETik 250MGf TAB 65862 0699 2410��" �$87 97 �CEFUROXIME AXETIL 65862 0700-60 , 5001vMG , TAB r 20_ _ .. _ b S4s0•od _ _._ e_.._ C 00Q87 7720-6O-�L_,�.-_,_,. 60 5486.56 � TAB.. `�__'-___-'____�'_ CEFZIL(100MLj zSunnGfsML _ SUSP " , 00087 ir19.64 � � GEL,CEL R 200MG �;: CAPS 4 00025 1520 3 2Q0�� nj $1,143 9Q CELESREX " _ 200MG CAP 00025 1525 31 ;, _____ _ _100 -- _ $1,876.31_"__ GELECOXIB 10pMG' f CAPS" 69d 97-0422 1 00;2,308.45 iw - --_ ti_ u� ,CELECOXIB G E OXIBp^ " 2001VIG CAP 69097 Q421-12 'ECAi' 69097 0423-43 504 _ ;r $3,790 20 K.,..__. .__ `CELESTONE SOLUSPAN (SML-EA} 6MG/ML MDV 78206-0118-01, ti0 $47 O8 16 CELEXA �. 10MG ,l* TAB $g 00456�401(7-4 wr 5 i Y_51089.254�wA_ _ CELEXA - 20MG__ TAB, 00456 4020.01 , lOQ .. ..-_-_ ICELEXA __ ___ s_ 40MG j`_ TAB j00456 4Q40 Q 3Q0 _$1,135.32_ CELEXA ORAL (120ML) _ 10MG/5ML SOLN_- 00456-4130-04 . 100 _ _ _ $53 60 _ ..-s r-_...=�____"._ 2501V1G CAP lr 0 0040259-01 i 120- _ _ fI_ _ $1079 51 _ CELLCEPT g OMI} _ 50QMG _ f0000000044-00260-r091. G/ML 12 100v. 2(0, $2�,1559?._002 $6200MCLLCEPT 4 CPV1 CLET _j 00MG. V004 0298-09 SCELLUVISGOFHTH 30ML� __ _d—PSTUAS: �_ 0Q_2_ !; SOLN __1„!OQ02� _3-45 S4Y30; CENE_STIN 0.625MG TAB _ `' 51285-0442-d2 ; _ _._ 30 . $436.80 _ _h ,CENESTIN��_ 4:9MG TAB 51285 044 0 w_ _ w —_ 200 �z _ _� $?36�8Q _ __ _ CENESTIN r 1 ?SMG TAB 51285.0444-02 , - 100 $427.60 C l TAVITEA-Z TAB. 01013-5224 53 1 1Q0' 4 j�Y W4 513.56 M� 'CENTRAL LINEDRESSINGTRAY W/TEGA-OERM ' 08333 0612 49 130 $200.00_ CENTRAVITE SENIORS[ _j' TA63 ti 3445 08 1, 20I$465_ - CENTRUM LIQUID _ -OQS36 - LIQ 30005 4343-&1 t� 60_ $8.09 _ _ _ CSILVER SLVER MEIVS'S0+ X �F� 1i� 7AB 045 4758-70 - _ 240 j $17,99 _ CENTRUM SILVER WOMEN TAB 96295 0137-24 } 240 $15.29 RUMVITAMINS _ �' _- .� ABA. L 80681 d142-02 204 CEPACOL LOZENGE EXTRA STRENGTH i LOZ„ 63824 Q715 16 130 $4 88 w _ CG ACOL MOUTHWASH GOLD_ m_? SOLN "v (63&24 0790 80 iT A 16 . py J $7 94 CEPACOLSUGAR-FREE_ _ _ CHERRY LOZ? 63824 072216 710 CEFASTAT-SUGARFREEYLO 1 Z� fi3736 01 _2f 16$ 59 CEPNALEXIN_ 250MG ;' CAP 67877-0220-05 I 18, _ :.. _. - ; _ _ $414.80 _ _ _ ._. _ _ _ _ .., -..: i 500MG" CAP 678� �77 0219 05 GEPHALEXIN�_�� �500 L$9$5.35 I ;GEPHALEXIN (100ML) ;_ ?SOME/SML w 00093 4177"73 500. - $28.75 i EPHAtEXtN 200ML_.Y _!. " _SUSP _ ." 250MG,SMLUSP y I'67877 0545 6$ 200 $4050 _.. 4- ,CEPHItADINE" _ 2SOiVlG CAP, , 00904 2837-60 " _ _ _. _ 200 $55.Q0 E UA O t}009 SDLN. �47335 4508 96 100 $-67U ;CERAVE-(340,GM) CRM 00187 0248 13 . _ ,.. CENAVE 355NIL}_- -Tf®��j LOTN j 0Q187137112 i 340� $1044 ; CRM CN]187-1373 i6j t� 35S 518 91 GENE 56ML l_.. .... _ y I_e"w- -, CRml ... " 10EREFOLIN NAG__ _.01871-0373-32 s: CFLT _i _00525-0555=90 i GEft{3VITE(t` �CEROViTEJR _. _ _ Tqg M"] 0053 6 442 3µ M 90 _ 645 L _ .. CHEW # 00536-3443 O8 _ 130 _ _ ` _ $4 40 _ _ CEROVITE;SENIOR '" TAB 00536 3445 08 - 64 �� 65 �� SYRG 58150 4830-52 100 �,�__,_1;589 58 ,CERVARIX4 5Ml-EAPI)j�_,_„ _ CERVICAL COLLAR_(2;5) ,_ UNIVERSALj; 73838 4234-57 r _ 5 - CERVICAL COLLAR STIFNECK UNIV 99991.6 (?281t30��� ; 1 �I 1200.a CETACAINE"(S6GM) SPRY i 102`23 0201 tit CETCETL- N02990 0241 33 y 10.Q8 P i -.� 473ML �_ :-` L--_LOI::. _ __ CETAPHILCLEANSER;(S1BML)_ _ _ I __ lOTN4 ! 0�2993921td0 , A73 1 118 $3.66 -6 Y yCETA�"� PFiIL�LFJiNSER'(237~ML LCiTN jO2990-Q110-? ------------------6 CETAPHIL CLEANSER (473ML)_ �__. }�. ; _ LOTH,'- I. 00299 3921 16y 237 'GETAPHIL'DEEP SAR:�127GM} w _ _ _. _ _ _ _ I _ _BAR 30299 3923 57 , W7~473,_ CETAPHILGENTCLEANSR_(473ML) UC: ;f 02990-0110 22 j 127 GEiAP"HtLGEhEiLErBAR 127GMW _ _ _ __ _.. BARS{ 44Z99 3923 04 473V354 0299Q0241.32 7_ — IEA :CLAFORAN (1-EA) LARAVIS L GM AL 00039- 0019-50 310 20 -ViAL" IV600��.601�46!� �d E,=00555-_1054-86 :CLARAIM 3-6, ZIARAVIS 61694 7 40MG CAP 00555 1657-96 Y' 3-6' #47.43 LARIFOAM EF �FQAM Q.=678=1-=QJ-=54-60 38A, 4 CLARINEX two 77- L Q.SMG� ML �W=RP- E:OZDO—�85-1334�0�li INEX-I) 12 HOURAB" - J� 876.00 0 -- _G—OL4 5-- 2 5-16-0 S-100 < -q16539 `CLARIPEL,W/SNSC JRM RiTHROMYCIN �250MG 1�--'�ASL6 360.92' ----- - $360.92 L 01MYCIMER C A - �500M�G--537.04 ,PLARITIN _TAB _j69 $22.3 60` 3--s=mL --1-10-0:68-9�4-63-� 5 —MG E" =RP,-�C�4 5; --- - - !,CLARITIN-D (OTC _§ -24#0VR TA�B-_Jl 41100-0802-89 BAN SELF-ADHERENTWRAP 1 6 INXS YDS MIS -$3; rip � 01018-104180 '1 (0A40-tffkfg-k l06 COCOA AB COCOv W VITE 10 N 71 61 0002-16 'COCOA —BUTTER -4-00-= A 0 it 2.68 BUTTER- L FRS 4 (QMQ L �QT N, l A A-94MP T— OIL 51552 -0093-03 'COD LIVER OIL, [=KKP=�ES:46�29-0124-01- C� �,400 ovti�di (IUML)� 00395-0635;94� r-59;1 4.13 �,� ;,13 27 -7E= LCqD �LIV-fq OW(4Z24L OIL G03=9=3546- 5=;Q6 WDAMINE EINESULFATE�- E =-3 0 �MG �,'[=='TAB' =.,0052�7-- 6=98 3 --fA 60MG 473-- 7 �60258-0771 36 F7 71-71 COENZYME Q10 3 IFTqEI 4� $9.qj tlf0-E—NZYME E]='CAP,-' [14�0985-027�41`347 F 77 ;COGENTIN 00006-0021-69 SICIN 9005 00 w 369 5456 67 _ 1 -- - COMP CUBICIN/NSS #v 9 9004 12 �- 1 � 4� OOMG/200ML ( iV W 49999 $456 67 _ COMP-CUBICINfNSS_- i� 42©MG�100ML ! IV _ 99999 911)t} $9 i 1_ . ` _456 67 _ COMP CUBICIN NSS' ;T._ 450MG%100M1 IV _':,M 99999 9120'11 - �- 456_67 . _. $456.67. COMP CUBICIN NSS; �,�6C}0MG%100ML IV , 99499 9002241�Y�F y 58110 COMP CUBICIN/NSS - - i_ 765MG/100ML_ ._ _IV : -1' 99999 9007 23_=i 1 . $9584- , _ COMP-CUBICIt� NSS __ SOQM100ML' IV 99999-9007-_�1_. _ jCOMP DAPTOMYC(N/NSS �; 50t}MG100M1 _, IV ,- I-, 99994 9002-2t __ __ , _ � - x � 1 , _ .._ . --� 630MC�/100ML� IV - ; 99999 40{71=9 CO DAPTOMYCIIV NSS _ ;CAMP-DILTIAZENI(30GMa -- .l: _ _ _ 0 02 _ CRM 99999 9002 33 S.._ _ l,m. -.., _$73 .000.C10 90 L0^-KPDIPHEN/LIDO NYSTAT µ j 0 04236112l SUSP + 9 9 9999-34 COMP FCUOCINONIQE/LUBRI/MENTH ' I _ CRM. '' 99999 9001 63 _ '30 ` - OMP-FdRTIFtED CEFA2QLIN OP7H L-_ +'50MG/141L SOLN 4 j 99949 0012 Od?- 1800��. $186.52 ;COMP FORTIFIED TOBRAMYCIN OP7H� _ - 15MC/ML SOLN ;' 99999 0012 01 ', 240 $192.23 ,CQMP.GENT/CLIND POLY B 500ML �M - IRR 99994 40Q1-37 25 " � $131.66 COtViP GE(dTAMICIN�NSS _ 120M�/200ML .: _ _ IV _99999 9005 $4 15.$25.00_-. [OMP GENTAMiCIN/NSS �r 75MG 100ML IL_SOL_N 94t�- 999 9002-48 500' �3 V 15.26 :COMP-GENTAMICINfNSS _', _ 80MG/100M1 ;, �IV_- _ 99999 9002-02 „ . _ 1 .� - � � $7S0 _ CAMP-ffC/IODOClUINOL 1%, .,_-.__ ih` _ Be_0099999-9999-2 _ - _ R_02,5_ CMCMP-HYDOCORT/HYDROCERIN COMP-HYDROCORT-VAL/HYDROPHOR�,v� 0.002._rtNT44999 9002-38 j_ 60 ' �_ $140.22 COMP-HYDROXYPROGEST CAP 200MG%ML [NJ 99499 9002-18 $134.85 _ ,. GOM D XYPR0GE57CAP . _ _ _� 250MiG/Mt VIAL �49999 9001-36 240 $89.90 200/25/300 _ TAB 619581101,02 - - ' $4,144.75 COMPLETENATE CHEWABLE COMP LtDQCA1NE VISC/MI-ACID TAB 138110014 90 30_ _ 43aT 99999-9000 62 ! 50 �� Y $67.06 ,COMP-LIDOCAINEjDIPHEN/ANTACID _�pUS _ _ 4% SU,SP ;, 99999-9001-57 90 �>25.00_ _ $9.00 COMP-MAGNESIQ�A/50D CHlOR-140ML 2GM 100141E N 49999-9 ) -44 240 CUMP-MAXIPIME%NSS .._ _._ -. _ . . � _ SGM%100ML IV_ 99999 9002 25 ' 30 _ _ ,' $9.15 C:QMPP P EROPENEM/NSS° �L.SQ MGj100ML �; IV 99999-9002-14 -100 COMA MIRACLE MTHWSN . ---_- - ,._ ,,, 99999 9002-43 -1 C MP M1'lA9T UDOVIS�DiCYGLOM ��?'M�--��� P,u COMP-NAFCILLIN/NSS (100M1 2GM/100ML IV ,99999 9009-11 t 240 _ , $45.00 y_ �Ct)MP-NIFEDIPINE 15GM _(„ -K 0.003 r I 0 NT,. 49999 9238 13 {�120;°�� 75.00 COMP NtFEDIPINE/LIDOCAINE 0.2%/ 2% ONT- �, 99999 9009 99 1,- _.. .._ -_ P -_... $80.00 �- �Y r O:: i NITROGLYCER HC - w Q 125;0/2% �..,�� _..._....J_ � .�. .�� OINT' :99999 9002_._A9�.��•_._,.__. - - ;COMP NITRdGLYCERINEjLtDO_ _ 0125 % DINT,-_ , 99499 9002--15 30 - _ rGOMp NYSTATIN/MYLANTA _ 4 2440 ; � _ _ .Jt�SUSP, 199999 4006 _$81,20 COMPOUND W (9ML) 0.31OZ GEL 75137 059110 41 _ 60 $10.45 COMPOUND W ONE STEP � - _ 0 4. PAD T � 75137-0595 10 204 [ 520.61 W �§ �COMPOUND W (FRZ OFFj �� 8 TREATMENTS i_ KIT 75137 044d 34 _ 9 _ : -._ _ _ $20.98 ;COMP -PEN G POTASS/NSS1 4MU/1flOMt IV .s 99994 9002-46 j 14 COMP PEN POTASS/NSS - __ _ - 51Y1U/100ML IV, 99999 9Q03„48. - J'M - ._ _$65.00 ;COMP-PIPERACILLfN-TAZQ D5W_� 3.375GiVf •100M j}� IV ." 99999 9002-34i� 10D • ,_ ��� �$5000 -_ I COMP PIPERAG►LLIN TAZO/DSVY _..---- - _4,5GM/1dOMl ;` - _ ___ _- -� --__ $50.00 TO� MP _PIPERACILLIN-TAR NSS 'I 3,375GNi%50Ml I'[ -a ' 99999 9003-. 35, __e__ 1 $28.00 i[OMPµPIPERACILUN-TAZQ/NSS _; _ 4 5GM/100M1 _„ IV - . ' 99999 9001-42 - - _ ?. _ _ - $50.00 Gt7MP-PIPERACIILN-TAZd/NSS 2.25GMZa00MQF V E99999-9001-66'C== ;COMPRESSION STCKNG EX FIRM -. THI'HIGH jr 00000 1222 69 1 _ $105.79 GCIMPRESStON STCKNG EX -FIRM ( THI-HIGH LNf00-1222-6868W-'-$105.79 `,COMPRESSION STKNG.KNEE3X _ - 20.30(IVIM HG) ;: _ ;� 24391043T 71 t_ 1 . _ _ ._ $4718 COMPRESSION STKNG-KNEE MED/LG-� �- �� 20-3p Mfvl`=H�a� 00000 0458 02__.1�$10.00 ,COMP J2tFAMPIN {90MLj 200MG/2ML SUSP ` 'y 99999 9003 40 1 _: $250 00 - __-. _; ...ram _25MG SUP. 00574 7226-22 1 {j w COMP SAL ACIDS%/AQUAPHOR '��SAL[CYUC -._..m .i; 000000010-10 E, .. 90 "_. _.; "� �' $35.00,J_ CAMP" ] HYDROCERIN® Q 1 CRM 99999-9000 0 _ 12 �a , 22.06m .06 � _ . ., -._ .- _ COMP 50LU MEOROL/NSS .,__________..______?GM/250ML y SOLN 99999 9002 32 3:_ - _. 60 _ _� M'_ _ $1500 OMP-TCA5096+E70H W/£R BEN ZQIG . SOLN , s .99999 999107i_ $14 25 '.COMP TESTOSTERONE PROP I /TMC OIN 500MG _ OINT, 99999 9001 ti0 1 . Z0-MP-TRIAM/HYDROPHOR 0.001_ _> OINT' 99999-9 -,08 1. ; .._ � 40,16 COMP VANCO QRAL SOLN - 25QMG/SML SOLN CCtMP-VANCO DSW E2.5GM/50oML ]C=] .., 999999999-99T 1 w Ci7MP VANDW CO 5 �:._.. / _- _. .__ _ _r;_625MG/2SOML u -_ IV _n i, 99999900162 {�. _ 100 - . � _$2500_ _ _ COMP VANCO NSS 11GM 250ML {Y 99999 9005 2°2 1 Y 15.09 COMP VANC_0/NS5 1.3GM 500ML ' / t_. IV ,z 99999 9002 40 a 1 _.. ._ . _." _. _ _ _ _ _ $15;00 C VANCO NSS - G41 M 500ML N, ' 99999 9999991 1 _ 25.00 ry _ __ _._ _, COMP-VANGO/NSS _ 1254MG/250ML ii IV ,-- ; 99999 9001 I1 i 1 .- $15.00 �{ CtJMP VANCOINSS _. 12S0MC%StiOML (V y399,,$ .W q : $35.00 w _._ CC±MPVANGO/N'_SS. m 1500MGj500ML„t IV �4 CCOMP VANCO/NSS . -� y 1750M 500Mt�4 N- F„� 99999,9IX12 Ji 99999-9002-27 ;° 1-, _ " _ $15 00_,. -- --- -. ;DEGREE DEODORANT SPORT 76G)_,�__j 2.70Z rL 07940 -- 7 0 0265 48 433 DEGREE SOLID {48GM} J§�fo id -- Spokf 0Lo, 5j-0 81 -DELES ROGFN IS - �6-TRO —GN �L- EA KE- F_10—MG=jML-- �O7-3-01�10-Or sm ;bt&TRIG--O-- 1 '0"0/ k'0- 1 -3'0- 0- f A t 6bodb� 566�--df';� I - - -, --- 1?-- ORSYM 12HA-COUGH aEL (I�BMD - �,JC =5YRP Lq5 F--s �3 0 —IAG $062 99 1, - �M- - i�-H-R- C 0--U--G--H--,RE-L- (89 M--�f- S-Y-Ro,--i'- 638.-.-0-17- - -6 30 --i *�7, - =1 =TAB 040Q9 01�932JL 148 bENS64C-' . ..... 9- 032-01 jGGO-, 0- aq ,15EL [:I �AO 7-7 0 ,PELTAspNE TAB 00009-0045. -_$27�49 ELZICOL I-= �ooumg-=—, 2=3 1OOMG _TAB_ 00004 OZ65 01 k idb IrDEMADEX 6' DEMADEX N -:, =TAB T E�4zff�6-2--"OU4 !QOVE 50AP SENS S[CIN 1 A ,z: „µ� x := :UNSCENTED12.24 � ,110 IONEX t120GAAy 01 CRM 5p222-0i60-:1� ,�6 f' 2 816�.70= _ 'Q VONEX 60GM 000Q1 V _ M -max CRM x 50222 026 Qfi 120 950.08 O�,OXAZOSiN,ME5Y[AT 2NIG � _ T B 16729 02110 60 134 S TABI16729 0414 17fi i001,34$t60 DOXAZ{}SiN MESYEA7EIVIG O AZOSINi .ESYETA E 4MG T B 16729 0213 0 1 141SS s i6iu 42fifV MEsYi € n j _� � 8iY1G E!!� i i6_icy tIS"fit" _ �0 —:i7t-6A gE7t}XEPtN =-:. 100 G CA 2332'4 4, 19729 ALL- DOC€PIN ems _ s?G a CAI i 719210162=41� 100 �ss4547 ¢ OQXEPIN 1�'S0 'G =�GAP�� 4988 222 01` 00 ;D(7?tEPIN ?SNIG . s c CAP 719210163 O3 1Q0� 58.94 - ;t?OXEPIN 6 G s4.�T� =:72819 0162={131p0 .N ;o 7SMG pOXEPIN j CAP;T r62332063j31��._ �.._._ CMG' ML CON3� 2 Q51 Q4 100 45:00 ^` yObEQIN`tAtASTiCi DOX€RCALCI{FEROL x + 2 5i2tGG CAPS] 66993 018T 50� 11$ _ r $1816.351 ?O RXE�CA[CfFEROL2ME EA=4M G 2ML 55150 0359 50 $270 OQ rDOXYCYCLINE DR �' 2EMG TAB 8�,23155 0611 t76 100 i� r ' 2 605 18 ' CAPS=22i35 09$5 t35 30 �� DpX(CYCLINE HYCLATE _. ; _ ,j` J 100MG _�_^ '1 G AB '941' 43 2112=5 _$2766>22 0 CYC WE HYCtATE D }(Y_ 2YC(INEHYCIAFE "n- ` G ' ?1A6 ,_.42806 i}362 Q1 , 50 $Z3 8wa {ROXYCYCLINEHYCLATE flt SOMG� ds CAPS401�139$R2-50 00!{YLCYC INE kGlA 1 E ,lOpMG�VtA 63323 013011_ 315 96 ()OXYCYCIINE MONgNYDRATE £ _ 100MGz CAPS °a 68180 4652 08 20 7 �: '�118 45p OXYG CLINE MO t3 YQRATE tEnnnr CAP" t 6880'0650 01.` S0 $14510 , OQXYIAMINE PYRIDOXINE i, t 10 iQMG _ STAB 4 9884 018tr01; 100 F# ;�$740 83 ORSCH00 „ v, INSOLES ;lQ2i-Q405=07 100?_ .-' URSCHOLIS BUNION CUSHIONS {Ei�..,.A yL 01101 7122w$8 F771 SCROLLS CALCE�S: -REMOVE ?i ce r2102 07 140=' R SCROLLS GEI INSOAEE MENS N 8853 0590.i 9 19.56 _' _ �QRSCHOELS INSOLES MENS C©MF/ENRGY i �; "853 050 6g 1 ry.� st?RSCHOE, tS,�M,ASS�INCGGEL HEEL[USHiON i1D1>743�2260 � 1 $66$ OR SCHOLIS 1Rl COMFQRT. , INSOI ES 'h=� `11017 0370 81 � I1R COMFORT STOCKING THIGH E EQ REG � m x3 4a� 8 0101 1S �3 �532.49 iQRAMAMINE j SOMG STAB 8 QOQ199 ,j -r 1 r 14<8 312477 q _ DRESSING;CHANGE KI ;� 510 1 �� ,,3G� �25 ;QRtPDROP HYDRAT[OtV$� vv �w PWDRx;503T9 0003=- 1 . = _ _ _8 26 $0 IEl RhL S0024 ORISTAN NASAL 15ML r, - SPR1f` eU 043100 54 790 ,� !QRiTHO`�''A� GCE HP O;DI, CRI i108,6�0037� ,° 420.00 t7R1XORAE SA 120-6M T 8 ' 00085-0�'1�{i3 5� 7 99 ELIGAkD LE ,WI --T .,,KIT 62935-0453-45i' =00612- 1 EU14tST(28'-EA"). 0.3MG,10.03MG TAB 16714-036-04 �5183,12 08M- 5MG TAB WOP3 -0994 _ 60-2i $672�.9O �7�2!90 `ftLZIA PAK =TAB=' E%-0102-09fl--OD: 60 � A2 ELOCON (15GM) I.N lbc)"- $69.66 TLOCON (Nmo 0 �d,-- 6k .Qll -2 _DINT,_ .1i ---- -- 30 __,$127.98- �0001 _L36.08 ---o.-o--oi- CRM i�, O��-05 60 SU6 cy LOCON CREAM 45GM), OW =CRW- �85=-0567-02 SLO4.15 F �jfA LITE (240ML) EE L=TA LTXR- !bTN 02 --][NT 7==—-----�]E6a2-f4 O3:--l—O04- -45- $7.51 A-9 - -3- _. _6 'EM40WE 0,0005 $159.20 EPOGEN (1ML EA) V _ _ 10,000U/ML .'_ VIAL 55513 0144 10 -- 30,_•_, .. $1,989.60 _. _ . �_� '55510 ©i26.10 - 1° ? � EFOGEN 1ML EA} - _t Z�QOOU ML VIAL . ' 397 92 ` `EPdGEN (iML-EA) ...... _ M 20,000/ML MQV 555i3 0478 10 A. $3,979 26 EPOGEN iML EA} i` y ` 3 QOOU%M VIAL, 55513 0267-2fl 14 _ 596.88 EPOGENaUML EA}. T.._r _ _ . __ ;_ _ , 4400U/ML _ VIAI ..I; 555T3 0148 10 -- _.10. _ _ _ $795.84 ;EPOGEN (2ML EA - 1 i0 owu ML MDV 55513 0283 1-0 9° y f � $3 979.2,�0 '�] EPSQM SALT P OM SALT 1360GM) "„ ;_ * • LLf '11068 0010 12 454 EPTDIGITAL STICK (2-EA)!'KIT.., ,�, 125470329-92; 1360 $12.50___ EPT DOUBLE TEST '(2 = �� 04561-i952 02 . , - 956 f PT'SIN6LE TEST.._ 'EPTTRIPLE TEST � . ! KIT` L 04561 1953 4 iEPZICOIVI 600/300MG TAB = : t, A9702 020tr13_ 3 EUALACTIN - SW MG. �J TAB 38!185-000027�30 "��,, 10.15 ,A-- ,EQUETRO- _10OM6 .._ _ _CAP 30698 0419 12 _ ECYUETRO 24QMG CAP ^34698 042 k 120 $62f0 ECtUETRO m 3ddMG _, - CAP . 30698-0423-12 4r, , 120 $704:24 ERGOTAMINETAR�CAFFEI'NE1MGj2001VfGj244744917-10 (x120 j 51,387.J8�) ;ERRIN 0 351V1G TAB 00555 0344 58 1^ - 100 _ $221.52 �ERFACZO (60GM) _ 2:40t � CRivt 401$7 5115: 64 168 ti � $1079.42 ERTAPENEM SODIUM,(1-EAj _ 1GM VIAL a 55150 0282_24 ' 60 $1,500.00 ERYDERM TOPICAL (60ML_ _200 =SO L00074-2698 02 10 E _ _S�l$.33� _ �ERYGEL (30GM) _ -_ 2.00% � GELL _.�4^EO__ Q476-0315 60_130 .� �$320Q09..77,ERYGEL OGM} 91 :ERY-TAB EC 333MG TAB 24338-0124-03 - 60 M _ $396.90 - TAB 24� _ 3388-0126 03 j ,ERYTHROCIN (4-b%j SOOtvIG ADV 00409 6476-44 t 30.... $1,014.42 ERYTHROMYCIN _ 250MG TAB 13668-0606-30 _ 10 _ _$396.87 - iERYTHB�MYCIN {Z{70NI .f _� �' 20MMd/SM SUSP ! L338-013� 4 02 � .. ERYTHROMYCIN (200ML),- 200MG/5ML SUSP 24338 013640 I 100 _ $793.96 n_ _ �ERI'THROMYCIN B�__ BASE FILM �F�TAB ,_13668 Ofi07=01�� ,ERYTHROMYCIN dR_ _ 250MG CAR 68308;0250 1O,u-- _ _ 100 - $919.81 �ERYi'HROMYCIN ETfiYL5' _� .a_____��_ 40QMG�v;r��TAB'� 2 33� 8mplpQ-p3_� �Y 1.04 ;ERYTHROMYCIN OPHTH (3.5GM)__- _ . - -- -. _0.005 DINT 24208 0910-55 30 $19.00 _ ERYTHROMYCIN PLEDGE � I �0,02 �, A ` 45802-0962-72 92.65 _ 'ERYTHROMYCIN TOP (30GM) �' 2.00% GEL 45802 0966-94 60 $60.48 -_ _ _ ... -_.._ _. - _..__... t_ _ _ ERYTH �µ E;OMYCIN TCiF {GtiGM R' �L_�.w 2.OQ%� GEL �. s256'���5-0033µ5_ 3Q ,}' ��..$z22.92_� ERYTHROMYCIN TOP ($0ML) u 2.00% _ SOLN p45802 003$ 46_ 60- _ $50.00 ERYTHROMYCINj8EN2TQP 4fi6_ _ 00781-7094-59 60� ��_$41479�1_�a .. ;ERYTHROMYCIN-BENZOYE PEROXIDE EGEL 80 6490328-DI _46 6 _ - _ $207.39 267ivt6 • " CAP _ _ .. , i� �t 50242'0121'QI � p_ 23.3' _ �' S12L53.9 ESCITALOPRAM _ 10MG TAB 13668 0136 05.,. 270 $2,163.25 � ' ES GALOPRAM QMG �1 _ TAB 4353 0282 11 =4 500 F 520,OQ +ESCITAt.(JPRkM -TAB 43547 0284 11 OF- IOQQ S MG$4150.GC3 ESCITALOpRAM (240ML �� _1 SMGjSMt SOLN j 16571 0769-24 1604 ;_ESGIC - _ _...__ _. _ -_ ._ _ _ _ CAP 00535 0012-°1 I 240.- _ _ $215.74 n_ _.-._ ESGIC PI US -_ TAB 0045fr0678?0� 100` ��„�-__-_ $184.51 `ESOMEPRAZOLE _20MG CAP , 43598 4509 90 100- T $812.10 ESOMEPRAZOLE 1 40MG' iE CAP 4359805109t? ji-� 90 [_ _ $812.10 r _ IE$OMEFRAZOLE,(U[D) w _ - _ 20M6' P�KT 69097 0528 34 g0_ _ $292.67 _- IESO CA y E= � =F : CRAM LL 99207 0290 02 �y 3Q�_ _ _�:c. 56 28 J ESTAZOLAM 1M6 TAB ; 005910744-01 _ - 70 _ _ $88 78 ESTj R ED ESTROGEN METNYLTEST jj 0 fi25/1.25M TAB 5374ir0077 °1�� 100 177 95 ,g IMG 4 t' _ 100__, fa $152.:24 ©. _104 ;ESTRACE CREAM/APPL. ; D.000i CRM ' 00430-3754-14 +, 100 t' $413,74 ESTRADIOL ,_ _ ,0 SM�G� TAB 00555 4899 02� y 42 5 $5512 ESTRADIOL n „_ lOMCG k;__ TAB 00093 3223-b8 100 $193,98, ESTRADIOL C= l=MG - TAB 00555 08$6 02 2M,G_ 1, _ TAB ! 00555 0887.04 f 100- _-$459.40 _ t ESTRADtOI 1 EAR 4 0.025MG DAY �PTCti 40378 3349 9900j �,592 83 ESTRADIOL (1 EA) 4 0375MG ! . PTCH , I, 477810205-0A i 4 $88.40 „STRADIOL 1-EA „71^` 0 05MG DAY _V P� TCN 47781 0206 44� 4 _ ESTRADIOL(1 EA) '006MGjDAY iI PT�GH _ `. 003_78-3361=99 _ 4 _.. ESTRAD�IUL(1EA �' 02MG.j - PTCH 651620997'OSW 4- $14423 ESTRAD[OL{i EA} ,t__ OIMGJDAY PTCH 00781 7104 54 E TRADIOL 1GM EA 1L 0.001 PCKT . 70740 01455 }t 34 ��� �$189`68 _ ��-�__ iE5TRADIOLVAI (SML-EA) 20MG/ML MDV 00517 0420 ESTRALVA DIOSMt;EA} " 40MGf Ml MDVI�00517�p O j 5 �4276 $6 __ r ESTRADIOL W/APP (42 SGM} _. _ _ _ !. _ _0 ESTRADlO NORETHINDRONE�__ 1MG/0'S'µ,MY TAB = 52992 04 4 28 425'u '} _ 136.7 ESTRATEST _ ' .. _. _ i • _ 2.5 1.25 - TAB__ i 000321026-Q1 FAGTQR'Vtlt HELIXATE F x 74t1= c:� - " fAL (FAG7OR VIII _ HEUXA7'E FS}„ t_�,_,,�„� -;��i� 77d -��• VIAL ��r 00053 8132-42; h* _ � 2 � �._'_„r�W a _,$1293 60Y "FACOR VIII „ HELi7lA°CE FS z ,g995tU ,` VI, AL 04053=$ 3 D �1 67L60� , tFAM V111+ K0AT6=DVIj 10101t1 V(A4 76125 8667 50 z 1 r 1414.4Q A r QR AIR .. D 1? 1;0201t1 � VIAL 76125 0667 5D' *FACTOR VtII'{KOATE-DVi FF R Vtt�KQAT F _,.1,0401€J VtAt 76125-0667 50� m� , $1,456 00 - p u (AG Z 7b1 52 0667 FAGTORViIi KOATE 01IrVIAL 76125 06675Qi 1,S2 554 {i0: I 1FAGi M AI f KOATEaDV�IAG , 76`� 125: 066? 50 1 c g 1 68 40 -1F=A fOR VIIl,(KOATE C)Nt , , a .,' 1�13f)tt S i VIAL 7b125r0667 5d �ZEIENZ :, LZ $2 00 Q, FACTOR UE iCQATE Q 1180 IJ VfAL * 13533 0665 50 1652 00 VIALt"13533 0665 50' �1 , ��51,666OOz 20lEt Vf 353 0665 1 f= 1708- 'g] FAGTARVIIi.. KOATFDVi11901f ACTOR Vlif CQA7 VI FACTOR V111'KOAfiE=CiVlj� _ k ,; 440(U,' ; DIAL `6125 4500-30 E 7x "616 µ 13533 066'ad FPiGTQRV(lI,:KOATE1%1} 560iU k ,'VIAL 7{125=0667 30 11?$4Q0 ; FAGTORIV fI KOA aQV. 5701U VIAL 13533-06-65 3�_ 1' i98 00 CAGTQRVI!({iCOATE»t}Vt }_. ��201U 8'�VIAL76125066754 «ter 1,28800 ,,_ FACTR Vp{KOGEWA?� • .3 10231JVIAL� 0002fr3785 5,a i ury 82' _- __t470 � GTORVIII 4GENJi FS 10 2U VIAL ., 00026'� 'FACTORVItt:KO6@HATEFS " �,.�...�..� ��, IA � J2 .v. _ - OR It K4}G TE FS i d 7f;1 V G 00026-37$,_,,,.5 1 � �� ��µ�- _A aAt�iOftVtif: KOGENA7 FS} fi 10i21Fr ,VIAI: a OOd23 3785-5 FA%,TG U K{1GEN F5 10 6U V L 26 37 5- 5 1 ° ` Z b03 92 iFACti}R V111' KOGENAI FS{{ ` 1087C1 VIAL " 0002C LB S7 , S 1 3 ' +1$2 630 54: �ta�f«.`E,-ss®=:.w_.4.��` «.r;�.. k t _ FAGTOt3iV1t1(KQGENATEsES 1'1239#(1 AOAL M ,6W 6—79--a50 1 -` � 2�86 28 FANAPT J - 6MG TAB' j A3068 0106 02 60 S2.599.29 'r FANSI4AR0161-03_ -- .,'_ -- 4 FARXIGA 10MG TAB �04310 6210-3U 25 _ 67835 4RX6G4 4 5M TAR J tj03'f 0 6205 34 G r IFELBATOL �v� �t. 400NIG -AN , QQ03? 043001 9t?T$1763.93 . 5 F"tLBAIUL 600fV(Ca IAA UUU37 lUo jL V21.57 �FEL0MG _ .593 OMFEON_ j 00069 3230 66 1 $1,674.43 LODIPINE EXT REL, _ :µ tE=- SOMG ' y TA$ 136� b 01 -. FELODIPiNEEXTFtEL 251Y1G J_ TAB 1355$0132,01-'M._- 100 IFELODtPtNE'EXT-REL" $151M .Bi 00o7A-0z'49-i5 TA FEMCAR@'StlPP7 FEIVICON EE CHEWABLE (W4) 0 4MG/35MCG `. TAB- _._. _k_ ._... r FCUTIC%VILAN,(69GM 301NH)100MCq/25MCG ►NH , . h 66993 0135-97 . _ .. __.... ,'~ $437 58_ _ FLUTIGfV1t-AN tiQGM 301NH 2�OQMCG%25MCG INH ; 66993-4136 9 t 6Q _$437.58 FlUTICASONE HFA (10 6GM); 44MCG INH 66993 0078 96 , _ . _60 t; - $233.18 _. _.._ ___.•.. r_.. -� _ _ - . _. . FWTICASONE HfA'(12GML _��J 110MCG I IL NH ' 6699� 3 0079=96 F- 1Q.6�t �-�- $3z2.17 FLUTICASONE HFA (12GM) 220MCG INH 66993 0080 96 x _ I2 $484.88 - FLUTICASONENASA I6GM d V 54MCG SPRY: 60505 0829-01 32 m 585.26 `FLUTICASONEPROP(30GM) _i'_ _OINT y� 45$020221T11il' __.._ 16 ; _. $34.30 .r FLUTICASONE PROP 3QGM 0.0005 CRM L4580� _�30 � $34._30 } ;FLUTICASONE PRO0.0001 QT P (60GM} _ __.. _ i. _._ . 1Pd_.t. 45802 Q221 37 !'__v Y,.. 30 . __-, - _ '__..__ ___ _ _$54.14_ EF, LUTI(ASONE PRCiP' 60GM � - .00 5" �=RNi_ 45842 0222-37 [ S0 _ �,$54.10 _ FLUTICASONE PROP (60nn1) _ .._ __. 0 OQ05_, _ _, _ LOTN� _ r._ 45$02 0441'02 ,; 6U.� j. _. _. __ __ $389.95_ IFLUTICASONEfSAlME71-EA-�113(14MCG E INHL �`L93-3608=82 - 60 o ]��~- $146.25 FLUT(I ASONE/SALtv1EF(1 EA} ?32/14MCG .-_ ._ , INHL 00093 3509 82 $146.25 IFLUTICASONE SALMLT (1 EA 5 1GMCG fNHI �fl009t�- 3_�360782j 2 �( LL $146.25 FLUVASTA7IN !: 20MG _ I+_ ,CAP i t)0378 802Q 93 _ 1_ h __ _ . _ $150.19_ _ _- FIUVASTATIN jF - 44M-G _. - CAP 30 5449.8i A FIUVASTAWhf ER 80MG rdfi__ w 0U378 Sup 93 3 y0 $252.07 F, UVOXAMINE MALEATE _ 00MG TAB i 62559 0160-00160-02�] __ 30 1 -263.00 � -_ ;FLUVOXAMINE MALE ATE. "25MG TAB 62559 0158 Q1 1, �- 100 FIUVOXAMINE M1AlEATE _-� ��L50MGu _ TAB.TM �� 5!00� 2 59-01 J i57.00 fLWCtXAMINE MQLEATE.ER 100MG CAP 10370 0175-11 104� $305.51 TFWl OXAMINE MALEATE ER 150N1GM j{ __CAP 1 10370 0136-1I i 3Q_ � �� $327i87_��. 'FML FORTE OPHTH (SML}- 0.0025 SUSP _ 11980-0228-05 ' 30 $202.10 FML FORTS oPT-H OML} W.I.OPTH (10ML} 0.001 SUSP 11980-0211-10 . 10 $404.22 aEML OPT13_{3 5GM1w-_ ,_w .._ �0 001 _ �''s_ OItUT 00023 031604 10 �1 $192.48 'FML OPTH (SML). 0,001 SUSP 11980 0211-005 3.5 , OAMlN-GANTACCE 355ML , F SUSP "=24385-0397 4i7 I 5 � S5.99 _ FO�CALIN 10MG TAB ; 00078 0382.05 355 T $166.70 FOCAUN '~ 2 SNiG TAS 00078-0380 45 �_ 100 FOCAUN _ 5MG TAB 00078 0381-05 100 $115.91 a- FOCALIN XR 15MG CAP 00078 0493 05 100 _ $170126 OCALIN XR E 20MG { CAP 00078 0432 05 �_`_� IQO FOCALIN XR _ .. _ _ 30MG CAP 40078 0433-05 10O _ $1,638,85 _ FOCA N XR _. _0875.i0036 _ "FOCALIN XR _ 5MG CAP 60078 0430 05 100 $1,630.18 _ _M _ _ _. FOLBEE 519910084'90 iQO $61.75 EOLBEEPLUS _ _ _ 5MG TAB 5199100820 ,[,- _ 90 , $47.77 FOLBiC �7A6 519910384 90 �R 90;w S32.33 FOLIC ACID_ iMG TAB 11534 0165 03 90 $76.80 Cti� FOLIC ACID SMG TAB ii534 4__ i65 01 Q�'- - $22 80' _ _- FOLICACID , 800MCG TAB 806810074 00 1000 S2.15 I +FOLICACID 10ML - _ `� -��� 5MG/ML �VIAI ,4P 0 FOLIGACID- B12- B6 _ 2 5/1/25MG TAB` }. 51991-0084-96 1t7�._ _ $61.75, _ OLICA.�CID`400MCG _ �L.-_0.4MG=TABS 4$Q LO-0-9900 90_L $1,94 CD CL FOlITAB 500MG TAB ; 64980 0173 03 _',` 1U0 $19.68 a. , FOLTABS 800 _Tji TAB 61269 0325.60$30 00 ' TAB._`_ 519910813 90 fi0 _, $129.91 - F FAO TRIN_y`ni1a05MG CAP DE04185 5380 76 FOLTX TAB 60 '$2118-5 FONOI _, APARINUX SOD 0 5ML-EA) j 2 SMGJ0:5ML �'�- {t - SYRG 55111 Qo7$ IO� 90" FONOAPARINUX S00 (0 5ML EA) _ _ 7 SMG�0,6ML r SYRG _ f; 67457 0584-06_ ; f 5W_$128fi 10_ iFONDA�- PARINUX SOD (0�8ML-EA 1QMG O.SML SYRl 67457 0585'08 _ 6- . � 52,286.10 FORA _1 _AcuOLIZEn A2pr4P = F nnn85�en� m a FOREARM -PADDED _ $�9i 5S _r .-... sQ-JL 70;QQ FQREARM PADDED _ RT/lG 99999 9001 90 1 $70 00 IFOREHEADTNERMOMETER 7'`� FORFIVO XL 450NiG _ ; 1i _ _ 7A6 i52427_0575-30 _.. _ 1.._" _ _ _ $56314 4 WORMOTEROL FUM 2M! EA v..µ (� . 20MCG- 2ML �AFvIP,� Q03 �- 30 -- ®_ l�a - $60157 FORMULA B PLUS TAB r ? y 00904 7929-60 fi4 $19 94 ;FORTAMET ER--11�--r-- _ _. 10DOMG � TAB e 5963QW t?575 60 , $2 530:12 FORTAZ (1 EA} 1G _ _ M ; - VIALI, 24987 0378 10 _ _ . � 6U ._ _ __ •' _ _ . _ _ _ $142.32_ _- - - - -: ;Ft1RTAZ (1'EA `ZG{t/I� : ADV L 9987 043s-0(10 . ,. S306.00 2GM �`�� ADV._ 24987 0435-00_ _ _ - 1d�._ _� _ j1?6.UU� fOR zGM _ ALA 498 1Q T[_ _�284>53.` _ ;FORTgZ EA MGh 500MG h� VIAL 4 24987 D377-10 ,;. 10 $79.20 fORTEO 2 41VIL E _ 20MCG DOSE PER; `. L Q0002 84OQ Ol "4 410 ��� _ mm $4 997 93 FORTESTA (bOGNI) _ __ _ 10MGi `_ 634810183 FORTtCAL IU MLSPRY OQ24 �5 00`Q8 354 50 y ' _ 142 89'' _ 10MG TAB _---- 0935 31 _ 3 7 M _$10013_ ;FOSAMPY 35NIG TAB �- I QOW EQSAMAX _ _. _ _ SMG_= w.. TAB ___ { 00006 0925 tER RTyERM, FTER,e EiA(5.Min � � 7 .z 79rr73ua� ra r�k T9z �a$132 7184 d' x 100z r � 175- �54LN 42 99i173 414a 4 DRY iT 57599 4Q410 1 � ��,� T3�39 �.nw�. ��.✓ STkP' 1� Tito ' 99073 UZi026 2Q0 $24 Ot}_ SOLN 139194", a ' TA8 �69315011T`10�f 140Q.,�,., i�� r���950� S 4354� 7,�-a40 S i000 '� �SDV v bU00-02$2 25 $63 4Q � ��4 _50 SOLN 60432 Q613 60 _ ' 120 x ,; $14 40 __ CAp 527„ 4,, 7�_Q5Q2 30 60�..�?. " 3S 05 a 0-1 i AT 28Sfi 0�`�'2$4"43Q 64, ; 329. TAB 62856 OZ$2 3Q. 34 g ��'$1329 60 C. TAB _ b2 5 724� 3 w . s 673.20 TAB `: 62856-0276<. 4�°`�'. •1373,6Q � -mom 67877 Q�2�22 I0 3Q" 53 CFA 7�� ) R 5nn _ aa�irTMRf4? T B 71093-0112 OS S(3i 1525 Q4 O 'GOLYTELY$29S9 a GOLYTELY-PINEAPPLE PWDR . 52268 010101 4000 $24 56__ GONAK tSPTH 15ML (T 0 025 SOLN lC17478-0064-32 4000 i $24 20 _ � I GOkDO UREA OINTMEN7102. 0 4 O1NT 104813005 Ol GOWN SMOCK jYELLUW _ —_ .... 94999 9001-88�1 15 57.95 $ �0 E GRAUSE ER 300MG TAB _' 52427 d803 9d 50 $1,099 78 xGRAMSETRON HCl1MG TAB j 00093 7485 20 _ 90 _ _ 51,180.18 480MCG/0 8ML IN.l. - 63459 0912-11 . 20 _ �,. _ _ _. $479.87. _ _ GRANULEX SPRY 00514 00d1 {3 _ _ QLLg - GREEN SOAP {i20ML� GREE�� N SOAP 480M—L� TINC .00395 1049-94 ;. 120 $8 ZS ( llQ 0039`—' S 1049N1 124 ! 15 00cn GREEht TEA 315NiG, _ .._; CAP 07431 2331-31 _,a. _ 480 . „_... `6.53 :GRiFULVIN V 500MG TAB [�Od62 0214-60 M 100 i 907.56 GRIFULVIN-V(120MLj _ SUSP LG SlR PULVIN . _ 325MG TAB 64980 0184 0 1-'� 120' � $i72 51 RISEOFULVIN - . _,. _ _' 250MG TAB !' 68682 0520-01 30 GRtSEOfULViN „LL `„ Y iv -` 500MG 1AB Y:ve�d0783 5515 41 100 ;; � .� _ 935y08 v !; > 'HERNIA BELT SMALL ! _ 96295-0124-89 _!'_. 1 - S4U.UU _._ . _ .. _ _ {HERNIA BELT �V T QR DOUBLE ,— = • - . -- j ?tX IARGE 7$ 1013-50 ` 1 - HERNIA BELT LARGE FLAT PANEL r_ ._, _ _ ._ Y784784061-57 1 $75.00 - HERiUTA'GUARd LTLT%RGHT OR dOIJBLEf{ - - _-, 7(�l ARGE ; 38 5223� W `W 1 `1�A 90: OQF� .._ ,HEXAVITAMIN tl _ _ _ TAB. 00245 OQ$211 _ 160 FIIBERIX (1-EA M v 10MCG j AL S$160 - HIBICLENS (118MU 0.04 LIQ 00234 0575.04 „ - I18 _ GLENS (1290Z 0._ y a 0.04 ,_, LlO,= 00234 0575.91 L 384 iHIBIC,LEOSS (236ML) OA4 , __. ;ti UQ - w,00234-0575 0$ i _ -__ 236$5 54 _ FIIBICCENS(32QZ 004 �( SQLN00234 057532 946 3145 _ HI6ICLENS,.(473M1) UQ._ 00234-057516 HIBICLENS U d 15NIL EA _ _ 0.04 UQ_ 04234 0575 17 Y 7S0 $55 05 HIPREX 1GM _ w_ TAB 00068 0277 61 s_ .__ 100,_ tt1STACOL to-� TAB j 519910164»4]� _ �kiISTATAB PH S/F _.._ _ _ 20(SJ1.25MG • ; _ _TA18 _ 519910424 01 ' _ 100 _- _ _ _�' _ _ _ _ _ $§4,64 ; _ fits A-VENTA »_ 022704"G 1 _ T877 a - _ ,HYDROCORTISONE {PLSTC) - _ RM 00472 0337 3q 2380 4 _ $11003q RTSONEfPRAM 45$02012469OCO$142.031l ; HYDROCORTISONEjPRAMOXINE(30GM) s 1%/1 CRM =FlYI._��$45802 0144 64 -115*�8 30 �4 DM 1% CRL001680154 7 3ROCOTISONE-U/ ' w 14MG TAB 54505 0332 ZQ 100 $57 30 ;HYDRaCORTONE_ _ IHYDROC`ORT VALERATE ISGM a ._4 j.. _ 0 002 „ , CRM 51672.1290 01 $89 54 -- N HYDROCORT VAtERATE (15GM) _ 0 002 PINT k 51672 1292 01 18 $98 40 HYDROCORT VALERATE 45GM) - _f�,,,= _ 0 402 CRM j 51872 2290 06 } Y - 45 '-,---_$280 S0 .. HYDRCtCOR7 VALERATET{45GMj _- _ -- 0�°_ ....__ OINT„ 00713 0560a37 , _ _ ___ 4S, __, . „ $198 37 ;HYDROGORT VACERATE 64fM 0 40y2 CRM 51672 1290 03Y60 w, ,�r217.11_ _ HYDROCORT VALERAT,E OGM) 1292_60 HYDRODIURIL - -�._. 100NiG -' TAB # 04006 0410 6& 100v _39 75_ { __ _ e HYDftODIURIL _ , 2SNIG TAR ' , _00006 0042 68 __ _ 100 _ _ __ _ 516.81 fH- RODIURIL t SOMG TAB 00006 0105, 6_5 100 $ 5 45 " Y .®. HYDROFEQ(473ML) -_- � � _ _ CHERRY , . , i, SYR _68047 0200-16 HKEfR FERA BLUE 4X4'�"' �� FOAM 08573 0144-14 HYI?RUGt�i YtRVXIDE (4t3rnGtA) u,vs wtN }' 70000 wGir02 S`v78� _ $2109 _ ;HYDRO-9P (480ML � � ! E SYRP 6 8 0782-16 473 ,HYDROMORPHONE 2MG TAB 428580301-01 ;_ 100 _ $1080 HYDROMORPHONE ,,I . ; M4MG ; TAB �I 42858 0342-01 100 $14 69' HYDROMORPHONE SNIG TAB 00054-D265-25 is 100 - _, _. _ ., HYDROMORPHONE 473ML F 1MG M� } SOLNy 42858 030w04-16i 473 $189.12 (4 _ ML) wart _ � _ _.. _ �� HYDROQUINONE _ 0.03 SOW 59366 2781 03 29 _ $12.07 --tYBRO{2USNONE 28.35GM) �I 4.Od �;j CRM -69367 0174 OI L 2835._$305.88�____ HYDROXC)COBALAMIN {34ML-EA) _ 1000MCG MAV 00591 2888-30 30_ $38.26 _ _ HYDROXYCHCOROCIUINE _ - 200MG� 7A6_�j( 43598 072101 W 100. 1}5408.75 _._ E HYDRQXYPROGESTfiAPR0A7E (IML) 250MG%ML SDV 67457-0967-01 1 _ _.y$342._00 N9DROXYPROGEST CAPROATE {1Mt) �t 250M/Mt p SOV°. ; 59 01 ER -_ GE _ HYDROXYPROGESTONEOAP (SML) 250MG/ML INJ - 71225 0104-01 NirtiRPXYUREA _ u �500MG?(_ _CAP 69315 0864-01 }�_ 140 �i S67.20Z HYDROXYZINE HCL 10MG TAB 23155 0500 10 100Q �$411.74 sHyDYZINE HCL _ 4T 25MG -'# . TAB i 23 551 0501-10 lOQO ¢� 5647.80 _ HYDROXYZlNE HCL 50MG TAB 16714 0083-11 500- $S14.67 NY XYZINE HCC()Ml-EA ,, 25M jMI" i� SIW �0517 4201 29 25 � _ 1 �$696.60 ] HYDROXYZiNE HCL {473ML) 10MG15ML SYRP _ , 54838 0502-80 _ - 473 _$78 50_ _ H pROXYZINE PAM� 1dOMG CAP 04555 0324-02 109 5219 21 HYDRC?XYZINE PAM _ _.. 25MG _ CAP 04185 0674 05 S00 $145.20 MYDROXYZiNE PA9Vl _SgMG _ _�" CL � AP y 0018� 5 0676 OS� HYGENIC CLEANSING PAD _ _._ 50.00%_ ,'_ PAD 00904 6829-60 100 $4 9Z H ROTON CIF' 11MG j TAB 00475 002Z-0Ci 100 p 5691q__ HYLANDS LEG CRAMP TAB, ; 54973 2956-01 , _ 50 $8 02 HY� LOREL.00585 0787 71 (IOQ gS78 61 HYLQREL _ _ - 25MG _TAB 00585 0788 71_I, 100.. - , - - $108.35_ - _ N 2CYAMiNE 0.125M- -' 701 b OlU4 tt.1 _ - 100 �?� $57.00 _A IN - HYO5CYAMINE SL 0.125MG _ _ TAB' 70156 0105 Ol 100 $57.00 �} 0.375fNG TAB" 51525 0115=4 ""< 98.78 ._ tiY05CYAl NE SR _ [ "m 100 598.78 HYPEi2CARE (35ML) .� 15Y SOCK - 58980 0155 11 35 -, $8 O6 _ µFIYPERCARE 37,5fi9r 8 80 Oi54 10 i 37 5 _j6 45 HYPERRAB SJCJ (2ML-EA) 150Uj[flL SDV -, 13533 0618(}2 ,� - 2 _ $804.53. , - HYPE RHR O EULLDOSE � SYRG 13533 0631 LL02 1 � $ 26.71 w HYPERTC)NIC SOD CHLOR (30ML EA) 23% _'; SDV 00517-2930-25 750_ ' _ $56_25_ Y OTEARS (15ML j� SOL;�00078 0519 24 �35�$9 54 v� HYSINGLA ER _ _ _ 20 MG „ TAB- 54011 0271 60 60 - _ _ - , $826 63 _r 625.58 YT}tIN- 30MG CAP, W074 $237.86 H9TRIN 1MG _ GAP 00074 3845 1,3 100 ',_ � _. $237.$6 2MG _ ; _ CAP _ _ ? _00074 3806 13 I 140 $237 86 NYTRfH®_-' _- - 5M1G CA,P 0Q074 33 C 5237:86 - _ - ,HYTU55- _ -_ _ ,_ _ •' 100MG_ j;; TAB - I Q0314-021010 1000_ _ 58518 _ HYZAAR _ 10QMG 12 SMG T�._ AB 1i _0000 0745'� 54 100MGj25MG _ TAB , m00006 0747.54 HYZAAR 5-0MGj12 5MG' 7A8 00006 0717µ54 90 " _ 442.80 150MG ' _.. TAB' I' S5111 4575 03_ i ._ _.E ?_:_-_ {BERET:500 FiLMTAB 500MG" TAB 04074 7235;30 30�, 35.08 : BUDONE 1200MG iAB6aa6y vxc8=10 i _ _ iuv �i14.38 ;IBUOONE �W $%209MG TAB 66869 0118,10 N 100 _ I 4 .` $86.88_ IBUPROFEN �` - __.�200MG - - _ TAB,._?-009047912 S9_, _ _ _ iQOU`e__ 'iBUPj R09EN "'�F - 200MG- 7ABy V00904 67780I ` 14.46 _ IBUPROFEN_-- TAB 500 $17L04 iBLtPROFENfi00Iv1G .,T_AB} �157877 0320 g5 257:65:^J BUPROFEN800FIIG TAB &77 032105 SOtI ]- $402.45 IBUPROFEN 120ML 100MGI ESUSP �V ,170080--018101 . _ 1204? _. 1[BUPROFEN (240MLa_ 140MGj5Ml_ ;' _SLISP _00904 4309 09.m:. _ 2_ _ _`. __ _,- $_8.29-- -- - WSTA-GLUCOSE _._ _ .____., _ _ GEL „ 00187 4746 33 _ _ 93 $13.43 _ ._- _ g( 61678 4451-23 24 a__ _ i5 56 " , " _• iN5TANTCOLDPACK'N T-sue,__ i _ - - - - IN5UUN ASPART (10ML) _� __ _ r ,. _� _ 100UJML ' _- VIAL _ 73070-0100 11 _ _ - -_ 10 ,' $173 62 tNS' tJLIN:G'LARGINEYFGN 10OUML VIAL 49500� 10_ 1183$ ;[ivSUL: GtARGINE�YFGN(3ML EA) _ 100U ML__-• J PEN ,' 49502 0394 75 1S $177 58 @NSULIN SYRINGE 1 zCC _I Z8G 1 21N SYRG 04536 9916 01 104 - $23 85 ,INSUIJN SYRINGE 1CC _ ._._i� 28G 1(2IN ,_ SYRG _08290 8294-24 - _ ,_ 140 , iINSULIN SYRINGES 1 2CC -,�-;� d8290 3294 140.,��3154 V� �- INSUEiN,SYRlNGES (S00) 289I2CC SYR , 38396 0441-64 ,INSULIN SYRINGES 1 2CC J_ _ r _. - ��30G X 5 161N INJ 56151 1722 91 104 $24 50 INTEGRA CAP 52747 0710 30 INTEGRA Fv _ ? CAP_ 52747 473130 _ 30 30CAP 2747 0712 EAtT'EENC5676 000�^$3$,2762.706�8;INTELENCE y ZOOMG TAB ! 59676-0571-01 a_ 60, m T !INTERMEZZO = 1.75M(3 TA6 9011� OZN5636 ��- 30 446,76 ' .._."EZZ - 3 SnliG TAB c10110255-30 0 $eel 76 'INTERMEZZO 3 _ _ _ L[ TRINSICAPS - ` : ®� AP OQ364 1057-0J ji 104 $39 15 �INTUNIV ER _. - _ 1M� , _ ._'� _ TAB _ _54092 0513 02 _ • _ I00 , _. _ - _-- $1,165.68 IRITUNIV ERV_ 2MG _� TAB' 54042�0515-1a2i Yv 100,$1 1-55.6?� 4NTUNIV ER 3MG _ TAB_ y _54092 0517-02 lNPUN1V ER j[ TAB ES4092-0519 02� 1d0 INVANZ (I -EA) - _ - . 1GM ADV 00006 3845 71 10 _ _ $1620.96 INVANZ NON ADDVANTAGE� _��, O�Of?06 3843-?1 'i 10 INVEGA 1.SMG TAB _ 50458-0554.01 30 $441.43_ 5045 TAB 'i 8 05_S 30 5441.43 - - INVEGA - 6MG TAB 50458-0551-01 30 $441.43 _ -� _ _nay9MG_-_ TLL-._TA�B'r__04580_�- 6INVEGA 39MG $68.30INVEGA SUSTENNA PFS (025M�W✓_ I 25M INVEGA Si3§TENNA PFS 0.5M ��A~ "78N1G%0 SML i SYRG ? 50458 0562-Q1i_� - 0.5 s $7 x76.66_� INVEGA SUSTENNA PFS (0.75ML) 117MG/0 75ML SYRG 50458 0562 01 0.75 $1,915.01 _ - NINVEGA SUSTENNA PFSS( SML)11- 234MG/15ML l � SYRG 50458 OS644001 E ~� INVEGA SUSTENNA PFS (1ML) 156MG/1ML SYRGe 50458 0563.01 1. $2,553.44 _ _ NGA VETRINZA 1.315ML EA)_ V 410MG iN1 .Tj SO45& 0607-01 ¢� 1.31 M (�_, •y;; 5,577}70 _ .INVEGA TRINZA (1.75ML-EA) _ 546MG - SYRG - 50458-0608-01 1.75• _ '' - _ _ $7,660.33 _ 319MG Z.625M ,( IN1 5d4_ 0609 01 1 2_6 51359 17 W' 1 INVEGATRIN7A'(2 fiML EA)� 1 _ _ m _ L.,4a_ n.., t y _ -_.._j INVELTYS (2 8ML-EA) _ - 0.01 SUSP 715710121-28 .! _ - 2.8 $362.02 1NVIRASE m -_�( 200NfG I CAP }? 0 04-0245:5 IL.- 270 - i 4 $1,411.15w R INVIRASE v TAB -000...04 0244-51 12d500MG _ a~_000NG��I 048041-_6$16484420.07ViNOKAMET_TAB 9 INVOKAMET 50%500MG: _ TA,B 5045 80540-60 60 " _ $684 07 lNV01{ANA 100MG TAB ]! 50458 1140-30 30 _ 684.07 INVtJKANA _ 300MG TAB 50458 0141-30 30 $684.07 000FLEX _ _ w} FAD.=.40565 5122-51 �_ _ 5 .:m,_r$87 92 I000FORM PACKING 1/21N X 5Y0 - STRP 08080-7832 OpOFORM PACKING S 41N X SYQ j STRP '_ 0 219 783:f o0 F7- s p60"SO RB (40GM) GELF 40565 0122 49 ; 40 I, aFE4 PD60MG (- CAP 61646 0302 01 _ 140 _l $44.50 IOPHEN DM LIQ' ,- r 00472 142416 4a0 $4.00 _ Lv- : LIQ.M I 0 4?2 1421 66 tOPIDINE OPHTH (5ML) _ _- - 0.50°l0 DRPS_ 00065 0665-05 E, _ 5 __ $200 21 ,IPRATROPIUM BROM (2.5ML-EA m YV� 040002 ^T� 1 SOLN LL 762Q� _ 4 0140 25 J�� 62.5 _� $44`00 - IPRATROPIUM BROM(30ML) _ 0.0003 SPRY 60505 0826 01 _ _ _ 30 $11167 [PRATROPIUM BROM NASAL {25ML � 0.0006 - SPRY (00054 0046 41 -- � $95 71 1PRATROPIUMALBUTEROL{3ML EA} 0.5MG/3MG.,- AMP 47335 0756 52 'i 180 $131.22 EQUIX`5ML 0.015 -� E SOLN 168669 0145Y05 g` S j $9198 IRBESARTAN 150M6!; TAB - 62332 0442 94 '; 90 $276 34 :`P IRBESARTAN 'E=: G - TAB. ��2332- 90 1332.28 75MG s TAB 62332 004130 + 30 $87 52 'IRBESARTAN HCTTABZ Iz-( 7030t150MI Mr 354F_ $11200 442522___125GrTAB40090 $364 33 ESSA5MG 1 TAB Q0314 0482 30` 34 59 346.66 TAB . i 60258 014101 ; 100_ - $27 72 Y-p; ;IRON W tT B-C Mj� i " TAB 00 82 1223 26 60 .. _ �L, 5 10 ;ISE�YIRC55 t"wiMG �-'_�n�`v _44vciuw7i 61 w y ISENTRESS _ - 400MG [TA8 . � 6 67 -61 r � m 2 292.48 •f� _. 1SENTRESS HD _ w 600MG , _-_„_ TAB_- _ 00006-3080-01 s, _.__ _ 6fl�_ __ _ $2 292 48 . _. SAND DRESSING STERILE 25 j 4,X'A - 66597 3006.0 25R$20.00 ,ISLAND 99999 9003 42 25 _ $25.00_ ISOETHARINE-INHSOL. Y � 0_Z-��� SOLN: 000543408-44 `� 30'���`� '_ S?44'.75 ISONIAZID SYRUP _ 50M01VIL $YRP_ 46287 4d9a01 J jISOPROTERENOLIM SM SYR � 0 G ML LL =SYRG]00674497&Q:L -•,25 F $8583 1 Q0065 ISOPTO ATROPINE {ShIIL} - -1.00% ry __ __ �%- __ S�LN , - . 0303-55 _. - : _ _ _ 5 _ ._.__ -.:. ....-.. $60.91 i N. FOTRIGfNE EXT REL s 1O01vIG TAB ' �55111 ff719 33Q J 54d w _ 3+_ 4?0.77 $ { _ ;LAMOTRIGINE EXT REL _ _ 200MG TAB 65162 0986 a3 30 �� $448.70 I fAMOTMINE EXT REL _ 25DMG _ TAB 498 D4 11 30 r _ _ 3611.88 —J 'LAMOTRIGINE EXT-REL 25MG TAB . 65162 0949_03 30 $196 43 LD fW(jfRIGINE W-REL _T 5pMG ,a TA6 5511I 0718-30 z' _ 30 392.81 ry I ,LAMOTRIGINE ODT _ gMA :OTRIGINE ODT 104MG ; TAB_ 49884 0486 11- I 2S/50 100MG w KIT 49884 0882 99 ;� -! 3d _ _ _ . $304 13, 30' LAMOTRIGINE ODT 25MG CHEW 49884 0484 11 35 $266.29 ,� .-Z0.5850MG w:i LANCETS {100) 28G ;'. 561510142 60 - 140 _ _ ; _.. _ _ ._- $5.50 LANCETS uLi ,LANCING DEVICE . _ a _. - _ i°_ 53625 9500 00 10Q _ _ $13 19 LANOLfN 113GMI j; ._ ; ` "; OfNT`' g 6192 4 Q4� l( S7 50f LANOLIN_{40GM) 44677 0100 20,!' UNOLIN ANHYDROUS 41OGM `. ]EOINT ' 54162 0596-1R [�40 ' - _ :.._ - ,.v._• - : � 2` O.2MG f 00173 0274 5S .. _. _ ,� _ .._ 410 o i._, _ $76.80 LLUlLfy!AXJS MJ �A u.uua �.__.J' nu. - t c4ct.._..... v° u?v?'v L..�_. _ a.a,....._4...._.---- :LOTEMA-X (5ML) _ m. . 14o j , SUSP 24208 0299,OS 5 $360.14 a LOTERtAX_ SM (SGM} _ _ j 0%,� GEL _]I 24208 b507.07 LOTEPREDNOL ETABON (5ML) _.. _ 195 _DROP(Sj _ . 62756 0232-90 ' _5 _ __ $225.36 OTREL _._ _ _ _ _ _ _ _ _ 10 20MG CAP; 0 8 364-05 4 _ LC1TREt CAP. ;, 00078-0379.05, ;; _ 1001. F _ $1,777.13 _ �IOTREL .. .. _ . _ _10/40MG _ _ _ Z 5 10MG ' ji CAP Q 7$ 044 t 140'837.90 d I.OTREL ,. - CAP 00078 0405-05 100 - $1,314.58 _ . :. �- LOTREL _5/lOMG --- _ �_, 520MG l� 0007$ 0406 C?5 ' 1, OE 1388.22 - ! OTREL YCAP - 5/40MG . _ CAP 00078 0384 05 __ 100_ LLP1RIMIN 90GM L 4 PWDR :1100 05 7-29. 10 V j��,_ _;�__$7.92 . 'LOTRIMIN_,(lOML) 0.01 SOLN D0085-0182-02 _ 90 .__ $14.29 _ ,tQTRtMiN 15GM _._ 0.01 CRM 00;02� 085 061310 l_ --_- 16.21 _ C6*MIN AF (12GM1 __..�__._.��.__ 0.01 CRM 00085 0963 15 _ _ _� 15 �w LOTRIMiN AF 133GM 0 02 P DR'' ] 1523 0544 02 126 +38: Y ,lOTRIMIN AF SPRAY (133GM) _ _ T PWDR j 11523 4140 02 O tC4TRlMhN ULTRA 1ZGM��CRM : 11538-01 2343 133"- ., _ $8 56 _ _ _ _ _ Et ATfSIRAIR1ItI TOA 7'1�i`R Al - _ _ �'- _ -, AA9 ror Aiini7_m-ac_7G --___ _ - MARYS MAGIC MOUTHWASH ' SULK 9ylVVV VUUL Z8 1 >ly_yV !MASK NEBULIZER ADULT ter- 73796 0099 MASSENGILL FEMININE-(240ML) ` WASH 05310 0001 13 1 $2 23 M__ ATTRESS �� 1z 99999-9000 77 240. $0 00 MATULANE — .. _ _ _. SOMG ' CAP 54482 0053a 01 1 _ _$11�750.40 ivIwATZIM LA u1 1$0MG . TAB, ` 2544-0691-J:9 1 100 �y_...__.�..._ 267.$0 �MATZlM LA _ MATZlNrt:LA _ 240MG, TAB 52544 0692 19 i j 300MG. TAB` 52544 0693,19 �90 90,_ $300.12 �ii390 43 NiATZINi to 4 - -`-1[�- - ry 360fVIGW_ TAB_ 52544 0694.19 90 r - �. _ 5420.08 _ MATZIM LA _ _: _ _ _ - 1 42bNIG i� TAB ':.1rl525! 44- 655-30 - 91;L _ _ MAVlK _- _$252.60 _. . ,MAV(K 2 IG. TAB 00074 2279Y13 ._._». 252.60 4MG _ °'--- '_ . ;! 00074 2280 13 100 $252.60 MAVYRET _� , _.- ,TA8 - 100-40MG ! TAB�~00074 2625 2$ i_00 � jj_ -$15'840.00 10M . , TAB 00006-0267 YS . -- _84, SMG JAB 00006-0266 18 F' 18 _ .A �•:.�•.•.-..7r.--- �� z,�r-^:.;^-ar----r_ ,.•-W--p----� �.,..,;,-. ..v...,.. INE ROL ®4MG k 8-00009 0056 d2 25 3 C jMEDROL _ '� �',� 1` $MGM #� r 7A8 ���„00009.0022 014� 100 •"" �' �`�53 S9 �` EU� R�,,CDt}SEPAK + ;y 4 G T 8 00009-4056 OA 25k 7`67 MEDRaXYPROGESTERONE ; lOMG° [ TAB 04555 0779 02 21 $4 4�jf,s � NIEdROXYP.,ROGfSTfRO f 2SMG' TAB 00555 0$72 02 00$3129 DROXYZ GESTERONE 3Ml 3 . 150 G :MI * ... UtAC 66993-0370=$ .20b.. F 97.8 N EpROXYP.ROGESTERONE {1Mt EAj s ls*97 L� _ E SYRG, � 66993-43717 MEGRCE O LL', 625MG5ML SUSP 49884_0949,69�s '' 1205 94 `MEGACESUSP 244ML 40MG/ML SUSE?OOQ15450842; 150x $18054. 1 Ms -` 32 ' . tA8 OO5S 6�0 240�' 104 44 MEGESTROi [MEG"ESTROL . �' w }`. 40fVIG TAB .00555 Ufi07=02 3 100 �µ S170 83 _ - _._ "iVlEG C}L 154ML . 625MG C SUS : MEGRSiROL 240ML ` 40MG IL � SUSP 49g OT 907 38 I.U. tA7aN[N +gclOMG CAP ' , OT68019 ss� 24� s15 6S _ MELATONIN �� e SMG TAB..,$(I68100d 02� 240 �� w}i _ _Si7 33 11lIEIA7QNtN`ER rn 3MGu= _u �k Tr 47463000458 { t_ 59 Y $1045 tM Tt3N{N t3{SSOLV 10M1�IG. TAB �1d98�302?5�i}3 140 ��y±r � v �� �fi2I24 MEtATONiN FASTC?ISSQEVE �E y , 12MCa TA_B43 010210 x " 120 =--";T701 MELA AN(fdtdSTtJtSS 11L SM, T B :A—nRAt 101 IIFEDIPINE" 20MG CAP__ y 23155 019501 100 - $99.48 JIFEDIPINEERER " I 30MG TABS 507A2426401 100_-_, 132.45; _ ;-•- --� _ JIFEDIRINE ER 60MG 'i TAB 50742 026101 ,� 100 $229 15 _"_, _ _ " 41NEDIPINE ER__-� 90MG��j T 6 50742 0262 Q2 „lOQ $25 6.15 150MG CgP'_r 3 640110163 JIFEREX �50MG J TAB 0Q2312200'86µ _ JIFEREX_(240ME) Y_ _ - ' 100MG�5ML ELIX - 1 00131 5066 68 1Q0_- $2$ 54 JIGHTGUARD -= z C - �'- _SM/MED g4203779912 236°` $2009_ 4IGHTGUARD MEDIUM r _ - _ 42037 0799 12 - 1-1 ffl(l {28- A} 3 0.02 TAB ' 6S180_088� - 6-73 1 212 44 •: JtLANDRpN 41LANDRON 150MG ,; TAB' ";, 00088 1111-14 _. _ ._ _ ._�. SOMG 7AB'QC?988 1120 Y3yS - $S,030,40 _ _ JIMOD[PINE �: 69452 -0209 20 36MG CAP ` 90 $1,841.00 d1MOTOP .., ! 30MG '� P : r 2 555 70 _ 10d. $322.45 _6 41SOLDIPINE 17MG TAB : 00378 209701 _ _ _ 30:. _ $769.76_ ... ,. . _ 41SOLDIPINE r - - .__ . - 20MG �}'s _ TAB : 00378 2222 q7l _100 -- JISOLDIP1iyE ' 25.5MG T�;B Z093 01 ._. _ j0o ; $839.48_ _ _a_00s1a 41SOLDIPINE ER _ 40MG 8 �00378 2224m02 4 200rm S2 794.20 4TAZ6XANIDE SOOMG TAB 619800526-03 ! 100_ ,. _$4,604.46 JiTRAZINE PAPER _ r 15FT: } i p0003 D526f2Q - 30 _ _ 39:77 41TRO-BID " 002 OINT° 002810326-60 1 - _$85.18_ 4_fTAO BID f V 2.5MG _ 41TRCi-BID 6:51VIG CAP 00088 iS51=47 `' ld0 $18.25- JITRO 61D 3OGM - - 0.©2 _� OINT�I 002810326=30 4 Ya 41TRO-BID FOILPACK. 0.02"- OINT 00168-0326-08 , _ 30 _ _$37.97 -_ - dlTftt7DUR _ _._ 1 43WiG/tiR __._PTCH.tr 00378-81� Q2"9 =_ n_ ._v " _ _ _ 4 � 547.44 41TR6-DUR OAMG/HR PTCH 00085 3305-30 30 $16536 41fiRO DUR �, �...®:: 14 02MGJHR TjiPTCN t 00085 3310-3i 41TRO-DUR 0.3MG/HR PTCH 50742 0515-30 ' 30 $1,907.68 ITRO�DUR00485 3320-30 $200.16 41TRO-DUR 0 6MG/HR PTCH, 00085 333030 ! - 30 _ $217.08 J[TRO DUR_0.8MG _ HF y It PTCH++ 44085 08190819 35t T _ aITRQFURANT6iN 104MG CAP 47781 0308-01 ', 30 $337.64 4ITROFURANT0IN .� ; �l SOMG _ ^{, CAP _� 4781 0347 01 g - 140 � _ 4ITROFURANTOIN MONOHYD {MACRO) 100MG CAP" 477810303-61 _100_ $381.39_ -�M _ u� _;,..:_ „ " n•n� E ninir `I nnar nl n3�u; _., <i. 9tttt 7,,- Cstc lit: 1 a�tni'itittccnin_-. dtTROGLYCERIN O:1MG PTCH 00378-9102;93 60 $55.76 _ 41TR LLYCERTN - �j+ 0.2MG� � ! PTCfi ! 68382 43Q9 �- _� dITROOLYCERIN _ 0.3MG - TAB w 59762 4921-01 ; _ 30 ' . JtTROGLYCERIN _ _0.4MG� PTCH: 003132-93 I 100 JITROGLYCERIN _. v 0.6MG PTCH 49730 0113 30 ", - - 30 ` $61.90 11TROGLYCERIN _ _- _ 0:6MG�- �I_ 7AB 59762 6489=0l 100 47.47- JITROGLYCERIN ER _ 2 5MG CAPS 49483 0221-10. _- 30 ;_ $88.80 41TROGLYCERIN ER �E6 Y µ CAP 039 Q 460 _ 100 ,�L S79T97 a { JITROGLYCERIN EEt 9MG CAP' 00185 1217-01 ,, 100 $99.59 UrROGLY_CERIN SL 4X25�_ 0 4MG_::��TAB : 5971 62 330-4 03 � 1Q0 - ^$lO2 69 SITROL 41TROLINGUAL 12GM} 2.00% 0-INT. 002810038-56 100 $10 41 ©4MGOSE •SPRY 70007 4340-2d 60�^ $482 OQ ;w JITAdUN_ GUAL {4.9GM) " 0 4MG%DOSE SPRY _ 70007 0300=65 ; 12 $330.12 dIT OPATCH 4.2MG0Q536-4d98-07 E�_ ; 4,9}��-$40.55 ' 41TRO PATCH OAMG 10MG _ 04MGjHR . _ _ 49730 0112-30 _ _ _ 30 - ._ _ $56.30_ dITROQUICK -„ _ r . 0 6MG IL AB' 58177 0325 04 30 �' 8.37 JITROCIUICK 1/200 -, 0,3MG TAB $8.37 JITROSTAT 1 150} [ 04f G �+- TAB L__d 0418-24 100--,.1E rT�4.67 JITRO$7A7 {i/150) 4X25 ;; 0.4MG - TAB 00071.0418-13 :._ _ 100.__ JITR17STAT (1/2Q0}r=_ pIf 0:3MG TAB - i 00d710417.24 F1d0 it $84 67 a.. __ lITROSTATSL_. -__ B y' 00071041924rv. ".._ 100 --_� �_ .. ._ d{VEA (240ML} 4 _ ._..-_,�� ._.,06MG _�� � ' '� LOTH,'= _ 77mFA(60Mt)___�_ _ _-_.._-...__.{_ _ __-_:_.._- _�' CRM�'n72140040776ir240 JIVEACOCOAOUTTER'SO4ML) 7-1 t LOYNp 72140�74Q1.65 V� 60-!__, $248_ $800 IIX CREME RINSE _ _ i 63736 D120 02 ` _ 540 ' _-_ S1S,S8 If CREME RINSE {59ML-EA i_ V 10d% 'r ' '-01 �...._._ _ __ ` 637t_ 36 �120 03 59.i;� 525 03 . , $5 36- _ IIZATIOINE-[ 15QMG CAP QO 50 6� 150W 143 79 r 8220 10 $498 14 iIZORAL 12QML) . 0.02E• Lr SHAM' SO458-0680=0$- •200 _,,,_,� . I[ a $SO.17 IIZORAL(60GM} 0 02 " CRM '50458 022160 IIZORALAD __:_ y, (" ' y" 4 SH_ AM-a•.'EO 45 0895 tI4 6O $9 74 IIZORALA-D {200ML} SHAM- 55505-0192-40 ; _ �t _ 125 ., . _.� _.-$14 54_ IOHISTPLUS7R - Wy4' ' `-1�= �� TAB=,6$097 0Y 1 5 d) 2001 536:4$ tONADHERENT PAO-STERILE I - 3X4IN ;`_n PAD .1'_616780b421 • _ 100 IORA-BE �- _ 4Ra 4 35MG TAB ' S254(_ - 4 0629 2$ ° 1200 L,"I $2X1.52 ' IORCO -. 10/325MG _._ _ TABp;__1 52544 0539.01 ; -_ 8 _ 16- 4NY5TATIN(473MLj _ �100,000UJML SUSP.v- INYSTATiN �OGM}R a,.' § ldi7 d{)dUGMWDR = `, INYSTATIN (60M1) 100,OOOW SUSP' 4 iNYSTATIN ORAL r_ _ 000_01 OU TAB°=::, jOBRif WJUMBiLICALSCISSQRS -OBSTETRICAL KIT(DISP #1727� 017 _SOLN ;OCCLUSAL -HP 10ML 026� �- LIQ OCEAN NASAL (45GM} �� i 0.0065 _ SPRY ' E CELtA 2& EA = w 3/003MGTAB OGTREOTIDE ACET {1ML PA}„ „ _, d dSMG/ML `_ OCUFEN OPTH 2p! ML) j=6.- d03 3OLN , QCUFL07t(SMIL) _"_____. _ 0 003 ; DRPS ,O U54FT EYESGRUB} PAl?S OCUVITE OCUVITE dCt_)ItITE F}{TRA�j _ TAB OdLMTE LUTEIN CAP 'OCUVITE PRESERVISiON ODEFSEY OFE_ V_. :... - TAB z vai 100MG CAP OFEV FLOXACiP1�__. OFLOXACIN 150MG CAP r60MGti_ TAB 400MG TAB 637- _ 465,60 473 130.72 -:. _ 008-02!. 60 . $14.40 I055 b2 L_ 6_0_1 =r _L$142.08 001-04 0 100 $50.00 260.03 _ 10 -- " - 132.67 5 IL 230.05� 84. 54.00 80i•03 1 _ id - .; y,M.__$51.50 387-62 30 ,... - $1132 38 6 (_"_. 120.- 10.91_ i s0 ._ . _ 120 443-19 _ 043-26l_ 50 :----_. _.. .510.79 101-01 120 $4,144.75 145-60 j�14 701.97 60 _ _$14,701.97 i _ ,vtwlvcr+r llv[ ..."_ _. G.71VIV __; liitl ' 77111^U103-U7 IUUU - 75,�`JYS.25� OI.ANZAPINE _ _ 20MG} TAB 55 0168 05 _ 500' ==- 915,17 i;OLANZAPINE OLAN711PtNE - w _ _ 5MG TAB,- 60505-3111-08 S00 _ _ ��'� ?.5MG. $13 215.67 �� TAB __��435980165d �� .M 1040 i� �4$8,041.67 6LAN2APINE(1-EA} _ VIAL _.. ... _ .. 10MG �' SOV 005i7 0955-01 500 $45Z2 ._ _ °LANZAPINE ODT �j; 10MG TAB' L33 342 0084-0`1 - _$620.00 _ �) OLANZAPINE ODT Q ZAPINE OQT _ _ 15MG TAB 33342 0085-07 30 �3" 20MG �f� TABV 33342 DOg6.07! : 30wi 910 OQ _S?,200.00 OLANZAPINE ODT__ . 5MG TAB; 60505 3275 03 OLANcAPINEJFLUOXE:INE _30 � 12MG 25MG -CAP 498840252 11 30 6LANZAPINE/FLUOXETINE 12PflG/SONG _, .CAP 49884 0253-11 _30 �, $654 76 LAOLAO NjAPINE/FLUOXETINE 3MG/25MG CAP 9 4 0277 11 [ 30 $317 82� OLANZAPINE/FLUOXETIN_E _' 6MG%25MG . ; CAP 49884 0250 11 30 $-4--- „ OLANZAPINE FLUOXETINE 6MG SONG -IP 4 9 84 025i . _11=: 30 w.,._�_�{ S434.46 OLD SPICE_BODY (473M1) WASH _ 37000 0167 70 ; 30 j Q PTRO_ �] �' 150MG TAB�43595 0080.03 [�1+ 473,�r1aS115 20 C QLMESARTJAM1flLOD/HGTL„ 40J19 12j 5MG TAB 57664 0798 83 ' , _ 30 m w _ ....•_ $171 94 1 r1t RACCA DT(A RRIAP1Ii2f"f�... ra�� j•"r{':�'n :^—'^`."�'�•'- PRED FORTE OPTH (�,OML �j _ 0 D1 SU5P 129$0 0180 10 i PRED FORTE OPTH (11.1. ML) o.of SUSP i2980 6180 15 200 - 10 �$384 47 $577 44 REDTORTE OPTH (5MC_ j 0 01 i SUSP '� 12984 0180 05 fI 25 � $292 48 _ ¢ PRED'G OPTH (3 SGM)�_ 0 006 OINT 00023 0066-04 5 $192.481 tPRED Ca OF_TH SUSP T, � 0 3%TT-.' 94 i SUSP t 00023 0106 OS:� 3 S $192,48 PRED MILD OPTH (lOML) 0 0022 SUSP 11980 0174 10 5 $384 97 _. i R:EDNICARBATE 15GM �(_� 09'a �i OUYT _ _� _. �2. � . �..i= 00268 0410 1S i' m 10 � �`� $30 QO - _) �PREDNICARBATE (60GM)- PREONICAfiBATE {EMOLLIENT) - �OSo li 090� OINT� 00168 0410.60 �_ _ CRM 00� 168-0381,2E �u�_ _ 15 _- _. 60_��_ _$73.79 $21,98 __ PREDNICARBATE{EMOLLIENT) ' O.OQl CRM - 66993-0880-61 ' 15 $94.70 PREDNISOLONE (240ML}� , 15NlGJSME J'Nd383 0042'24 160 $21557 PREDNISOCONEACETATE (lOML) 0.01 SUP 623140637lb 240 �?EONiSOLONE ACETATE i5Ml 0 01 SUSP 62324 .RREDNISOLON€ ACETATE (SML) 0.61 SUSP 61314 0637 OS 15 $55 32 -77 IPRE NISOCONE ODi 10MG `--0 i-LTAB^ t 66993 0844-35 ' -Ti- _PREDNISOLONE ORAL ) 15MG/5ML SOIN 50383 0042-48 PRE EDN150LONE SOD PROS (1 ML) 'LL_jj_ 1041 j_, SOLN7 24208 0715-10 __ 480 $185.01 ^- $63 25 i " _ ` 27MG-1cnLG is TAB 695?1KNMS- 10 d v i7L28`' W itVE n z�r s x dR(1N TAB 3932$_06101, ^ '106 5/SMG �T—Klzc p 60?58 0179 41 iQ0 s "" 572 8 tA!-GUMMIE5 GUN! Z7927 QOi9-S4 $100 2� 00 V11NS xr TABS �00904 531364' I a fi 90 3 86 u $} )U ACi 840MCG CPT flOS36.4Q85- 1 SOfl 6 21 CAP 75854 fl312 3Q: 0 426 97 - �� AMS 842 CP � 81 Q0-0400 00 3Q ����325�00�" 2 GMT CRM 5733-0868 ..0(NT!05732-087193'a A 26 $7 99 x €€` 51GM W OOL1NG � I-aEC ^' OS732 0840 1� � 28 {51GM} i}CRM OflS73-286$ 20 51$1158� 4iDQ �28GM} [ L. ,CRM OSfi32 0843 1QK ` S7 �52160 " OO W/H6{26GM} �CRM 04573-OSS 11. 28 47 6$ D TOE 4XI x 7"2�� - 99999 900197f 26 -BE TAB 2Z4$ 0432.72' 2Q 26 03 EL AREDS'2�� CHEWj24?GSQ697 AREDS MmlgFTGEI.l*24248 069 62 120_2936 1SNIG.4 =CAP . Ofl3U0 1541 30 dY Z6 w F 18744 3 pTCj� a 1SMra.� 00067 5286 141 $ 253 AB 15MG' TAB 64764-A 43 11: �,�1 �� 1660 38 O CARE $ 08 02, — 2 100 k 70 59 PCEC(,.i ...:'d�w.....,.....,.0-..-4.,: t� } 04245 OQ36 60 72 305 80 - 100M4 SEPJS PISTE 40126 00 100 2{}30 ~ BOOSTER PLUS: 11090 PISTE OD136 0072 92 ,1Q0` t " $20 30 _ .,.r m_�v .. PISTE .. 126 007 -92, 20 30 �� OD226=4286 b6' " 100zr=2Q30 t473ML� fl x00126 0033 16_ 51 211z: 9 M! EA EWE RG Q s 197r1 OS _4 Z80 O6 A$l EA _ SY C ? 5 314,IS �'�: ,172, ce�A-rt --5 7 !, '"$47356' 1Et3 5� �43 88 $38718__ rt di $240 82 O �:s 00904535124_ _. 24.,_ EPSEUDOEPHEDRtNE 473ML it 30MGi SML Y, SYRP O05 0 85 � P$EUDOEPHEDRIRtE(118MLI_ _. 30MG/5ML SOLN _ 00121 042104 W �PSEUDOEPHEDRINE P CL 34N G �v� i 7AB 00904 5- W Q53 S L 1QO M� � $3 15 PSEUDOEPHEDfiINE kiCl12 Htt 120 v1G r CAPL 45802 6107-52 � C:q 66-Qi72: 60 60 a<" $22103 =PSORIASIN (119G_Mj.; - . - - 2 00% _ OCN7 _ i 72959 Q020 52 <4_, _ _ 119- _._ _;, _ -_ _ $8.22_ LPULMICORTFLEXHALER ,.. _. [-180MCG INHL 001�&6-09IM12 1�--�.._=E'--�1V 317.52 � PULMICORT FLEXHAGER __.__ ___ _, 90MCG . k- 1' 00186 0917 $237.12 °PULMICORTRESPUIES f�0.5MG 2ML 001861989+ m 60 $369_.�2fi m� PULMO AIDE NEBUL(ZER _. . - COMP/NEB 16958 0684-58 i, _ -. _ - _ -__1 .__ ._ .- _-_ _ . _ _ $55.80 'PULMOZYME 2 5ML-EA M %IVIL SM 50242 0100 40 ] 539.43 J `-LL75$4 $0.00 U4- E �• B P -_-._, .'t 1 0004� O 0000 27, �. v . ._a_�� ��, 0.00 ,PULSE OXIMETER _ . BLACK_ t KIT 15224 087-52 _ _ _._. _ ,PULSE DXlMETER _ _ _- _ , _ �!? PORTABLE- , 53167-9900�00 F- EU -BE OXIMETER202.49 _ 09629 5133 ?1 1 _=-. 54.49 PU BE OPTH 3`.SGMJ, _ _ _ I' _ � �OINT f, 00 4025 3 L� _ _. _ _ 3.5 PURE EYES DUAL -ACTION -_ SCE"": ''. 04711 36d2-40 ' _ . _ 355 $3.60 PURELL HAND SANITIZER i u_ __LIQ� 00 0658 $1 j;� 240 jsT _ $4,40 PURELL HAND SANI7IZER (60ML) LIQ_ 73852 0096-50 ' _ 60 50M� _ ,t TABSl[57844,0522-d7 25; $117.19 _ PYLERA 10 DAY PACK CAP 58914 0601-20 120 1105.85 P A INAMIDE SOdING s,iy_ t B�7 70954-0484-30 1=�_ 100 PYRELLE NB TAB -- 66663 0702-01', - 30- $46.21 ~:�m� ?PYRIDIATE .-J_:e100 _ _ ~� 'PYRIDIATE-_ 200MG TAB 00536 4392-01_ 100 -$23.95 {U 100MGTAB,, fQ1340014rS3 �_ Y4.60 -� _ � f ,PYRIDIUM PLUS TAB 00430 d182 15 30 $56 48 ` �PYRlDOSTEGMINE BROM ER 180MG j� TAB " 4 81 Q_ V_ 335 30 j Q 744 23_ C PYRlDOSTIGMINE BROMIDE 60MG TAB Y ,. 68682-0302-10 100 $122.40 wPYRIDOXINE 8-61(4lIL-EA � _ ,_ ;, _100MG/MIL SDV, 63323_y-_0180y01 _ 25 - $_49_7.10 TYRIMETHAMINE 25MG TAB 43598 0672-01 lOfl $79,687.50 PYRINYL PLUS 60ML _ r . _ LIQ 0053 6-198-96 64 f 4.12��� - PYRINYLSHAMROO A .__.���� _. 00472 1583-92 60 $3 57 KN:A-LL (10.6GM) Q-TIP SINGLE iIP 61N (100EA) 08884 5414-00 200 ' $6.00 Q-TIPS COTTON FLEX {17Q�_:]L 30521 5070.0Q- _ Q-TUSSlN CF LIQ:,, 00603 0862 54_z - 118, $3.50 _ Q A CANE TIPS- 21N ��` SMALL BASE '?_169 Q 036 _. IN! 492810562 1O ;_. 5_$7?7.56 QUAIAQUIN :._ _ _m 324MG: CA� P� 1331 Q�Q15307 _ . 30 " 1~x $235.74 f _ QUASENSE (91 EA) _ 015%0.03MG TAB S2544 0966 91 273 $482.09 Q SIRANLIGHTPKT!� PAI{ `r1�d0487 0589-03 6d _.ST1836 QUESCRAN PACKET PAK _ _i_.00087 0580 11 60 $142.34_�� QUESTRAN POWDER �{ PWDR tQ936 66 g 378 $186.79 _ ? QUETIAPINE 100NtCz TA8 lj 67877 0250-1f1 1000 4$6 859 50 QUETIAPlNE _r; :. 2Q0MG i TA6' , 67877 02460 1000, i2 945.201 ,QUETIAPINE ._ . 25 VIG _ TAB, 67877 0242 10 s 1000 ,_ _$3,999.50 QUETIAPINE '' ��,� 304MG 67877 Q24761Q 1004 QUET[APINE .,...�[� _TAS 400MG TAB 67877 0248-14 ',, - 1000 $19 743,50 - QUETIAPINE 5 MMG TA8 " 67877 0249 lO' 1000: _ ]; a�r d $6 5669.50 Tm j UET Q_ IAPINE EXT REL - 150MG ' , TAB 68180 0613 07 60 $955.53 QUETIAPlNE EXT REL.; } 200MG TAB 6$180-0614-07 - -- 60 - Y $1053 69 t u 300MG _. �, _CAPL_ 6$180 0615 07 '; .. _ _ _ 60_- QUETIAPINE EXT REL 400MG TAB 68180 d616 07 � 60 " _ 162d.57 4UETIAPINE EXT REL '_ .. _ _ SQMIG.__, TAB _ zi 681$0 0512 Q7 �,_ � - 6Q _ . ;_v: _ . $532.13 QUtETCRUSHER _ -�- '----• ly - -- 80000-0126-s,5 2 s �557.50 __ .. .:_ .__ QUIET CRUSHER BAGS100 , s UlLLICHEW ER �_�� OMG CHEW 0076-D0� y 100 3- y ry$1491,10 '7 QUtLLIVANTXR)60ML ._24478 SMG ML SUSP h 24478 019Q 30_ �,. ..,_. iD.. �._.. 4 60 ._.. C32844 ..X_._-. .,t UlNAPRIL F lOMG =TAB 43547 0411W09 90 QUtNAPRIL F .- 2QMG TAB 43547 0412,iI9 ` 90 _.,._ CLUtNAPRit - �- =_-J[ , 4QMG QUINAPRIL 5MG f, TAB 69097083905.44 �_._ _�.� 11007 QUINAPRIL/HCTZ - s = 1O%12 SMG TAB `t 43386 0710.09 90 :"��_ �I„� q „$11d 14 QUINAPR(L/IiCiZ 20/12.SMG TAB _ :; 43386 Q ,tNAPRILjHCTZ " .. '=20MG 25IG-_ T 31722 d376 9 L ^9(?�--��114:i0 C1UlNARETIC _ _ 10MG/i2.SMG _ ,' TAB . ,52152 023$ O8 ; -_ 9Q .�$110 _._. 04 _ OUINARETIC rI 2Q 12SMG AB 5215'202 08, 90 u.__r_ ,UINIO Ntd LUCONOE,ER_ .324M -- ;._. TAB 53489.014101 `_ ..- .- 166-„_ _,. w $906.2S ttGYU NV MUt3 YY(tIYIULA BUG, ` JVL :- VIVII-Vuil-GU Li! RE U REWETTING DROPS {15h1L� LL ���SOLN 10114 0052-08 v. _ - RENVELA _ 2 4GM PCKT 4 58468 0131 02 90 r v� _ a $1,927.57 REPAGLINIDE -.. _ TAB 5723: OZ57 01 _C._ 100 365.45 REPAGLINIDE MG TAB- I` 57237-0158-01 �- � 100 'REPAGLINIDE 2N3G ,_TA$7' S7?37-Q159011 Z0 �.. $365;95. _� REPAN (ISOCET) TAB 00642 0162-10 100 $120.-82 RE ATHA 4� 140MGJML I� SYRG'L 55513 0750-01 1 670.30 ,RE-PB HYOS ELIXIR 16 2MG%5ML ELIX 68032-0395-16 ' 473 mm $74.55. Ii EPLENS VAGiNALMO15TUlZER {8)�i I GEL. 1226 0 -0 REPLICARE =. 4 X 4' DR5G 40565 0115-72 5 :: $50,04 FtEPLIVA-21/7 (3X28j y — TAB � � 6401` 1 p165-34� 84 y $92.94� REQUIP`, 0,25MG TAB 00007 4890 20 1(l0 - _ :a_ �_. _ w $674.33 EQUIP w_ w _ a L d.SMG ' �L -TA1.-J O007 4891-20 j1 = ! 100,.,. �( ` $674-33_._....�.. _ REQUIP SMG TAB ' 00007 4892-20 100 V R UlP _ 2MG 7AS M]=OODQ7 4893'2$674,33 w �C REQUIP 3M6 TAB 00007 4895-20 _ _ _,_ __ ir 100 $699.44 o - :rursr�� SEIEGILINE 5MG CAP 60505 0055 01 ;r 6 O $138.10 _ ._ _ . 5MG �� ABM 00378 9290 9 60$177.72 SELENIUM_ �,.." 100MCG TAB,;: 11845 0796-01 100 _ $615 _ SL _� 03016121`63 Q, -?43 _ SELENIUM 0709980544 t -TAB _. 79_0 _ s LOTSHAM120} _ ^�5�0MCCG '_ 250a� 4542 64 10 SUFENIUMUL $9.854 SELENIUM SULFIDE (180ML} 0.022S n '; " SHAAA _ 69367 0229$ ' _ _ 180. _ . =_ _ SELF G4THETER COUDE i 14FR 161N 08131 7006 14 { 30 J $133.09 SELF -CATHETER STRGHTTIP : iDFR 76IN 08131.7004 10 SELF GATHETERSTRGHTTIPr12FR _. - ._ _ _ w _ _ _ 16t�N-{�c Q8 0 1 _ 30 -$3933 �- �SELF CATHETER STRGHT TIP 5EL mCATHETER STRGHT-FEMALE 20FR 61N 70893 2278 60 '- 30 '� V$24.63 y 180 SELSUN BLUE 330ML} E._�0"_ 01_, _,ILSHAM ` 4116T O603 52 'Sc 5UN BLUE DRY SCALP {325ML)_ 0.01. SHAM S ISUN BLUE NALS {325MLj _ - : i�-�0.03n 41i67- 0618-d3 325wT-_,.: 51111 - SELSUNSUSP(120(VPL} . <<- 0.025 - SHAM �_ 000742660-O4; $12.44 SEMGLEE } 100U ML T IAL r 4950�02 0250 80 _120, 10 ry �$323 26 SEfv1GLEE (3ML-EA) 1000/ML.. PEN j, 49502 0251 75 __.. 15 : $484 85 S MPREX b _� _, . .j ;... 53g14 0404 10 �L. 100 SENNOSIDES - +CAP 15MG TAB _ 70000-0443-0.1 ;, 30',_ _. _ $5.49 _ ®i ;SEN 0 ES 4T_.._. {I $.6MGL� _??S , 16103 0363 11 10t10_ _ $21.57 _ w� _ M. SENNOSIDES _ _ 8.6MG TAB j 1fi103-0363-68 r 100 $3.27 _ SENNQStDES (237MLL^ _! _ is 8 8MG/58vILwJ[_ IQ~ 5789 Od52.0$j 23T w" 1 531.70 SENNOSIDES/DSS 8.6/50MG TAB 16103 0378-11_,. 1000 SENNOSIDESJDSS - __ _ v_ 1'� 8 6/SONG , : '{STAB .ems 70000 0526-01 SEIVSI-CARE SKIP) BCRR (113GM) OINT 43553-3256-04 113 $8.59 'SEN_S[C_ARE�STERILE-PF �V \VINYL LARGE _4 290 4844 07 50 529.23 SENSICARE-STERILE P/F VINYL-MED 08290-4844-02 „ 50 $30,77 tSENStPAR M �]_ 30M8_ -^� TAN 5� 5513�0073, 0�1 3 m_ _ 1__ _ 5968.04 � -1 SENSIPAR 60MG TAB 55513-0074-30 30 51,936.08 SENSIPAR 90MG TAB 55513 0075 30 34 `` I $2 904.12 _ ;SENSITIVE EYES DAILY CLEANER SOLN 10119 0010 04 30 5EN tS TIVE EYES REGVETTiNG DRQPS _: ?_ DROP S)�( It _Oli9 OOgl 74} 30 Wv� __$616 $SS9___ SENSITIVE EYES SALINE SOL 31011 9001-07 120 SENSITIVE EYES SALINE (355ML � �;� PLUS - _I,-SOLN _ 4 0001.07 SENSITIVE EYES SALINE_(355M_ 1.) ' � _ P1. LUS ._ SOLN 10119 OQ02-3$ _7i0 355$3.47 SENSITIVE SALINE'SOL _.__,.�_ DRPS` _lg1012 900107$2.75 SENSODYNE (113GM} FULL PROTECT GEt' 10158-0985-50 113 $7 89 _ _ SEN500YNE FRESH MINT (113GM} r SENSODYNE PR9NAMEt (113GML f; PSTE - 10158 0081 11 MIN7 00135 0464 113 SENSORCAINE (50Mt-EA} 6.0025 MDV. _ E 63323-0465-57 ; i250_ . $30180 =� .ENSORCAiNE ((50h11-EAR SENSORCAINE MPF (10ML=EA} ! _ 0 5090 �� M__DV a 63323 0467 57 I � i250 0.25% VIAL 63323-0404 17 250 $336 W n� _ - SENSORCAINE-MPF 10ML-EA O,S090 r SDV 63 0 66 17 t 254 }�- y �i _. L� �$13680 SENSORCAINE MPF (30Mf:EA)- 0 5096 j. -SDV . _ �' 63323 0466-37 750, '� $189 00 PTRA � ^DS _ 800 16gMG TAB 51570 �53 01 _ / a _ r _157 _ $25612 SEREVENT DiSKUS'(60) `_ . SOMCG _ _ INHL 00173 0521-00 '! - 60 _-" _ SEROFLORA VAGINAL APP 30 u"CREAM - _ ' j�9 9999,905__0_01,.' 30 T 7 $18,50 =- - - w_ _ _ TAB_ _ ..,._ __3 O 0271 10; _ _ ._ Iq0 _ $80U 04_ ; s 200MG _ TA8 �"" 00310 0272-10 00 _.. .�. - �P L_e 1i _ $1 9,30 TAB 0310-0275-IO .'_.. _ . - 100 ff ROQU€L � z 3gOMG ETAB EGO 0274 60jN _ 60 2,187 38 SER04UEL - „_ TAB_ _ _tt 00310 0279-10 i_. _ 100_ SERQQUEL =_ SON-,.G- TAB Oq 0 78-1 100 J[ 66:20 SEROCIUELXR._ :_ __.. 150MG �_TAB - a 003100281 _ SEgOCrUEL XR �„ . i` nmm 200MG TAB .'; 100310 0282 µ60 �_�_ 605�1,168 56 SEROCtUEL XR 300MG y_ .. _ TAB 00310 0283 6Q 64 $1,532 14 ESRQQUELXR 1 400NtG _ TA8 1 003��.10'0284 6 € 60 . SERQC4l1EL XR _ S QSTIM?� . .. .. 0 _ - - 50MG !': _ TAB 00310 0280-60. i _ .,. - _ - _ {MG ~IN1 44087 0006 47 tom"T 7 ` -�- _ __ 5,615`06_ SEROST!MN/DILUENT(S EA) _. ; ' . _ 4MG W wERTRALINEL MG TAB~ 65862 0033 05OQ 2 424.15 ;SERTRAUNE_ _ _ _ _ _ .- ------,__,. � ( 4 ...,... 25MG_._ _ TAB t 65862 0011 OS _ _-__. _ __u_s�: . _. . $1.424.15 _ m SERTR LINE (q SOME fi B l 65862 0012 0,5 y 500 : i� 51.424_ _ _15 SERTRALINE (60ML} _ .,_._ _.. ._ " _ �. _ �. _. ZOMG/ML_ _ �;_ -GONG 64980 0409 46 1. _. __. _. _- . ` _ _ ,567 09 SERVIRA:. TAB''_ 68032 0256 10 [� 100' (� . 117,86 SERZOhtE - . , . _ _) ,-_ _ 100NIG . - 1: - TA8: ,087 0032 31.+, . _ SERZONE 1 150MG [ TA8 40U87 0039 31_ ( 6q=-,:t$Sg9 75 SERZONE 200MG_. . f _ TA9 ! 00087 0033.31 .. _ . . _60 _ ,-5�106 50 S ZONE �t 2 50NIG TAB 0008�_ ___70�04_1�31]I 60 i _ $11390_ v SERZONE 7, w SONG _ _ TA8.._. h_ 00087 0031-47 _ _ 60 _ . _. . _.. _ $105.20' +JICYljq Ill j.KCANI '_ :: .:. U Vl - l,`"" LK4YL„ •`, a 4y2fS4--4JbVlNib- " : ,CU f--° ' J: $�3 L6., ._ ...., __ StLVADENt DREAM x a 4 00488 ;1a5Q 20 { ssa� 413 .rr CRM� fi1570 a13185 85 - StC11A0ENE DREAM {S5GMj � 51LER NITRATE {964ML� 1%r SOLN' 4L1093_-9614 13-"�960 _� _ r it ' ER N...... APPIh- RS .., $; t2874 i0a1�1 p �� 82,25 `r d _ 1 GUR 750.2aN16 TA8 :' 00074 33159090 '' �'"�,4 lMEiH1C0Pt 3aMt��r2aMG f a 3ML' SUSP 408045$94� 3� 3 5a METHIGONE Utl 8OM" 1 3!£ 63739-0225 AlN1lASANSTYE EYE REUEE _ i3 SOCN h S1NiPtYSAII(NE NASAE �, ? V r 0 aQ9 „� j mSPRY," ,226Q0�, -53420' _9 3_ iMPONI P, to 5MC EAi. SaMG 0 'M YR6 57894a4070-01�Q 5 y6 68654 " .._ _. _ ,SODIUM BICARB (50ML EA} � � $46 SYRG -1, 00409-491B 34 500E= OD' DIU .M Btt1lRB 5 ML'EA} � � � 5Q 00409 6625 42 Y , ��29215'A 50DIUM BICARB �OlVIE EA} * " � "` "' 0 0$4 ,; 'SYRG ; �g 76329 3352 0��, i250 fit; y �$178a08 ' ,; t7QtUM BtGARB 5ML EA O 0 r� SOV 004D9 6609 02 125�22$9d y SOQtUM BICARB�SML 'tom_ 0 042 SDV x}L 63323 0026 05 125 i� $ 6 SOS1tUM CHIOR 100OML EA 03'0 iV OORBB 0043 04 14000 96 46 EC Doi GHLOR (100UML EAj 3 t O Qt)9 kI IRR y d04Q9 7138;09 FCLa _ SODIUM GtiLOR 10t30ML EA �;� ', 0 QQ IV 0033& 99 1 0040 _ ; `82 70 ` y SQDIUM CFiIOR (1dOMl EA}� { 0 OQ = ADV 004p09 71d1 figk9600 OQIUM CEIEOR 1OQ LEA z 0 O ! 0Q338' 049 18 51HN} SOdRJM CHLpR (10ME EA�} F4 0 409 q, 5DV� 63323 0186 iq 2 lit $30 60 . s SYODIUM CHEt}RF IOML EA ire_ �„ w 0 Uf39� ,� f SYRG � 0$290 306 6 300 ` $18,65 _ SOQIUM CHIOR (10ML EA} t I� . 0 009 SYRG i 63$47 O100it} j� 1000 j $359 00 QQ►UM C H OR 2QMEA d i}09°Vf1�E 0040_9 4888 2tI 500t 3914 _ k _„� SODIUM Ct EQR (250ME EA}� i - 0004 } _ ADy ,F 00409 71014 E �000" S40d 00_ "l ` 0033 004$�Q2 600d 953-477 OQIUMCFtLOR 260 EAR�0 00 t R _ CHLOR (250ML EA} Q OQ €{�. IV 00338 0049 titm_ 60Q0.< $169, 87. �'`! SOQIUM _"M>m ., r _.I STEIAZIIVE� ;7 14MGfN�! i CpNC y OU108 490i 42ir GO- I $123.85 S7EL4ZWE_H#tf MGiTAB. � 04148 4903 2104 ,69 Q Q' STELAZINE�' , m � 2fv�G �jw TAB` `��° 00108 49Q4 20 j � 100 { '' w�; ,$122 90 "St RF PRED UNI PAE� 5M T B " 4n259 039Q 2I 21 58. 5T R1LE WATER (SIYft EAR 2, l _ IR}J 1 63323 0185 05.i .„p._ 2 .... F StERILEWATERINI 10M! EAR}' 56V 004p@4887,1i} 250 2824 _ _ STERILE WATER IN1p(20MLSDV633230185 20 SQO n 3- $149 4t1 STERit!WATER IJ 50 t EA}-u`ss ` I�t1 Qd�t09 4 B? 50 1250 72 ZO T _ STERILE WATER IRRIG `, 2000ML �j 50LN' �00338 4004 0? 12 ¢ $3336 j d STERILE WATER IRR G 250ML EAR 25 ML a Sp 40338 0004 2 L 6400 118.81 'i �'�_,,._ �� SOLN=� �� 00409 6139 fJ3 i,�. , 120fl0N,.,_ a -?�, $151-20 $TERIIE WATER IRR►G (SOQML EA) ,,, � y __ _ �_ SfERi�57 R[wP 30- 1' 4X4[ STRP d8333 1546 t}9 80 18+40A STETHOSCOPE _x�;,,4UGHT4EIGNT� ; 38673 040001 s _ . 1 «$5 99 ` 5:1 MATE DS NA5AL25«C 51YG ML SRRV ° QOQ53 6871(14� r�2$ , J!!►�t�v�c ; � is,.,� ovwv�v � �� �eaa,,.a z uww-votia c.� $ � �u 4.. +3 .t ....x �ovy w , t�EA of loot 25� 19'a' is 000Q7 7 0Q�o1 sf1CONA20tE 1(4 6GM� �,� �2 OiNTi 24385 ti374 $2 a 4 6 ti_. ODD TIAa [Is3 i iQQMCG GAP ?�iQ9tt Q495 $Q `� 28 143 45 h3Q� 13MCG� P ?1858-OOQS Qd 159 ,TIROSiNT �E� � ISOFIIGG w CAP 24090 0499 84 2$ ,` * 143 45 cm _ tiAO SNT; 25MCG�� CAP 24Q90 0491 84�28 ''` �' 143 _ TIROSINT '�,.. rn SOMCG� CAP , 71858 OQ15 Q4--77T �� xfi159 84 , �itRiSCINT $8M <LiJCAP E'24090 Q494-$4i; . M �2 � k 1434 v ?IRQSINT (4X7jxt_SMCG CAPS jr 24090 0493 84 f r$ f it r43 45 ` STAAWC ,420 MR, F'C E m- 0 12 O8 3344, 4a54 Y �TIHICAY F` ' 10MG ; TAB 497Q2 0226 13 ; _ 3Q j� rfi51143 " SCAY _PEN SOMG9702-022 13 2�55�, 7 O VI4MG �" �tLWIDISdE` CS 2 TAB 57664 0503 18 1000 _�`146s.00 F 1,22166 � sTiZANfD(NENCl '` r 6MG i` CAP ti 507A2-022615yu 150 $773 24 -.aw..t r...�.,�...... .,rn wn•.t,. ,� ,._. ea:+: ��+nrr.:..:'1 nnn-ee ne-ic,na,. ,iu,�-r .. ....Ha'crn `": :."�„`.;�..3 � ii-i`c v SSIONEX e fi_ _5U5P 53D14-054$-6473' 393.04 Y TWINRIX (iMl-EA} ,' 24MCG/ML ° SYRG 58160-0815-52 10 $11453.80 -" TWO -CAL HN i000Mt EJA ~ LIQ EZ-0474 0680-48 d w 800N $69.60� TWO CALHN RT U,,(237ML EA) VANILLA-,, ' CAN , 70074-0407-29 5698_ $37.68 LTW YN51Ay__�y__ _ 00597022737 _' 30:°.y; $278.60{ TYBOST _ 150MG TAB" _ 61958 14ol O1 36' ' $09.96 LtYLENOl8 ffiOUR (� 650MG ALE TAB �E0580,0309�02 J 4�16,74 � '? TYLENOLALLERGY MULTLSYM - WL"" -� 50586-0274-24 24 - $,4.78 iTYLENOLARTHRITIS ER_ 650MG��� TA80580 0783-32_ TYLENOL C00 #3 - 30/300. --- , - TAB„° ' . 00045 0513-60 100.. $79.81 ?YtEN{?LGOLQ ANQ PAIN SEVERE ` _ 325j10/200 5 CAPL " • 50584.0270 24 24 �_� $5.27 - _ . TYLENOL COLDMEAD CC1NG/SEV 10-5 325-.200, CAP " , 00045-0261-24 2.4 $5.45 TYLENOIE$" a _ 4 S00MG , � TAEL_I4,3004�'5-04 99-9 j' _ 150j $11.89 `- t TY[ENOLEXTRASTREPIGTki ,- 506MG CAPL,'_ 56580-0449-09 -lob, $9.46" TYLENOI E}CTRN STRENGTH SOOMG 15N1L� G1CZ E 0580.411108 ]'-- 240 . + _ $5 22 _� J TYLEW LGELTABS 500MG ,TAB 00045-01N-10 S00 $9.85 TYLENOL HEAD CONGE571ON __tom�_ __ ___.... .Y......._ SEVERE may. CPLT �II.9p58,pw 0 0261.24 _ 24rr45.49 TYLENOL INFANTS PAIN+FEVER 160/5ML SUSP ' 50580-0191-01 ' 30 . $5.36 TYLENOI PM�i _ TAB- . jI 50580 0482-10I _ _ _ TYLENOL PM TAB 56580-0176-10 100 $10.84~ Ems, LENOLSINUS &PAIN SEVERE4_ _ 50580 0262-24 TYLENOL SINUS CONE & PAIN CAPL 50580-0275, 24 24 $4.98 _ _ �IYLENOLSORE THROA240ML}. - ._ _ _� 50DMQ/15ML _ TYLENOL W/CODEINE 612 15/300 TAB 00045-0511-60 100 $28.63 LTYLEO-DV/COD84EINE -J_.._�_...._.._ _ - _�Ir_j ~fi0 300 TAE3V,]! 00045-0515-60 l�.__ TYLENOL W/CODEINE ELIXIR ELXR 00045-0508-16 480 $66.95 " LENOL X STRENGTH L1QU[D _ i - !3 `Y_-� _ �- LI it a0045 0500 08 ` 2 _ _1._ ._ _�.._.� _ �$5.23_ TYPHIM VI (10ML-EA) _w_ 25MCG/0.5ML MDV 49281-0790-20 10 $2,023.44 a:Y EKA TAB i 00078 OS38 15 fii _ �00482-4760-15 30 _. - --_. ._ 51,285.26 MINENASAL(15ML) 0.061 SPRY 15 $68.88 �UBRELVY_ _ _50MG' _' TAS 4D00236498.11 14 $,180,79 :UCERIS _�i 9MG TAB 68012-0309-30' 30 $2,151.41 00 _ iLU.I ESFIA 2 PACKj` >� 0.05 ! LOTN � 69202-0780-881�_ 454`'y 568.17 ULORIC _ 40MG TAB ` 64764-0918-30 30 ULORIC � - 80MG j TAB -� 64764� _ _ _0677-30_t_ __ _ _ L µ _ _$396.04 5396.04 L CCL ULTRACEF 500MG CAP 00015-7271-50 50 $178.27 _ tJLT(�RACET -- _. �_ 37 5/32SMG TAB ` ` f; 00045 065060 i J 500 � ULTRAM SOMG TAB 00045 6659-66 100 $163.64 ULTRAM ER�TA8 00062-0653.3+3ii_ 30 iL�$133.31 �a ,ULTRAM ER 62-065 200MG; TAB 0005-30 30 $242.29 ULTRASE w._ m _ #----� MT-20 ..II,: 2_._AP..:-__:_.,, _ ULTRASE CAP '05891-40.45-10 100 $45.22 LULTRASE MT-12 _ L~�. CAP . [05891-40021.0 1002 �]s+ 4 -$270.05 __. '!Uait SE MT-18 CAP 58914 0018,10 100 $264.58 _ , _._ !LILiRASiTE NEEDLELESS _ CONNECCOR 99999 5000-01 1 ;� M 270, ? 'ULTRASITE VALVES � _ _"I - 00000-4151-10 100 i ULTRASOUNQ GEL 250ML-EA .__:......�_...__._�}.-.�.M. t= 30884-5270-17 ..._,-,.....,._...._�-,�--•---_._.�,��_.��.M-..e 3000 .__.tee_____,_ $40:00 1 ^$4.28 'ULTRATHON INSECT REPELLENT _ SPRY 51131-061747 170 UL7RAL VATE Y _ 0.0065 _1C NT' , : 00072.1a50 50.€L M ULTRAVATE (15GM} 0.0005 CAM. " ` 00072-11400-15 . is, $60.99 ULTRAVATE USGg- � OA005 ( 0 JE00072-1450 L 15 ULTRAVATE (50GM) 0.0005 CRM 00^0�072 1400-50 SO $146.67 U RAVATE SOtiM _ _ �i 0.066 y 1_' OINT `]C WV72�1450-5`3 ULYTRAZYME ENZYMATIC CLEANER _ TAB, _ '' 11980-0212 20 20 $14 30 IUNDERPAD=DISP��` _ r`I�23X24:'1N_1-1253-34� 200-�'$31-?3 UNO1 RWEAR tVIENS(MAXABSQRB) UX-LG_ 57627-1766-06 18 $9.57 UNI-DECONSA,,._,.___-•,_-_y- _ _ TAB 677.0472-0 j 104�-'� 'a13.NSJ, ;UNIFINE PENTIP _ 29G 12MM _, 08470-3529-01 - 100 " $38,97 U MFORTTOUCH (100) { SUPERTHIN LNCT L08470.0465-0 . 000 ',UNILET EXCELITE II _ LNCT ..- 08470 0535 OS S00 54•17 •UNIL` E , PG 08214 0418 01 f[ 200 UNIPHV'L 400MG TAB 0781-62ik 01 100 $151.69 UNIPNYL '" I. a 600MC� rfi TAB, j 67781-0252=0,1j 100 - a I? _ 219.18 _- UNIRETIC y 15/12 5MG TAB 00091-3726-01 , $300.17 Ut NIRE7ICjZSMG� _' _I00 TA8 00091-3725 01 I _ _ ip0 KK 00.17 UNIRETiC 7.5/12.5MG , ; TAB - 00091-3712-OS ' 100 $300.17 UNP SOLVE ADHSVE REM '_ � V�2fP`E;, -- r:= 40565 0115- 55 ice' �® 50 : , i $8.63 iUNISOM. '. 25MG _ . , .. TAB ... 41167-006049 ` 16 $10.00 UNISTIK2 yE I S38$5 0636=10 ~, 100- ,. t 24.4D_ iUNSTIK 2 EXTRA 08214-0712-01 100 , .°, e $16.98_ . _ .,•,� UIUISTIK 2 NORMAL 300) �"�,;,,,���„,���� 08470-0702 01' 60 :UNISTIK 2'NDRMAL t50) 08470-0700=01 50 $13.83 ;UNiSTtK 3 COMFORT '•` _ __ _ . ,I LNcT` $4701042 01` L 100 " .�___ 26:25 1 UNISTIK-3 COMFQRT INCT 08470 1647-01 50_ - $22.50 15MG '; TAB 100. .. $327.06 UNIVASC 7.5MG TAB 000913707-01. 100 $312.20 UPTRAVI lbUUML 1Ats ; - t74L15-VO1D-tio Dy. UREA' 198.4GM � ✓' U.4 CRM T; i6477 0340 07� __.._. - 198.4' $171.99 UREA (85GM) 0.2 CRM 00536 1109-45 , 85. 4 $14.50 iUREA (85GM}�_� -,�_�. � _T_,•"� ��+�,_,:_ O.A� � �1_�CRM �_ � 16477 d340.03���.� �5 ��,,�i? �,,_,_.�161.02 � m ____� UREACI-N 20 CRM 00884-0449-04 113.4 $19.90 _ URECHOLINE 25MG TAB 51285-0691-02 100 $669.90 ;URECHOLIPlE �- 24MG TAB�j51285 Q692 {}2 ( _ _ URECHOUNE _M _ �!- _ 5MG TAB 51285 0697 02 100. _ �.5932.20� $267.78 81/'0.12MG_' ?_ TAB---] (__666630219,O1 i!_ 90 µ __j;__�__ _ �$610.39 I URE-NA POWDER 1SGM 62530-0000-11 8 $33.60 _PCKT 00076 0111- 1_ 1e _100 $37613 - 4 URIMAR-T TAB 00682-0333-01 100 $65.85 URINARY LEG BAG W/FLUID PATHWA LARGE (9805) 10610.0750-98 10. $46.16 URINARY LEG iiAG-F4015fVt� __ `i� MEDIUM - �.� q__.�. 99999 9gG177i.� 40v�- $136.69 URINARY LEG BAG-P4017L LARGE 99999-9060-85 40 $171.71 00143218421�r_M_� 100 UROCIT-K IOMECI, TAB 00178.0610-01 100 $256.69 'UROCIT-iC_ TAB a0178 0615 01 I ._ ._ 100 :_}.� _._ _ 5437.04__ UROCIT-K l SMEQ TAB 00178-0600-01 100 $183.14 500.5001viG_$6475_. UROSTOMY POUCHES 1.3/4 INCH 00003-4015-35 10 $31.63 UftOXATRAL 10MG _ _ ._ .. TAB . x. OOQ24 42Q0 10 I 140 µA $1478.40e URSO TAB 58914078510 100 $660.89 FORTE _250M_G 500MG TAB 58914 0790 10 I 140. _ ;`-_ ,URSO URSODIOL _ _ 250MG TAB 49884 0412 01 100 _ _�$1,171.14 $268.24 300MG _ CAP.. 9238 1 654D 01 y{_ ._ 100 i' � $735 14 - URSODIOL 500MG TAB 49884 0413-01 100 $475.34 UTIBRONTNEOHALEft UD(10X6}Y4 27 2/15 61V!CG ~ CAP. _OD07$ 066_4-19 $` 4Q 64_._. VAGIFEM __ 10MCG TAB~ 00169-5176-04 18_ $459.43 r VAGIFEM Y._ ~- ; TAB y i.OQ169 SS73-04 ;; 18, _ .. _ _. VA61SIL (28GM) _25MC6_ CR_M _ 11509-0003-72 28 $4.15 tJAGISIL INTIMATEeS6.07 VALACYCLOVIR IGM TAB 57237-0043-30 30 $379.26 TAB_ a'-572370042-90F1! 90 y�_NY_$650.16� - VALCHLOR (60GM) 0.0002 GEL 66215-0016-60 601 $4,384,80 VALCYTE _ _a __ . _ _ _._ _r __ _...___. 450Mf _I;___TAB __.I'_ 004 0038 22! _ 6Q _. _ _..._ $6 364.97 __� VALGANCICLOVIR 450MG TAB 31722 0832-60 60 1tALiNE DS (SOOGM). ^ _. _ !e_ __. :' PWDIt'_ l; 38779_035808) SqQ���� 4 $2,707.50 VALIUM 10MG, TAB 00140-0006701 100 ` $1,068.22 UM VALPROICACID 2SOMG CAP 69452-0150-26 100 $84.00 VALPROICACI6 473M1�µ v4" _.4 s` Z50MG%SML J SYRP:"I�001214675-85 ': _473 _ _ _ -}532.50 _- VALPROIC ACID (5ML-EA) 250MG/5ML SOLN Od121-4675-40 200 . $67.42 VAISARTAN-16OMG _� TAB µ]( 547-0369 g9� -- 90 _ VALSARTAN 320MG- TAB 43547-0370-09 90 $585.09 ;VALSARTAN s_ _ ;". 40MG _, _ ry� _TA_8 _�j SSl1 -r6731 30 .� _ 30 T $48.66 VALSARTAN 80MVIG TAB_ 43547-0368-09 ` : 90 $434.78R ;UALSARTAN/HCR V .. _ �. 160/12.5MG _ i�TAB _ ` 00378 6322-77 }� 90 � � j $384.34 VALSARTAN/HCTZ 160/?5MG_ 00378 6323-77 90 t436.26 _ _ _ VALSARTAN/HCT2_ _TAB- ,)320 12;5MGr.�? -- TAB` 0037E 8 6324 77 I 90"�]a� 48733��i VALSARTAN%HCTZ 320/225MG TAB - ; 0037 8-63 25-77 90 $552.87 VALTOCO 15MG D05E iSMG SPRY. 1, 72252-0515=04 2 $$784925..882 - l0_07;ATREL___ 3-055-04_- _ 30 r 9 ; VALTREX SdOMG TAB ;. 06173-0933-08 " 30 ,- $4$3.36 iVALTURNA _ 150/160M 4 TAB 00078-0572=15_ 30 - VANCOMYCIN.(I-EA) IGM ADV :; • 00409 6535-01 10 $100.61 _ - �-.- ---_------__......__..� VANCMMYCIN 1-EA)_ M _ .._ _', ._,_.I.____.,� 2GM - ,i_(_ VANCOMYCIN (1-EA) 500MG VIAL 47781-0598-01 10 $96.48 IVANCOMYCIN 1-EA SGM (': VMAL, lr 67457 0341-05 { 1 $106. 2 •VANCOMYCIN(1-EA) 750MG ADV 604096531-01 10- $80.17 tVANCOMYCIN (1-EA}ADV m :_ _ I 500MG .- ADV ' 11 00409 6534-01 _ TM 10 VANCOMYCIN (25dML-EA) 1.256M/250ML INt 70594-0057-02 1500 $136.80, ,VANCOMYCIN HCL00121-0867-20 i -� 20, VANCOMYCIN HCL 250MG CAP ; 00121 0890-20- : 26, _� , $1,154,32 _ UANCOMYCIN HCL 200ML-EA , iGM 2Q4ML �IV 705940042-0 s 2400 _� V1 5230.40=-�-; VANCOMYCIN HCL (30bML=EA) 1500iVIG/3obr l IV - 70594-0043=02 1806 $165.60 .. 72611-0761-10 10,;. VANCOMYCINP/P(1-EA) ,� SQOMG VtAL- - VANDAZOLE VAGINAL- �!J a.o0�f GEL" tom' O0245-0860-70 ��� VANICREAM (1-EA) - , . BAR - 45334-Q320-39 1 • .• $169 Vy ANICREAM,{453GM�„-# �] CRM45334 0300 01. 453. VANIQA (45GM) ". __- 0139_' _ CRM- .• 00023-4857-45,-.-, 45 $199.20 - MANISHPOINTSYRINGEICC 27GX1/29NCH � 01370=310131 � 100 .:_ � $75QO — 7] VANOS {60GM) . 0.001 CRM 99207-0525-60 60 { $1968 97 v VANrjX� jpE HC ,,,_ _ -0 SCSp �� LOIN —,Y 11086-0032-01D 25 ':i�359 99 Y TAB _ 00009-3617.02 200 $659 88 VANTIN 9L _ 266 TAB 00009-3618-02{ { _� _10a —y 871.81 VAC;TA (O.SML EA) 2W .5ML SDV 00006-4831,41 5 $438.40 _ I ARENICLINE - _ �=. L ___ 05MG qr TAB .. 49884 01 S 6 '� 56 492.07 n VARENICLINE SMG TAB 49884-0156-76 5b $492,07 = -- VARIVAX VACCINE(FRBEZER 4827-00 10-���$1,918.39___ V SCEPA 05GM CAP_ 52937-0003-40 240 $497.77 _ VASCEPA _ 1GM_�CAP } 52937-000120 �i 124 _ 'm'��j� „_'.425.46 VASELINE (106GM) 05212.0326-00 106 $3 00 ! ASELINEJ M-EAL _ [•_ UP THERAPY;_ �OINTr ,VASELINE (368GM) 605214345 00 368 $3 04 VASELINE(49GM .-___:_.-..;.. Ir� i��_ _ _ ]i a5212-0311-Q0 __� 49 VASELINE (52 5GM) 00521-2311-00 52.5 $0,98 iVA5EUNE`{SGMPCK70888-43320(}? ~� VASELINE GAUZE (50) 3 X 9 STRP 38884-4136-05 50 $225.13 _ VASELINEfNTCARE7_95_MLADVREPAIR _ LOTN-Yj00521-3084-0t1'4V_a_ 295'��J$466��_ VASELINEMTCARE (295ML) - COOLIFRESH LOIN 00521-309100 295 $5.04 MSELtNEINTCARE(295ML)M_ w-, W ffSCUE L07N l 05213-L1840-08� 9.6$___.__ _ VASERETIC 45224 TAB - 64455-01,46-01 100 ' $375_,38 VASOLEX (64GM) OINt 58980 4790 21 60 $54.75 VASOSULF OPTHDRPS _ _ _ _ . y 8768�0883 OS ? ._ _ _ '_v _ ?12.49 VASOTEC 10MG TAB 00187-0142-36 30 $186.59 �. r_ QTEC 'vi `2 5MG W TAB _) Q0187 014© 0 3€ _ 3.. _' 0 616.7 VASOTEC 20MG TAB 00187-0143-30 30 $1,119.40 bASOTEC 5MG = TAB. 00187-0141-30 {s v 30 } � $715 34 ,a) VAXNEUVANCE-15 (0.5,M EA) SYRG 00006-4329 02 0.5 �1 WT , 00299-2012_-10 "L_ _ _ 10ii 'w w� _$267.26 $2,090.2fi �I VELIVET(28-EA) TAB " 00555-9051-67 84 $110.01 y tt �'i UEIPATASVIR%SOEOSBUVIR~� 100MG 400NtG . ' TAB °. 72626-270101 t 28�' ~ �y9 60fl�00 VELPHORO VELTASSA S00M.G CHEW 49230-0645-51 r-16.8GM PWDR I#53436-0168-30 ? 90 30 $1,837.54 _ `, ' 30 S1,188.08 �J VELTASSA PWDR (1-EA) 8.41GM- PCKT :53436-0084-30 VL EMLIDY _Y 61958-2301-01�L VENELEX {56 7GMJ OINT_ 58980-0780721_ _ 56.7 $37.50_ � VENLAFA}CINE j 100M.G ], 5 7-0176 01 1 100j � 1 $231.38 VFNIAFAXINE 25MG TAB 57237-0172-01 idO $194.29 ■ VEREIAN PM .- VERSACLOZ Vt ESICARE VESICARE _ VEXOLOPTH (SML).-- ,1tEEN0L_,_ WEND 777 VIAGRA CAP 62175-6570-37 100 $62142_ CAP, {�62175-0572 37 SUSIP 18860 6121-01 100 : $925.02 _ TAB ; 51248 0151 03 9Q ,� 4 $1�,387.84 TAB 51248 0150 01 36 $462 61' SUSP'; 1 0006,_, S 062? 03 _ _ 10 4.56. SU5P 09065 0627-07 5 _ - _ .10230 TA&E00A9 3184-30 M 30 :$134.05� __ TAB 00049 3170-30 ., f-00069 220-3 i 30 30 h ,52.997.54 TAB 00069 4200 30 34 _ _ - $- §07 54 _ _ TAB` ..-71F D0069 4210-3a }i 30 ji _ $2 9��97�5d VICKS VAPORUB 100GM _ - �r '3700 0544-03 VICOPROFEN TAB 7 SMG/200MG TAB 00074-2277 14 100 $479.93 {VICTOZA 3ML-EA). _ _ 7� 18MGj3MLfF PEN at. 00269 4060 12 ` 9 VICTdZA (3NiL EA) 18MG/3ML PEN 00169 4060 13 _ 6 �~ $1340.17 VIGTRELIS-- �` 200IVIG Mi( CAP E 00085 0314 42 k _ 336' _ ___J _ __ $8,024�06_______ _i _ v_ _ VIDEX EC 125MG CAl[ 00087-6671-17 30- _$162.02 VIDEX PEDIA7RICe�SoMG/ML _)i_ SLISP Tj 00087 6632 41 , _ 100 $6650_ VIEKIRA PAK (12.5-75-50-250)� _ TAB 00074 3693 28 112-$33,327.60 ,..,_.. ___-- _ __..__ _..___ _ -- „-- }•' TAB -�' 00474.0063-28 84 `_____ ___$33f327.6t} VIENVA (28-EA) 0.1/0,02MG TAB 70700 0118 85 _ - 84 - $88.30 ;t � +,-__- -_-•-- 3V0,005 ON k�10006540133' VIIBRYD 10MG TAB,,00456 1110-30 30 $397.09 1; 8?0456 112QM30_.; 30 ._ 097.09 VIIBRYD 40MG TAB 00456-1140-30 30 _ $397.09 14MG f TAB ` 62332 0232-3Q 30 $252.12 VitAZ000NE 20MG TAB - 62332 0233-30 30 $252.12 t11LAZODONE �1 40MG ;f TAB62332 0234-30 30 1 $252.12 VIMOVO 375/20MG TAB 75987 0031-04 60 $2,978.64 - -- ViMOVO500%20MG �__ TAB_ 75987 0030 04 �� 6000 __;?_"$2 978.64 D VIMPAT - 100tViG TAB 001312478-35 66 _ $1,268.65 _r 001315410w70 J;- 465$883.91 VIMPAT 150MG - - TAB G0131 2479-35 - 60 TAB 100131 2�38Q 35 ° 6Q_ vL_ _I 343.98 VIMPAT _ 50MG _ TAB 00131-2477-35 60 ~ _ $811.46 VINEGAR 99999 999111 }}=_ lT~_ _ VIOKACE 20880 TAB 58914 0117-10 100 $761.84 !} �- r- tVtOKASE _ _ _ _�34' &-30y FAB Yip S8914 0111150 =- F 5Q0� _ ji `f $326 80� ! VIOKASE (80Z) _ PWDR . •58914-0115-08 . � 22'7_- $Z81.74 SL 8914 0VIORELE (28 EA) TA8 69462 6318-29 84 _$179.94 > VIRA-A OPTH ]i 0 03 y_ 01N7 61570 0367+71 . _ .� 3 5, $,24.81 I VIRACEPT _ ~ ' 250MG TAB, A 630104010-30 300 $1,456.80- _ UtRACEPT 625MGTABt630104ti2770 - 120Y $1,456.80 __ t..- -___ .-, VIRACTIN (1 O 25OZ) 0.62 . _ CRM _2200 086101 7.5 VVIMMUNE - _ 20oMd TA B 7 0046 ',. VIRAMUNE XR 400MG TAB , D0597 0123,30 30 $1,008.38 _ VIRASAA IOML)___ _ � ]j 4,275 1_ Lid -42783 0312- 4 1 V{READ" 300MG _ -_,. TAB`..- 61958 Q401 Ol 30 $1,504.20 VIROP7IC OPTt DROPS 0 01 � iCDRPS 61570 0037 75 7 5 " _,_ r. M $447 44 R VIRT-ON PLUS CAP 69543 0243-30 30 $72.29 _ UISICOL,•_,_, VISWE A.C. SOLN. 74300 0004 01 15 - - $4 20 U15 INE A C ISMtj. rY i'. �. 743! 3 0604-0 VISINE ADVANCED RELIEF (15ML) SOLN74300 4008 48 ` 15 $4.85 VIEADVANCED..RELIEF 30MLM ksY4_wM-=.- SOLtVµ 7430004Q849i3Q-�s;g9 8INy VISINE OPTH (1 - SOLN 74340 0008 03 15 $3.86 _ iVISINE A {15M!)^may w� .� OPT{i SOLN 69968 0006 3L 1ST® �$5.82�_ _ VISKEN_ _ -10MG TAB, - ,� 00078 Q073 05 _ 100 -_ $153.78 ISTARIL y Jl 25MG _ t= ,CAP `_� OOQ69 4-1666 .._. ;14( ..;;�•_.� - 21,92 n_ I VISTARIL SOMG CAP' 00069 5420 66 100 $365.03 VISTIQE' 5Mt j . ? 75M+ �M=L [=V AL :' j "61958 0101 1 ,VITA DROPS W/IRON (SQML_) DRPS : 00904-5100-56 5Q - $10.79 _ MITA S FORTE _ j YL GAP 98C� 0-010i-C?1 G� 100 '_. ii� 29.99 VITA -BEE WITH C TAB. 31604 0027-34 60. -. $3,29 UITAFOL'� VITAF6L-OS 65/iMG CPLT 00642 0079-12• 100 : , . $468.38 Strength Dosagg _ Nt mnber. PWha.e�sa OB+OHA .:1GAP, __ 00642�007b•30�_ _ 6Q ONE _ GCAP 30 �5159,72 149.03 FIBER GUMM1 . W ;,-0&_ �a INS _- ;, 99999 9002-36: 1 W90ON 0;00 A _10000I t1 _CAP 'K 00304 20$5-6Q.^�j S.Od _ - - ... 8,000IU- _ , -'. SFTGEL' 54629-0110-01 .. _ 100 $191 A+D 113GM-~� O T- } 4 t7ti-Q811-24 I 113 �(mr`�$46fi w PINT , i,, 11523-7204-01 m 42 5 AtD 42SG .- r 01NT, ' 70000-0035$ 01 j 4 If� 59.0 Atp (454GM) DINT` 41100 0811-34, - 454 $11,62 A+D (SGM-EA) =i r OINT • s 16784 0115-0 _ _ 720®.µ m�25.92 B COMP y1l/FA AND VIT-C TAB. 74312-0005-30 r 100 $6.42 B COMPLEX,.' L �(_ TA$ ;,� �s 546 �) , _ 100. ' '# _ .. B COMPLEX W%VIT C - __ - - -COLT 8068,1=012(r00 130` $164 B-1 _ E:: G , Ad= 8068l-0p9&00 i _ 1000 B-1 10006" TAB 1000fi-Q700 11 6-1 - --= - -_ -`•`� -__- 250fVi��}f�TAS �..A.7�9Q4-4177-5b 100 , ���t� $36.11 -$5.09` B-1 _�?_�.____.___lOt} SOME - _ TAB. - 80681-OQ97-00 100 $3.19 B-12 10DOMCG:. LOZ _ 1 31644-0027-17 i 1000MCG. TAB ` 10006-0730-43 ' 56 $3.82 _VITAMIN B-12100MCG -AB)-80681-0071-00jm 100 l $1.70_� l VITAMIN B-12 TAB 40985-0271-12 110 $5,76 UITA..�:MIN-B-1 254MCG ' i TAB ffi .846$1 4165 OU.a V_ _.�130_ _ _ VITAMIN B-12 500MCG ; TAB 80681-0072-00 100- 4 . $27 >VITAAifIU 812 SUBLINGUAL _ ���---iQWMCG� TAB f'' 11845 0496-6i !; ______ ~v 1Q0 _--- 8.69 VITAMIN B-2 (RIBOFLAVIN) 100MG, TAB 74312-0006-40 100 $6.19 bVITAMIN B 50 {BALANCED}_—:{ ; w :`_ TAB?mOQ9044184yS. j 60� VITAMIN B-50 (BALANCED) TAB 0090A-4184-52 60 $6.34 100MG��',Y TAB9 p40985_0211 9fi'_-1 _ __. _?10.. VITAMIN B-6 25MCi TAB 00536-4406.01 1 100 $144 Kr . y__. _ Q73016.�;1400"»._. ?I11.92 .a._. VITAMIN B-6 50MG. TAB' 10006m-0306--0170_ $2.95 !"I iVIAMIfiC 06G _100 -- VITAMIN C • 250MG TAB 20555-0001-00 100' $1.78 ,VITAMIN _ VITAMIN C 500MG TAB 00904-6523-80 100.0 $24.15 VITAMIN C (118ML� _ 50QMG Sf SYRP 00 536-0160-.97! 11$ m VITAMIN C CHEWABLE SQOMG TAB 54629-0308-20 _ _ - - V 60 •$6.10 ,VVII_TAMIN G LVJROSE�HiPS............74312-0006 40 100 i1� $9.28 ` VITAMIN D-2 50,060U CAP 64380-0737-06 100 $197.19 VITAMIN D-2 ERGQCA! CIF) ( —®. ,2;OiT0t1 � �. CAP , 40985-0250-T3 t 60 i $10.8Q VITAMIN D-3 • 2,000U- SFTGEL `i 96295-0138-69 300 $8.99 _ VL ITAMIN D-3TAB6245-0128:45 _ f'� 100; VITAMIN D 3 S,000U CAP 80681-013100 w 100 $2.86 NIT�A�MIN0-3 I, 5000(QU` CAP `; 5 362;4 ! 100_ VITAMIN D-3 1,000t1- SFTGEL 40985-0274-15 ' 250 $6.48� t11T{ AMIN D 3 (25MGG adOU,- TA8 ; 96295 VITAMIN Q-3_(50M1CG) , 2,600U TAB 80681-0770-g0 S00 $3.26 -VITAMI _ _IN D-3 CHEWABLE } �- 1,OOOtJ "� TAB 30768 0503-56) ~� 120 '' �i y4 59 VITAMIN E _ 1001U CAP' 00904-0276-66 . 100 $3.07 VITAMIN E -t 2001U�:���c CAP'; 8068I-01S9 00 100 _ =wv-, -$4.93� VITAMIN E _- .400 IU, SFTGEL• '-86681-6011-00 140_ , $14.59- VI} TAMIN E 4000 P Tj[ 74312-0017-51 ' 120 VITAMIN E 6001U "• CAP, 67431-2026-21 56 $7.77 - - _ YIIHIYikt\ C: SLV4iYi ,.,. _, .,� ...-._-.,. _.>„ ..:,r �--�J V�V�ILI ^ -.:.""`a.rilYt."::�f,.:_7J.UV�'VVilT7't' �' _ .. _....,,^12V 'n'..._..�...__I���� .. _ j3:J8•' _ _ �"-1 VITAMIN E (120GM)- 71661 00_ CRM 09?4 VITAMIN E (120ML) 7C=,j TN 71661-0049-72 VITAMIN,E (240GM): ;_ - CRM_ _ - .71661-0009 74 240", $3_.90 �11TAMIN E (30GM} � � I CRM,::][-5 40 -606 60 VITAMIN E-(45 MG} _ 1,000IU '_ CAP ,- ! 60904-0277 60_. 160 MINE 490Mt, .� LOTN~ .``: 716610009 ' 480. -. 1 $5 04 VITAMIN E(57GM) 60001U r CRM E 743i2,0006 10 ' S7 $3.19 ' VI ITAMI E MGM)- 00Q IU 6 0799 43) VITAMIN E (60M} � i"- 64000!a _ CRM_' 07431-2006-10 60 iVllAfyllNE;t74MC c _ ._ _ a 30�OMIl7i _,.QILa=_ 74352-0008=1�,_74 ��:.e._` VITAMIN E 202 _ '. _ �,_ OIC -' ? 00536-8533-96 .-.- _ 6ij _ $6.96 VITAMIN K-1 J1(}OMGG TA8 54623 084121 100 _ w 54.9d_� VITAMIN K-1(0 SML,EA} 1MG/0.5M1 AMP _ .00409-9157-01 12 S $142.37 VCfAMIN K=1;(1MGEA � 10tvIG,�MLi. AMP-�0Q4d9-91 8 01 2S$1469,02 �? VITAMIN K-2 _ WITH VIT;D3 7A6= ._'' 35046-0002.-94 60- VITEKTA ' I AS i, b1958 1342-U1 „ l �._ . 30 .'.' =_ I ' �fi13S2.05 VITEKTA _ 85MG- - n TAB :. 61958-1361,01 ' w " 30 , $1,352.05 , VIL TRON-C'63736 .' VIVARIN = 200M,P 46017 0018 4d 46 3VIVELLE D©T (3X8 _TAB _i_ 0 0375MG/DAY j , VNELLE DOT (3X8) _ _ 0 075MG PTCH 60078 0345 45 24 $437.39� _ - lF0 425M,G �L VIVELLE-POT (3X8)- 0 05M�%DAY _PTCH _ 00078 0344-45 _ 24 _ - $436.73 _ .. eVNELLE DOT (3X8jw'. w _ 01MG PTCH ; 00078 0346 45 : 24 _• (� $437.42 VIVITROL 380MG VIAL 65757 0300 --, _$1,908.26 N , iVIVQtut x _ = 7j PCKT 3900 0713 19 � a s 36 . _ 5216.36 VIVOTIii EC CAP• - 694010000 02 4 $119.08 VOLTAREN {100GMJy�� ti - 00] _„ `j^ ' GEL r63481 Q684 47 - 100 VOLTAREN XR -� _ 100MG TAB 00078 0446-05 , 100 $1,239.72 {VOLUMETRIC INCENTIVE r SPiROMETER _ _`; 99999 9001 83 j?ny�_ 1�_�_$22.00_ VORICONAZOLE 200MG TA6; "; 272410063 D3 ', 30 $2,385,49 _ � SdMG TAB G 27241 0062 t331 T µ 30 _ .596.36 j iV4RICONAZOLE v . _M V05EVI �� - 400/100�100 TAB, 61958 2401.01 28 $29,904 00 _ _ 6 _ �6620GVdTAB 087TN vRALAR _ 1.9vtG CAP 51874 0115$30 34 $210,625533.2.20 1,653.20 VRAYLAR _ 4.$MG CAP 61874 0145-30 ; 30 $1,653.20 , CAP:;�6i874 0160 30_1 30� _ rw_ r VSL93 _ CAPS . ' 45749 0017-81 60 $56.52 Y4y vSL#3 _ii - PCK� Ty j, 749 VUSION (50GM) Q 25%/15% DINT 40076-0002-50 50 _ _ $699.95 VYTORIN ,._ _ N 10/10MG MORIN 10/20MG TAB_ 66582-0312-54 90 $1230.12 II� TAB; a 66582 0313-54 � i g0 .v VYTORIN �- _ ._._10�OMG -� _ 10/80MG TAB 66582 0315-31 ; . _._ 30 _ _51230.12_.-._.. $410.04 VYVANSE ___ _._ _ _...._,!_ 169G C` _ � 59417 0101-10_!�_____--_ �_. __ 100 _. �_ _ ,$1,477 27 -- _ _ , _. VWANSE :CAP 20MG CAP 594170102-10 100 $147727 NYVANSE 30MG 59417 0103-10 h 104 $1477.27 _ VYVANSE " .CAP 40MG CAP 59417 0104-10 100 $1477.27 50MG ; 59417 0105-10; _m .__100_$1,477 27 'VYVANSE 60MG CAP 59417-0106-10 ; _ 100 $1,477.27 VYVANSE 70MG , _ CAPmm'59417 OlOTiit7;r 100 ' $1477.27 VYZULTA OPTH (2,5ML) 0.0002 DROPS) 24208-0504-02 2.5 $289.07 _ 4VALKERBQOT _ __. LOW:TOP s1999999001H9'1_.a wfr it �� _ _ $80.00 �. WALKER -FOLDING 1N/WHEELS 236010018 71 1 $91,06 w WARARIS ~Y_s+w10MG TABy 00093 1720-ti1 ( _ _ 100 ii-''$101.75 WARFARIN Tj 1MG TAB 00093 1712-10 1000.$613.02 WARFARIN v� - ZSMG iti TAD'L00093 1724-10 j _ .._ 1000 _ __._ _ _ $659.35 _ WARFARIN ___. TAB_ 00093 1713-10 1000 $639.69~ _2_M_G 2000�v� v�P $630.72 _� WARFARIN 4MG - TAB,- 00093-1716-01 100 $66.41 51VIG TAB_ _ u _ - ---; $668.65 _ WARFARIN _-� - _- 6MG TAB` 00093 1718-01 _ , 100 _ $94.82 -0 - _ 7SMCt TAB j 0 093 1723 .r 100 WARM COMPRESS 99999 Dill-01 1 $0 06 V/ARNih►G LABELS M _ _!! �,L 99999 999112 ]' __ _ _- 1- �_q •� 10.57 4 WART REMOVER (15ML) 017 LIQ - - 96295 0112-87 , 15 WART REMOVER (9FgLj� WART REMOVER MAX STRNGTH (14) 0;4 . STRP 70000 0331.01 14 $7.99 AWASH BASIN_. _ 7QT�DiSP _ 99999 9d0411 _ WATER (H20)- __. 99949 999i-13 1 $5.Q0 - _ LiM1IATERPR00FADNESIVETAPE 11NXSYt3 i 09629S102$1 L_1 _L _ WAVESENSE CONTROL -HIGH, AGAMATRIX . SOLN, 08554 2011-01 ;_ 1 . _ _ _ _., ., - . $3160- „ _ WAVESENSE CONTROL -NORMAL !? AGMATRIX, 11 SO LN ; 0 41333-01 = WAVESENSE TEST (100) PRESTO STRP'-, " , 08554 3337-02 - 100, VIjAVESENSE TEST'(50-)_ ;_ PRESTO 11 :STAP =08554 3329 001 � WAVESENSE PRESTQ .. � ,, . _ K1T 68554 2649-01 ,;- . 1 -_, r _ -- _ ; - $24.60 �WAXfOR'BRACES � _ fi '`'`4 _70942 2007-24 `�_'-'��1 ,.�,�i:�, - :;,�;�; ,�.�;�_ WEIGHT _ ...�.,,�.�...��. ,i _ 99999 9991-14 1 _ . $0.00 _ EWELCH01 _ 62SMG TAB - i 65597 0701- 8803.52 _ WELCHOLPWDR(30X375GN1) 3i5GM PCKf b5597090230-- 30- WELLBUTRIN 100MG TAB00173 Ol� 78'SS� 100 �� 390.34 vLELLoi3T^niL "' 755MG ;. Trio v`i7' - .-45 i 1.'��D _ `� $292.fs.° WELLBt1TRINSR , 1dOMG ,i TAB 00178 0947-55_, 60 ii $528.91 WE( LBUTRIN SR_ 150MG TAB 00173 0135y55' '' - - 60 $566 87 WELLBUTRIN SR 200MG I TAB .' �40173 0722-663 60� ( � $11052.65 _ WELLBUTRIN-XL 7-07 - 150MG" T18 AB �• 0030=30 - $2,180.71 WELLBUTRIN XL __ is 300MG TABI 00187-0731-3 30 _ _ $287863 -M WESTAB PLUS 27 11VIG - , TABS 69367 026i-01 100 $71.28 ,WHEELCHAIR �" 4 99999 9991 15 - 1 ' a .� _ - 0.00 j m_ WHEELCHAIR CUSHION FQAM _ 23601-0031-02 , S �; - ,- $32.36 ¢VVMMLUIAIK UR.111UN li" -84389-0111-38 'WHITE PETROLATUM (28.4GIVI OINT' 28.4 $1.21 W LTqH !LA2E L (jZ3 M L- EA Iq [1163-3 --0000- .70 WOUNOCARE 99999-9991-16 i $0.00 �MEA§U`RING GU(D-- WAND [:9 9-j -9 9 - 9 0 5 -1- i5- *OUND-WASHSAIINif SOLO'_._ 2126-60-06951-S2 210 $7J9 EL �,J[�11701-01�61�i6-] 'WRIST BRACE- 392$4-.#341-02 $11.30 WRIST BRACE ELASTIC IL - 962951121-57 WRIST BRAd Wl SPLINT ONESIZE 96295-0121-55 1 $10.75 W=RIS*rBR-ACE-CA�RPA[T-U-NVEL--=-_-="'-------'----'==. =62q-S 1245-6:ji= WAI§TdRACEAEFT L/XL 96295-0124-47 1 514-99 'WRISTBRACE-RIGHT('x $4.98 ',WRIST BRACE-RiGH-[ LSL_ WFdStSTAWU2ER-AMBIbEX---.- .,LG/XLG 7-4676-0308.101 ARISTS-[A8lLIZER-,kMBIQEX WRiSt$U0ORT UNIVERSAL 96295-0121-56 1 $4.00 'ARILTSUPPORT �,Pl 3 Rlt 5.72 ,WRIST WRAP UNIVERSAL 96295-0121-57 1 $7,50 5A�afAk OPft! ML) .60 4 001 OL XANAX 0.25MG TAB 00009-0629-01 100 $622.61 8 9.00§5 100 $775.67 XANAX lmG TAB 00009-0090-Pl. 1010 $1,035.01 15�A-N TAB ,XANAX XR IMG TAB 00009-0059-07 60 $895.82 $7kc XANAXXR 3MG TAB 00009-0068-07 60 $1,783.32 XARELTO G 1 TAB 50458 0580-30 i 30 XARELTO XARELTO 15MG TAB 50458-0578-90 90 $1,859.86 fl� , XARELTCI 20MG TAB 50458-0579-90 90 $1,859.86 =XCOPRI $1,335.86 ,XtOPRI 20OM'G' TAB 71699-0200-30 30 $1,335.86 - ----- 50MG TAB -0E0--Yd- 71 99 1,335,86 XEUANZ SMG TAB 00069-1001-01 60 $6,816.52 AB j 00�66-90�-Cl;3-6-� 0 6616.52 MODA 150MG TAB. 06004-1106-20 60 $976.15 XEROOA 120 $(6 77 -------- XENICAL 120MG' CAP 00004-0257-52 90 $703,33 I:iE-R-A60MLF-- SA�L_ !1- LN::][ _jE ' E_ S-1% CRIVI 00187-5104-Oi 5 $1,474.55 - XERESE,(SGM) - d2�� 2 IN RR.- L 0 S $143.70 XEROFORM 4 X4 IN DkSG 08080-4335-01 25 $265.44 -:0-8-08ZEI- $218.56 XEROFOfFM- SX91N DRSG rL _ �3q:O5 XGEVA (1.7ML-EA) 120MG/1.7ML' sbv, 55513-0730-01 1.7 $3,452.95 �s irmur N TA �Q 60 3-66 60 $678-35 1-3.6 30 $914.29 XCILAIR ISOMG SYRG. 50242-0215-01 1 $1,538.65 F-- 0.02 jF_.qEL 16 1 0080-45 �45 )bPkEk, (3ML-EA)0.31MG AMP 63402-0511-24 72 $259.24 5�0-PENEX (31VIL-E�)_ lOPtNtX-(4ML-EA)_ ,X6-Pf-NEX RfA- N5 1.25MG AMP 63402-0513-24 r7- -1 Qfl� : 72 $235.68 ,XTAMPZA ER 27MG CAP 24510-0130-10 -=F---409-G 100 $1,935.47 XTANDI 80MG' TAB 00469-0725-60 66 SI5,599.96 qE MCGajF -p -0- TCH 378414V-L�C,[�- 3 152.69 -XULTOPHY (3MGEA� 1000-3.-6/M,L PEN 0016-9,-2911-15 is $1486.46 ---==E-4, �X-::V:I-ATEg Rt -5-89-80---06-25--�- 199 T�-M E i85-dk 4)-., 6.4- ckm 58980-6625--3'0 , 85 $32.15 -X_YLOCAINE L-0.02 �VIAL,�j iyLot& !NE (ZOML-EA) W-LOCAINE (20ML-EA 0.01. -MDV, 63323-0485-27 =DV[ 6=33273 -04�6 7- §:OT= E =5 _-2-7 'E-500 Sco __$115 20_] XYLdCAINlf QCAI�E 0.01 MDV 63323-0485 57 �O02. 6&-23--0486-5-71'- JL_ _�]F: �� 1250 1-2 5 d'� $471.60 5186.00 �F-Plh 68372-005 ZEGERIO-OTC 20MG/1100MG CAP 11523-726 -TAB.i 00187-045 ZEMPLAR iMCG CAP 00074-431 ZEMPLAR 2MC_G ML #` . t� 00074-463 ZENATANE 30MG �SDV CAP 55111-011 ZEhtPEPl0,OQ011 L_ _ CAP 00023-6_13 ZENPEP 15,000U CAP _ 00023-611 ZENFEP_�� _ ZENPEP 25,00OU CAP. 00023-611 � Z_ENPEp_ AO - - oo0u _ _.. _w __.. CAP ; 173562 Oil ��_ ZENPEP 5,000U CAP 06023-611 ZEPATIER - 50M4/100MG j TAB-W-ff 00066-307 ZERBAXA (1-EA) 1.5GM VIAL 67919 003 tZERIT _ -- �{�40Q03-196 ZERIT 20MG CAP 60003'166 Y RIT _ 30MG _CAP f 3403 196 ZERIT 40MG CAP 00003-196 _ 00310 014 ZESTORETIC 20/12.5MG TAB 00310-614 42 $26.45 36 - $468.38 _ - 30 $744.86 _ 10Q 100 $652.34 106-: _ _ _ _ _J $986.13 M$1,096.55 100, L _ 106 $228.49 p� 288,73600 10 $1732.32 60� $511.27 _ v60e 60 $553.12 s540`.6D� A ~$540.00 10o (•_ TAB 52427 0443=90 . ' _m � 90, __. _�, ' $1435.58 T ZESTRIL 5MG TAW- 52427 0439-90 _ 90 _ _ _ Y1- 43.OQ_.�...�....•__,. 21AGEN 20MG/ML SOLN 49702 0222-48 240 $176.23 ZIAGEN _ _ _ . 3QQMG. TAB `i4970Z 0221 18 !} _ 60 . I S670.37 ZIANA (30GM) GEL: 99207 0300 30 30 . $440.40 ZICAMCOlO ___� Ao _ __..: �i____. _ :, �62750•t?408 2$ ( - 25___ T__ jl $13.14 21DCiVUDiNE :_TAB 100MG CAP 65862-0107-01 i00 $201.94 2iDOVUDINE_ 300MG TAB` - 6 317Z2 0509v6; _ 60360.97 ZIDOVUDINE SOMG/5ML_ . _ SOL_N 65862 0048-24 _• 240' ,211ACTIN-B (7GM�y. ' _ . 0.2 y.'y q-E SO486 0550 42 Z(NC .. 100MG „ 54629-Q180-01 ;. _ _ , _ ].;QO_ _ $6.62 3L - OMGy _ :TAB'. 60814-0580-0 r 1Q0 ZINC ZING 22QM6 SULFATE}��_ _?: 0M _:_ , 5G TAB _ .� 94312 0020 6Q�. _. _ D� 50MG CAP ;� • 80681 t}i6S 00 „�w __� _c _ , 100;_ 100 _$4.34 53 _ ZINC 6LUCONATE 50MG •. _ - TAB„ 80681-QD02=Q0 _ 100 ZINCOXIDE (28.4GM)y } , _02 �j! Olk , 758340170-61 ZING OXIDE (454GM} .. 0.2 OINF ` .: 00536 1316 98 : 454 ZINC OXIDE fi4 M om!" -052 IE: 16.25 � T ! 00536-1360 �_ ZINC SULFATE _ Zib'ry d' TAB" 57896 0865-01 „ 100_' ZINC+VIT C LOZ _ ; � _ lOZ ',::, 00� 5 183-01 1� lOiU: �_? . $3.32 Y �ZINCON DANDRUFF (236ML). 0.01 SHAM 35379 0210F28. 210PTAN OPTH PF (30ML0��1 _ �SOLN 17� 478 06Q930 _ 30$276.06 Z1P LQ[KBAGS 3 X4 _ LL 6033$ 2101-60 t 1404_ , $16.70 _ _ _ - 3X5. _._,w�Y'_ 60338 21Q170 )_ ®_i $_18.19 ZIP LOCK BAGS 4 X 6 6033&2101-90 - lobo $18.56 ZIP LOCK BAGS 1� _6X 9 I It 60338-2102-70 Il - -1000 ZIP LOCK BAGS 8 X 10 60338 2302-90 1000 $67.63 21PF IDONE HCL _ 20MG CAP 65$62 0702-60 }rY� 60 � � ry�$531.83M� ry v ZIPRASIDONE HCL 404G CAP _ 551110257-60 60 $531.83 ZIPRASi00NE HT _ CAPS55211- i� __0258- ! 60MG- , ;� 60�,�„ ZIPRASIDONE HCL 80MG_ CAR 5511170259-60 60 $645.41 z CR N OPTH l 0 0015, l . �_24208.0535 35 llF, 5 :.. i 5532.15 ZITHROMAX 100MG/5ML SUSP 00069-3110-19 15 $3LB6 �v ZHROMAX _i IGM PICKET �!rPU1t5R 00069-3051�75~4{ ZITHROMAX 250MG TAB, _I 00069-3060-30 30 THROMAX (30ML) 200MG/5ML 5USP 00069-3140-19 30 $31.86 THROMAX [V (1-EA) � . ��; 500MG j ViAI 0006� 9 3154^8 a 10 i $73.08M_ _ )COR IOMG TAB 00006-0735-54 40 $498.96 _58764'8 ZOCOR 40MG TAB 00006-0749-54 90 $870.48 _ _ _ ?MG -,_1, ^80MG _ TAB � 00005 0726 31 30_ l�90 _u 124.5_6_. ZOCOR TAB 00006-0543-54 $870.48 %ZO:FRAN ' _ 4MG -- TA_6_ ��_00173 6446-00 `- 30 _ _____ _ ZOFRAN 8M6 TAB 00173-0447-00_ 30 $1,394.50 ?Q_ RAN ODT y _ _ _ _ 4MG - - TAB ,' R0173-0569- ZOHYDRO ER IOMG CAP 65224-0310.60 60 $720.00 w __$2,897.47 ZOLADEX 3.6MG SYRG 70720-095036 1 $1,033.43 sLQLMITRIPTAN _ _ __.5 2.5MG - 7AQ B _` 272410021-$mod_._.-_ s _ ,_$303.81 _ ZOLMITRIPTAN 5MG TAB 27241-0022-38 3 $167.93 ?QLaFT_________.- ____;.. ji 000494910F30 30_$495.85 _ ________.____..-___..___..100MG ZOLOFT 25MG __TAB. TAB 00049-4960-30 30 $495.85 ZOLOFT{60ML} 20MGJML CONG 00049-0050-01 60 "" $340.86 ZO'LPIOEM MG !: 5MG TAB 00378 5310 05, f TAB 13668 0007 01 500 100 $2,309.84 $462 54 ZOLPIDEM ZOLPIDEM ER_ 12 5MG E" TAll 04955 1703 30 ' _ __ 100 C160 80 _ ZOLPIDEM ER 6 25MG TAB 47335 0307 88 100 $611.63 ,ZOMETA~~� _ � l� 4MGf10t7M1� If _ _INJ` •, OOil78-0590-61I L 100ry _ 51100.98_ ZOMIG 2.5MG TAB' 64896-0671-51 6 $931.42 vZOMiG�__.___.. 5M6 _ TAB 64$96-D67750;{_�_� __ 3 ..�._.__`€_�� r.._._�465.7fl -ZOMiG NASAL 2.5N1G SPRY 64896-0682-5,1 6 $703.88 MMIG NASAL 5MG_ _ SPRY �, 6489fr0681 51 F 6 $703 88 ZONALON (45GM) _._' 0 05 _ _ _ CRM 00378 8123.45 _ 45 _ $802 56. ZO'NEGRAN ~ I M 100MG �'- CAP �( 59212-0680-10 _ -- 1(}0._ __ _ •: �__ _ $ 424.04_ r . 20NEGRAN 25MG CAP 59212-0681-10 100 $1,872 00 Z40ISISAMIDE tL 100MG_._ ._._ ? _ .1tF596Si- 38E6 1 $219.45^ _T ZONISAMIDE 25MG CAP 68462 0128-01 100 $54.86 -�� ^ SONG j CAP 68462 0129 Ol , -- 1 N4{$109 60 U ZONTIVlTY 2 08MG TAB 66992 0208-30 30 N�- 'W_RW0LEX 18MG CAP � 169344.0203-Z_3 ? 90 �mm� I ��2_2' m _ ZORVOLEX 35MG CAP 69344-0204-29 90 $942.08 ZOSTAVAX EAj _ _..... __._.__ I VEAL j'M6 4963-4. VIAL VIAL 40076-0953.96 473 100 CRM 00197-0994-45 5 nna !f n"i3 :n�s7.an 4i �n $164.81 $123.61 _$567.44 -. $587.66 $1,10L28, _ ! $2,141.32 ZUB§OLV SL 11.4/2.9MG TAB , 54123-0114.30 30 $706.62 URI GLOW FADE NORMAL(48.2GM CRM_ ,j 21959 0170 21w � _ _t�_____._ .. _ 1_.A 150MG TAB 00173.0556-01 80 _ _ $297.32 ECC RA' 28GM a_® - � ��_ 6_�QB75 I! CRM 99207 62 00-28 %, 28. , - 51478.59 `_ _ J voi. 3 9 5 Pg. _ 1"� BRAZOS COUNTY MASTER ARCHITECTURE PROFESSIONAL SERVICES CONTRACT - 2022 PURCHASE ORDER No. 23-02 —JAIL SHOWER AREA RENOVATIONS This Purchase Order No. 23-01("Purchase Order") is entered into between Brazos County, Texas ("the County") and BURDITT CONSULTANTS LLC ("the Architect") on A PRL Z— t 1 , 2023 under the terms and conditions established in the MASTER ARCHITECTURE PROFESSIONAL SERVICES CONTRACT between The County and The Architect dated September 20, 2022 (the "Agreement"). ARTICLE I PROJECT UNDERSTANDING 1.01 Renovation to existing shower facilities in the Brazos County Detention Center (A) Brazos County Detention Center 1835 Sandy Point Rd, Bryan, TX 77807 Each shower facility floor finish is to be removed and resurfaced to provide adequate draining and prevent water pooling. Drains are either to remain, relocate, or to be added to provide adequate drainage based on required work for each layout. Floor slabs above may require observation by a structural engineer to verify, the structural integrity of the slab. ARTICLE 11 SCOPE OF SERVICES 2.01 The Architect shall provide all applicable services described in the Agreement for the following Phases: 2.02 Design Phase (A) Preliminary Design (B) Final Design & Permitting 2.03 Bidding and Construction Phase (A) RFQ Preparations & Evaluation (B) Construction Observation (C) Project Close -Out 2.04 General Assumptions (A) All restrooms/showers will be designed in accordance with the City of Bryan International Building Code (IBC) version 2021, International Plumbing Code version 2021(if applicable), 2012 Texas Accessibility Standards, the Texas Commission on Jail Standards, and inclusive of any adopted amendments. (B) Awarded Contractor shall field verify locations of all existing drains and fixtures, and is to assume this responsibility as a part of the Contractor's bid. 2.05 Supplemental Services: (A) Services include certain project requirements potentially necessary for the fulfillment of the Basic Services, but which are treated separately from Basic Services due to unknown need, timing, scope, and/or cost which are indeterminable at the outset of the project until preliminary design matters are determined. (B) Such requirements will be determined collaboratively between the County and the Architect throughout the project duration. Any of these services which the County determines should be addressed as Supplemental Services by the Architect will be followed by formal proposals from subconsultants to be approved by the City with costs reimbursed to the Architect plus applicable administrative markup fees. (C) A separate budget will be established in the Fee section as a limit for which any required and approved Supplemental Services will draw down from that limit. Services required beyond the original established limited that arise beyond the Architect's reasonable control will be scoped and negotiated with the County as Additional Services following applicable provisions in Article VI. (D) For this project, the potential supplemental project requirements anticipated to include: (i) Plumbing Design related to relocation/reconfiguration/replacement/addition of floor drains and/or other plumbing fixtures and piping required to execute the Q Vol. Pg. ici (ii) Structural Consultation and/or Design related to substantial floor recesses, cutting and patching of foundation systems, and/or additional weights of built-up mortar beds required to execute the Work. ARTICLE III DELIVERABLES 3.01 The Architect shall provide electronic plans (enlarged plans, interior elevations, notes, details), specifications, and Opinions of Probable Cost as required for each applicable phase and as described in the Agreement. Paper copies may be provided upon request by the County, and within limited quantities agreed upon prior to printing. ARTICLE IV SCHEDULE 4.01 - The Architect shall complete the design phase (ARTICLE II, 2.01, A through C of this Purchase Order) Within 60 calendar days of notice to proceed (NTP) date, established upon acceptance of this Purchase Order by the County. Project Schedule is subject to modification due to changes in Scope or absence of required County approvals to complete the Project design documents. ARTICLE V COMPENSATION 5.01 The total not -to -exceed amount payable by the County under this Purchase Order is 48 920.00 and shall be invoiced as hourly not -to -exceed (HNTE) according to the hourly fee rates set forth in the Agreement, Exhibit B, and as summarized below: Basic Services (A) Architecture Principal N/A Program Manager N/A Project Manager $4,320 Project Architect/Coordinator $8,910 Senior Planner N/A Planning Associate N/A Architecture Project Designer N/A CAD/BIM Designer $8,400 Administrative Assistant $450 Subtotal Architecture $22;080 Supplemental Services Utilized only as required upon completion of Preliminary Design to complete the Construction Documents, in coordination and communication with the County. Detailed hourly NTE proposals will be provided at this stage. (B) Plumbing Design Services— HNTE $22,000 (C) Structural Consultation/Design Services— HNTE $4,840 ARTICLE VI OTHER PROVISIONS- 6.01 The parties agree to the following provisions with respect to this specific Purchase Order: (A) Any services rendered by the Architect beyond those described in ARTICLE II shall be compensated as Additional Services on the same basis set forth in ARTICLE V, or on a lump -sum basis if not appropriate or typical to estimate as an hourly fee. (B) All terms and conditions of the Agreement are incorporated herein and shall control in the event of a conflict with this Purchase Order. The County and the Architect hereby agree to the terms and conditions of this Purchase Order as of the date set forth above. The individuals signing this Purchase Order represent and warrant that they have the power and authority to enter into this Purchase Order and bind the parties for whom they sign.19 Vg.. 3 5 pg• THE COUNTY: THE ARCHITECT: By: By: Name: PG Name: Nathan Brandt, AIA, RID, C51, NCARB Title: D f.l TLAD& E Title: Director of Architecture VOL Pg. 2 BRAZOS COUNTY BRYAN, TEXAS DEPARTMENT CC 2023 - Utility Permit - Wildfire Road and Bridge NUMBER: Energy Operating, LLC - Della Love Road - 4" crossing 1,060' NE DATE OF COURT MEETING: 4/11/2023 ITEM: Consider and take action on the Wildfire Energy Operating, LLC utility permit to install a bore for a 4" pipeline crossing under Della Love Road located 1,060' NE of Deep Well Road. Site is located in Precinct 2. TO: Commissioners Court FROM; Darrell Kolwes DATE: 04/03/2023 FISCAL IMPACT: False BUDGETED: False DOLLAR AMOUNT: $0.00 ATTACHMENTS: File Name Description TyJ)-q Utlilly Permit - Wildfire Energy Operating LLC - Utility Permit - Wildfire Energy Operating, LLC - Della Backup Material Delig Love Road - Love Road -4" crossing 1,060' NE of Deep Well Road 4 crossina1 060,NNE of Deep Well Road.pdf Duane POM Date County Judgo 395 21 VOL - �9 'P rP MIN& ILAWW % T-.:'** AFOW -IRE "M AY -PLA;1EME-NTc--QF DESIGNATING.= -UTILITY-IN'COUNTY! GHT F . .......... . . -BRAZOS COUNTY, TEXAS.': -T TO.: THE.CO.UNTY:ENGINEER'OF' Comes now Vildfife Energy Opdfating.LLLG comp qyVan 10reffitftef refei r6d to zs d- C-( Q*I*V�'Ofi, -with thbrii�totrafisaiibuiine�ii au n:T ,qxas, acting ahrouh its duly, aptbprized.representative,: and -hereby ii pe titions the Cdpit� E6gine�fbi: the t6w.. la. w..."d.6...nit maintain; anj/o�.66e�te.c4 0ffient'undqr, over, acs a16ng certain County Roads. as,ifionon:drawi"gs .. and dgiamsaftached heietoi6d Salflcihtipn -e'scr'ibedis.&II OWS: .. ....... . -:-:r-a6fljtvio:Crass Road �.R 'Iftne M�&Ntimh�r - Lcng'th' r, . : :1 'CrdssihA : TYPE DF CONSTRUCTION: .. . . .... ..=':(CHECK ONE JackedBored Delia LoVe . -Rodd_ . .... x ::.x _777, PIPELINE UTILITY APPROVAL 0 '0'6 r Earth. ,r 800 ft WildFire LEGEND Eni.egy WIRE FEIWE- DITCH - CENTERLINE R.O. W.'RIGHT OF WAY -HALO SURVEYING LLC fMIS FIRM )REGISMATICUMM IaJ-W259 NOTES: 335 'I) ACC STATIONING is B,4'skD-ON' CY 3,47' 335 HOAlZON7AL. DISTANCES. cr UJYD UTILITIES 2) ALL UNDERGRO AlAY NOT BE SHOWN ON THIS PLAT. 3) PROPOSED GAS LINE CASING PER 334 3.74 ra MOFIRE ENERGY OPERATING, LLC;: L :8,W7O-D-, GRADE B FUSION BONDED EPDXYCOATED STEEL: PIPE. 0.250' 333 33.7 lVXL,THICKNESS. CATHODIC * PROTECTION TO BE PROVIDED. PIPE 332 % CROSSING SHALL CONFORM TO 49 'b;' CALLED; 61-18AC CODE OF FEDERAL PEGPLATIOiVS, PART 192, TRANSPORTA770N OFNATURAL NICRAEL LOVE Er At qs C 3 v, PAGE 42 GAS AND GAS BY PIPELINE AND BYAU voLumE DESC276RMED IN u_; Ilk oco c% Q 711 rp + + TXDOT AND COUNTY REGULATIONS. + + VOLUME 226 PA : 01Z 425 . . -g -4 to to to 4). PIPELINE MARKERS SHALL INDICATE THE NAME, ADDRESS. AND EMERGENCY." . TELEPHONE NUMBER OF7?fF UTHJTY, -lAf-30.87140072 PIPE TO BE INSTALLED 4P -.4"FPISO THE PlPELINEPRODUCr, OPERATING PRESSURE AND DEPTH OF PIPE BELOW l LON-196.31912 01 iV/vo x GRADE."- 1p- 5) CONTRACTOR TO'FouowALL a T. At. 0. T. c, D. FOR uriLrrr INSTALLATION. CALLED., 45,75AC. PIPELINE MARKER .70 BE IMNSTALLED, b ll�� I, l/ . - I : . 4MED J. GARY, JR. a :TIE FENr VOLUME 966, FACE 118 CS, % rpoazi fe 7 A; % X3 RESIDUE OF CALLED: 58 AC,: 0ARBARAMADISONErAC'.- 17418, PAGE 231 LAT.'30.87129848 o L LON;96.3189.9125 ' / f/• - �' ¢ / / / ' N TITOAMS SiKAYNES o`� J 'o b, SURV�o A-1 9 PIPWNE MARKER V TO BE BWALLED . h, ..... . ......... . CE $6410 00 Z2? J2. AS?i --- --- ...TH J..:... 04. 101 112111 (�l+0'��:1�CFN5��'?�'��~ cl *%j'ZELEVATION VIEW �F 7 Z OF.PIPEUNE �E CROSSING ROADWAY JON J-, N0rTDSC4LE SEAL-1 4'FPI —448b.D.X OlSb', Wr -ERW STEEL PIPE At 'REVISIONS CLIENT.'.. WILDFIRE ENERGY OPERA77NG LLC DESCRIPTION �A-- 103?2312023.`!°:- ISSUED FOR APPROVAL 77nE PERMIT PLAT PROPOSED PIPELINE CROSSING 2 fs VELLA 4OVE.ROAD BRAZOS COUNTY, TEXAS DRAWING, NO. r PELL�� SCALE -l" Fi-30. -M -R low ' �;—,... ..' .......�-.... �.— Y, �„� ..� Fyr.. _ - a'.{A`^y ... ,. l4(`� v .. '�4... q A!^u' r: •3.. -�`�„R�lrl'�"5,.�:' :�. Ml'^ 'V.,,� = � .. Project Wildfire Energy Della Cove Road, Gas Pipeline Crossing cation Brozos'County, Texas Pipe and Operational Data ' Nominal Outside Diameter of Pipe rthj*.'..'' - D - Maximum Desigh.Pressure MAWP IOU P _ Specified Minimum Yield Strength [psi] S Design i=actor F = Longitudlnai Joint Factor E _ Temperature Derating Factor (Applies to 1331.8) T = Corrosion Allowance [in} -CA Minimum Nominal Wall'Thickness - Steel Puce ' •i`, C4linirnum Nominal INai1 Thickness pn} .: = . - = • _ . t P D ( 300 psi) (8.625 in) - ' } CA - 0 in 2 S E T F 2 (35,000 psi) (1.00) (1.00).(0.50) 8.625 300 35,000' 1.0 = 0.0739' in Selected Wail Thickness [in) _ •0.250 MAWP Calc - Steel Pioe -'for Selected Wall Thickness P 20112 (tw- CA) T F :;2 (3S;000 psi) (1,00) (0:25 in -'0 in) (1.00) (0.50) '1,014 .: D 8.625 in S, Material Suess [psi] at Selected Wall AT in prig . i ( 300 psi) (8.625 in) S P D - 10,350 psig- 2 E (tw- CA) T F 2 (1.00) (0.25 in - 0 in) (1.00) (0.50) Material Stress as .Percerit of Allovi &e14.8 percent.'" Since the;latehded Maximum Operating Pressure (MAOP) for this pipeline:wiil be 300 pslg, the calculated _;; :: a ' besign Pressure of.1,014 psig of the casing is far greater than, what is required. = Calculation assume a rupture of the pipeGrre inside the casing and that the casing pipe bears the pipeline :. Design Pressure, Note that the casing seals.am not rated to.hotd pressure. NOW that each end of the - casing has iient pipes to the atmosphere. Vt'. E OFT Vol.Tli P. jig-2-7+�'o'• .z, ... o:•�w�'''-. jAv SM References:: ASME 831.4 Pipeline Transportation Systems for Liquids and S►urries, and #1S DOT, Pipeline Safety Regulations, CFRA92 Transportation ,of Natural and Other Gas by Pipeline . Prepared ey: Thomas P. Chesney,-P.E, : TX firm 41838 Date:. March 31 2023 .: t" X y 2:w �•�; i.:rri .. rl.r .�Y. ... ,`:r'Ii� '....en:. ;I •�:; �;. t;_,�__..• .._,.�..�...-.....-_..uw'�"��*.S:w„<^,.,.:..,.--;:�l:ute�s:==, i.5,,::_.it:...,+�G.�,'�r,�1.t�,,:...�.._..:..�__:.5;.�..�:...��•:?;+:.w!�'V.�zcsc*,.�:�..�.:.:r•.4:".J:.� __ .._.. :�,w"z:. tl. • I l... .ram•+:..' i- -'.' _.... .. • .. ...- _ .ro.:y',._. , v.__ , ... CrisoNlla Lov"a'Roai! 4;lneh`FP750 ProJect:[NONEJ, i ssing Highway {Gas) Datec3129120Z3 API 1102 - Pipeline Cro J Pipe Type Pipe Llne - API Specir=tion 5L Location Class 3 Namlual Pipe Dlameter 8-5181neh .. Design Factor 0.60 0041de Diameter, - 8.925 inch Joint Type API SL Seamless Will Thickness 0.250Inch Longitudinal Jdhi Factor 1.0 Walt Thickness in Analysis :`. NA Youngs Modulus of Etasticity 29000000.00 psi Pipe Gtatla ' B Sid :... Poisson's Ratio 0.3 SMYS . WIM psi Coallictent of Thermal Expansion • 0.00000651/deg F ; ,,'• 0!7_ ting Temperature " ' 140.0 deg F Temperature' ; "' 250.0 or less deg F ratln Fressuio -300.00 psi Temperature Deratin9 Factor 1;000 Soli Chdracterlsties: Soft to medlum clays ghil sills with high plasticities •, IF'- Modulus of Soll Reaction• 200.00 'psi Pipe Depth 8.00 it _ Er Resllfont Modules 5000,00 psi Bored Diameter 8.M inch Average Unit Weight of Safi 120.00 IL-JR3 Allowable Total Stress Factor : 0.5 • Pavement Type:. Rigid Installation Temperalure 140.0 deg F „ lmpael Factor Method: ASCE - Highway Design Wheel Load from Single Axle 12000.Q0 iN t Design Wheal Load from Tandem Axles 10000 QD !bf • ' • APt'1102 Procedure Hoop_StFess 5176.00 psi • Highway Stiffness Factor far Cydia Langltudinat Stress 12.1 'Allc able Hoop Stress 17500.00 psi _ Highway Geometry Factor for Cyclic Longitudinal Stress 1.1 5tfffness Factor itu Earth Load Ctrcumfeiend2t Stfes5 1886 Cyclic Cvngitudlnat5tress . 1172.00 Bidet Factor for SiM Ldid Circumleren1W Stress 1-.33 Maximum Clrcumferentlat Stress 7123.94 psi Ezcetiratlon Factor for Earth Load Circumferential Stress 0.63 " • maximum Lor4tudinal Stress 2982 27:psi ,. i Clidihrferential Stress Win Eadli Load 1041.94 psi Maximum Radial Stress Result .300.0010 impact Fedor: 1.41 Total Effective, Stress 6443_.O0 osi;:, ; CrtOcal Caser,Tendem.Akes _ ;' . 69A Allowable Eft dive bass ' ' 17500.00 psi Highway Stiffness Factor Idr Cyclic Circumferential Stress 13.8 Fatigue Resistance bl Girth Welds ... 6000.00 psi Kgtiway Geninatry Factor tot Cyclic Circumferential Stress 0.87 Fatigue Resistance of Longitudinal Welds 10500.00.ps1' ' Cyclic Circumferential Stress • 1057.00 psi.. _ ry!'S�tres'"s ° = Celcutaled_Psia " z able-psfi .,._.•: ;�.- ~A1�'-'"� Harlow Stress 5175.00 17500.00 E98dive Stress' 6443.00 17500.00 6000.00- : 10,M0.00 t3lrlh Welds 1172.20 Lcirg, Wefde 1057.00 t� OF El Holes: Calculations being tun to ensure 8-Inch casing pipe can withstand external loads due to highway traffic a u erf i iyplurea •nett g 9 . .*'Is bearing loads} using 0.9 DF to confirm this conservative design, TH .ASPS Raferenco APi RF 1102'Steel Pipelines Crossing RaIlRoads'Apd Flfghway ; / �' }_ .. BRAZOS COUNTY ROADWAY SAFETY AND ROAD PRESERVATION STA�4.DARDS FOR WORK CONDUCTED IN BRAZ09COVNTY RIGHTS OF WAY - A. General Re4a iiinienfs i. Mequate draina,,,,,e'shall be maintained in ditches at all times. 2. Permittee will use best management practices ("BMP") (EPA and TCEQ both provide lists of examples of 9MPs) to 'Minimize erosion and sedimentation resulting from the proposed installation 3. The permi.ttee shall take precautions to avoid damage to property., All Cotinty Right of Way and property. shall be.i6stbred to its original condition, -as far iis practical, in -the opinion of the,County Engineer or appointed representative. 4. The construction and m aintenance .'of such utility shall not interfere with the property or rights• of a prior occtip4ot." 5. Permittie shall not interfere with. other utilities located in the r * ight of way. ln'the event damages occur, permittee will be liable to the County or other utilities'running through the right of ivay. 6. Count e inconvenience the public. If it is yEngineer shill determine whither or not permittee'� 01"s-shall incoiivLnid deNtr6inied'ihat inconvenience to th6 public exists, then the County Engineer'will decide whethe"r such, Project will b6'allowed, 'or if an alteinative'ekists 'so as not to inconvenience the public. p , B. Safety Re4 and remain in place during I Proper traffic control measures must be put in place prior to beginning work. the duration of the job. All traffic6onfrol measures mu . st follow the Texas Manual of Uniform Traffic Cofitrbl Devices (TMUTCD). See'Traftic Contro'l kequ iremeritibeiz low. 2 .During construction, stru , all safety regulitions of the Texas D&paitrhent of Transportation shall r be"observed.- .3'. -PeftriKt66:n1'4it taki such -preca'uti o' n*s''and measures, including oWing: and dlipli i 'y qg safety,, devices,' as ' maybe; necessary, order to sAfel:Vtondudt the public throug4:th6 prcjeicfaiea,'Company 4hal 1 provide :S!gns,.s agryi ' * ignals'or devices necessary to provide complete" safety to the public. fl en, o 4. Adequate provi§ions must be made (..cause minimum inconveniences to traffic and aidjacem property... o%vncrs..:. -5. Nd cable, conduit and/or pole line shall be laid, Constructed, maintained and/or. repaired so As to constitute a danger hai&d 6 o p6itbris or v suchroid. Any poles placed in 'the Right. of 9, f any kind to vehicle's using VV�y & Rii�re iinstallitionshall b6-01aced.at.the back of the Right. of Way'. 'Exceptionsmaib6'a-pproved". : bythe nt . 76 ngineer U .. ..... ric COAtroi Plain TMUTCD or Engineered , 1. A triff ' iii control plan, pursuant to.the Traffic Control Plan must provided for the fdllowing: a. Any, construction (i.e. pit, excavation,'.hole) left open overnight requires.snecirjc nighttime traffic control measures pursuant to the TMUTCD; 29 Vol. Pg. f;^. -y,.�_ .. _-.. fY-.''^•I• .S >°rY^ice! - r. - _ ...y�,�wtvg, �.7'r_'?rr.'.w-. � <S,-. .N.�:... r-....... t• b. If construction is within ten'(14) feet -of the roadway; or " c. • Any work performed in the raad right-of-way; 2: Plan in6it be attached to the penmii And kept at fhe job site any, time work is being performed. 3. Plan must set forth the time of completion for the job. & Design Standards I. All overhead installations shall conform. to•clearance standards of the Texas Department of Transportation' . and We pole be placed in the designated area for power specified as set forth in the Tears. Utilities Code, -Section-184045. - 2: All pole installatiori (including l Shting) shag be placed at the backside of fh'e' Right of Way to ensure safety to. the public.: Any pole placed•in violation -'of this requirement will be required to be moved to the ' appropriate location at the company's expense. •Exceptions may be approved by the County Engineer. 3. All underground installations shall (these are minimum depths — utility:may place deeper): a. be placed at a minimum depth of forty-eight (48) inches below the top of the pavement; , b, be at least thirty-six (36). inches below ditch flow line when installation is within the area measured . from top of bank to top of benk;:. ; c.- beat least forty-eight (4)in ches below ditch'flow line if low-pressure gas or petroleum,•Iines. Poi. high_ pressure gas and petroleum ,lines, see High Pressure Pipelines requirements listed below;- = d..: 'not be closer than ten. (10) feet from the edge of pavement.:Excep'n rriay apply in rights of way bf: ; :. less than 60 feet. 4. Water Lines: All water lines must be a minimum 36-inches below the ditch flow line and. cased. Waterlines shall be cased if crossing. urider the roadway. S. ' Utilities in all new developments that have 60 feet or greater of right of way shall be installe'd.within designated locations based upon the•type of utility. The locations. shall be as follows: (measured from back of right-of-way).. P I'';:.' :,.., ;, ,' • .. oweC� 0 to 2• feet, nominally :... ' '. .. • . - - -- _ - -- Phone — 2 to 4 feet,' nominally 3' to 6 feet, nominally 5',•' ;. Cable-6 to 8 fee4,nominally T 6. UtiIities'with less than 60 feet right-of,-tvAy in, all new developments: shall install the utility in a similar manner as referenced in No. 3 above; however, the County_ Engineer or. its designated tepttsentative will provide final approval of each utility location. _ 7. .The length of any trench to be.openedIn advance of the pipe, condgit or ducts may not be'longer than 400': if left `open over night or•unattended.: : 8. Crosthi"gs.under'd county road shall::: a. be bored -or jacked. ABSOLUTELY NO OPEN CUTS WITHIN COUNTY ROAD PAVEMENT' . b. ' be'p'ressure grouted for the full length of the. crossing if the annular space between pipe and casing and s6il'ekeeeds one (1) inch. Brazos County must be given 24 hours notice of pressure grouting operations and have the opportunity to have an inspector on site to observe pressure ';routing .• operations;' - • vol... P 3 ®9. . ?. . {ti ♦ ,.� •bf f-j.- w .::2-hv. , •`A'"2a"•}5:+.^.:.v-•f-3d: 4ic1 .�.- _c3��J•rt.. .--. __�kai+....�.�_ ..1•..i. _-r.• +i-•+.+rov'°Rr. �,r�,.�. it{M1u 'C.i .... -. i -Staiidbid Spiecifi: at c TiDOT c ion'ltem 476.,shall be follow6.6,for all boiingjackin' iunfi6lkg'and` "t g, join s_. 9 a. pq pit.s. shall fi .2 4ys;:..: remain open long9r.than 61' hill .have traffic dontrol-m6eiqures inp ace.,See Tra.ffi c. Co trol• Plafi*listod above. oVe. ._.C.. pits shall N.O,T:be:]O'&.ted wit.hirf ten (10)Ai3*om_th'e'edge'of paveffehtWithout pri6i.iibproValifro` the 'C6ufity:En&eiii or his ..... . A. when tqm�ln open, for tK&t 9'hours, due 'diligence will bt" tis' protecting the gpo'iF. pits are, to. r o ed in prbie . p g ikio oi66nfl raidage.probjen-s- 'h :':top" t t'; .... . .. ... e.: :66ndftions. the Couqt�. Enkirieer or. his te�reseqfative.-fi*: rd ro ec based u'p'on so I quire.s ort Mig bqe.dupqn*soil: 6ohditi6ns,AheCountyE 4ginder of his re�tescnfative may requ ire' Pi.tb 'Iaced Iuid4r'fon ih.edge . of road -rdeet the NI �V n 10.' Any..'iTistillation **�viihin'ten(IO feet edge 6f ijaVement*shall a. atio'n must 4y'the County or his representative_, :b. :`.ba k-filled'With cement sta i iiW material,.*'::*:..: c upon p0il.ppv it' ui�i shoring t di ioni,�th� Qbunty- En his.representative hi# ieq Fe oring o protect pavement gi.neer or ..r. integrity A':-aff excess water- an d mud shall.be :tmoved'frdffi the ttehchpiortoadkflli-nybackfillplaced rA during it ram y:Iiiod-or it 6&r ilme.s• wfl*:Okes§ ivit6f, '6nnot.be prevented from -entering the P '...... tt0h6h Will 4i6.ddMidered TEMPORARY and shall lkw EkMANET dd ith N cement N material As*_soon 7 as -weather .•pem-ts., .... ... on:bf e all -disturbed ase.an -Paveibentpoafedd§4611 be removed -and iestdre'd.to,the satisfk4'the Coufiiy,Engin60:of -his' repieseniiatives. tamping to t base se and p4vemefit'rna 6idilsis allowed;. : J. VS unde. 1-1:CQT ymugt-be*c: _ to 'not jeopardize the SIpe o integrity .-,of the shQuidcr,of the road.,An the eveni-% Cq00anydqffiqes• the, slope,shoulder other portion of the, right -of -*ay; C.6mpiiJyy11be respoirsible.for repairing the d"6 and replacing -the right-6fway-tq'thdcondit'on it waspnor , (d corftmencinzconstruction.: ... .. ... .... ...... uipmen -on etraveled.surface III pqrqtjop Q construction and/oi'miintehin-c"e"'�e'q"'�- i -6 :'df�ny i roved C6un Tofo dty --road;w,iilnot ,,*b'e.peittt6�. i.excot in an instance' her6by the ihg, construction, inidfiidnan"'ce"an-dio"r',;'..-;..., .... . .... .. . . 'nk uits and/or polil'. :-ii6a�co 6lis h�d. O�' ih ines; cannot' -any- ... ....... hall be' provided -11 uc 'equipifii�ni 'shall b6 ofih,6*r'�A6 r, fir6 Voietyi Appr pflAtd traffic co I e • TML)TCD'i*4u!ieniqrits.i' �meeting . .. ... ... 1hq..qy.qpt.sqid 66figti-tiction and/or 'maintenance 'and/or repfitr:reqWfcs.Qorfi0aHy. to remove: cut or . section omppy:wp qrgqi1tre to provid JI J66p d' "(16* the 'road.' road iZ, 0, gpze.any sec; Qf Iasphalt,"cerfi6fif,' edo nance b6fid*.of letter "of 'credit securing necessary repairs: Said b 6 nd.'i ''wiltbe d6termine'd- y ... .. ....... . ,C 'E f % ineec h, W, ro imy 14.7he ap- I submit letti- `V'N Obje�666n` iri'thi�Ai ""C pigiileers rall . plfqqqt'4.'a.... . III . 4' _r;0 - 0 PrP 9 e 16nds. wetlands' -and dnvirbinm;;�r4lly stnihfv6i wet . ...... . ... . . .... . 'r-: eovent :ompanyU'r6quir&d -to:Oerf orffi�6m& gency AervIcis,:ihat requires ekcAvati6h,in'a.count y County - inee prioetd6o'*nd6iitibAieih'e"r-g'encyrep4�t$;:�Z6riipany.-,,r mi h - I. v: ." ` f6f Way. and: able -to o Witht ..... . . ... . Alf ......... 35 Vol" P 1. 1•L 14• Ftl 14-9 1/'1 ' SODOM IDUD)}uanuo3 ..sp00H IDu014•UDAUO3 SP008 IDU0!4,uanu0:) »301f10HS NO 'S.3 UIMA MUOM U30'UIOHS NO 33US MUOIA . 8301noNS UV3N 33VdS MHOM •, itD•11.1•id. la. )1�1UM.'a30'UIOHS' .. IOt Z) del Z) .del YI ?; . ....OVO�t.'lYPd0I1N3Aidd� ., , . .. •, ,1 a,w aas ,, .. , . � �� Icy NV3d 10HIN03 3133VUl ' •Dahl v!' e ,, ., c 01.Ox•0 Pl lx Dlw aa51 � '' Jl Ili L p �N +�lgm(harxi ial�u9artivQ fail,(. ' !,�'a fllfo�„ay .•L z•oeo 11 D-w oas I ,.�I t[.•utlotx ..y^'-. •� OY311v I amldl p:� . .Or • Dr ,rt, 11 alw ars J•� r;' = nUOu .' 1� /� 9aUN gVDU 1•oi°a ' 1/ A. L_aoly I `u' •'i •Y.Y, i OrOa .'I:' qN3 91t ►x ■nor 001 Oii7• OV311V • I x'00 uuoaS • flaOirgYOa , OY3NY M 4.5� .Z' avou qN3 I B lluom 1tlC .I 4 :f,0^GDaJ Ihnllw,.ICa W •4• JIOIDDu/ AJ 114(r .Of]V/ ncD Olod.• ! : ` � • OVOy ;c � ' ' 01-It•7 1D aaDld VI p11M, p !b n07..flPa tl}7YDlll. O• Ilal Y •' ' •Jm11ou1 pnfa aul w wt.m lou aA wu /aa.lD,lWl, ! b`q' R Q I .. � 8 .,, � aw .mal br.Jia ap DIaoV1 Iw3ptrof XVIv A.ala(Y4 t4. m(Ixul •1 ! : �. .. � I I �', � .Y �� "i :•Dga,l 1 3• t �o (•.;':OL9 9/D•9faJlU 4ldaOlV•MO plp w vo+ Jml,w+'roi iu:SId11 ar. b' j . I ., ... :' a ;, .:;•iaDai r/M iipla D,fa11a4.a! JSDA Y( a.G1A;D,iA Di Ilu 'amlJat j• . paut(111Od M Acm .ial VII• SDIatINA •ODDUL'lDAlf twr 'S ::. .• .. ... .. 1 . •Mt"a{014.A�aDDWi•ul-As=111IIOR ,. w .. li •.I •• ...>i!( i?C, ,.� 1 '„ W va 7Nl.fn, W1f11C4atP Jana A OMDa1JJ (i i tY11 'abla j ' ' r •' '. }'.z' '' : u; ulmpJaf ,IwivaDalUoil, a.fl aJlro,JiwpID�,Vm. Jo, plw, 1/0 A '.?�'•. "� IwuJo JiaaCl tV 'D'r NtA•�J7 "Vw .YII la lLftVp,.v'Ciw»jNo. . !• ' o qg :: . , a: . cut WliallJv 91"'1140 4mul(. 0^.d•.p /00.4 .NI ! ', I i •'� 11R r-mm Ill IDq tdl 01 Or wa011lam 90.lm 11 _118M Data as Pl•vlil Vol a'VII. Olotw.. W4 1 :.11/Ill 441,11, ADDI IDI ISDIa 1 YS • r talw aaSl a C tullnall vitlo,a, tn1w4ul 10140101D1 wl• a�alliaa •ooaF',Y I 1` " .. I : ° I 3�+1 ;:� te. Nl aap/I.,NA"1 1. 1t�1 , i!• 'I wj l Nrl Ix l0 rN(Yj■ 0 DaaD10 a0 Ol�olt 101Ja1Da all;'Ot,DIS,'[ 1 � ■ -A u adl 0.0 w-.am moll. 4A/ log -a' lae rllll: Am m M ampo-mat I A f ;lg ,i - o 'Is • / lalw osL1 �xa .• Wi Y( D.lall a,ll.D.,II•D q k.1-$1.1v a10Wl J.1 VIl•:11DIn j•. J_ a ••, •F v atwl ,gala '07.1ro7tl .n oa,aftanl laslaly Ia,IwD allia,l nY 'x y .+, I ■ I�" .; ' � �' 'O7alron1 a4 •s.wl fl,ua slag 0l p"Is. doll •l / i1 'jam j' - Id .* •..� -AIL 7 r .alw Dial• "btu ■ I aja ' S310N 7Ya3tl3q 1� J I iiG� Y. 1� 1}.. � �•Dwa 110 lD ,+•y ■ wl vWl .OL JD 1 a.�. j .}• . I faa(•aD b112}II.uOtfa ?: uVlulw D •l DaA r,o. ..1 :. i . _ _ .. a Dfllpu la aaml au. �1 /a (.o a0 Jotir 7 w�. p Ep' j $ uml'lim°'..1 l o+ l * o I 0 ■ • I,.aW9 R1� .. I r:Himr . a r „i? :'. 111.$lIDriOS, DaitDJ•4 IIll la/J/0 1p Wpl Ola 9lfl la[bl /oO,tMaal•1 •1 •,. -'� '1.y�arlJi 6D�Vaaan ` '•J,o oapirol waa a.ou *I"", : capl.uu j'. _ 1' '4u1DJrao ll p t;r I :r 'w- , iib..::..•. ' ' LIlO •DOOc louo(,vollp7 M a o MA ml }: i:•. ' I .uw+uf�rnaRJ 110 .wa ; Jar101IrtS 1w11 Olgl ,0a1Dl trlf mil Lr10Lv17 W1 /bl■011.15 MI IYWL lAlltltq I/DaL 71107a 'Ir91dA1 ors I7oa ..Dsl .11 ON .5LD a.• Sp•1 L/ Ol G9 09 SS OS Gil .Slr ,009 .Orl .Ol .DrO .0 x .001 ' .Olr• .001' 1 .S9 .QVL. Ali ,0 . .OSL• .009 .091 .09 .01..099 .M ••.SSL .DOL 1011 •.SS A9 AD9 OSS ••.Ore. .00r loci •OS .001 ,OSS .00 " M.,D.A. '•SSt' .OrL .00 1 Af loll 59 �•� • 'Or" SC Or " .OLI.. .011 .Dxl :0 C .09 .09 .5•L .091 .SSx .5tt . O .591 .OSI ' .avvL 'lur'o Iwlwl!tWw Du. NWII ID ai+.oaL N1S lal.lwn 1IW01.a1 Jtlll In11(�In,I D' wN al•ruol Dnlot Inl•.a e.•t/ll� Du In•,:oll oln.eons wfODal +wDl ao+,�s^0 10. .: +aD1J 5luDJf. • : '.' :.IRIS .�.. I:,gJI •+011 aODa1M �OI/P.DtmIq 01W1Ad .tyl{ �j7 aAoO aaL1 0D•V{01l aD1UnJl 'J+ItaJl " •IfTll , 111 Dallmll M.e1Jl � , al D(VaA'VAD {.00a •aa!•a00ulx(lelanu) ■ p IWOal JJOn i aptl ..>� ON3031 a:llaolyil F o�"-I' pIZ olw .IaLI .►L,f .OY r•ora sla a�Yoa , iplx Dlw DaLI x•Dx9 11 a1Dp aaS UaoA gYOU .w ..0r 01.OLa7 . . Uv311v xuow . ,'UYDU is BRAZOS COUNTY, TEXAS BUDGET AIMENDMENT(S) FOR THE 2022-2023 BUDGET YEAR NO.22/23 27.01. — 27.02 On this the 111h day of April 2023 at a regular meeting of the Commissioners' Court, the following members were present: A. Duane Peters, County Judge, Presiding B. Steve Aldrich, Commissioner, Precinct 1 C. Chuck Konderla, Commissioner, Precinct 2 D. Nancy Berry, Commissioner, Precinct 3 E. Wanda Watson, Commissioner, Precinct 4 F. Karen McQueen, County Clerk The following proceedings were held: THAT WHEREAS, on 11 m day of April 2023 the Courtheard and approved a budget amendment(s) for the 2022-2023 budget year for Brazos County, Texas; and WHEREAS, expenditure is necessary due to the necessity to meetunusual and unforeseen conditions which could not be reasonably included in the original budget adopted 6 September 2022, the following amendment(s) to the original budget are hereby authorized, as described on the attached page(s). ADOPTED AND APPROVED this the 11°i day of April 2023. THE COMMISSIONERS COURT OF BRAZOS COUNTY, TEXAS. By: Duane Peters, County Judge Original: County Clerk's Office and Attached to the original budget 34 E . q r� Pg. BRAZOS COUNTY, TEXAS BUDGET AMENDMENTS No. 22/23 - 27.01 4/11/2023 FUND NAME DEPARTMENT NAME CLASS DESCRIPTION ACCOUNT CATEGORY INCREASE DECREASE General Fund County Records Management Departmental Support Ex enditure 660.00 General Fund County Records Management Capital Outlay Expenditure 660.00 County Records Management Reallocation of funds to purchase a scanner with the ability to scan thick cardboard like aerial maps, and the rinting of ry etailed maps or photos. �m;�, CouriyJud�proval,�, �.�:��-�fi .bate' OWQce.Eu�C5an13a FUND DIV ACCT Change in Budget ACCOUNT NAME 01000 50000100 60211000 (660.00) Software - No Tag 01000 50000100 80281000 660.00 Electronic - Capital !Vol.Pg. BRAZOS COUNTY, TEXAS BUDGET AMENDMENTS No. 22/23 - 27.02 4/11 /2023 FUND NAME DEPARTMENT NAME CLASS DESCRIPTION ACCOUNT CATEGORY INCREASE DECREASE General Fund Purchasing Administration Departmental Support Expenditure 31,024.00 General Fund Brazos Center - Non Capital Departmental Support Expenditure 4,618.00 General Fund Expenditure 26,406.00 Capital Improvement Fund Revenue 26,406.00 Capital Improvement Fund Tax Assessor - Collector - Capital Capital Outlay Expenditure 6,714.00 Capital Improvement Fund Sheriff Office - Jail - Capital Capital Outlay Expenditure 6,714.00 Capital Improvement Fund Juvenile Services - Capital Capital Outlay Expenditure 12,978.00 Purchasing Administration Reallocation of funds to purchase replacement copiers for the Tax Office, Jail Administration an nile Sery ces. „ r `CountyJutle Approval y �'� D,atMe 1,7°i8 ''$"�'.y °A P` Y'i� E Y�-:...zax�ii �S X5_.d�1 �?�� .�7 �334r' K 4 ?. a'A.`� �„'7s. .�`'�'+��..T',."`6x'a`�'x�a f`�..., � ?r« .°...'A iN rw���,1.� FUND DIV ACCT Change in Budget ACCOUNT NAME 01000 16500100 60500000 (31,024.00) E ui ment & IT Enhancement 01000 36500006 60500000 4,618.00 Equipment & IT Enhancement 01000 00000000 91110000 26,406.00 Transfer to Capital Im r. Fund 45000 00000000 49028000 26,406.00 Transfer from General Fund 45000 63130001 80230000 6,714.00 Copiers - Capital 45000 63280021 80230000 6,714.00 Copiers - Capital 45000 63310001 80230000 -12,978.00 Copiers - Capital Vol. pg. 36 Personnel Change of Status ( Apr 3, 2023 ) Commissioners' Court Date: Department Submitting Information: Purpose of Submissions: 04-11-2023 Human Resources Consider and Take Action on Change Employment 'DepartmentName ; r,ra ,3� EmpfbefName, r8F i t . } A S .sit A W ri_ t" il. M r7 r I a'.• y i Y to d .bs W5. Vyi Separations DepartrnenENaf:rtiployeeName �w,• '!'` �` �, r2 k�� x t .... o 4mt, .. {1 zy:< J MCI ! ^�r, r ? h ;i _ t�k�., t. Juvenile Services - Detention Jackson, Brandon Exposition Center - Administration Stewart, Sara CountyJudge Zavala, Jasmine Approved in Commissioners' Court: 04-11-202 CountyJudge's or Commissioner's Signature: (This Copy to be attached to minutes) PERSONNEL CHANGE OF STATUS REQUESTS Commissioner Court Date: 04-11-2023 Department Submitting Information: Human Resources Purpose of Submissions: Consider.and Take Action on Change Requests Department Submitting Employee Request Action Requested Request(s) Applies To Road & Bridge Alvarado, Rito Change of Status Approved in Commissioners' Court: 04_ 11-2023: County Judge's or Commissioner's Signature: (This Copy to be attached to minutes) Vol. Pg. 38